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ABSTRACT 
___________________________________________________ 
 
Objectives. The Pregnancy, Nutrition & Diabetes (PND) study aimed to evaluate the 
dietary status of urban Black pregnant women attending the Antenatal Clinic at the Charlotte 
Maxeke (Johannesburg General) Hospital. In addition, the study investigated the effects of 
maternal dietary intake and hormonal levels during pregnancy on fetal growth, birth size and 
the early postnatal development of risk factors for future Type 2 diabetes. The study analysis 
precedes a detailed description of the study population, including its comparison with other 
populations. 
 
Methods. 126 women were enrolled in the study before 24 weeks of gestation. Twice 
during pregnancy (weeks 20-24 and 30-36, visits V1 and V2) and approximately six months 
after the delivery (visit V3), volunteers participated in a standard 75 g oral glucose tolerance 
test (OGTT). Blood pressure, anthropometric and socio-demographic data were taken and a 
food frequency questionnaire was administered at each visit. The daily maternal intakes of 
total energy and macronutrients expressed as a % of total energy intake (%E) were calculated 
and further evaluated. A comparison with the crude nutrients intakes was also performed. 
During both pregnancy visits, an ultrasound examination was carried out to obtain estimates of 
fetal biometry and fetal well-being and the postnatal anthropometric parameters were also 
measured.  Blood samples were collected at fasting, 30min, 60min and 120min of the OGTT 
for the measurements of maternal glucose (GLC), insulin (INS), C-peptide (C-PEP) and 
proinsulin (PI) and fasting samples for the determination of placental lactogen (HPL), insulin-
like growth factor 1 (IGF-1), insulin-like growth factor binding protein 1 (IGF-BP1), free 
 x 
thyroxin (FT4), cortisol (CORT) and leptin (LEPT). Infant fasting blood samples were used 
for the analysis of the GLC, INS, PI, IGF-BP3 and LEPT. The plasma glucose samples were 
analysed on the Beckman Glucose Analyser 2, whilst all the other analytes were measured by 
an immunoassay method on 96-well plates.  
 
 
Results – DESCRIPTIVE DATA. 
Study participants. The majority of the study participants had completed high school 
education, however were unemployed and of low and very poor socio-economic levels. In 
comparison with another study from the developing world, the Pune study in India, the women 
from the current study were older, heavier with greater body mass index (BMI) and they were 
also taller. They had higher head and arm circumference.  
 
Birth outcomes. The birth size of African babies in the current study, although smaller 
in all parameters, was still relatively closer to the size of the Caucasian babies seen within the 
Southampton (Godfrey et al. 1996) or Helsinki (Forsén et al. 1997) studies than to the birth 
size of the babies from Trivandrum (Jaya et al. 1995) or Pune (Rao et al. 2001) in India. 
These relatively smaller African babies have comparable (or even larger) maternal placental 
sizes in relation to the mothers of both European studies. However, in comparison with the 
small Indian babies, the major difference noted was a substantially smaller placental size of 
the Pune mothers.  
Compared to z-scores from the World Health Organization (WHO) child growth 
standards (WHO Anthropo 2010), the PND study babies were born lighter and shorter with a 
larger head circumference (HC). A growth delay observed near the neonatal visit was followed 
 xi 
by catch up growth in weight for age, however no catch-up growth was observed for length for 
age by the second postnatal visit. 
 
Dietary intakes. The PND study women had pregnancy energy intakes slightly below 
the national level intakes (Steyn et al. 2006), except for the energy intake at V3, which 
exceeded the national level. The lower energy intake during pregnancy is attributable to a 
lower intake of dietary protein and total carbohydrate. The fat intake was substantially higher 
in the PND study, with levels almost double at the second postnatal visit. This discrepancy 
may be due to differences between investigated populations or due to increased requirements 
of energy during lactation.  
 
In comparison with the Recommended Dietary Allowances (RDA), during the 
pregnancy period women in the current study had lesser crude protein and higher carbohydrate 
intake. Intake of the crude protein after delivery was low in comparison to the RDA for 
lactating women. Total carbohydrate intake exceeded the RDA. The relation between the 
intake of macronutrients expressed as a percentage of total energy (%E) and RDA was similar.  
 
The current study participants had a lower intake of energy, especially during the 
pregnancy period, when compared to populations in the developed world. They had a lower 
intake of protein at all visits in comparison with the national average for women or with that 
found in the Southampton study or when compared to the usual American diet. The energy-
adjusted intake of fat and carbohydrate were comparable with the Southampton and American 
data. This population in our study was therefore more comparable to that of Pune than to 
American or Southampton populations. However, despite similar total energy intakes as the 
 xii
Pune Study, total protein and fat intakes were higher in the African mothers, which may 
explain their higher weights and birthweights of their babies. 
 
Results – ANALYTICAL  DATA 
Dietary intakes. Maternal dietary intakes showed significant effects on the fetal 
biometrical measurements, mainly involving the fetal head, femur length and the size of 
abdomen. The outcomes also show a significant relationship between maternal protein intake 
and baby’s birth weight. Associations were also found for maternal dietary intakes and the 
neonatal length and BMI and the markers of the infant β-cell function.  Intakes of the plant 
protein and polyunsaturated fat supported the linear growth. There was no correlation between 
maternal dietary intake and the fetal growth rate. Effects of the total energy intake and 
carbohydrate seemed to be direct, while the effect of protein and fat may be delayed, possibly 
involving metabolic adaptation of the mother and the partitioning of nutrients between the 
mother, placenta and fetus. (See Table: Associations between the maternal dietary intake and 
the neonatal INSF1 levels, Pg. xiv). 
 
Maternal hormones. The data of the current study show significant relationships 
between maternal pregnancy hormones and fetal growth rate and the postnatal growth rate, 
although maternal anthropometry and fetal gender and BMI are also significantly involved. 
The maternal thyroid hormones seem to play an important role in fetal and postnatal growth 
and insulin metabolism (N=76, p=0.002, ß=-0.343; AR2=0.106) in the association with the 
neonatal fasting insulin. 
 
 
 xiii 
Discussion. The outcomes of the current study show that the African pregnant women 
in the study had lower energy intakes attributable to a lower intake of dietary protein and total 
carbohydrate.  
Maternal dietary intakes showed significant effects on the fetal biometrical parameters. 
Protein dietary intake was positively associated with baby’s birth weight and was shown to be 
statistically significant. Associations were also found for maternal dietary intakes and the 
infant postnatal BMI and the markers of the infant β-cell function.  Quality of the protein and 
fat has different effects on fetal/infant growth.  
Maternal hormones showed correlations with fetal growth rate and the outcomes of the 
current study also show that maternal hormones can affect neonatal and early postnatal infant 
glucose levels and β-cell function. They are also linked to the programming of early obesity.  
The maternal thyroid hormones seem to play an important role.  
 
The maternal low energy, protein (especially plant protein) and PUFA intakes during 
gestation may be the reasons for the lower z-score birth parameters of the infants in 
comparison with the World Health Organization (WHO) child growth standards (WHO Anthro 
2010). The disproportionally larger head of the newborn may be an outcome of the brain 
sparing effect. A suggestion for an increased maternal dietary intake of energy, protein and 
PUFA has been made. 
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Table: Associations between the maternal dietary intake and the neonatal INSF1 levels. 
 
NUTRIENT  
 Intake V1  (N=76)   Intake V2 (N=75)  
Variable p β 95%CI (b) AR2 Variable p β 95%CI (b) AR2 
TOT PROT1[%E] 0.002 0.231 0.01; 0.06 0.108 PL PROT2[%E] 0.010 -0.298 0.00; 0.00 0.076 
Crude amount 0.045 0.231 0.00; 0.03 0.041 Crude amount NSF    
AN PROT1[%E] 0.007 0.307 0.00; 0.01 0.082 TOT FAT2[%E] 0.004 0.327 0.00; 0.00 0.095 
Crude amount 0.020 0.267 0.00; 0.02 0.059 Crude amount 0.004 0.330 0.00; 0.01 0.096 
TOT FAT1[%E] 0.022 -0.263 0.00; 0.00 0.057 MUFA2[%E] 0.007 0.312 0.00; 0.00 0.085 
Crude amount NSF    Crude amount 0.008 0.304 0.00; 0.00 0.080 
PUFA1[%E] 0.012 -0.287 0.00; -0.02 0.051 PUFA2[%E] 0.003 0.335 0.01; 0.03 0.100 
Crude amount NSF    Crude amount 0.001 0.389 0.01; 0.02 0.140 
     TOT CHO2[%E] 0.005 -0.321 0.00; 0.00 0.091 
     Crude amount NSF    
     TOT ENERGY2 0.029 0.253 0.00; 0.03 0.051 
* The units for the confidence interval (CI) of the slope (b) are expressed in the units of transformation as stated in Appendix G.              
p (probability), ß (Standardised regression coefficient), N (number of subject);  CI (confidence interval); b(slope); NSF (non significant association) 
INS F1 (neonatal fasting insulin); TOT (total); AN (animal); PL (plant); PROT (protein); CHO (carbohydrate);  
PUFA (polyunsaturated fatty acid); MUFA (monounsaturated fatty acid);  
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CHAPTER 1      
 
LITERATURE REVIEW 
 
Conceptual Framework  
In this presented Report the “Pregnancy, Nutrition & Diabetes (PND)” Study is being 
introduced.  The research of the PND study overlaps different research fields, namely 
nutrition, endocrinology and obstetrics. Due to the study complexity, a rather broad literature 
review was produced, enabling the reader to gain a better understanding of the current 
research field and the placement of the PND study within the context of this research.  
 
The Literature Review begins with a historical background of the fetal programming 
hypothesis, introducing the first studies investigating associations between fetal environment, 
birth size, postnatal growth and later offspring health. Complementary studies on animals and 
new epidemiologic studies on humans are also discussed. The knowledge gained from these 
studies gave rise to a new hypothesis, the “Thrifty phenotype hypothesis”, which introduced 
the idea of metabolic “programming”. Opposing this theory is the “Thrifty genotype 
hypothesis”, which explains chronic diseases on the bases of thrifty genes. The “Thrifty 
phenotype hypothesis” was subsequently revised and broadened into the “Developmental 
origins” hypothesis.   
 
 2 
The PND study investigated the relationship of maternal nutrition and hormones with 
respect to increased risk for Type 2 diabetes later in life. As this is a prospective study, only 
known markers for this disease were explored. However, the second section of Chapter 1 
provides information on the pathophysiology and epidemiology of Type 2 diabetes with a 
special focus on gestational diabetes and the development of the pancreatic ß-cells.   
 
The third section of Chapter1 reviews stages of human development, concentrating on 
stages of embryonic and fetal development and the infant birth size. A comprehensive 
understanding of fetal development and maternal adaptations during pregnancy is important in 
a search for their determinants, which are crucial for the interpretation of the outcomes 
observed in the current study.   
 
The last section of the Literature Review Chapter explores in greater detail the 
determinants of fetal growth and birth weight, as many of them are closely linked to the 
current study.   
 
 
1.1 INTRODUCTION 
Epidemiological studies carried out worldwide during the last 20 years have shown 
that chronic diseases may have their origin in fetal and early postnatal life by a process of 
“programming”. Programming was defined as a ”permanent or long-term change in the 
structure or function of an organism resulting from a stimulus or insult acting at a critical 
period of early life” (Lucas 1998).  
 3 
The original observation that initiated the fetal programming hypothesis was that low 
birth weight and poor fetal growth were associated with coronary heart disease in adulthood 
(Barker et al.1986). Further studies observed similar associations between different patterns of 
early growth and increased risk of future metabolic and cardiovascular diseases (Barker et al. 
1993a; Barker et al.1993b; Eriksson 2001; Hales et al. 2001; Barker et al. 2002). Maternal 
health and nutritional status were implicated in programming the development and function of 
pancreatic β-cells, kidney nephrons, or other organs, leading to future health problems (Hales 
et al.1992; Barker et al. 1993b; Yajnik et al. 1995; Ravelli et al. 1998; Robinson 2001; Fall 
2003a; De Boo et al. 2006).  
 
The first studies were carried out on populations of older people, retrospectively. The 
existing birth records were compared with current occurrence of illness or death and risk 
factors were thus identified.  A few studies investigated children and young adults. In parallel, 
a growing number of animal research studies and in vitro experiments investigated how 
nutritional manipulation in early stages of growth and development could program birth and 
adult size and their relation to future disease (Barker et al. 1992; Lucas 1998; Ozane 2001). 
 
The outcomes from animal studies, in vitro experimentation and epidemiological 
surveys were the basis on which the present “Developmental origins” of health and disease 
hypothesis was developed. Thus Barker’s “Fetal origins” theory gave rise to a whole new 
discipline in biomedical science.  
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The research activities and directions since the very first pioneering studies can be 
chronologically illustrated in following categories: 
1) Establishment of the relationship between birth parameters and later disease 
2) Investigation of patterns of early postnatal growth and later disease 
3) Focusing on fetal growth in relation to the birth outcomes (with known links to future 
disease) 
4) Nutrition and other determinants of fetal growth  
5) Molecular mechanism behind the programming effect (mainly animal and in vitro 
experiments) 
6) Early detection, treatment and prevention 
 
Although the knowledge in each category progressed, the research is not closed, as new links 
may be discovered and different conditions and different populations can still be compared. 
Early disease detection and the possibility of early treatment in combination could prevent 
many debilitating, life shortening and costly chronic diseases. 
 
 
1.1.1  Fetal origins of adult disease  (FOAD) – historical background 
Observations that adverse events in childhood may have long term effects on the 
individual’s health existed already early in the 20th century (Barker 1998; Barker 2002; Fall 
2003a). Explanations were attributed to different living conditions during childhood. It was 
the study of DJP Barker and his colleagues (Barker et al.1986), who retrospectively 
investigated neonatal and post-neonatal death rates among babies in England and Wales, 
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from which a novel concept of “Fetal origins of adult chronic diseases” evolved. This 
hypothesis states that poor nutrition during fetal life causes disproportionate fetal growth and 
results in coronary heart disease (CHD) in adulthood (Barker1995). Results of this study 
showed that the geographical pattern in rates of neonatal mortality early in the 1900s 
coincided with the adult mortality rate distribution of coronary heart disease in the 1960s and 
1970s. As the most commonly reported reason for the infant’s death at that time was low birth 
weight, a suggestion was made that low growth rate before birth may be linked to coronary 
heart disease later in life. A similar pattern was discovered between mortality rates among 
mothers with a poor maternal health and later death rates from stroke among their offspring 
(Barker et al. 1987).  
 
Barker’s original observation was followed by a series of epidemiological studies 
carried out on groups of men and women from Hertfordshire, Preston and Sheffield in the UK, 
for whom birth and early infancy growth records were available. 
The Hertfordshire study (Hales et al. 1991; Barker et al 1993a; Barker 1995) 
investigated present cardiovascular mortality of men currently in their 60s’ in connection with 
birth weight and measurements of growth in infancy.  Those who were born small and who 
were small at one year of age showed the highest risk of death from ischaemic heart disease 
(IHD) and stroke as adults (Figure 1.1).  
Also in Hertfordshire, babies with slowest prenatal and early postnatal growth had the 
highest incidence of impaired glucose tolerance (IGT) and Type 2 diabetes in later life (Figure 
1.2). This was the first indication of a link between Type 2 diabetes, pregnancy outcome and 
infant development. Low birthweight was also associated with an increased risk for the  
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Figure 1.1 Ischaemic heart disease (IHD) in men in Hertfordshire at age  
of 59-70. (Weight at 1 year in kg: 8.2, 9.1, 10.0, 10.9, 11.8 and 12.3) 
 (Source of the data: Barker et al. 1992) 
 
 
 
 
 
 
 
 
 
Figure 1.2 Impaired glucose tolerance (IGT) and Type 2 diabetes prevalence  
expressed as odds ratio in men in Hertfordshire at age of 59-70. 
  (BW in kg: 2.5, 2.54-2.95, 2.99-3.41, 3.45-3.86, 3.90-4.31) 
  (Source of the data: Barker et al. 1992.) 
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 7 
metabolic syndrome1, elevated concentrations of fibrinogen and markers of ß-cell function - 
proinsulin, 32 – 33 split proinsulin and insulin. It was suggested that metabolic syndrome and 
insulin resistance might all be linked and determined by factors reducing fetal and infant 
growth. A possible influence of maternal nutrition on pancreatic ß-cell development was 
considered as an alternative to the “thrifty genotype” theory (see Chapter 1.1.3.2) (Hales at al. 
1991; Barker 1992; Barker et al 1992; Barker et al 1993a; Barker 1995). 
 
In the Preston study two high-risk categories of babies leading to hypertension later 
in life were identified according to their birthweight and placental weight (Barker et al. 1990; 
Hales et al. 1992; Barker et al.1993a). The first group of babies, who also developed insulin 
resistance and/or impaired glucose tolerance in adulthood, were babies born small at term with 
low ponderal index, small head circumference (symmetrically growth restricted) and with 
disproportionately large placentas.  
The second group, who developed high blood pressure in adulthood, were babies with 
above-average birthweight, large placentas and head circumference but of a short birth length 
(asymmetrically growth retarded). These babies did not develop metabolic syndrome but they 
                                                           
1
 The Metabolic Syndrome (originally named Syndrome X or Insulin Resistance Syndrome) was 
proposed by GM Reaven (1988).  It referred to metabolic and vascular abnormalities i.e. hypertension, glucose 
intolerance and dyslipidaemia (elevated plasma triglycerides and low high-density lipoprotein cholesterol levels) 
occurring together in individuals more commonly than could be explained by pure chance. The original factors 
were extended to visceral obesity, hypercoagulability and microalbuminuria (WHO 1999; Zimmet et al. 2001). 
These abnormalities represent a high risk of progressing to Type 2 diabetes, coronary heart disease and other 
diseases associated with insulin resistance (Turner et al.1993; Reaven 1995; Bogardus 1995; Johnson et al. 
2006). The above metabolic and physiological disorders may have a common aetiology in insulin resistance 
(WHO 1999).  
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were predisposed to development of other abnormalities such as raised plasma fibrinogen 
levels later in life (Barker et al. 1990; Barker 1992; Barker et al. 1992; Barker et al.1993a; 
Phillips et al. 1994; Barker 1995).  
Individuals who were found with the lowest blood pressures as adults were born large 
with small placentas. These effects were irrespective of the social class at the time of birth or 
social class in adult life (Barker et al. 1990). Similarly, as in the Hertfordshire study, it has 
been postulated that the blood pressure in adulthood is related to the intrauterine environment 
and factors constraining fetal growth. As the systolic BP in adults rose with the increasing 
placental size at birth, a suggestion was made that the large placenta might be an adaptive 
response to a poor maternal nutrition during pregnancy (Leon 1999). 
 
A study in Sheffield (Barker et al. 1993b; Barker 1995; Barker1998) investigated 
how fetal growth and size at birth were related to later disorders in cholesterol metabolism, 
blood coagulation and subsequent death rates from cardiovascular disease. Research was 
based on detailed obstetric and delivery records of only men born in one maternity hospital 
between the years 1907 and 1924. Findings were consistent with the earlier Hertfordshire and 
Preston studies (see above; Barker et al. 1993b). Reduced fetal growth associated with 
changes in blood vessels and pancreatic β-cells was implicated in programming of blood 
pressure, glucose and insulin metabolism and cardiovascular disease. Again, as in the previous 
studies of Hertfordshire and Preston, the maternal undernutrition during mid- or late gestation 
was suggested as the factor causing disproportionate fetal growth. Changes in length of 
gestation or social class had no influence on cardiovascular mortality.  
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As the hospital records on the birth, placental and infant size showed consistent trends 
with development of later disease among the older population, the interest of some studies 
focussed on younger population groups. Two studies in Salisbury and Southampton 
investigated a population of 4-year old children and 20-year old men respectively. Also 
outcomes for these age groups were found in agreement with the above studies on older 
people.   
 
The Salisbury study (Law et al. 1991; Barker 1992; Barker et al. 1993b) found 
relationships between fetal growth, birth weight, birth size, placental weight and blood 
pressure and insulin response similar to those described previously.  
 
The Southampton prospective observational study (Godfrey et al. 1996) investigated 
the effect of maternal nutrition on placental and fetal growth.  The results showed that 
placental and birth size correlated with maternal intake of carbohydrate and protein. High 
carbohydrate intake in early pregnancy suppressed placental growth, having a greater effect in 
combination with low dairy protein intake in late pregnancy, whilst the birth weight was found 
inversely related to the meat protein intake also in late pregnancy. Not only the protein source, 
but also protein density appeared to be important for placental and fetal growth.  
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1.1.2 Worldwide epidemiological studies in developed and developing 
countries.  
Similar trends have been reported from epidemiological studies carried out in different 
populations and ethnic groups in Europe (Uppsala study; Helsinki study; Dutch famine study), 
United States (New York Nurses’ Health Study; Pima Indians in Arizona), in China, India 
(Pune study) and others (Hales et al. 2001). The only exception to this is the Leningrad Siege 
Study. Some of the most important studies will be discussed below. 
 
The Uppsala studies (Sweden). Two cohorts were retrospectively investigated for 
relation between the birth size and a future disease outcome. The Uppsala Longitudinal Study 
of Adult Men (ULSAM) found an inverse correlation between birth weight and hypertension, 
and with some other components of the metabolic syndrome (insulin resistance, truncal 
obesity and high plasminogen activator inhibitor-1 levels) in later life (Byberg, et al. 2000). 
However, contrary to the Preston study, where the risk for future hypertension rose with 
increasing placental weight, in the ULSAM cohort this trend was opposite. The men with 
lowest blood pressures had higher placental weights at delivery, irrespective of their birth 
weight (Leon 1999).  
In the ULSAM cohort, it also has been established that the indirect relationship 
between size at birth (as low ponderal index) and later development of Type 2 diabetes was 
mediated through insulin resistance rather than through impaired β-cell function. Obesity in 
adulthood added to the risk (Lithell et al. 1996). 
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The second cohort (Uppsala Birth Cohort Study – UBCoS) study based on detailed 
obstetric records of Swedish men and women retrospectively studied a relation between size at 
birth and mortality from cardiovascular diseases. There was found an inverse correlation 
between fetal growth rate and current mortality from IHD (Leon et al.1998; Leon 1999). This 
finding shows that the fetal growth rate may be even more important predictor of the future 
disease risk than are the birth parameters.  
 
In the Helsinki study (Finland) first a cohort of men born in Helsinki University 
Hospital between 1924-33 was investigated. Later, this cohort was extended by a group of 
men and women born between 1934-1944.  
The first study aimed to evaluate the relation between birth size and death rates from 
coronary heart disease (CHD). Further follow-up tried to establish if the childhood growth 
could alter links between impaired fetal growth and the later death from CHD (Forsén et 
al.1997; Eriksson et al. 1999).  
Low birth weight and body size at birth (i.e. low ponderal index), as well as low 
height, weight and BMI at 1 year of age were associated with increased risk of later CHD. 
Rapid catch-up growth after 1 year of age in men born with ponderal index below 26 kg/m3 
contributed to a further risk increase (Forsén et al.1997; Eriksson 2001; Eriksson et al. 2001). 
However, gaining weight during the first year of life was associated with decreased risk for 
developing CHD later in life, especially for those who were born with an above average 
ponderal index and had an above average height and BMI at 1year of age (Eriksson et al. 
2001). 
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Further investigation showed that the early adiposity rebound2 was connected to the 
development of both obesity and Type 2 diabetes (Figure 1.3, 1.4). Two different pathways 
leading to these diseases were identified. Low birth weight, thinness at birth and infancy 
followed by an accelerated growth during early childhood were associated with type 2 
diabetes, whilst high birth weight and high neonatal ponderal index were linked to obesity 
later in life.  However, some people born with a higher birthweight also developed Type 2 
diabetes, if they experienced slow linear growth during early infancy and had a high childhood 
BMI. Therefore the association between the birthweight and Type 2 diabetes was actually U-
shaped (Eriksson 2001; Eriksson et al. 2002; 2003a; 2003b; Barker et al. 2002). This pattern 
has previously been reported in other population groups, e.g. Pima Indians (see further; 
McCance et al. 1994). 
                                                           
2
 During period of childhood, a child passes through a stage, when its body mass index (BMI) decreases 
to a minimum (after age of 2 years) before increasing again after 6 years of age, the so called adiposity rebound 
period.  Age at adiposity rebound corresponds to the age of the lowest BMI between one and 12 years (Eriksson 
et al. 2003a).  
 13 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Age at adiposity rebound in relation to BMI at 1 y and 12 years  
of age for both genders combined (Helsinki study; Eriksson et al. 2003a). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Age at adiposity rebound and accumulative incidence of diabetes  
(Helsinki study; Eriksson et al. 2003a). 
 
15.5
16
16.5
17
17.5
18
18.5
19
19.5
≤4 5 6 7 ≥8
Age at adiposity rebound [y]
B
M
I [k
g/
m
2]
BMI at 1 y
BMI at 12 y
0
1
2
3
4
5
6
7
8
9
10
≤4 5 6 7 ≥8
Age at adiposity rebound [y]
Cu
m
u
la
tiv
e 
in
ci
de
n
ce
 
o
f d
ia
be
te
s 
[%
]
 14 
Dutch Hunger Winter study. This study analysed the period of famine in Holland 
during November 1944 to May 1945. During this time, the daily energy intakes in this 
otherwise adequately nourished population decreased below 1000 calories per day (Ravelli et 
al. 1998). Due to the relatively short duration of the famine, this study enabled a comparison 
between different pregnancy exposures.  
 
Those people who were exposed to the famine in utero early in gestation, showed 
higher rates of subsequent obesity, measured by BMI and waist circumference (Ravelli et al.  
1999). They also had higher prevalence of CHD later in life than non-exposed people, 
independently of their birth weight (Rosenboom et al 2000).  
Individuals exposed to the famine in mid and late gestation had the highest blood 
glucose levels at 2 hours of their oral glucose tolerance test (OGTT) as adults, especially if 
born thin and becoming obese as adults (Figure 1.5; Ravelli et al. 1998).  
Undernutrition at this time of gestation led to impaired glucose tolerance and Type 2 diabetes, 
while exposure to famine in early gestation was associated with abnormalities in lipid 
metabolism. Outcomes also showed that maternal diet during pregnancy could programme 
metabolism without altering size at birth. Only late pregnancy exposure to famine caused 
variations in birth size and body proportions (Ravelli et al. 1998; Rosenboom et al 2000; 
Hales et al. 2001; Stein et al. 2004). 
 
This study has not found any relation between the low birthweight or small birth size 
and later development of hypertension, as did other previously reported studies.  
Recent findings for this cohort are also discussed in Chapter 1.4.2.1.2. 
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Figure 1.5 Glucose and insulin levels of offspring born before famine, exposed to famine 
during different times of prenatal life or conceived after famine (Dutch Hunger Winter study). 
Data expressed as geometric means; n=702 (Ravelli et al. 1998).  
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involved those who were exposed to the siege in early infancy only (at least 10 weeks old and 
adequately nourished during pregnancy). In the third cohort there were people born out of the 
city, therefore not exposed to starvation. No association was found between intrauterine 
starvation and glucose intolerance, dyslipidaemia, hypertension or cardiovascular disease later 
in life.  
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This outcome differed from the Dutch Hunger Winter study, however, the conditions 
of both studies were also different. As discussed above, the famine in the otherwise adequately 
nourished Dutch population was of a relatively short duration and soon after the liberation of 
Netherlands in May 1945 the daily caloric intake more than doubled (Ravelli et al 1998).  In 
contrast, the children born during or after the siege of Leningrad, continued to be exposed to 
poor nutrition and had no catch-up growth (Hales et al. 2001; Stanner et al. 2001). 
 
The American Nurses’ Health Study. A cohort of registered nurses with mean age of 
42 years was followed between 1976 and 1992. An association was reported between low 
birth weight and the later increased risk of non-fatal coronary artery disease and stroke (Rich-
Edwards et al. 1997).  
 
A study in Beijing, China, followed records of people in their 40s’ born during time of 
chronic malnutrition in China. The mothers of studied offspring were thin and short (155.6 
cm) in average. Low maternal BMI (20.9 ± 6.2 kg/m2) at 15 and (24.8 ± 2.4 kg/m2) at 38 
gestational weeks, as well as the baby’s birth weight, were significantly correlated with 
increased levels of plasma glucose, insulin and triglycerides in adult offspring (Mi et al. 2000). 
The birth weight, but not maternal BMI, was also inversely associated with the offspring’s 
blood pressure later in life.  
 
Pima Indians in Arizona are a population with the highest reported prevalence of 
Type 2 diabetes, following their transition from farming to sedentary lifestyle (Turner et al. 
1993). Birth weight was found to be associated with the prevalence of diabetes in a U-shape 
manner (McCance et al. 1994). Thus, low birth weight was associated with a high risk of adult 
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diabetes, as was a high birth weight. A high prevalence of parental diabetes in the low birth 
weight group of infants, suggested possible genetic predisposition of these babies to insulin 
resistance and Type 2 diabetes. Due to a relatively high mortality among low birth weight 
infants, the authors proposed, that those who lived and later became diabetic, might represent 
a selective survival mechanism. The association of the high birth weight babies with later 
diabetes may be due to gestational diabetes. 
 
The study in Mysore, an urban area in South India, investigated the relationship 
between data from birth records and current glucose and insulin metabolism of the 39-60 years 
old adults (Fall et al. 1998). The high prevalence of Type 2 diabetes (15%) correlated with 
short stature at birth and high ponderal index (obesity). The high ponderal index was 
associated with reduced β-cell function.   
 
Pune Maternal Nutrition and Fetal Growth Study in India is a large community-
based observational study involving women from rural areas near the city of Pune, 
Maharashtra and their offspring.  This was the first study to follow maternal pre-pregnancy 
anthropometric measurements in relation to the offspring’s birth weight and size. Maternal 
nutrient intake during pregnancy was also evaluated (Yajnik et al. 2003a). The birth 
parameters of Pune babies and maternal size and nutrition were compared with the 
Southampton babies (Godfrey et al. 1996) of a relatively well-nourished population in the UK 
(see the Southampton study). 
The mothers in Pune study were lighter (42.0 kg), shorter (1.52 m) and had lower BMI 
(18.0 kg/m2) than mothers in the Southampton study (63.0 kg, 1.62 m, 23.5 kg/m2 
respectively; Yajnik 2002: Fall 2003b).  
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The full term babies in Pune had lower birth weight than the Caucasian babies (2.7kg 
vs. 3.5kg), they were small and thin with low muscle mass but centrally obese (“thin-fat 
phenotype”), preserving fat during their intrauterine development (Yajnik et al. 2003a; Fall 
2003b; Yajnik 2004). Nearly 30 % of the Pune babies were born with the weight below 2.5 kg 
(Rao et al. 2001; Yajnik 2002), which was in accordance with the national data. Indian babies 
are known to be among the smallest in the world. This is associated with chronic 
undernutrition in the Indian population (Yajnik 2004). The size of Pune babies reflected 
parental size. The nutritional history of the mother was reflected in her anthropometric 
measurements, especially in her head circumference, which in turn was strongly correlated 
with the overall fetal growth of her offspring (Yajnik et al. 2003a, b). 
  
In Pune, the links between offspring’s birth weight and future insulin resistance and 
Type 2 diabetes were also studied in 8-year old children (Yajnik 2002). The systolic blood 
pressure, plasma LDL cholesterol, fasting and 30-min plasma insulin, 30-min plasma glucose 
and HOMA-IR index of these 8-year old children were all inversely associated with the 
children’s birth weight (see Figure 1.6 A, B, C; Bavdekar et al. 1999).  
Taller children of shorter parents were found to be at higher cardiovascular risk. The 
strongest predictor was the growth velocity between 4 and 8 years of age (Bavdekar et al. 
1999; Yajnik 2004). Together with rapid childhood growth the “thin-fat” phenotype 
represented increased risk for future obesity-associated diseases (insulin resistance and 
hypertension) and Type 2 diabetes. Risk was higher than in Caucasian population (Yajnik et al. 
2003; Fall 2003a; Yajnik 2004).  
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Figure 1.6 A        Figure 1.6 B       
  
 
 
 
 
 
 
 
 
 
 
Figure 1.6 C         
 
Figure 1.6  Systolic blood pressure  (Figure A), LDL 
cholesterol (Figure B) as cardiovascular risk markers 
and the HOMA-IR index (Figure C) in 8-year old children 
of Pune study plotted according to their birth weight. The 
differences across the birthweight categories became 
stronger after adjustment for age, sex and current body 
weight (adjusted p value). 
 (According to: Bavdekar et al. 1999) 
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The South African Studies. 
There are a limited number of studies investigating the relationship between birth and 
postnatal characteristics in respect to the health - disease risk within South Africa.  Fields of 
interest, which have been partly assessed, include obesity, metabolic syndrome, bone 
metabolism and osteoporosis (Levitt et al. 2005a). Some examples of these studies include the 
following. 
 
The Birth-To-Ten (BTT) study is a longitudinal, prospective study of urban children 
and their families. It included all births during a 7-week period from April to June 1990 in 
Soweto-Johannesburg, enrolling over 4000 cases (Richter et al. 1995). The original 10-year 
follow-up period was extended by further 10 years into the Birth-To-Twenty study. Systolic 
blood pressure in 5-year-old children of this follow-up inversely correlated with their birth 
weight. This observation was independent of confounding variables such as current weight, 
height, gestational age or socio-economic status (Levitt, et al. 1999b). 
 
Low birth weight and rapid weight gain in childhood led to poor glucose tolerance in 
7-year-old BTT children, using the oral glucose tolerance test for assessment (Crowther et al. 
1998). Low birth weight children without catch-up growth had diminished glucose tolerance. 
Catch-up growth between birth and 7 years in the absence of catch-up growth between birth 
and 1 year was characterised by elevated proinsulin and insulin levels. The catch-up growth 
within the first year of life as well as between birth and 7 was associated with lower proinsulin 
and insulin levels (Crowther et al. 2008). 
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Other South African cohort studies: 
Levitt et al analysed the birth records and traced individuals born in the Groote Schuur 
Hospital Maternity Center in Cape Town 20 years ago. Those born with low birth weight had 
elevated systolic and diastolic blood pressures and elevated fasting plasma glucose levels at 20 
years of age. Low birth weight individuals had high blood pressure and glucose levels without 
being obese as adults. The hypothalamic-pituitary-adrenal (HPA) axis has been implicated in 
early life programming of future cardiovascular and metabolic disease in humans (Levitt et al. 
2000b).  
In a cohort of 100 prematurely born or SGA infants in the Johannesburg General 
Hospital, glucose tolerance was associated with baby’s birth weight irrespective of gestational 
age (Gray et al. 2002). Mothers treated for hypertension had babies of lower birthweight.   
Neonatal catch-up growth rate was negatively correlated with birth weight, and positively 
correlated with insulin sensitivity. 
 
 
In summary, these epidemiological studies, with the exception of the Dutch Hunger 
Winter study and the Leningrad study, all demonstrate the negative effect of low birth weight. 
Low birth weight, thinness at birth (measured by low ponderal index) and a short stature 
reflect reduced intrauterine growth. The published data show that these parameters are 
associated with a high blood pressure, coronary heart disease and metabolic disease later in 
adulthood. Large placental weight (in the Preston study), failure of catch-up growth in infancy 
and a rapid growth in childhood with subsequent obesity (Helsinki study) further increase the 
disease risk. The relation between birth weight and future disease has a U-shape character, 
therefore also babies of above-average birth weigh and high ponderal index at birth may 
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experience increased risk of future disease. Poor maternal nutrition has been implicated in 
programming effects leading to impaired fetal and infant growth.  
 
 
1.1.3  “Thrifty genotype” and “Thrifty phenotype” 
Two possible hypotheses have been formulated to explain the mechanism by which 
poor fetal growth is linked to adult chronic health status. Both hypotheses will be discussed in 
the following sections. 
 
1.1.3.1  “Thrifty genotype” hypothesis (JV Neel, 1962). 
This hypothesis proposes that the genes selected during human evolution, adjusted the 
carbohydrate and lipid metabolism to an optimal use of energy resources between times of 
abundancy and times of shortage (Turner et al.1993; Coughlan et al. 1997; Zimmet et al. 
2003). These “thrifty” genes represented a survival mechanism in the time of irregular nutrient 
resources. However, in the environment of continuous high-energy food availability combined 
with a sedentary life-style, these genes became diabetogenic (Neel 1962; Cassell et al. 2003). 
Pancreatic β-cell overstimulation leads to hyperinsulinaemia, insulin resistance and exhaustion 
of pancreatic islets, ultimately resulting in diabetes (Neel 1962, Turner et al. 1993; Mackenzie 
et al. 1996; Coughlan et al. 1997). 
 
The application of the “Thrifty genotype” hypothesis was then extended to fetal life. 
The relationship between adult diseases and in utero environment was explained by suggesting 
that in times of poor maternal nutrition the babies that survived were those that carry genetic 
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polymorphisms (i.e. the “thrifty genes”) that make them less insulin sensitive. This insulin 
resistance ensures that glucose levels are maintained for brain consumption.  
 The “Thrifty gene” hypothesis also suggests that some of the mutations neither 
presented any survival advantage at the time of the unstable food supplies (hunter-gatherer), 
nor were pathogenic. However, they possibly accumulated (silent polymorphism), and in an 
altered environment became detrimental (Turner et al. 1993; Figure 1.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 “Thrifty genotype” and “Previously neutral polymorphism” hypotheses 
  (Adapted from Turner et al. 1993, Fig. 1) 
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1.1.3.2 “Thrifty phenotype” hypothesis.  
The “Thrifty phenotype” hypothesis (Hales et al. 1992) proposes that Type 2 diabetes 
is possibly an outcome of environmental factors, namely maternal undernutrition, which act in 
utero in the process of metabolic “programming”. The metabolic programming is an essential 
tool for survival under conditions of inadequate food supply. The postnatal environment 
(nutrient availability) will decide if the predisposed individual will eventually progress to the 
disease in later life (Figure 1.8). The genetic factors are not considered in this theory or they 
may have a minimal effect. 
  
During the periods of rapid cell replication or growth, the organs and other developing 
systems become sensitive to environmental effects (Barker 1997). Inadequate maternal 
nutrition during these critical phases of early life can permanently alter the structure or 
function of different organs and tissues, including blood vessels, during their development 
(McCance 1962; Ozane et al. 1999). The timing of the external insult could determine the 
kind of future metabolic problem. This process is known as the “programming effect” (Lucas 
1991; Barker 1997; Hales et al.2001). In an optimal in utero environment, the programming 
process is part of natural development. 
 
A fetus exposed to low oxygen or low nutrient environment has insufficient energy 
resources for normal growth. For immediate survival, it adapts to the situation by a selective 
down-regulation of the growth and metabolic rates of different tissues. The oxygenated blood 
flow is diverted to vital organs, such as brain, heart, lung and adrenals (Campbell 1967; 
Barker 1997; Barker 1998; Ozanne et al. 1999) at the expense of the liver, pancreas, spleen, 
 25 
kidneys, muscle and gut (Desai et al.1996; Haugen et al.2005). This mechanism is also known 
as the “Brain sparing effect” (Barker 1997; Barker 1998).  
 
Therefore, temporarily, the fetus will benefit. In the long term, if the low nutritional 
environment remains constant, programming would be appropriate and aid survival. However, 
if there is a poor intrauterine nutritional environment followed by abundant nutrition, these 
changes could have harmful consequences (Figure 1.8; Ozanne et al.1999).  
 
Pancreatic islets of Langerhans are highly vascularised (see Chapter 1.2.5.1; Bonner-
Weir 1990). Therefore, changes to the islet vasculature induced by poor fetal nutrition will 
affect the pancreatic β-cells and limit their insulin production (see Chapter 1.2.5.4). In 
combination with insulin resistance caused by poor fetal nutrition and enhanced by adult 
obesity this would lead to impaired glucose tolerance, and Type 2 diabetes later in life (Hales 
et al. 1992; Barker et al. 1993a; Ozanne et al. 1999; Hales et al. 2001). 
 
In a similar way, a low number or size of nephrons in the kidney could lead to 
increased susceptibility to hypertension later in life. Alternatively, changes in hepatic 
development could cause an increased risk of cardiovascular and metabolic disease in 
adulthood (Haugen et al. 2005). Experiments with rats (Desai et al. 1996; Lucas 1998), 
evaluating a low protein diet to mothers during gestation, showed an alteration in hepatic 
carbohydrate metabolism in these offspring.  The metabolic shift was associated with 
increased liver PEPCK (phosphoenolpyruvate carboxykinase) enzymatic activity and a 
decrease in the glucokinase enzymatic activity, stimulating glucose production rather than 
utilization.  
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Each of these enzymes originates from the hepatocytes of different liver zones 
(catabolic periportal vs anabolic perivenous –linked to glucokinase), therefore it has been 
suggested, that programming affects these zones differently. Similarities with this outcome 
were observed also with activities of other liver enzymes of carbohydrate metabolism (Desai 
et al. 1995; Byrne et al. 2000).   
 
Figure 1.8  “Thrifty phenotype” hypothesis. Effect of maternal undernutrition on the 
aetiology of Type 2 diabetes (adapted from Hales et al.1992). 
 
 
POOR MATERNAL 
DIET
Low nutrient supply to pancreas: 
low β-cell function
Insulin resistanceNutrients to essential organs
Normal glucose tolerance
Sufficient β-cell mass Insufficient β-cell mass
IGT/Type 2 diabetes
Normal/low calorie intake
High calorie intake
Po
st
n
a
ta
l e
n
vi
ro
n
m
en
t
In
 
u
te
ro
M
o
th
er
 27 
The risk of future chronic disease can be modified by additional (lifestyle) postnatal 
factors such as catch-up growth and adult obesity (Eriksson et al. 2001; 2003a,b). Thus insulin 
resistance or metabolic syndrome are more common in subjects with low birth weight who 
became obese as adults (Phillips 1996). Low body mass index in adulthood has a protective 
role (Hales et al. 1992; Wilkin 1993; Barker et al. 1993a). 
 
The Thrifty Phenotype Hypothesis may be further supported by the follow-up studies 
of Danish diabetic twins (Poulsen et al. 1999a,b; Poulsen et al. 2006, Poulsen et al. 2009) or 
of a large cohort of Swedish twins (Iliadou et al. 2004). In the former study the Type-2 
diabetic monozygotic co-sibling had lower birthweight than the unaffected twin and the non-
diabetic monozygotic twins (usually sharing one placenta) were more insulin resistant than 
dizygotic twins (developing in separate placentas).  From these outcomes the authors 
suggested that the intrauterine environment is an important determinant of future disease 
development, where low birthweight or monozygosity negatively influence glucose 
homeostasis, irrespective of genetic cause. There are, however, other studies on twin 
gestations that have been published, which were inconclusive and had variable outcomes. For 
example, in the New Zealand twin study (Williams et al 1999), mothers who smoked during 
pregnancy when compared to non-smokers had babies of a lower birth weight and of a higher 
blood pressure at ages 9 and 18 years, supporting the “Fetal origins hypothesis”. However, 
opposing this hypothesis, the twin vs. singleton babies had a lower birth weight associated 
with a lower blood pressure at age 9 years.  De Geus et al (2001) investigated blood pressure 
among participants of the Netherlands Twin Registry in their adulthood, comparing them with 
their singleton siblings. No significant difference in blood pressure was found, despite a 
significantly lower birth weight among twins.  Similarly, comparing the differences in birth 
 28 
weight within twin (monozygotic and dizygotic same sex) pairs with their blood pressure at 
age of 7 years, the authors (Zhang et al 2001a) failed to find any significant outcomes linking 
the in-utero environment with the blood pressure in the child. Contrary to this, a similar study 
in the UK (Poulter et al. 1999) investigating female twin pairs, found an inverse association 
between the birth weight of a twin and her blood pressure later in adulthood. Therefore, more 
studies on twins or multiple pregnancies, where the fetuses develop in a shared environment, 
may be needed to clarify possible in utero effects linked to future adult diseases. 
 
With additional knowledge emerging, the “Thrifty phenotype” hypothesis has further 
been revised by Barker and Hales (Barker 1995, 1998; Hales et al. 2001) and quite recently 
broadened into the “Developmental origins” hypothesis (DOH) by Gluckman and Hanson 
(Sharp 2005; Gluckman et al. 2006). The Developmental Origins Hypothesis accepts the 
concept of gene-environment interaction and explains the origins of human disease from the 
aspect of human evolution. This hypothesis will be discussed in the following section. 
 
 
1.1.4 “Developmental origins” hypothesis of future health and disease. 
As the early life events involved in programming are not restricted to the prenatal 
period only, but also include the neonatal period, infancy and childhood (Forsén et al. 1997; 
Eriksson et al. 1999b, 2001, 2002, 2003a,b; Eriksson 2001; Barker et al. 2002), a broader 
terminology of “developmental” instead of “fetal origins” has been used.   
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An important natural feature (in many plants, animals and humans; Crespi et al. 2005) 
is a “phenotypic plasticity”. In this process, a single genotype can lead to a range of 
phenotypes suitable for different environments (Barker 2004; Gluckman et al. 2005b; Denver 
et al. 2006; Gluckman. et al. 2006). While one phenotype may represent an advantage in one 
environment (selects survival/fitness in early life), others may be disadvantageous and carry a 
disease risk (Gluckman et al. 2005a). These developmental trajectories may be programmed 
by an insult acting during “critical windows” of early development through the mechanism of 
“developmental plasticity” or they can be a consequence of the circumstances to which the 
parents or grandparents were exposed (Bateson et al. 2004). Once the organ development is 
completed, the plasticity cannot apply.  
 
During fetal or postnatal development an environmental insult may lead to a so called 
biological “trade off”(Kuzawa 2005; Crespi et al. 2005), which produces an immediate short-
term advantage (survival, growth) at the cost of a future long-term disadvantage (e.g. in 
reproductive health, longevity, disease). 
 
Contrary to the biological trade-off, the “Predictive adaptive response” (PAR; term 
was introduced by Gluckman and Hanson; Gluckman et al. 2005a) does not have any 
immediate effect. It is believed that maternal information (metabolic and endocrine signals) 
allows the developing fetus to sense and evaluate its environment during the plastic period and 
to “predict” and adapt its development to the expected conditions in postnatal life (Gluck et al. 
2005b). This is a natural process, in which phenotypic changes may be mediated via 
epigenetics (changes in gene expression; see Chapter 1.4.2.1; Cassell et al. 2003).  
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The correct assessment of the future environment (“Appropriate PAR”) brings benefit 
to the individual in respect of maximal fitness in adulthood (Gluckman et al. 2005a). 
However, if the selected trajectory is incorrect (failure in maternal signaling or sudden 
changes in future environment; termed “Inappropriate PARs”), the individual may be exposed 
to an increased risk of future disease (Gluckman et al. 2005a; 2007). According to this 
hypothesis, the fetus is able to sense the availability of nutrients in utero and infer the 
postnatal nutrient environment. The fetus adapts (during critical windows of its development) 
to the expected future nutrient supply in a manner that brings it maximal survival and 
reproductive fitness benefit. The programmed changes are irreversible and result with 
permanently altered responses to the nutrient or other stimuli during future life (Srinivasan et 
al. 2003). Therefore, if a mismatch between prediction and reality occurs, the selected 
phenotype will lead to a disease.  
An example of a mismatch between prenatal and postnatal environmental conditions 
may be seen in offspring of the Dutch Hunger Winter study (See Chapter 1.1.2), when 
compared to offspring of the Leningrad Siege study, where the selected developmental 
trajectories led to a “survival phenotype”, as the prediction was correct (Rickard et al. 2000).  
 Mismatches between pre- and postnatal environments are common, particularly in the 
developing world where the environment is changing grossly with industrialisation, 
urbanisation, nutrient availability and climate deviations.  Human life span extends far beyond 
the reproductive years, as many previously deadly diseases are currently treatable. As a 
consequence, the manifestation of chronic diseases is on the increase. The mismatch in 
prediction is of a little significance when life span was short, as the disease manifestation 
could not possibly occur (Gluckman et al. 2006). 
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Intergenerational effect. 
Interaction of genetic and environmental components in the “Predictive adaptive 
response” system includes the intergenerational effect, namely the adaptive response of the 
fetus will reflect experiences (nutrition, life in utero, birthweight, health…) of recent ancestors 
(Cassell, et al.; 2003 Kuzawa 2005). The birthweight of the baby was found related to the 
birthweight of both parents, however only to the height associated with the maternal female 
line (height of the maternal grandmother) and to the maternal grandfather’s social class 
(Emanuel et al. 1992). Thus the growth and development in utero of female ancestors may 
affect the birthweight of the offspring three or more generations later.   
 
On the time scale, the intergenerational effect might be seen as an intermediate kind of 
human adaptive mechanisms similar to plasticity (Kuzawa 2005). However, as it responds 
gradually to environmental changes experienced across generations (carry-over effect), it acts 
more slowly than plasticity (real time response to environment), but much faster than the 
genetic response (non-inducible, driven by the natural selection process; Jablonka et al. 1995).  
 
The intergenerational effect was seen also in the Dutch Hunger Winter study offspring. 
Mothers exposed to famine during their first trimester had offspring with normal birthweight. 
The birthweights of the first-born child correlated with mother’s birthweight. According to the 
research data, babies born in consecutive pregnancies are usually heavier than the first-born 
children (Billewicz et al. 2005). However, in this study, the birthweight of all further offspring 
and the second-generation offspring were decreased (Lumey 1998b). 
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The possible mechanistic links between poor fetal development and adult diseases, 
particularly Type 2 diabetes, have now been described. The following section will provide 
information on the pathophysiology of Type 2 diabetes in order to bring it into context with 
the fetal programming hypothesis.  
 
 
 
1. 2.  DIABETES MELLITUS  
 
1.2.1  Aetiology, pathophysiology, complications and diagnostic criteria for 
Type 2 diabetes mellitus. 
 
1.2.1.1 Aetiology and pathophysiology of Type 2 diabetes 
Type 2 diabetes mellitus is a metabolic disorder characterised by chronic 
hyperglycaemia. It occurs as a result of a combination of insulin deficiency (secretory failure 
of pancreatic β-cells) and insulin resistance (decreased sensitivity or responsiveness) of target 
tissues (WHO 1999). Type 2 diabetes is the predominant form, accounting for 90-95% of all 
diabetics (ADA 2008). 
 
The aetiology of Type 2 diabetes is still unknown, although it is believed, that both  
environmental and genetic factors contribute to the disease.  
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Genetic factors. 
There are genetic differences in susceptibility for Type 2 diabetes (Zimmet et al. 2003; 
see also Chapter 1.1.4 Intergenerational effect). Several studies investigated the first-degree 
relatives of patients with Type 2 DM. Despite the normal glucose results during an oral-
glucose tolerance test, they had several metabolic abnormalities (Eriksson et al. 1989), such as 
hyperinsulinaemia, decreased C-peptide levels and C-peptide to insulin ratios (Humphriss et 
al. 1997). Insulin resistance and impaired insulin secretion were both necessary for the 
development of impaired glucose tolerance in these subjects.  
 
There may be genetic defects of β-cell function (such defects are known in types of 
maturity onset - MODY diabetes (Polonsky 1995; Byrne et al. 1996) or mitochondrial DNA 
defects (ADA 2008)) or genetic defects in insulin action, e.g. mutations of the insulin receptor 
(WHO 1999). However, these mutations are rare and explain only a small percentage of the 
genetic input into Type 2 diabetes. 
 
Recently new loci containing relatively common genetic variants, which are 
significantly associated with Type 2 diabetes risk, were identified by Sladek et al (2007). The 
genes at these loci have a role in the development of the pancreas; they possibly regulate 
insulin secretion and may be involved in many other functions (insulin sensitivity, cell 
proliferation and specialisation). 
 
Age. 
Type 2 diabetes mellitus used to be commonly associated with elderly people. However, 
during the last two decades there has been a decline in age of onset, now being seen in 
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adolescents and more commonly in children (Arslanian et al. 1998; Rosenbloom et al. 1999). 
An association with childhood obesity has been made. For example, in Japanese children Type 
2 diabetes is seven times more common than Type 1 diabetes (Rosenbloom et al.1999) and a 
high prevalence of Type 2 diabetes in children is also found in the United States, Pacific 
Islands, Hong Kong, Australia and the United Kingdom (Zimmet et al. 2001). This creates a 
serious problem with respect to earlier onset of diabetic complications and reduced quality of 
life. 
 
Diseases. 
Diseases of the exocrine pancreas (e.g. pancreatitis, trauma, infection) or different 
endocrinopathies (e.g. acromegaly, hyperthyroidism, Cushing syndrome) may also cause Type 
2 diabetes (ADA 2008).  
 
Lifestyle. 
The prevalence of diabetes increases in parallel with obesity, hypertension and 
cardiovascular disease, the products of the so-called “epidemiological transition” - rapid 
cultural and social development in a form of “fat-rich” or “energy-dense” diet, urbanisation, 
migration, unhealthy sedentary lifestyle and changes in behavioral patterns (Coughlan et al. 
1997). The lowest prevalence of diabetes is found in developing non-industrialised countries, 
where the traditional lifestyle of hunter-gatherers or farmers still exists (Fall 2001). Thus 
sedentary lifestyle, overeating and obesity are high risk factors for Type 2 diabetes. 
According to the National Center for health Statistics in the USA and based on The 
National Health and Nutrition Examination Survey (NCHS), one third of the American adults 
were obese in the year 2005 - 2006 (http://www.cdc.gov/nchs/data/databriefs/db01.pdf).  
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This means that one in three American adults were obese, reaching the prevalence of 
approximately 40% among people 40-59 years old, with similar rates for men and women. The 
highest prevalence of obesity (61%) in the USA was seen among non-Hispanic black women 
aged 60 years and above, compared to 32 % of non-Hispanic white women. The lowest 
contribution towards the national average was found among men aged 20-39 years, from 
whom only 28% were found obese (http://www.cdc.gov/nchs/data/databriefs/db01.pdf).    
 
Obesity represents a high risk for Type 2 diabetes (WHO 1999).  From research 
observations it is known, that the abdominal visceral adipose tissue correlates with insulin 
resistance (Bergman et al. 2001) and decreased insulin secretion (Cruz et al. 2002).  The β-cell 
of a person who is obese, insulin resistant and chronically overnurished, is trying to 
compensate for the high glucose levels by hypersecretion of insulin to maintain euglycaemia. 
Therefore, these subjects’ insulin levels are elevated, while the glucose levels may appear 
normal and person is metabolically healthy. The compensation mechanism involves an 
expansion of the β-cell mass (by proliferation and/or neogenesis) and enhanced insulin 
secretion to various stimuli. However, once the ability to compensate fails, a person progresses 
to Type 2 diabetes via progressive impairment of β-cell function. The changes in the β-cell 
most probably occur in very early stages before the disease manifestation. It has been 
suggested by Prentki et al (2006), that this situation occurs in people with “susceptible” islets 
(e.g. due to programming in utero) while people with “robust” β-cells can maintain the high 
insulin output.  
A number of epidemiological studies investigating the role of low birth weight in 
aetiology of Type 2 diabetes have been performed. Insulin resistance, especially if 
accompanied with obesity in adulthood, was suggested as the mediator of Type 2 diabetes 
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rather than impaired β-cell function e.g. in Uppsala study, (Chapter 1.1.2; Lithell et al. 1996), 
Preston study (Phillips et al. 1994) and Haguenau in France (Jaquet et al. 2000).  
 
1.2.1.2 Assessment of insulin resistance 
Insulin resistance and impaired insulin secretion serve as indicators of the development 
of Type 2 diabetes (DeFronzo et al. 1979). The euglycaemic-hyperinsulinemic clamp is 
considered the gold standard technique for the assessment of insulin sensitivity (DeFronzo et 
al. 1979; Bergman et al 1985). However, this technique is invasive, and involves study 
conditions, which are not completely physiological. This also applies to the frequently 
sampled intravenous glucose tolerance test (FS IVGTT) with minimal model analysis 
(Bergman et al. 1979), although this method is less invasive than the clamp method. 
Frequently, only the fasting glucose, insulin or C-peptide samples are measured or an 
oral glucose tolerance test (OGTT) is performed. The application of these methods is simpler, 
less invasive, and less costly, and therefore more practical especially for larger research 
studies, when compared to the clamp and FS IVGTT methods. From the plasma glucose levels 
and the insulin responses measured during the OGTT insulin resistance (or sensitivity) and β-
cell secretion can be evaluated by means of various indices (Radziuk 2000; Soonthornpun et al 
2003; Muniyappa et al 2008) such as the Insulinogenic index (Seltzer et al. 1967), Insulin 
sensitivity index (ISI; Matsuda et al 1999); AUC Insulin/AUC Glucose (Strumvoll et al. 
2000b), QUCKI (Katz et al. 2000), HOMA index (Matthews et al 1985).  
  
The standard OGTT, originally introduced for the diagnosis of impaired glucose 
tolerance (IGT) and diabetes mellitus by the World Health Organization (WHO), uses 75g of 
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glucose load and the sampling times of fasting (0 minutes) and 120 minutes (WHO Criteria 
2006). In many clinical and research studies, the duration of the OGTT is extended beyond 2 
hours and/or additional sampling times are included, according to the purpose of the test. 
Commonly, the blood samples are collected at fasting (0 min), 30, 60, (90) and 120 minutes 
(Matsuda et al 1999; Strumvoll et al 2000a; Yasuhara et al 2003; Pontiroli et al 2004; Keskin 
et al 2005).  
 
 
HOMA INDEX:  
 
The Homeostasis model assessment (HOMA) is a computer-generated model for the 
assessment of insulin resistance (HOMA-IR) or of pancreatic ß-cell function (HOMA-ß; 
Matthews et al. 1985). 
The HOMA method has shown that both increased insulin resistance and decreased ß-
cell secretory function are associated with Type 2 diabetes (Haffner et al 1997). However, as 
the HOMA-ß model extrapolates from fasting steady state data to the assessment of dynamic 
ß-cell secretary function, the evaluation of insulin resistance from HOMA-IR is preferred by 
the majority of studies (Muniyappa et al. 2008). 
The HOMA-IR index (and its logarithmic and reciprocal forms) correlate with the 
clamp technique in many studies (Bonora et al 2000; Yokoyama et al 2003; Wallace et al 
2004; Chen et al 2005 and others) and in combination with its simple and less invasive 
application and lower costs it is considered a valid and effective method for the assessment of 
insulin resistance/sensitivity in both Type 2 diabetic and non-diabetic subjects. The HOMA-IR 
index was also previously applied for the assessment of insulin resistance in pregnant women 
(Moses et al 2006; Parretti et al 2006; Ozcimen et al. 2008; Retnakaran et al 2008) and 
children (Arslanian 1998; Arslanian et al 1998). An agreement between HOMA-IR and 
 38 
glucose clamp derived values was demonstrated in a South African Black urban population 
(Ntyintyane et al. 2010) and the HOMA-IR index was also used in other South African studies 
involving urban Black men and women (Ferris et al 2005; Crowther et al 2006) and Black 
pregnant rural women (Mamabolo et al 2007). 
 
1.2.1.3. Long-term complications of Type 2 diabetes  
Long-term complications of diabetes include microvascular damage (neuropathy, 
nephropathy, retinopathy) and macrovascular complications (coronary artery and peripheral 
vascular disease, stroke), leading to renal failure, blindness, foot ulcers and amputations 
associated with diasability and reduced life expectancy (ADA 2008).  
 
1.2.1.4 The diagnosis of diabetes mellitus  
In respect to the fundamental feature being hyperglycaemia, the diagnosis of diabetes 
mellitus is based on blood glucose levels. 
According to the World Health Organization (WHO 2006) Criteria the diagnosis of 
diabetes depends on fasting and postprandial glucose levels as follows: 
Fasting level of plasma venous glucose ≥7.0 mmol/l  
or 2h post glucose load* ≥ 11.1 mmol/l or both. 
 
*A glucose load represents 75 g of anhydrous glucose dissolved in water, which is applied in a standard oral 
glucose tolerance test, OGTT, after an 8 hour fast.  
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The American Diabetes Association (ADA 2009) uses three ways to diagnose diabetes 
mellitus: fasting or 2-h plasma post glucose load levels as described by the WHO criteria or 
symptoms of hyperglycaemia and the causal plasma glucose >11.1mmol/l.   
 
 
1.2.2  Epidemiology of diabetes mellitus and costs to society.    
Diabetes is a chronic disease and one of the most common non-communicable diseases 
and is a leading cause of morbidity and premature mortality. It has been declared as a world 
pandemic, affecting 246 million (6%) people in 2007 in the developed and developing 
countries. The numbers are expected to rise to 380 million (7.3%) in 2025, which means that 1 
out of 14 adults will be affected with diabetes. Diabetes is among the first five leading causes 
of death in most developed countries (3.8 million deaths per year world-wide), which makes it 
comparable to the magnitude of death due to HIV/AIDS (http://www.diabetesatlas.org; 3rd 
edition). It has been observed that 80% of deaths in Type 2 diabetic subjects are due to 
cardiovascular complications (Zimmet et al. 2003).  
 
The estimated prevalence rates of diabetes among adult people by region predicted for 
the year 2030 (http://www.diabetesatlas.org, 4th edition) are as follows: 
1. North America and Caribbean (12.1%) 
2. Middle East and North Africa (10.8%) 
3. South-East Asia (9.1%) 
4. Europe (8.1%) 
5. South and Central America (7. 8%) 
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6. Western Pacific (5.7%) 
7. Africa (with the lowest prediction of nearly 4.7%)  
(Presented with the permission of the International Diabetes Federation.)  
 
Although at present the non-industrial African Region accounts for the lowest 
prevalence of diabetes (3.8% assessed for the year 2010), the highest increase in the number of 
people with diabetes in this Region within the next 20 years (98.1%) is expected   
(http://www.diabetesatlas.org, 4th edition, Table No 3.1). Also for other countries undergoing 
rapid industrialisation and urbanisation, such as the Middle East and South America, the 
predicted rise in prevalence of Type 2 diabetes is high. On the other hand, the lowest increase 
of 20% for the same time period is forecast for the European Region, where programmes for 
the prevention, early identification and treatment of diabetes were formulated and 
implemented on national and international levels. These strategies are summarised in the Saint 
Vincent Declaration, a document formulated by the European health experts together with the 
WHO and the IDF organisations in Italy, 1989 (www.ncbi.nlm.nih.gov/pubmed/11918624; 
www.idf.org;) 
 
Costs to society 
Chronic diseases mean a lifetime cost to the individual and to the health care system. 
More than 80% of present diabetics live in low- and middle- income countries and the 
treatment is either not affordable to many of them or they receive care below optimal level 
(Fall 2001). As a consequence, these people have a higher prevalence of diabetic 
complications and face a more rapid progression to end-stage renal disease than diabetics in 
developed countries. In the US the total estimated costs of diabetes were $ 174 billion in the 
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year 2007, which includes medical expenditures and reduced national productivity (ADA 
2008).  
 
 
1.2.3 Diabetes in South Africa. 
Nearly 80 % of the 40.5-million South African residents are represented by Black 
South Africans (Motala et al. 2008). The majority of this population lives in rural areas, 
although increasing numbers are migrating to cities seeking a better quality of life and job 
opportunity (Levitt 1996). Historically, in rural areas where the traditional lifestyle still 
prevails, diabetes mellitus is almost non-existant (Bourne et al. 2002).  
 
Significant disparity still exists in South Africa, with the result that there is an obvious 
unequal distribution of wealth and opportunities between developed and developing areas. The 
lifestyle in the urban areas has changed dramatically and primarily, because of increasing 
obesity, the urban areas have higher prevalence rates for diabetes mellitus than rural areas 
(Bradshaw et al. 2007; Motala et al. 2008). The highest prevalence of diabetes was found in 
Asian Indians, followed by Coloured, urban Black African and White groups (Mollentze et al. 
2005; Bradshaw et al. 2007). Among the Black African population, the highest prevalence for 
diabetes of 8% was found in an urban area near Cape Town. Obesity and the pattern of fat 
distribution were identified as independent risk factors (Levitt et al. 1993). In Durban (Omar et 
al. 1993) the diabetes prevalence rate in the Zulu ethnic group was shown to be 5.3 % (age and 
sex adjusted), being twice as more common in women than men (Bradshaw et al. 2007). A 
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cross-sectional survey (Motala et al. 2008) of a rural northern KwaZulu-Natal revealed a 
crude overall prevalence of diabetes of 4.6%, which was similar for both men and women.  
 
Diabetes mellitus was responsible on average for 4.3% (22 412 cases) of all deaths in 
South Africa in year 2000, which represented the 7th commonest cause of death in the country 
(Bradshaw et al. 2007). Obesity and the pattern of fat distribution were the highest risk factors 
for Type 2 diabetes, next to age and urbanization (Levitt 1996; Motala et al. 2008).  
 
 
1.2.4 Gestational diabetes mellitus.  
 
Gestational diabetes mellitus (GDM) is a common metabolic disorder during 
pregnancy. The GDM prevalence varies among different populations (in a range of 1-14%) 
and it is in direct proportion to the prevalence of Type 2 diabetes in particular 
population/ethnic groups (Perucchini et al. 1999). GDM is defined as carbohydrate 
intolerance causing hyperglycaemia in pregnant women with onset during pregnancy (WHO 
1999; Ben-Haroush et al. 2004).  
Risk factors that may warn to the development or presence of GDM within the current 
pregnancy include history of glucose intolerance or large-for-gestational age babies within a 
previous pregnancy, an obviously large baby at current pregnancy, high-risk ethnic groups or 
high glucose levels (WHO 1999) and obesity (Ben-Haroush et al. 2004). 
 
GDM diagnosed in early pregnancy is associated with increased number of obstetric 
complications, recurrent GDM in next pregnancy and future development of metabolic 
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syndrome and Type 2 diabetes (Ben-Haroush et al. 2004; Vohr et al. 2008). The offspring of 
women with GDM are more likely to develop metabolic syndrome later in life.  This seems to 
be related to maternal glycaemia in the third trimester, maternal obesity, neonatal macrosomia 
and childhood obesity (Vohr et al. 2008). Pregnant women diagnosed with GDM should be re-
tested 6 weeks after delivery and re-classified as being diabetic, having impaired glucose 
tolerance (IGT) or normal glucose levels (Peruccini et al. 1999). 
 
Normal pregnancy is associated with progressive insulin resistance that may reach 
levels of Type 2 non-pregnant diabetics during the last trimester (Dunne 1999; Buchanan 
2001). Increasing maternal weight, increased secretion of steroids, secretion of insulin and 
increased secretion in growth hormone all make pregnancy “diabetogenic”. Insulin resistance 
may vary significantly among pregnant women and the reduction in insulin sensitivity is 
linked to increasing requirements for placental glucose transport and supply to the fetus 
(Dunne 1999; Jansson et al. 2001). Women with a history of GDM showed a higher degree of 
insulin resistance in comparison to non-pregnant women without a history of GDM (Buchanan 
2001). 
 
Gestational diabetes mellitus can lead to fetal overgrowth and large-for-gestational-age 
newborns, more commonly known as macrosomia. This condition may be associated with 
complications during delivery and with neonatal hypoglycaemia. In addition, the mother has 
an elevated risk for pregnancy-induced hypertension (Jansson et al. 2001). 
 
 
It can therefore be seen that the aetiology of Type 2 diabetes involves both insulin 
resistance and ß-cell secretory failure. Many studies have now shown that low birth weight is 
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associated with insulin resistance in adulthood but some studies have also shown reduced islet 
cell mass and poor ß-cell function in low-birthweight subjects (Crowther et al. 2000). 
 
The next section of this report will therefore describe the developmental pathways for 
islet ß-cells in the fetal pancreas. 
 
 
 
1.2.5   Endocrine pancreas and pancreatic β-cells.  
Poor early development of the islets of Langerhans and β-cells has been suggested as  
a major factor in the aetiology of Type 2 diabetes mellitus (Hales et al. 1992, Swenne 1992). 
 
1.2.5.1 Development of the pancreatic endocrine cells. 
Human pancreatic endocrine cells can be detected already at about 8 gestational weeks 
(Clark et al. 1983; Piper et al. 2004). Mature islets of Langerhans consist of four distinct cell 
types with exact topography within the islet and within the pancreas. The β-cells (producing 
insulin) are found in the central core of the islet surrounded by δ-cells (secreting somatostatin) 
and α- or PP cells in the periphery (Vinik et al. 1997). Islets with a high population of α-cells 
(secreting glucagon) are found in the body and tail of pancreas, while islets with a high 
population of PP cells (producing pancreatic polypeptide) are located in the head of the 
pancreas (Bonner-Weir 1990). Recently discovered glucagon secreting endocrine ε- cells are 
still poorly understood (Prado et al. 2004; Andralojc et al. 2009). The islets of Langerhans 
represent 2-4% of the total pancreatic mass at birth, decreasing to 1% in adulthood. The β-
cells account for the largest proportion (60-80%) of all islet cells. The development and 
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function of islet cells is regulated by expressions of specific genes further controlled by 
transcription factors (Reusens et al. 2006). 
 
Each islet is highly vascularised (Bonner-Weir 1990) starting from 14 weeks post- 
conception (Piper et al. 2004) with greater blood flow directed to the islets (10-15 %) than to 
the pancreas as a whole (Hales et al. 1992). The human β-cell can produce insulin from 
between seven and eight weeks in utero (Scharfmann et al. 2008), however, its secretion in 
response to glucose is absent until about 28 gestational weeks (Nicolaides et al. 1989; see 
Chapter 1.2.5.7).  
 
1.2.5.2 Regulation of β-cell mass 
The β-cell mass can change by increasing or decreasing cell volume and/or cell 
number in order to maintain euglycaemia (Bonner-Weir 1994). The islet mass increases by 
neogenesis, enlargement and replication of existing cells (Bonner-Weir 1990) with cell 
atrophy and apoptosis contributing to the islet mass decrease (Vinik et al. 1997). 
 
The pancreatic β-cell mass increases rapidly from about week 20 (Bouwens et al. 2005) 
of fetal life until about the fifth postnatal month (Wilkin 1993; Khan et al. 1994). It 
approximately doubles from the neonatal to the infant period (Rahier et al. 1981) reaching at 
least half the adult complement at the age of 1 year (Hales et al. 1992). The β-cell 
proliferation during the fetal period correlates with gestational age and from weeks 17-32 
decreases until about 6 month postnatally.  
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Apoptosis shows a different pattern from proliferation; in the early fetal period and 
after 6 months of age it is rare. However, there is a “wave” of β-cell apoptosis in the human 
fetus occurring during the perinatal period (2 months before and after delivery; Kassem et al. 
2000). In the rat fetus, the wave of islet-cell “developmental” apoptosis occurs between day 12 
– 17 after birth (Petrik et al. 1999), during which many original fetal phenotypes of β-cells are 
replaced in the following “wave” of neogenesis (Hill et al. 2000). The mechanism regulating 
the apoptosis is still unclear.  
 
In human adults and other mammals, the β-cell mass has some but limited flexibility, 
provided by the balance between cell regeneration and cell apoptosis or decreased replication 
rate. This ensures an appropriate production of insulin for maintaining euglycaemia in 
conditions such as pregnancy (see below) or obesity. If this balance becomes disturbed, 
impairment in glucose homeostasis may follow (Bernard et al 1999). 
 
 
1.2.5.3 Maternal islet adaptation during pregnancy 
 
During pregnancy, the maternal β-cells undergo changes in order to cope with the 
increased metabolic demands of the fetus (Swenne 1992). These changes include increased β-
cell proliferation, increased insulin synthesis and glucose-stimulated insulin release at a lower 
threshold. Lowering the threshold for insulin secretion allows the release of larger amounts of 
insulin at normal blood glucose concentrations (Sorenson et al. 1997). Inadequate 
compensation may result in gestational diabetes (Bouwens et al. 2005). 
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1.2.5.4 Effect of nutrition. 
Nutrition plays the major role in the growth of pancreatic β-cells (Wilkin 1993).  
Prenatal undernutrition causes impairment of fetal β-cell growth and results in glucose 
intolerance (Seckl 2004). Infants who are small for gestational age show selectively reduced β-
cell mass in comparison with other types of islet cells (Petrik et al. 1999; Hay Jr 2006a). 
Amino acids are the major factors controlling β-cell growth and development and promote 
insulin secretion in fetal pancreas until late fetal life (De Gasparo et al. 1978; Cetin et al. 
1988).  
 
A low protein diet changes the balance between β-cell replication and apoptosis (Petrik 
et al 1999). Rats fed a low protein diet during gestation had growth retarded offspring with 
reduced β-cell mass (volume) at birth and permanently impaired insulin response to glucose. 
Reduced pancreatic expression of IGF-2 (islet survival factor; see above) was associated with 
the lower β-cell proliferation rate and increased apoptosis in the fetus and neonate (Petrik et 
al. 1999). Contrary to this, maternal total caloric restriction during pregnancy affected 
neogenesis but preserved β-cell proliferation rate (Bertin et al. 1999). Again in adult rat, pre- 
and postnatal low protein diet decreased pancreatic islet blood flow and insulin release. Low 
blood flow values may reflect an adaptive physiological response, an impaired pancreatic 
vasculogenesis or dysfunction of endothelial cells (Iglesias-Barreira et al. 1996).  
 
Overnutrition during pregnancy, and also maternal diabetes, leads to β-cell hyperplasia 
in the rat fetus (Armitage et al. 2005). An increased exposure of pregnant rats to dietary fat, 
irrespective of total calorie intake, resulted in hyperglycaemia and hyperinsulinaemia in the 
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adult offspring (Martin-Gronert et al. 2006). This condition led to β-cell exhaustion, 
associated with decreased insulin sensitivity and decreased insulin secretory capacity 
(Armitage et al.  2005).  
 
1.2.5.5 Effect of glucose. 
In experiments with adult non-pregnant rats, glucose infusion for 24 h nearly doubled 
the β-cell numbers. This effect was reversed later after glucose withdrawal and was associated 
with increased beta cell apoptosis (Bouwens et al. 2005). Also in rats, high maternal blood 
glucose levels (as in maternal diabetes) in pregnancy cause hyperplasia of beta cells in the 
neonate (Wilkin 1993; Bonner-Weir et al. 1994) and glucose intolerance in the offspring 
(Srinivasan et al. 2003). Further, a high carbohydrate milk formula administered to rat pups 
during suckling period, which is the critical period of pancreatic development in rats, leads to 
adaptive changes in islet function and results in a life long hyperinsulinaemia in these 
offspring (Srinivasan et al. 2003).  
 
1.2.5.6 Effect of hormones. 
The pregnancy upregulation of β-cell mass is possibly directly mediated by the 
placental hormones lactogen and prolactin (Brelje et al. 1993; Sorenson et al. 1997). Placental 
lactogen, prolactin, growth hormone and various growth factors (see below) stimulate directly 
the β-cell proliferation (Bouwens et al. 2005) in islet cultures in a dose dependent manner 
(Billestrup et al. 1991). This includes insulin-like growth factor 1 (IGF-1), platelet-derived 
growth factor, epidermal growth factor and others. Placental lactogen seems to be the principal 
hormone responsible for this regulation (Brelje et al. 1993; Bonner-Weir et al. 1994).  
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The timing of apoptosis is regulated by insulin-like growth factor 2 (IGF-2), which acts 
as a pancreatic islet survival factor by reducing the apoptosis, as was demonstrated on isolated 
islets from 5-day old rats (Petrik et al 1998; Petrik et al. 1999; Bouwens et al.2005). On the 
other hand, hyperinsulinism during infancy is associated with constantly elevated β-cell 
proliferation and apoptosis (Kassem et al. 2000). Maternal gestational food restriction caused 
fetal growth retardation and a long-lasting decrease in rat fetal β-cell mass, associated with 
development of glucose intolerance in adult rats. The reduction in fetal β-cell mass was caused 
by an elevation in glucocorticoid concentration as a response to maternal undernutrition 
(Gesina et al. 2006). Glucocorticoids can inhibit insulin release and β-cell replication, acting 
through the glucocorticoid receptors in pancreatic islets. Normally, glycaemic stimulation 
supersedes this effect. However, steroids in an excessive amount may override the limited 
compensatory potential (growth and insulin production) of the β-cells, causing development of 
diabetes (Swenne1992, Dodic et al.1999).  
 
1.2.5.7 Fetal insulin. 
Fetal insulin production starts early in fetal life (Scharfmann et al. 2008), reaching a 
plateau in mid gestation (Fowden et al. 2004). Insulin has major fetal growth-promoting 
effects, which may be mediated in many ways. It can increase the rate of transfer of nutrients 
including amino acids into cells, promote protein synthesis and inhibit the effects of catabolic 
hormones (Milner1989) and any abnormalities in fetal insulin secretion disturb fetal growth 
(Fowden 1992).  
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Fetal plasma insulin concentrations correlate with maternal hormone level 
(Milner1989), although maternal insulin does not cross the placental membrane (Kalhan et al. 
1975).  Fetus increases insulin production in response to maternal hyperglycaemia, stimulating 
its growth (Murphy et al. 2006). Insulin effects on fetal growth were confirmed in gene knock-
out animal models and also in humans with mutation in genes related to insulin action, such as 
the insulin receptor and glucokinase, resulting in lower birth weight and size (Ong et al.  
2004).   
 
 
Studies have shown that β-cell function in adults is related to birthweight and other 
birth parameters. Therefore it is important to understand the basis of human fetal development.  
The following section of this report will cover this field. 
 
 
 
1.3 THE STAGES AND THE “CRITICAL PERIODS” IN THE 
HUMAN GROWTH AND DEVELOPMENT. 
As described in Chapter 1.1, the process of programming occurs at critical periods of 
prenatal and early postnatal development. However, as various organs and structures develop 
during different periods, the timing of programming extends over several stages of human 
development. In this Chapter, some of the human developmental stages with respect to their 
critical periods will be reviewed, with major focus on the embryonic and fetal periods. 
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1.3.1 Maternal adaptations to pregnancy 
Pregnancy is associated with adaptive changes in maternal organ systems and 
functions in order to accommodate the increasing demands of developing fetus, placenta and 
uterus. The metabolic changes are mainly related to the production of polypeptide and steroid 
hormones by the feto-placental unit (Picciano 2003) and begin early in pregnancy.  
 
From about week 6 of gestation there is an expansion in plasma volume reaching a 
maximum around 32-34 weeks (Ciliberto et al. 1998).   The plasma volume expansion has an 
influence on uterine blood flow (Fall 2003a). An insufficient volume expansion may lead to 
pre-eclampsia, IUGR, premature labour or oligohydramnios (El-Haddad et al. 2006).  
Cardiac output increases due to increases in stroke volume and heart rate. The red 
blood cell mass rises, but to a lesser extent than the plasma volume. This leads to 
haemodilution and a relative physiological anaemia with normal haemoglobin levels at term  
(Ciliberto et al. 1998; Picciano 2003). Haemoglobin concentration below 10g/dl is usually 
associated with iron deficiency (Hoque et al. 2009), although definition of anaemia in 
pregnancy is said to be present when haemoglobin level is below 11g/dl (Rastogi et al 2002; 
Milman 2008). 
 
 
1.3.2 Embryonic and fetal development  
1.3.2.1 Introduction. 
The first eight weeks (56 days) of human life after fertilisation are known as the 
embryonic period (See Figure 1.9). The conceptus, placenta and the majority of organs and 
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body structures undergo a rapid cell growth, cell divisions and differentiations during their 
establishment (Moore 1993a; See Figure1.10). During this period the embryo is highly 
vulnerable. The term embryo is used from the second gestational week, when the bilaminar 
embryonic disc is formed (Moore 1993a).  
 
The fetal period extends from the ninth gestational week post fertilisation until birth 
(See Figure 1.9). Organs and structures established during the embryonic life develop further, 
increase in size and mature.  The periods of rapid growth are also critical for further 
development, as the organs and tissues are sensitive to external insults.  
 
During the third to fifth month post fertilization, the fetus is characterized by growth in 
length and increasing calcification. During the last two months of pregnancy fetus gains 
weight rapidly due to fat deposition (Luke 1994; Sadler 2000b). At 36 weeks the head 
circumference (HC) and the abdominal circumference (AC) are approximately equal. After 
this, the AC may be greater than that the HC. The male fetus is known to grow faster than the 
female and weighs more at birth (Moore 1993b). 
 
Early fetal growth is rather slow, followed by accelerated growth between 16-17 to 26-
27 weeks (about 85g per week). It reaches maximum growth between 26-27 to 37-38 weeks 
(about 200g/week) and finally, at the end of the gestation it decreases, with fetus gaining about 
70g per week (Neumann et al. 1984). The median growth rate of a singleton pregnancy is 
about 250g/week at 33 gestational weeks (Luke 1994). 
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Fig. 1.9   Scheme of time periods and events during gestation with incorporated timing for the “Pregnancy, Nutrition & Diabetes” 
(PND) study visits. (Drawing based on O’Rahilly et al. 2001a, Figure 8.1.)
Size: 90 days, size 90 mm 250mm, 1000g
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First Trimester Second Trimester Third Trimester
-2 0 ….12 ....24 36 ….38 40 weeks
...266 days
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PND - V1 PND - V2
0 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 …. 40 42 weeks
...280 days
Embryonic period Fetal period
0 3 8 26 ….38 40 weeks
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Chances of survival when born premature:
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May survive with intensive care
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1.3.2.2 Early development 
After fertilisation of the ovum, a rapid cell division gives rise to the zygote, then the 
morula and then the blastocyst. This period is often referred as to the pre-implantation stages 
of the embryo. Already at the 2-8 -cell stage, human embryonic gene transcription is activated 
(O’Rahilly 2001b).  
 
The blastocyst stage represents a spherical structure of approximately 16-32 cells (day 
4 post fertilisation) with a cavity inside (O’Rahilly 2001b) and differentiated outer and inner 
cell layers (Lewis et al. 1990d; http://embryology.med.unsw.edu.au). The inner cell mass 
consists of two layers forming together the embryonic disc – bilaminar embryo (Week2). The 
placenta and the placental membranes originate from the outer layer, termed the trophoblast 
(Kliman 1998; http://embryology.med.unsw.edu.au). The cavity within the blastocyst later 
develops into the extraembryonic cavities – chorionic, amniotic and yolk sac (Lewis et al. 
1990d).  
At approximately 3 to 4 weeks (p.f.) the bilaminar embryonic disc becomes trilaminar. 
From the three germ layers, ectoderm, mesoderm and endoderm, organs begin to form (See 
Fig. 1.10; Sadler 2000a). 
 
The development of placenta. 
The early placentation is stimulated by the blastocyst implantation process. The 
blastocyst attaches through the outer trophopoblastic cells to the uterine lining (uterine 
endometrial epithelium) at approximately day 6 p.f. (Moore 1993a).  
 55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.10  Embryonic period and the Carnegie developmental stages.  
(Diagram based on that of Moore 1993d and O’Rahilly et al. 2001a) 
 
14 21 28 35 42 49 56 Days (p.fert.)
MORPHOGENESIS and ORGANOGENESIS
EMBRYONIC PERIOD
2 3 4 5 6 7 8 Weeks (p.fert.)
Chorionic villi, amn. cavity Pancreas (dorsal)
(Stage 6) (Stage 12)
Formation of CNS (neural folds) Rounding of head
(Stage 8, 10, …) (peak 10-18 weeks - 250000cell/min produced) (Stage 23)
facial form completed
Somites Rapid development of brain (nose ,ears, eye lids; fingers, toes)
(Stage 9) (Stage 15)
Primitive heart and CVS
(Stage 8)
Circulatory system
Angiogenesis (Stage 12)
(Angioblasts)
Upper limb buds Trunk elongation
(Stage 12, …18) (Stage 19)
Growth in length
Liver (hepatic plate)
(Stage 10)
Blood formation in embryo
Basics for the bone formation Ossification
By 5 weeks (Stage 18)
Development of kidney (mesonephrones,…)
(Stage 11) Nephrogenesis is completed before birth.
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The trophoblast rapidly differentiatiates into two cell layers – the syncitiotrophoblast 
(outer layer) and the cytotrophoblast (inner layer), surrounding the implanted blastocyst (9-10 
days p.f.) (O’Rahilly et al. 2001c). 
 
The maternal endometrium contains active glands and spiral arteries (Sadler 2000a; 
see Figure 1.11). The endometrium is transformed into decidua. Maternal decidual cells 
contain nutrients (glycogen and lipids; see Chapter 1.3.2.4) and start secreting various 
hormones and factors, such as prolactin, insulin-like growth factor binding protein-1, tissue 
factor, interleukin-15, and vascular endothelial growth factor (Sadler 2000a; Gude et al. 
2004). 
The process of decidualisation is regulated by the hormones progesterone (secreted by 
the corpus luteum), human chorionic gonadotrophin (HCG; secreted by the 
syncitiotrophoblast), human chorionic somatomammotrophin, human placental lactogen 
(HPL; promoting growth) and steroid hormones. These hormones are involved in the 
nourishment of endometrium and preservation of the corpus luteum, until the placenta is ready 
to maintain the secretory function (O’Rahilly et al. 2001c; 
http://www.embryology.ch/indexen.html;). Within the syncytiotrophoblast layer special 
cavities known as lacunae are created, which later fuse into intervillous spaces and fill with 
maternal blood (http://www.embryology.ch/indexen.html). During the first trimester, before 
the blood flow is established, the intervillous spaces most likely contain acellular fluid 
(O’Rahilly 2001d; Burton et al. 2002).  
 
The chorionic villi develop from the trophoblastic sprouts (“finger-like” projections), 
which are created when the trophoblast invades the maternal decidua. There are three basic 
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stages of villi development, being repeated in cycles until delivery. The primary villi are the 
trophoblastic sprouts composed of the sincitiotrophoblast in the outer and cytotrophoblast in 
the inner layer. In the next development, the primary villi are invaded by the extra-embryonic 
mesenchyme (as the villous core), and further by the fetal capillaries (vascularisation of the 
villi). These developmental stages are known as the secondary and tertiary villi (Castelluci et 
al. 2000). The villi further branch, increasing thus the mass and the surface of the placenta, 
and specialise (Castelluci et al. 1990).  
 
In mature placenta, the chorionic villi represent the essential functional unit, where an 
exchange of nutrients, gases and waste products between the mother and the fetus takes place 
(see Figure 1.11). The layers of sincitiotrophoblast, cytotrophoblast, connective tissue and the 
fetal capillary endothelium create the placental “membrane”, also known as the placental 
“barrier”, preventing maternal and fetal blood from mixing. The sincitiotrophoblast (outer) 
layer is directly in contact with maternal blood in intervillous spaces (Castelluci et al. 2000). 
Poor vascularisation and other abnormalities in villi formation or function are associated with 
reversed end-of diastolic flow in umbilical artery velocity waveform (Divon et al. 2002; see 
Chapter 2.5.2.2).  
The composition of the placental membrane changes over time. At the end of the first 
trimester the villous cytotrophoblastic layer slowly disappears and the membrane becomes 
thinner, providing a shorter diffusional distance (Lewis et al. 1990d). 
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Fig. 1.11 The structure of mature placenta.  
(Source: Sood et al. 2006; freely obtainable via PNAS open access) 
 
 
1.3.2.3 Trophoblast invasion and establishment of the utero-placental circulation.   
At the beginning (5-10 gestational weeks), the extravillous trophoblast invades into the 
decidua and forms temporary plugs in the maternal arteries. This causes an obstruction to the 
blood flow into the intervillous space, creating a low-oxygen environment (Kingdom et al. 
1999; James et al 2006). The trophoblast plugs are released at about 12 weeks of gestation, 
when narrow uteroplacental spiral arteries are transformed into “funnel-shaped deltas” (Lewis 
et al. 1990d; Jaffe et al. 1997). As a consequence, the continuous utero- placental circulation 
is established and expands to the rest of the placenta (Jauniaux et al. 2003).  
Oxygenated maternal blood carrying nutrients passes from the endometrial spiral 
arteries into intervillous spaces, where it partially mixes with deoxygenated (venous) blood. 
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Nutrients, oxygen and other substances cross the placental membrane into the chorionic villi 
capillaries and through the umbilical vein are delivered to the fetus (Gude et al.  2004).  
Deoxygenated fetal blood is carried from the fetus through umbilical arteries into 
capillaries of the chorionic villi branches where it reaches placental membrane and fetal waste 
products are passed to the maternal side. Maternal blood leaves the intervillous spaces by the 
uterine (endometrial) veins (Lewis et al. 1990d; http://www.embryology.ch/indexen.html).  
 
The trophoblast invasion is regulated by specific factors. These include the vascular 
endothelial growth factor (potent stimulator of sprouting angiogenesis) and its receptors and 
insulin-like growth-factor 2 (IGF-2; Myatt et al. 2006). Also the insulin-like growth factor 
binding protein 1 (IGF-BP1), which is produced by maternal decidua, may inhibit the 
trophoblast invasion, if present in excessive concentration (Krampl et al 2002). 
 As mentioned earlier, the first trimester development occurs in a low oxygen 
environment. This arrangement is important for organogenesis (Myatt et al. 2006), as it 
protects embryo/fetus from oxygen free radicals and also stimulates the extravillous 
trophoblast outgrowth (Burton et al. 2002; James et al. 2006). Hypoxia also promotes 
angiogenesis and up-regulates vascular endothelial growth factor expression and 
downregulates placental growth factor (PIGF) (Khaliq et al. 1999; Kingdom et al. 1999 and 
2000). The release of trophoblastic plugs is associated with a sudden increase in oxygen 
tension, meaning an oxidative stress (Jauniaux et al. 2000 and 2002; Burton et al 2001). It 
may have a role in the stimulation of normal placental differentiation. However, where the 
antioxidant defence is poor, it may represent a pathological condition (Jauniaux et al. 2000). 
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1.3.2.4 Early nutriton. 
During the first trimester, due to a low oxygen environment, the early metabolism is 
anaerobic and histotrophic (Burton et al. 2001; Jauniaux et al. 2003). It is based on uterine 
glandular secretions containing maternal plasma proteins, glycogen and other molecules that 
are delivered to the intervillous space (Burton et al. 2002). These nutrients (proteins in the 
form of amino acids) are transported by diffusion across the placental membrane to the 
exocoelomic cavity and the yolk sac (Wild et al. 1999; Jauniaux et al. 2003). Some proteins 
are synthesized by the yolk sac (Wild et al. 1999).  
 
The embryo prefers pyruvate and lactate during the cleavage stage, and glucose during 
blastocyst formation and the early post-implantation stages for energy substrates (Leese et al. 
1999; Burton et al. 2002). Amino acids are also utilised for energy production, and they 
stimulate blastocyst formation and are involved in a variety of other functions, such as control 
of pH and signal transduction, besides their main role in protein synthesis (Fleming 2006). 
 
With establishment of the placental circulation (9-12 weeks p.f.), the nutrition becomes 
haemotrophic, delivered from the mother across the placental barrier (Burton et al. 2001). 
 
1.3.2.5 Growth factors and blastocyst development. 
Based on animal models and in vitro experiments, it was concluded that the pre-
implantation embryo may be regulated by insulin and IGF-1 supplied from the mother and 
IGF-2 originating from the embryo itself. IGF-1 is known to have a stimulatory effect on 
development of human pre-implantation embryos in vitro (Wild et al. 1999). 
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1.4  DETERMINANTS OF FETAL GROWTH AND FETAL 
PROGRAMMING.  
 
With the establishment of the relationship between birth outcomes and diseases in 
adulthood (See Chapter 1.1), the research interest concentrated on fetal development/growth 
and factors leading to programming effects. However, especially in human trials, it may be 
complicated or even impossible to directly investigate such factors and their role in fetal 
programming. Therefore many pioneering studies used animal or in vitro experiments. The 
simplest indirect approach to evaluate effects in utero was to monitor birth outcomes.  
 
1.4.1 Assessment of birth outcomes. 
The size at birth reflects the length of gestation and the fetal growth rate (Thame et al. 
2004; Kramer 2003), and they serve as indicators of future disease risk. In epidemiological 
studies of the assessment of pregnancy outcome, birth weight was the commonest measure 
used, as it was routinely recorded in many hospitals and health centers (see Chapter 1.1). It is 
considered to be the single most important determinant of neonatal morbidity and mortality 
(Kramer 1987). However, the birth weight only approximately reflects the environment and 
growth in utero, due to a number of other factors influencing fetal development (Ounsted et al. 
1985). A better assessment of fetal growth is provided by the ultrasound technique, which 
enables a direct evaluation of the size from fetal biometric measurements (see Chapter 
2.5.2.2). Growth charts have also been constructed to assess and monitor fetal growth (Reece 
1993; Maršál et al. 1996; van Bogaert 1999; Mamelle et al. 2001).  
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According to birth weight neonates can be allocated into following categories: 
LBW (low birth weight) – weight below 2500g irrespective of gestational age (term or pre-
term babies) (WHO Criteria; http://www.who.int/whosis/indicators/2007LBW/en/print.html)  
VLBW (very low birth weight) – below 1500g 
Extremely low BW – below 1000g. 
 
Low birth weight is a consequence of a shorter duration of gestation or it is due to a 
slow rate of fetal growth (Kramer 2003), therefore such babies can be both, born preterm or at 
term. The preterm (premature) babies are born before 37 completed gestational weeks (see 
Fig. 1.9). About one third of premature babies with a birth weight of 2500 g or less are in fact 
small for gestational age babies (Neumann et al. 1984).  
 
According to the birth size, neonates can be appropriate (AGA), large (LGA) or small 
(SGA) for gestational age:  
AGA is a baby of a size within 2 standard deviations (SD) of the mean populational 
weight for a particular gestational age (Persson 1989). In practice a range between 10th and 
90th percentiles is used instead.   
 
LGA indicates a baby of a birthweight exceeding the upper border of the range for the 
AGA infant. Conventionally, for obstetric reasons, LGA baby is one whose birthweight is 
equal or greater than 4000g. High maternal BMI, excessive pregnancy weight gain and 
maternal diabetes are the main reasons for fetal macrosomia (Brudenell 1989). 
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SGA indicates size below a defined reference range for the AGA infant. Commonly 
babies born below 2 500 g are considered as SGA (Wigglesworth 1989). An expert committee 
in Manchester 2006 (Clayton et al 2007) set up recommendations for definition of SGA 
neonates, that uses a cut-off level at 2 standard deviations (SD) below the mean for the weight 
and/or length. Identification of the SGA baby can be done only after excluding the 
involvement of any pathological process (see IUGR; Peleg et al. 1998). SGA neonates have 
low lean mass and often central adiposity. Rapid weight gain in infancy leads to later obesity. 
According to research studies, the infants without catch-up growth in height or HC show the 
worst outcome (Clayton et al. 2007).  
 
IUGR (intrauterine growth retardation/restriction). Such a baby is small due to 
pathological restriction of its existing growth potential (Campbell 1989). Growth retardation 
can be classified as symmetrical or asymmetrical retardation.  The symmetrically retarded 
fetus/neonate is proportionally small (Peleg et al. 1998). This retardation originates in early 
pregnancy, before the 14th week, and reasons are mainly infections (e.g. cytomegalovirus, 
rubella, toxoplasmosis), or genetic malformations (as Trisomies 13, 18, 21; Mitchell 2001) or 
severe malnutrition. Because the insult occurs early in development, the “brain-sparing effect” 
(see Chapter 1.1.3.2 ) cannot apply and number of brain cells is reduced with possible impact 
on intellect (see Fig. 1.10; Hinchliffe et al. 1992). These infants will stay small, as there is a 
poor chance for catch-up growth (Neumann et al. 1984). 
 
Assymetrical growth retardation is more common. The fetus is small in a 
disproportionate way (small abdomen, lack of subcutaneous fat, normal body length and 
head), due to the “brain sparing effect” (see Chapter 1.1.3.2; Neumann et al. 1984; Hinchliffe 
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et al. 1992; Peleg et al. 1998). Placental abnormalities and insufficiency, poor utero-placental 
blood flow, general malnutrition, maternal smoking or multiple pregnancies may be the 
reasons (Neumann et al. 1984; Hinchliffe et al. 1992; Mitchell 2001). This type of growth 
retardation is related to late pregnancy (after 28 to 32 weeks), when growth proceeds mainly 
via cellular hypertrophy (Neumann et al. 1984; Hinchliffe et al. 1992). 
 
As the genetic growth potential is not known and the cut-off limit for IUGR fetuses 
may still include some normally nourished babies, the definition of growth restriction is rather 
complicated. IUGR babies have significantly increased perinatal and infant morbidity and 
mortality, as well as a higher prevalence of developmental and physical growth handicaps 
(Villar 1986; Hinchliffe et al.1992; Peleg et al. 1998). IUGR accounts for about 10% of all 
pregnancies, ranging from 3% to 25% according to the maternal health and also varies among 
populations (Dogra et al. 2006). Frequently, but not always, the IUGR fetuses are SGA 
(Campbell 1989). In developed countries IUGR is strongly related to maternal smoking, while 
in developing countries the major cause seems to be maternal malnutrition (Bergmann et al. 
2008). 
 
 
1.4.2 Determinants of fetal growth. 
As it was explained in Chapters 1.1.3 and 1.1.4, the fetus responds to the adverse 
effects of the environment during the critical periods of development by downregulating its 
growth rate, in order to preserve its energy for the brain and key organs. Depending on the 
magnitude and timing of the adverse effects, a low birth weight and disproportionate size are 
the likely birth outcome. For this reason, the fetal growth rate and also the early postnatal 
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growth patterns became important indicators of the future disease risk. A great research 
interest has thus been directed towards the identification and monitoring of the potential 
determinants of the fetal and postnatal growth and the mechanisms of their involvement in 
fetal programming.  
 
The control of fetal growth is quite complex, as it involves gene-environment 
interaction (see Chapter 1.1.4). One has to realise, that in fact it is the combination of various 
effects that leads to the fetal adaptation, although, one of these effects may dominate. If this 
dominant effect is also modifiable, an opportunity for a timely intervention in preventing the 
adverse programming outcome is present. Thus, better understanding of the growth 
determinants and their effects is important for early detection, treatment or prevention of 
chronic diseases of adult life.   
 
Already two decades ago, Kramer (1987) reviewed 895 publications and found 43 
potential determinants of low birth weight (See Figure 1.12A). As birth weight is an outcome 
of fetal development, the determinants of birth weight have to be common for fetal growth as 
well. The differences in outcome are then attributable to the different timing of the exposure 
(“critical window” periods) of the fetus to these determinants. Some of them may also be pre-
determined (as genetic background) or act indirectly via maternal exposure during her 
childhood. 
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Figure 1.12A. Potential determinants of fetal growth and birth weight (Based on Kramer 1987). 
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The following factors were found to have a relatively well-established independent 
causal effect on fetal growth in populations worldwide. However, the extent of this causality 
for each of these factors may differ with respect to the developmental status of the country 
(Kramer 1987; See further Chapters 1.4).  
Fetal gender  
Racial/ethnic origin  
Paternal height and weight  
Maternal height  
Maternal weight (her own birth weight, pre-pregnancy weight and pregnancy weight 
gain)  
Maternal nutrition (calorie intake)  
Maternal health (malaria, general morbidity and pregnancy-related illness)  
Maternal habits (alcohol drinking, cigarette smoking or tobacco chewing) Pregnancy 
history (parity, previous low birth weight infants)  
 
 
Figure 1.12B suggests a possible simplified mechanism for fetal growth and 
development in the programming of future risk for Type 2 diabetes. Well-known categories of 
determinants of fetal growth/birth weight are included and the effects of individual 
determinants will be discussed in the following chapters.  
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Figure 1.12B  Regulation of fetal development and programming. 
(Based on Fall 2003a, Fig 6 and Godfrey 2006, Fig 2.4) 
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1.4.2.1 Fetal genome. 
 
 
1.4.2.1.1 Epigenetic regulation.  
 
The term epigenetics refers to changes in gene expression, which do not result from the 
DNA sequence (Whitelaw et al. 2006). These changes include DNA methylation (enzymatic 
attachment of methyl groups at certain positions in genomic DNA) and histone modifications 
(histone proteins are responsible for packaging DNA into chromosomes) (Whitelaw et al. 
2006). These epigenetic changes are responsible for maintaining correct gene expression for 
any particular cell. They are inherited and they can be influenced by environment (Reik et al 
2001a; Whitelaw et al. 2006) such as maternal nutrition and health status (Wu et al. 2004; 
Junien et al. 2007). 
 
1.4.2.1.2 Imprinted genes. 
The majority of genes in the fetal genome are expressed from both maternal and 
paternal alleles, although some genes are inherited exclusively from one allele only. These are 
known as imprinted genes (Steinhoff et al. 2009) and can be influenced by epigenetic changes 
(Fall 2003a). 
 
Imprinted genes control normal fetal development, placental growth and structure and 
possibly influence the expression of placental nutrient transporters. In this way they are 
involved in the control of fetal nutrient demand and supply (Murphy et al. 2006). There are 
about 60 imprinted genes known in humans. Imprinted genes of paternal origin were found to 
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enhance fetal growth, while maternally-imprinted genes are associated with reduced fetal 
growth (Reik et al.2001b). 
 
A recent study by Heijmans et al (2008) provided the first evidence that environmental 
events occurring during early human development may produce permanent epigenetic changes 
with health consequences in future life. People who were conceived during the famine in 
Holland were investigated (see Chapter 1.1.2). The offspring exposed to famine during the 
first 10 postconceptional weeks showed less DNA methylation of the imprinted IGF2 gene 
than their non-exposed siblings of the same sex. Those who were exposed to famine during 
late pregnancy did not differ in methylation pattern.  
 
Epigenetic changes may not alter DNA sequence, but they can select which genes are 
expressed by silencing otherwise activated genes and vice versa. This may predispose the 
individual to future disease (Heijmans et al. 2008). 
 
 
1.4.2.2 Maternal factors influencing fetal growth. 
Besides the genetic component, the maternal factors that may affect the fetal 
development include the age of the mother, her body composition, health, number of children 
she delivered before and the spacing between subsequent pregnancies, her social class and her 
habits such as smoking or drinking alcohol, and most importantly, the quantity and quality of 
nutrients she ate before and during pregnancy. The majority of these factors will be discussed 
in the following sections. However, as already stated, although a direct effect of a single factor 
may have been studied and identified, in reality their effects add up or combine. Also it is 
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important to realise, that the final outcome depends on the equilibrium between fetal demand 
and maternal supply. 
 
1.4.2.2.1 Maternal age and body composition 
 
Maternal age.  
 
Adolescent pregnancies and higher maternal age are associated with a high risk for 
adverse pregnancy outcomes (low birth weight, growth retardation, stillbirth, premature birth, 
congenital anomalies, pregnancy induced hypertension, anaemia; Luke 1994; King 2003).  
An inadequate supply of nutrients in young mothers, who are still experiencing their own 
growth will lead to competition for nutrients with the fetus (King 2003). Pregnancy in older 
mothers may be complicated by pre-existing metabolic health problems, such as chronic 
hypertension, diabetes, hypothyroidism and during gestation by fetal karyotype abnormalities, 
gestational diabetes, pregnancy induced hypertension and pre-eclampsia, which may affect 
fetal development and delivery (Dildy et al 1996). 
 
Maternal birth size. 
Although infant’s birth weight shows correlation with both parental birth weights, the 
maternal effects are stronger (Fall 2003a). Mother’s own birthweight strongly correlates with 
her infant’s birth weight and placental weight, irrespective of parity and dietary intake 
(Godfrey et al. 1996). 
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Maternal weight. 
Maternal pre-pregnancy weight (adjusted for height as BMI) and pregnancy weight 
gain reflect maternal nutritional status (Neggers et al. 2003; Thame et al. 2004). Apart from 
the gestational age these are the major determinants of fetal weight and birthweight (Luke 
1994), which may be further modified by environmental factors (Neggers et al 2003). Low 
weight gain is a strong predictor of preterm delivery and LBW babies, especially in women 
who are underweight before pregnancy (Schieve et al. 2000; Neggers et al. 2003). Overweight 
women and women over 35 years of age experience rather low pregnancy weight gain (Strauss 
et al. 1999).  
 
High maternal body mass in pregnancy leads to childhood obesity and development of 
insulin resistance and CHD in her offspring later in life, irrespective of its birthweight 
(Godfrey et al. 2000; Eriksson et al. 2003b). 
 
Maternal height. 
Short stature appears to predispose to lower size at birth. In the Pune Maternal 
Nutrition Study, the Indian mothers were short, of a low weight and BMI and also their babies 
were short and underweight, although centrally obese (see Ch 1.1.2). Placental and birth 
weights do not correlate with maternal age and social class, if corrected for maternal height 
(Godfrey et al. 1996).  
 
 
Maternal constraint. 
 
The uterus itself has growth limiting capacity for the fetus, which is important in 
controlling fetal overgrowth (Murphy et al. 2006). From animal experiments (embryo transfer/ 
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manipulation studies) it is known that the intrauterine environment (uterine size) can override 
the growth potential set up by the fetal genome (Godfrey et al. 1998). A larger placenta 
enables the fetus to reach larger size (Godfrey et al. 2000). 
 
 
1.4.2.2.2 Pregnancy spacing 
 
Some studies investigated the effect of the time span between subsequent pregnancies 
on the pregnancy outcome and concluded that short intervals between subsequent pregnancies 
may result in maternal undernutrition and thus increase the likelihood of premature birth and 
low birth weight (Rawlings et al. 1995; Zhu et al. 1999; King 2003).  
 
 
1.4.2.2.3 Maternal race, ethnicity, socio-economic status.  
 
Maternal race and ethnicity may significantly influence the baby’s birthweight, which 
may reflect social class, development status of the country and is gender specific. (Kramer 
1987; Shiono et al. 1986; Scholl et al. 2002).  
 
1.4.2.2.4 Maternal health 
Maternal endocrine status, infections and diseases may influence fetal growth and 
development. Maternal hypertension (Law et al. 1991), renal disease and heart and respiratory 
disease (Murphy et al. 2006) are connected to an increased risk of growth retardation or 
preterm delivery.  
Fetuses of diabetic mothers have higher glucose, insulin and leptin levels. They are 
born with greater birth weight and carry an increased risk of future obesity and glucose 
intolerance (McMillen et al. 2006). 
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1.4.2.3  Effects of maternal nutrition. 
The importance of maternal nutrition in fetal programming has been emphasized by 
Hales and Barker (1992) in their Thrifty Phenotype Theory (see Chapter 1.1.3.2). However, 
nutrient effects on growth and development had already been shown in research studies, 
especially in animals. McCance (1962) performed experiments with dietary intervention on 
rats in different litter sizes and discovered that there was a critical period after birth during 
which the lack of nutrients resulted in smaller animal size and a permanent growth 
programming effect. Lucas (1991) described the effect of nutrition (human milk vs. standard 
or enriched pre-term infant formula) given to preterm infants during the first postnatal month 
on their further growth and development, and marked the neonatal period as critical for 
nutritional manipulation after preterm birth. Based on this finding and summarizing outcomes 
of animal studies, he established a concept of biological programming. He concluded that an 
inadequate nutrition during critical periods of early development might result in pathological 
processes later in life. Further research showed that inadequate maternal nutrition is one of the 
factors in utero, resulting in adverse changes in fetal growth and development (Campbell et al. 
1996; Cox 1999). 
             
In the following sections the effects of energy, macronutrient and micronutrient intake 
on fetal growth or birth outcome will be discussed. 
 
1.4.2.3.1 Nutritional deprivation. 
  This effect was seen in babies born to mothers affected by famine during the Dutch 
Hunger Winter and during the Siege of Leningrad (see Chapter 1.1.2). The birth outcomes 
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differed according to the timing of the famine exposure. Only the third trimester exposure to 
famine caused differences in birth size and body proportions. Changes induced by inadequate 
maternal nutrition in early pregnancy may persist into adulthood without affecting birth weight 
(Lumey1998a; Stein et al. 2004).  
 
1.4.2.3.2 Overnutrition. 
Pregnancy overnutrition in humans is associated with development of gestational 
diabetes and pre-eclampsia and may lead to development of cardiovascular problems (Martin-
Gronert et al. 2006) and/or metabolic syndrome phenotype in the offspring later in life 
(Armitage et al 2005).  
 
1.4.2.3.3 Macronutrients in fetal growth. 
In animal experiments, low protein diet has been studied quite extensively (see Chapter 
1.1.3.2). Also the study of Bieswal et al. (2006) showed that low protein and low calorie 
intake in rats during pregnancy had resulted in growth retardation and low birth weight. The 
extension of the restricted diet after birth into the lactation period led to a life-long growth 
restriction. However, overfeeding of the growth-retarded offspring during the suckling period 
resulted in catch-up growth with the weight exceeding normally fed controls. 
 
 Numerous epidemiological studies, mainly involving populations of adults with 
available birth records or of pregnant women, have investigated the effects of macronutrients 
on pregnancy outcome or their relationship with the development of chronic diseases later in 
life. Some examples are listed in Table 1.1. 
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Table 1.1 Epidemiological studies on nutrition. Dietary intakes of protein (milk protein), carbohydrate and fat (fish ω-3 
fatty acids) and their association with birth parameters and/or chronic disease later in life.     
 
Authors Population    Number Study topic 
 Outcome 
 
Campbell et al 1996 
 
Follow-up study of men 
and women born in years 
1948-1954 in Aberdeen, 
Scotland 
  
253 men and women 
 
Investigating how maternal 
pregnancy diet is 
associated with blood 
pressure of the offspring in 
adulthood 
  
The offspring of women 
with low animal protein 
intake (<50g/d) and high 
carbohydrate intakes in 
late pregnancy had high 
blood pressure later in life. 
The same outcome was 
also associated with intake 
of high animal protein 
(>50g/d) and low 
carbohydrate.  
Elevated blood pressure 
was associated with lower 
placental size and low BW, 
irrespective of maternal 
nutrition. 
 
Godfrey et al. 1996 The Southampton Study 
including pregnant women 
attending the Princess Ann 
Maternity Hospital, who 
completed gestation with a 
term delivery 
 538 women Maternal dietary intake 
during early and late 
pregnancy and its 
relationship with the 
placental and fetal weight. 
 High carbohydrate intake 
in early pregnancy and low 
dairy and meat protein 
intake in late pregnancy 
suppressed placental 
growth and reduced birth 
weight 
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Authors Population    Number Study topic 
 Outcome 
Sloan et al 2001 The New York Trial, 
including low income 
urban pregnant women 
 2163 women Dietary protein intake 
(evaluated by two 24-h 
dietary recall) during 
pregnancy (months 4-6 and 
month 8) and its 
association with pregnancy 
outcome. 
 
 A negative effect of high 
protein diet was observed. 
Mean protein intake ≥85g/d 
resulted in decreased BW 
by 71g in comparison with 
a mean intake of protein 
50-84.9g/d 
 
Moore et al. 2004 Pregnant women 18-41 y 
old living in Adelaide,  
Australia 
 
 557 women Maternal dietary intake 
during pregnancy and the 
birth size of the offspring. 
A dietary intake was 
assessed by means of a 
FFQ, administered during 
early and late pregnancy. 
 
 A direct association 
between the percentage of 
energy derived from 
protein taken in early 
pregnancy and the birth 
weight and placental 
weight was observed. 
The energy derived from 
carbohydrate intake at the 
same time of gestation was 
inversely related with 
neonatal ponderal index.   
 
Rao et al. 2007 A community-based study 
in a rural area of Haryana 
in India 
 140 pregnant women 
(3rd pregn. trimester) 
Maternal dietary intake of 
protein and total energy in 
association with BW 
 
 Low BW was linked to the 
third trimester mean 
protein intake of less than 
40 g/d (average was 
50.8g/d) and mean energy 
intake below 1500kcal 
 
Andreasyan et al. 2007 The Tasmanian Infant 
Health Survey (1988-
1989) 
 1040 mother-infant pairs Maternal dietary intake 
during pregnancy and birth 
size 
 High protein intake was 
associated with lower BW 
and PONDIX. High protein 
diet taken at the 3rd trim. 
led to decreased PONDIX 
in large BW babies. 
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Authors Population    Number Study topic 
 Outcome 
Milk (protein) and fish 
(fat) consumption: 
 
      
Rao et al. 2001 The Pune Maternal 
Nutrition Study including 
pregnant rural Indian 
women near Pune City. 
 797 women Maternal dietary intake 
during pregnancy and birth 
size 
 Maternal consumption of 
milk, fruits and green 
leafy vegetables at 28 gest. 
weeks correlated with the 
birth size. No such 
correlation was observed 
for maternal energy or 
protein intakes. The 
dietary fat consumption at 
18 weeks of gestation was 
associated with neonatal 
length.  An important role 
of micronutrients in fetal 
growth was suggested. 
 
Ludvigsson  et al. 2004 Swedish pregnant women  12880 women Milk consumption during 
pregnancy and the 
relationship with birth 
weight, IUGR and preterm 
delivery.(Questionnaire 
and birth registry) 
 
 Low milk dietary intake 
was associated with IUGR 
of the newborn 
Olsen et al. 2007 The Danish National Birth 
Cohort (1996-2002) 
 50 117  
mother-infant pairs 
Milk consumption during 
pregnancy and the 
relationship with the birth 
size 
 Milk consumption during 
pregnancy increased babies 
BW for age and decreased 
rates of SGA fetuses. 
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Authors Population    Number Study topic 
 Outcome 
Olsen et al. 2002 Swedish pregnant women  8729 women Consumption of seafood 
and birth weight. 
 Low consumption of fish 
was linked to preterm 
deliveries, intrauterine 
growth restriction and low 
neonatal weight. Beneficial 
effect of ω-3 fatty acids 
derived from fish or fish oil 
supplements on birth 
outcomes were observed.  
 
Mitchell et al. 2004 
 
 
 
 
Inconclusive: 
Auckland babies born  
between October 1995 
and August 1996 and 
their mothers. 
 844 cases,  
870 controls 
Effect of maternal diet 
during pregnancy with 
respect to size at birth 
(AGA vs SGA) 
 A reduced risk of small for 
gestational age babies 
(SGA) was connected to 
increased fish consumption 
in early pregnancy. 
Mathews et al. 1999  The Portsmouth study, 
including healthy white 
nulliparous women 
attending the local 
 antenatal clinics during 2-
year period  (May 1994- 
Feb1996).  
 
 693 women Maternal dietary intake 
and smoking during 
pregnancy and their 
association with plac. and 
birth weights at term 
deliveries. 
 Only a weak nutritional 
effect on placental and 
birth weights was found. 
The maternal nutrition in 
developed countries might 
only have a small effect on 
placental and birth weights.   
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The epidemiological studies listed in Table 1.1 investigated separate nutrients or 
nutrients in combination, intakes during early or late pregnancy and also separate food items 
such as milk, fruits and vegetables and fish.  In summary, low protein intakes and high protein 
densities were associated with decreased birth weight. The consumption of milk, fruits, 
vegetables and fish was linked to increases in birth weight and a beneficial effect of n-3 PUFA 
on birth size was reported. 
 
1.4.2.3.4 Micronutrients in fetal growth. 
At the time of organ and tissue development, during stages of cell proliferation and  
differentiation, micronutrients play essential roles in signaling (e.g. retinoic acid), enzymatic 
catalysis (e.g. copper) or as structural elements (e.g. zinc in transcription factors). Vitamins are 
important in cellular metabolism, maintenance and growth (McArdle et al. 1999) as 
antioxidants. Lack of vitamin B6 may impair pancreatic insulin production.  
 
 
 
1.4.2.4 Effects of placenta 
 
The intrauterine environment is believed to be a major determinant of fetal growth and 
development (Godfrey et al. 1988), where the placenta, a highly specialised organ supporting 
the fetus with nutrients and oxygen, represents the only communication pathway between the 
mother and the fetus. The complexity of this role involves the placenta in a variety of 
functions, such as transport, respiratory, metabolic and endocrine functions.  The placenta also 
mediates heat exchange between the fetal and maternal circulations and serves as an 
immunological barrier with mother (Lewis et al. 1990d; Gude et al. 2004; Myatt 2006).  
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The placenta constantly develops and matures during pregnancy. Therefore, any 
disruption during placental development will result in a modified function and adverse effects 
on the fetus. The timing of an insult will determine the deviation in placental function (Myatt 
2006). It is known, for example, that placentas of pregnancies complicated with preeclampsia 
and IUGR are associated with defects in transition of maternal placental arteries into low 
resistance vessels, which limits the oxygen supply to the fetus (Macara et al. 1996; Dugoff et 
al. 2005).  
 
 
1.4.2.4.1 Placental volume. 
Placental volume and the rate of placental growth are correlated with fetal size. These 
effects seem to be regulated by maternal weight and weight gain and her nutritional status 
(Neumann et al. 1984; Thame et al. 2000 and 2004). 
 
 
1.4.2.4.2 Utero-placental blood flow 
The Doppler ultrasound blood flow waveform analysis helps to identify fetal 
hypoxaemia, growth restricted fetuses (Maršál 1989, Dugoff et al. 2005) and utero-placental 
complications (Bower et al. 1993). Increased vascular resistance of uterine arteries due to 
inadequate trophoblast invasion (Chapter 1.3.2.2; Divon 2002; Murphy 2006) or umbilical 
cord abnormalities (Somerset et al. 1993) will show decreased end-diastolic flow velocity 
resulting in high values of placental indices - the resistance index (RI) and the S/D ratio (See 
Chapter 2.5.2.2).  
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IUGR fetuses have reduced perfusion of fetal tissues, and the umbilical vein blood 
flow is reduced in relation to fetal size (Reece et al.1993; Murphy 2006). 
 
1.4.2.4.3 Placental transport 
Depending on the nature of transported substance/solute and placental integrity, a 
substance may cross placenta intact, it may be metabolised, consumed or altered by placenta, 
or it may not be transported at all (Hay 1994). Transport can be mediated by diffusion, via 
transporter proteins or by endocytosis/ exocytosis processes utilising concentration gradients 
or transmembrane potentials as moving forces (Moritz et al. 2006).  
Transport of gases (oxygen, carbon dioxide) is regulated by placental blood flow and 
simple diffusion. The high permeability of the placental membrane to oxygen and carbon 
dioxide enables rapid exchange of these gases and placental blood flow is thus the rate- 
limiting step for oxygen delivery to the fetus (Sadler 2000c; Gude et al. 2004).  
Transport of glucose and amino acids depends on the availability from the maternal 
supply and on specific placental transport systems (Bell et al. 1999; Jansson et al. 2003). 
Their activity and expression is essential for delivery of nutrients to the fetus, and thus for the 
regulation of fetal growth.  
 
Glucose transport. 
Glucose is the most frequently transported carbohydrate and serves as the primary 
substrate for fetal oxidative metabolism (Gude et al. 2004; Myatt 2006). The placenta 
regulates the rate of glucose transfer and also consumes glucose in variable amounts. This 
regulation is linked to the magnitude of the concentration gradient between fetal and maternal 
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glucose levels, which are always relatively lower on the fetal side (Jansson et al. 2001). The 
fetus produces minimal amounts of glucose and only with advancing gestation, as pancreas 
develops, does the endogenous production of insulin becomes stimulated (see Chapter 1.2.5; 
Gude et al 2004; Hay 2006b). As maternal insulin does not cross the placental membrane, the 
correlation seen between maternal and fetal insulin levels may be due to a significant 
correlation between maternal and fetal glucose concentrations (Nicolaides et al. 1989). 
 
The fetus requires an increase in the glucose supply with maturation and growth of 
different organs and therefore, in order to maintain the maternal glucose equilibrium, the rate 
of maternal glucose production increases. This is accompanied by development of gestational 
glucose intolerance and a state of insulin resistance within the mother (Hay 2006b).   
 
Placental transport of glucose is mediated by facilitated diffusion, involving glucose 
transporters (Illsley 2000), which increase or decrease their expression in response to changes 
in glucose gradient (Leonce et al. 2006). In humans there are three transporters located on 
placental membranes: GLUT 1, the major and also rate-limiting glucose transporter present in 
placental membranes, and further GLUT 3 and GLUT 4 (Illsley 2000; Murphy et al. 2006). 
 
Long-term changes in fetal glucose concentrations may lead to programming effects 
with adverse outcomes in the developing fetus. Maternal diabetic pregnancy leads to fetal 
hyperglycaemia that is associated with elevation of the growth-stimulating factor: insulin, 
insulin-like growth factor 1 (IGF1) and leptin (Jansson et al. 2002; Myatt et al. 2006). This 
may result in changes to the glucose transporter (Hay Jr. 2006a). Indeed, an increase of the 
basal membrane GLUT 1 expression (whilst activities of GLUT 3 and GLUT 4 remained 
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unaffected) was found by Illsley et al (2000) and also by other researchers (Jansson et al. 
1999). Authors believed that these changes led to increased glucose transport to the fetus of 
diabetic mothers, in spite of her adequate control of the disease. No changes to glucose 
transport have been associated in women with gestational diabetes mellitus (Jansson et al. 
2001). 
 
The hypoglycaemia present in SGA fetuses may be a consequence of reduced 
supply/transfer of maternal glucose to the fetus, which may occur, for example, with increased 
placental glucose consumption. From experimental studies in sheep it is known that placentae 
of preterm IUGR pregnancies show increased glucose consumption in comparison with 
placentae of normal pregnancies (Leonce et al. 2006; Murphy et al. 2006).  
 
In addition, in pregnancy, glucocorticoids can interfere with the expression of placental 
glucose GLUT 1 and GLUT 3 transporters (Hahn et al. 1999), adding further to the likelihood 
of adverse effects, including restriction of growth of the developing fetus. 
 
Amino acid transport.  
During the early preimplantation stages of development in the mouse embryo or in 
cultures of human fertilised eggs a preference for amino acids was noted, changing from non-
essential (during cleavage) to essential amino acids (8-cell stage and later; Van Winkle 2001), 
with both contributing to an improvement in the conceptus/embryo development.  
 
The fetus utilises amino acids mainly for protein synthesis, or they also can be 
metabolised by the fetus. The placental transport of amino acids from mother to fetus is 
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mediated by transporter proteins, found in both microvillous and basal plasma membranes 
(Gude et al. 2004; Murphy et al. 2006). There are about 15 different amino acid transporter 
systems found in the human placenta (Myatt et al. 2006). Amino acids are more effective in 
insulin stimulation than glucose (see Chapter 1.2.5.4) therefore changes in their transport 
systems will reflect in fetal growth (Jansson et al. 2002). Reduction in the system A placental 
transporter expression and activity has been observed in hypoxia and IUGR pregnancies (Ayuk 
et al. 2002; Nelson et al. 2003), whilst in pregnancies complicated by diabetes mellitus or 
associated with accelerated fetal growth an enhancement of transporter activity was observed 
(Jansson et al. 2002).  
The amino acid transporter system A appears to be hormonally regulated by human 
growth hormone in early pregnancy, and by insulin and leptin in late pregnancy (Jansson et al. 
2003; Ericsson et al. 2004).  
 
Transport of fatty acids. 
Essential fatty acids and long-chain polyunsaturated fatty acids (LC PUFA) are 
important for fetal growth and development, namely during brain neurogenesis and adipose 
tissue changes in late pregnancy. The fetus depends on maternal supplies of LC PUFA 
(Duttaroy 2009). LC PUFA can cross the placental membrane by means of passive diffusion, 
however, it seems that their transport is mediated by several transport/binding proteins present 
on the membrane. These proteins are regulated by fatty acid activated transcription factors 
(Duttaroy 2009). Free fatty acids (FFA) from maternal blood can cross the placenta by passive 
diffusion or their transport is mediated by the fatty acid binding and transfer proteins located 
in placental membranes (Murphy et al. 2006), which control the direction and the amount of 
transported fatty acid (Gude et al. 2004). Elevated maternal pregnancy levels of triacylglycerol 
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ensure availability of an FFA source (Duttaroy 2009).  The triacylglycerol cannot cross the 
placental membrane, therefore it is metabolized by placental lipoprotein lipase to FFAs and 
glycerol. FFAs are transported to the fetal side and re-esterified with intracellularly generated 
glycerol phosphate (Myatt et al. 2006; Duttaroy 2009).  
 
1.4.2.4.4 Placental endocrine function 
The placenta produces numerous hormones in order to adjust maternal metabolism, 
enable “communication” with the fetus and regulate fetal growth (Murphy et al. 2006). 
Placental hormones are secreted into both maternal and fetal circulation and vary with 
development.  The majority of receptors for these hormones are located on the placental 
syncytiotrophoblast, supporting the endocrine and paracrine function of the placenta. There 
are indications, that the placenta may regulate its own function in response to outside stimuli 
such as nutrition. (Jansson et al.2003). 
The effect of hormones on fetal growth may be direct or indirect, mediated by changes 
in placental growth, fetal metabolism, including production of growth factors and other 
hormones by feto-placental tissues (Fowden et al. 2004). 
  
Thyroid hormones.  
The placenta is largely impermeable to maternal peptides. Hormones important in 
postnatal growth, such as growth hormone and thyroxine, are present in the human fetus from 
early gestation but their influence on fetal growth is less than in postnatal life (Girling 2006). 
Iodine crosses the placenta, thyroxine (T4) is transferred only during the first trimester and 
triiodothyronine (T3) and thyroid stimulating hormone (TSH) do not cross at all (Girling 
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2006). Fetal thyroid hormone concentration is reduced in hypoxaemic conditions, leading to 
assymetrical IUGR with reduced muscle mass (Fowden et al. 2004). 
 
During late pregnancy, the placenta supports fetal growth via hormones that affect the 
transport and/or utilisation of maternal nutrients. This includes growth hormone and insulin-
like growth factors (Gluckman 1995). With low nutrient income, concentration of anabolic 
hormones like insulin and IGF-1 is diminished, and that of catabolic hormones 
(glucocorticoids) is elevated (Barker 1998). 
 
 
Insulin-like growth factors (IGFs) and their binding proteins (IGF-BPs) play a major 
role in maternal tissue growth and development and in embryonic and fetal growth (Westwood 
1999). Production of IGF-1 is regulated by placental growth hormone (GH), both secreted by 
the placental trophoblast (Westwood 1999; Verhaeghe et al. 2002). IGF receptors are 
controlled by six IGF-BPs. IGF-BP3 is the main IGF-1 binding protein, however the 
biologically active free fraction of IGF-1 is controlled by IGF-BP1 (Qiu et al. 2005). IGF-BP1 
is produced by the liver and abundantly by maternal decidua, which points to its important role 
during the implantation process (Westwood 1999). The concentration of IGF-BP1 increases 
from early pregnancy (Krampl et al. 2002; Verhaeghe et al. 2002) and reaches steady 
maximum at mid-gestation.  Insulin may be involved in this regulation by acting on hepatic 
GH receptor or IGF-BP1 liver production (Qiu et al. 2005). There is a structural similarity 
between insulin and IGF-1 and IGF-BPs regulate IGF-1’s hypoglycaemic activity. Therefore 
IGF-1 may have insulin independent function in glucose metabolism and homeostasis. It can 
increase glucose disposal in skeletal muscle (Qiu et al. 2005). From in vitro studies it seems 
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that IGF-BP1 may have a role in endometrial development and elevated levels of IGF-BP1 can 
inhibit trophoblast invasion. Increased maternal concentrations of IGF-BP1 limit IGF-1 
mediated growth, resulting in IUGR (Krampl et al. 2002; see also Chapter 1.3.2.3).   
 
IGF-1 does not cross the placenta, but maternal levels may influence substrate transfer 
across the placenta and in this way regulate fetal growth (Lind 1989). 
 
Glucocorticoids. 
Glucocorticoids have a critical role in tissue development and maturation. An excess of 
glucocorticoids leads to growth restriction, hypertension, hyperglycaemia and upregulation of 
the hypothalamic-pituitary adrenal axis (HPA) (Myatt 2006). 
 
Glucocorticoid levels are low in the fetus, with an increase in levels before the end of 
gestation to promote organ maturation (McNeil 2007). Glucocorticoids are supplied to the 
fetus by the mother across the placenta. This transport, and therefore the fetal exposure to 
glucocorticoids, is controlled by placental 11ß-hydroxysteroid dehydrogenase2 (HSD2), which 
converts cortisol into inactive corticosterone (Fowden et al. 2004). The second source of fetal 
glucocorticoids is derived from fetal adrenal gland, regulated by the HPA axis (McNeil 2007).  
 
Deficiency (mostly due to mutation of the 11ß-HSD2 gene caused by chemicals) or 
alterations of the 11ß-HSD2 activity lead to overexposure of the fetus to glucocorticoids. This 
is the case in maternal undernutrition, protein deficiency, maternal stress, placental hypoxia 
(due to inadequate trophoblast invasion), and in maternal treatment with synthetic  
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glucocorticoids to reduce the risk of preterm labour (Seckl 2004; McNeil 2007). Reduced 
placental expression of the 11ß-HSD2 is associated with IUGR.  
 
11ß-HSD1 isoform, expressed also in placental tissues (maternal and fetal), can act in 
both directions, to deactivate and to regenerate cortisol from cortisone. Increased cortisol 
production was found during the third trimester (Chan et al. 2007).  
 
Leptin. 
Leptin receptors are present on pancreatic β-cells. This enables leptin to directly inhibit 
insulin secretion. On the other hand, insulin stimulates adipogenesis and leptin synthesis, 
creating a negative feedback loop (“adipoinsular axis”).  
 
There is a significant placental transfer of maternal leptin to the fetus, increasing with 
advancing gestation (McMillen et al. 2006). Leptin is also produced by placental trophoblast 
and is secreted to both maternal and fetal circulations. Leptin may have a significant role 
during the to gestational diabetes and IUGR (Sagawa et al. 2002). The study of Ong et al 
(1999) showed a correlation between cord blood leptin levels and the pattern of weight gain in 
early postnatal life. Leptin has a stimulating effect on fetal weight gain (Harigaya et al. 1997) 
and in angiogenesis (Cao et al 2001).  
 
1.4.2.4.5  Intrauterine hypoxia  
Low oxygen levels (hypoxia) can have harmful effects on placental tissues and 
placental function. Clinical conditions commonly associated with intrauterine hypoxia include 
maternal anaemia, pregnancy at high altitude and maternal pre-eclampsia (Burton et al. 1999).  
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Maternal anaemia  
In maternal anemia there is reduced capacity of the maternal blood to carry oxygen 
(Hoque et al. 2009). This condition is defined as haemoglobin levels below 11 g/dl in the first 
and third trimester and below 10.5 during the second trimester (Law et al. 1991; Milman 
2008). In South Africa the level of 10.0 g/dl is used (See Chapter 1.3.1.1). Nutritional derived 
iron deficiency is the most frequent type of anaemia in Sub-Saharan Africa however parasitic 
infections and HIV are strong contributing factors (Hoque et al. 2009). 
 
Low maternal haemoglobin and iron levels during pregnancy were associated with large 
placental weights, placental to birth weight ratio (Godfrey et al. 1991; Law et al. 1991) and 
proportionally low cord blood haemoglobin, serum iron, transferrin saturation and ferritin. The 
latter suggests reduced iron supply to the fetus in maternal anaemia, as fetus extracts iron in 
proportional amounts with the maternal levels (Singla et al. 1996). An increase in placental 
weight is seen as a compensatory mechanism (Burton et al.1999). 
Iron deficiency anaemia is associated with low birth weight, premature birth and SGA 
infants (Allen 2001; Milman 2008), while the anaemia caused by pregnancy volume expansion 
is not related to adverse birth outcomes (Rasmussen 2001;). However, a steep decline in the 
iron stores was detected in pregnant urban White and Black South African women between the 
first and third trimester of gestation (Guidozzi et al. 1995), pointing to the importance of iron 
supplements in these population groups. 
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High altitude hypoxia  
Pregnancies at high altitude (>2700m) are associated with hypoxia due to low 
atmospheric oxygen concentration (Burton et al. 1999). This is connected with 2-5 fold- 
increased incidence of low birth weight, growth restricted fetuses, high risk of preeclampsia 
(Zamudio et al. 2006).  
 
Oxygen level regulates development, proliferation and vascularisation of the villous 
trophoblast (Myatt 2006).  
Chronic hypoxia alters nutrient supply to the fetus; the concentration of placental 
GLUT1 is reduced and markers of hypoxia, erythropoietin receptor and transferrin, are 
increased (Zamudio et al. 2006). Also, amino acid system-A transporter activity and 
expression is downregulated in cultured term human trophoblasts (Nelson et al. 2003). 
Maternal placental hypoxia stimulates IGF-BP1 production, which is one of the mechanisms 
leading to IUGR (Krampl et al.  2002).  
 
Adaptation to altering oxygen levels is mediated by the hypoxia-inducible transcription 
factors 1 and 2 (Schäffer et al. 2005). They activate corresponding target gene transcription 
according to the level of oxygenation (Schäffer et al. 2005; Myatt 2006).  
Disturbance of physiological oxygen concentrations may lead to abnormal placental 
development (Schäffer et al. 2005). The Doppler blood flow velocity waveform analysis helps 
to detect fetal hypoxemia (See Chapters 1.4.2.4.2 and 2.5.2.2). 
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1.5 AIMS OF THE STUDY 
1.5.1 Introduction to the research study. 
Chapter 1 provides a detailed overview of the published literature that is relevant to the 
PND study research field, but, in some instances, also includes information that exceeds the 
research aims of the present study. 
 
The major research focus of the current study concerns the determinants of fetal growth 
and birth weight (excluding the genetic factors). Two of these determinants, maternal nutrition 
and maternal pregnancy hormones, were investigated and their relationship with maternal 
anthropometry, fetal biometry, birth outcomes, postnatal infant growth and metabolic 
parameters was evaluated in the study.  
 
Closely related to the current study research were also chapters including the stages of 
fetal development, placental transport of nutrients and endocrine pancreas as these were 
related to the study results interpretation.  
 
It is important to realize the magnitude of the global prevalence of diabetes and the 
necessity of its early prevention. The latter does have a bearing on the study aims and 
naturally outcomes will have important implication. Also the studies from both the developed 
and developing countries were relevant to the PND study aims, as the nutrient intakes, 
anthropometry and birth parameters of infants in this study population were compared with 
those from countries in a similar transient state and from countries at a more advanced level of 
economic development.   
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1.5.2 Aims and objectives of the present study 
 
 
In humans, various epidemiological trials have investigated the effects of maternal 
nutrition on birth outcomes and future disease risk. However, very few such studies have been 
conducted in Sub-Saharan Africa and South Africa itself.  
 
In South Africa, the national prevalence of low birth weight is 8.9 %, displaying a wide 
range from 0.6% in Gauteng Province to 24.5% in the Northern Cape Province (SADHS 
survey, 2009; http://www.childrencount.ci.org.za). The targeted World prevalence, established 
at The World Summit for Children (1990) is below 10% (Ramakrishnan 2004). As was shown 
in the Dutch Hunger Winter study (see Chapter 1.1.2), the programming effect, which will 
lead to disease later in life, manifests as low weight at birth. However, the majority of 
epidemiological studies (see Chapter 1.1.2) found low birth weight to be associated with an 
increased risk of future disease, and this was confirmed in experimental studies on animal 
models with dietary restriction during pregnancy. As maternal health and nutrition are factors 
influencing fetal growth and development, more research in this field in African population is 
required.  
 
South Africa is undergoing a rapid migration of people from rural to urban areas, 
which is associated with a transition in lifestyle and dietary patterns. Low energy intakes were 
seen in rural areas, while high energy intakes were recorded in urban areas (MacIntyre 1998). 
Urbanisation leads to lower physical activity and increased obesity (Steyn 2005). Although, as 
already mention in Chapter 1.2.2, the prevalence of diabetes is currently lowest in the African 
Region. At the same time the highest increase in prevalence of diabetes is expected in this 
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Region for the year 2030 as a consequence of rapid industrialisation and urbanisation. The 
prevalence of diabetes in South Africa (Chapter 1.2.3) is relatively high, ranging from 4.6 % 
in rural to 8% in urban areas.  
 
South Africa has one of the highest HIV infection rates in the world. The national 
prevalence is 10.8% (www.hsrc.ac.za/Factsheet-40.phtml). This has put a great burden on the 
national health services and thus the resources and facilities for monitoring and treatment of 
non-communicable diseases, such as diabetes, are limited, and in many rural settlements are 
non-existent. Less than 20 % of the global costs of diabetes are associated with the Africa 
region (http://www.diabetesatlas.org; 4th ed.).  
 
In summary, with increasing urbanization, the prevalence of Type 2 diabetes is 
expected to rise. Resources for the treatment of Type 2 diabetes however are limited. 
Therefore preventive measures need to be taken urgently. This should involve more research 
on nutritional status of mothers during pregnancy and what influence it may have on the 
developing fetus. Early detection of the problem and possible dietary intervention could 
influence the later outcome of the disease.  
 
The Hertfordshire study was the first to show that slow prenatal and rapid postnatal 
growth was associated with impaired glucose tolerance and Type 2 diabetes.  Also, a low birth 
weight, elevated markers of β-cell function (proinsulin, 32-33 split proinsulin and insulin) and 
a high BMI in adulthood were linked to the metabolic syndrome (Chapter 1.1.1). Further 
studies extended these risk indicators with thinness at birth (measured by ponderal index), 
small head circumference, high placental weight, short stature and disproportionate growth 
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assessed by the high placental weight to BW ratio all being linked to poor glucose tolerance 
and/or increased insulin resistance. Maternal nutrition was one of the factors implicated in 
fetal programming and increased risk of future metabolic disease.  
 
The purpose of the present study was therefore to evaluate the dietary status of urban 
Black pregnant women attending the Johannesburg General Hospital. A further aim was to 
investigate the effects of maternal diet and hormonal levels during pregnancy on fetal and 
infant growth and other risk indicators associated with future Type 2 diabetes.  
 
 This is an exploratory study attempting to identify effects of individual nutrients and 
hormones on the prenatal and postnatal infant variables in order to identify potential factors 
and areas for possible future intervention. Therefore it does not include a predictive, complex 
model building design. 
 
The aims of this study involve the following research questions:  
 
• Does maternal pregnancy dietary intake of macronutrients affect fetal, birth or postnatal size 
or growth?  
• Does maternal pregnancy dietary intake of macronutrients affect infant glucose and markers 
of infant β-cell function i.e. INS, PI, HOMA-IR? 
• Does maternal pregnancy hormonal levels affect fetal, birth or postnatal size or growth?  
• Does maternal pregnancy hormonal levels affect infant glucose and markers of infant β-cell 
function i.e. INS, PI, HOMA-IR? 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
2.1 STUDY POPULATION AND STUDY DESIGN. 
This prospective longitudinal study took place at the Johannesburg General Hospital 
and the Faculty of Health Sciences of the WITS (Witwatersrand) University in the Gauteng 
province of South Africa.   
 
The study population were pregnant women of a Black ethnic origin attending the 
Johannesburg General Hospital Antenatal Clinic. The study took place from March 2000 to 
September 2005 and consisted of two major parts in which pregnant women and then the same 
women and their offspring were followed.  
 
Study design. 
Twice during pregnancy (visits V1, V2) and approximately half a year after the 
delivery (V3), participating women had a standard oral glucose tolerance test (OGTT), blood 
pressure and anthropometric measurements taken (see Figure 2.1). Health status and socio-
demographic data were recorded and nutritional status was assessed by means of a food 
frequency questionnaire (FFQ). During both pregnancy visits an ultrasound examination was 
carried out.  
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  Figure 2.1  Study flow diagram.  
 
The offspring of these mothers were followed. Three to four weeks after birth and half 
a year postnatally fasting blood samples and anthropometric data were collected (Figure 2.1). 
 
Measurements and data collection methods in this study included: 
a) Interview - consultation, structured questionnaires 
b) Documentary source - patient’s file and hospital records   
c) Non-invasive measurements and methods - blood pressure, anthropometric 
measurements, ultrasound scan, biochemical analysis of blood samples 
d) Invasive methods - oral glucose tolerance test, blood collections 
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Ba2
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Week
20-24
Gestational
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30-36
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Diagram
Pregnancy
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Enrolment and ultrasound measurements took place in the Antenatal Clinic, while the 
anthropometric measurements, oral glucose tolerance test and questionnaires were carried out 
in the Day Ward of the Department of Chemical Pathology at the WITS Faculty of Health 
Sciences.   
 
 
2. 2  ENROLMENT AND FOLLOW-UP 
2. 2. 1 Sampling and enrolment  
The present study participants were enrolled from the Antenatal Clinic in the 
Johannesburg General Hospital. The average age of women attending the Antenatal Clinic was 
approximately 30 years (see Chapter 3.1, Fig 3.2), although the age range of volunteers at the 
study enrolment extended from 18 - 40 years. The average gestational age at the first visit to 
the clinic was around 30 weeks of gestation. There were some women who presented for the 
first visit as early as in the first trimester, but also individuals who checked in just a few weeks 
or days before delivery.  From all the pregnant women registered in the Antenatal Clinic, 
about 60-70% attended further visits and delivered in the same hospital (information obtained 
from the Antenatal Clinic records). Midwives and doctors closely followed all the patients at 
regular intervals for the duration of their pregnancy and at delivery.  
 
The present study benefited from the routine organisation of the clinic. The Antenatal 
Clinic utilised a Voluntary Counselling and Testing program initiated by the Department of 
Health (Gauteng Department of Health). All expectant mothers underwent counselling for 
routine blood tests, which included syphilis, Rhesus (Rh) factor, haemoglobin (HB) levels, and 
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HIV. The HIV test was offered to each woman registered to the ANC. Women who were HIV 
positive were allocated for antiretroviral treatment with Nevirapine during the labour. 
According to the clinic records 25 - 30% of attendants were HIV positive.  
 
The sampling and enrolment methods for the current study were designed to be in 
accordance with the routine of the Antenatal Clinic. The sampling was done in a number of 
sampling periods. These were of varying time intervals (from one week to one month), 
determined by the numbers of women successfully enrolled into the study (Appendix A). This 
procedure was regulated by the capacity of the Day Ward and ultrasound unit for study 
participants. Therefore, the convenient sampling method was used. Selection bias was avoided 
as all the women during the sampling periods had an equal chance of being selected (all 
patients’ files were investigated for a match with the study enrolment criteria on each 
sampling day). The subject characteristics measured in the current study did not differ across 
groups of women sampled of different time periods.  
 
Estimation of the sample size. 
As this study involved pregnant women and neonates, the intention was to keep the 
number of subjects as low as possible, while still obtaining a sufficient power for data 
analysis. Because of the complexity of the current study, the sample size was estimated using 
the general rule for the relationship between the sample size and the number of variables in the 
multiple regression model (Petrie et al. 2000a). According to this rule a minimum of 10 
subjects are needed for each explanatory variable entering the regression model.  Therefore, at 
the lower range, between 70 – 150 cases were assumed to be sufficient for the analysis in the 
current study.  
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In total, 126 pregnant women were enrolled and attended the first study visit (V1). The 
loss to follow-up is reviewed in Chapter 3.2. 
 
 
The selection criteria were as follows:  
1) Pregnant woman of a Black ethnic origin 
2) Age between 18 – 40 years  
3) Gestation below 24 weeks 
4) Non-diabetic (WHO 1999 criteria) 
5) Women with a chronic disease requiring treatment were excluded from enrolment 
6) Singleton pregnancy only  
7) Haemoglobin levels above 10g/dl 3, syphilis and HIV screening negative 
8) Blood pressure below 140/90 mmHg 
 
The patient’s file and the antenatal card information included personal details (name, ID, 
date of birth, address, hospital number, next of kin, demographic data), past medical history,  
history of previous pregnancies, family medical history and social status. During a patient’s 
visit the file and the card were updated with routine examination outcomes, test results related 
to the clinic practice, with clinical or ultrasound assessment of the gestational length, fetal 
growth and well-being. 
 
                                                           
3
 concenration of haemoglobin defining pregnancy anaemia in South Africa (Hoque et al.2007) 
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The present study was described to volunteers using pamphlets and in a personal 
discussion with pre-selected individuals. The pamphlets contained information on the study, 
contact details of study investigators and they were printed in the most common languages 
spoken by Antenatal Clinic visitors. A nurse, who spoke a majority of these languages, helped 
with sampling and enrolment.  
 
 
2.2.2 Organisation of the study 
All participants had their Antenatal Clinic files and cards labelled with study stickers. 
Nurses from the Antenatal Clinic were familiar with the study requirements. Pamphlets with 
study details and study requirements were handed to the staff and displayed on information 
boards of the Labour and Postnatal Wards. The nurses were asked to report any delivery or 
admission for delivery of study participants to the study investigator by phone.  
 
Mothers with their newborns were seen first in the Postnatal Wards. There were two 
Postnatal Wards in the hospital; one for mothers who underwent a normal vaginal delivery 
(complicated or uncomplicated), and the second for mothers who delivered by caesarean 
section.  
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2. 2. 3 Feasibility study  
 
The first fifty participants were included into a feasibility study. This was used to set 
up and optimise the enrolment and study routine.  
 
The routine procedure used at the Antenatal Clinic helped to exclude women 
unsuitable for the study at a very early stage and enabled close monitoring of participants 
during pregnancy follow-up. 
 
Further adjustments were made to the study protocol at the end of the feasibility study:   
a) The inclusion criteria questionnaire was reviewed and adjusted. Information 
available in the patient’s antenatal card or file was removed from the questionnaire, and a 
photocopy of the hospital document was kept instead. Evaluation of the socio-economic status 
was extended by information referring to the number of household occupants and family 
monthly income. 
 
b) Measurements of baby’s abdominal circumference (AC) during postnatal visits and 
of maternal head and mid-upper arm circumference, as well as the postprandial C-peptide 
concentrations and the leptin assay were added into the study (see also Chapter 2.8.1.5). 
 
The feasibility study and the main study data were combined together for analysis.  
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2.3  PROCEDURES PERFORMED IN DAY WARD  
(PRE- AND POSTNATAL) 
 
 
2. 3. 1 Anthropometric measurements of women and babies  
 
2. 3. 1. 1 Weight and height 
 
Measurements of participants’ weight and height were taken after removal of shoes 
and any heavy clothing. An accurate electronic weighing scale with an attached manually 
operated measuring rod was used (Modern scale Co. (Pty) Ltd, Johannesburg, South Africa). 
Measurements were taken to the nearest 0.1 kg, and the nearest 0.1 cm respectively. Babies 
were weighed and measured on a special weighing and measuring station. This included a 
digital baby scale Seca 736 equipped with the Seca 231 measuring rod, both distributed by 
Delta Surgical, cc, Johannesburg, South Africa. Babies were weighed undressed.  
 
Body mass index (BMI) in women and babies was calculated according to the 
formula: BMI = weight [kg]/ height 2 [m2].  
 
Ponderal index (PONDIX), measure of adiposity for newborns, was calculated 
according to the formula:  
PONDIX = birth weight [kg] / birth length3 [m3] *100  (Leon 1999)  
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2.3.1.2 Head, arm and abdominal circumference measurements 
The head circumference of the mother (at occipitofrontal level) was measured by an 
ordinary non-elastic tape measure calibrated in centimetres and millimetres. Measurements 
were taken to the nearest 0.1 cm. Mother’s mid-arm circumference was measured using an 
ordinary non-elastic tape measure.  Measurements were taken to the nearest 0.1 cm. The 
abdominal circumference of the baby was measured using an ordinary non-elastic tape 
measure. The tape was placed around baby’s abdomen at the umbilical level (measured on 
expiration). 
 
 
 2. 3. 2 Blood pressure measurement 
The participant’s blood pressure (BP) was measured in the supine position after 
resting. A mercury sphygmomanometer (Baumanometer, kompax desk model; supplied by 
Surgical Instruments (PTY), LTD, Johannesburg, SA) was used and BP was estimated to the 
nearest 2 mmHg by auscultation. An adult standard cuff size was used for all the women, 
except one case, when a larger cuff size had to be used.  
 
 
2. 3. 3 Oral glucose tolerance test (OGTT)   
2. 3. 3. 1 Procedure of the OGTT 
The same oral glucose tolerance test procedure was carried out on pregnant and non-
pregnant women (WHO Criteria 1999). The participant was instructed to abstain from any 
food and beverages from 10.00 p.m. the night before. Limited water intake was allowed. The 
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first (“fasting”) blood sample was collected between 8.00 and 8.30 a.m. (see blood collection 
procedure). An immediate blood glucose level was estimated by means of a Precision 
MediSense Blood Glucose Testing System utilising Precision Plus Electrodes (Abbot 
Laboratories; Abbot Park, Illinois, USA).  This was a simple test carried out before the 
glucose load to confirm if the woman arrived for the visit “fasting”, or to determine if she was 
a diabetic. In the former case the OGTT was performed on another day, and in the latter case 
the woman was referred to the Antenatal Clinic and was excluded from the study.  
 
The participant was given 75 grams of pure glucose (D glucose anhydrous; Saarchem-
Merck, South Africa) in 200 millilitres of water to drink over a 5-minute period. Further blood 
samples were taken at 30, 60 and 120 minutes after taking the oral glucose load.  
 
 
 
2. 3. 3. 2 Blood collection procedure during the OGTT 
 
An intra-venous catheter was inserted by needle into the forearm vein (antecubital 
fossa) of the participant whilst in a supine position. A baseline fasting blood sample was 
collected into a plain 10 ml collection tube to obtain serum and one 5 ml potassium 
oxalate/sodium fluoride tube to obtain plasma sample (Vacutainer blood collection tubes; BD 
Diagnostics; Becton Dickinson Vacutainer Systems; Franklin Lakes, New Jersey, USA). The 
arm was kept warm with an electric heating pad to encourage circulation for ease of blood 
collection. Blood samples were stored at 4oC until the OGTT was completed.  
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2. 3. 4 Postnatal visits of babies 
2. 3. 4. 1. Preparation for the blood collection 
Mothers of neonates were instructed to feed the baby before 6.00 am, so the babies 
would have fasted for three and half to four hours before the test which was commenced 
between 8.30 and 9.00 am. The older babies (5-7 months) fasted for 6 hours. Both fasting 
periods were selected in accordance with an average interval between normal feedings at the 
particular age category (Lewis et al.1990a).  
 
Babies were weighed and measured and their well-being was discussed with the 
mother. A trained nurse collected a blood sample by a heel-prick method (see below). After 
blood collection, mother was encouraged to breastfeed her baby. Baby’s formula for newborns 
(Nestlé NAN Formula Number 1; Nestlé, Vevey, Switzerland) was also made available.  
 
2. 3. 4. 2 Heel-prick blood collection method 
The fasted baby was placed in the supine position and kept warm under a blanket. A 
heating pad placed around the baby’s calf was occasionally used to encourage circulation to 
the heel area. The puncture site on the baby’s heel was cleaned with an antiseptic swab. After 
the site had dried, the skin was punctured on the side of the heel with a sterile lancet (size 
1.00mm x 2.5 mm). The first blood drop was wiped away. The Microtainer tube was held right 
under the blood collection site and blood drops were collected on the gel separator at the 
bottom of the tube (Meites 1988).  Two small-volume pediatric Microtainer tubes were used. 
(BD Microtainer Brand Serum Separator Tube (SST); Catalogue No 365960; Becton 
Dickinson Vacutainer Systems; Franklin Lakes, New Jersey, USA). Between 0.8 -1.0 ml of 
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blood in total was collected. After collection, the tubes were sealed with a stopper and left 
standing for five minutes at room temperature to clot. Then they were kept at 4oC before the 
separation step (see Section 2.7.1 Sample preparation).  
 
 
2. 4 QUESTIONNAIRES AND FORMS 
2. 4. 1 Inclusion criteria questionnaire 
At the volunteer’s first visit to the Day Ward two questionnaires were completed: the 
inclusion criteria questionnaire and the food frequency questionnaire, which was re-
administered at each visit.  
Inclusion criteria questionnaire was a structured questionnaire collecting information 
on personal data, contact details, socio-economic status, education, occupation, medical 
history (see Appendix B).  
 
Assessment of Socio – Economic Status (SES): 
Education level of mother/father was classified into following categories:  
        Age 
1) Illiterate       N/A 
2) Primary school level      <12 years    
3) Standard 6 – 7      12-14 years 
4) Standard 8 – 12, matriculation    14-18 years 
5) Post matriculation, tertiary education   > 18 years 
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Employment status of the mother/father at the time of enrolment: 
1) Student 
2) Employed 
3) Unemployed 
 
Family monthly income categories: 
1) Below or equal to R 1000 
2) Over R 1000 but below or equal to R 2000 
3) Over R 2000 but below or equal to R 3000 
4) Over R 3000 but below or equal to R 4000 
5) Over R 4000 
 
Physical acitivity: A participant was asked if she was most of the time active (walking, 
standing, physically working, excercising) or resting a lot (sitting, lying). 
 
 
2. 4. 2 Food frequency questionnaire 
Nutritional intake during pregnancy (V1 and V2) and postpartum (V3) was assessed by means 
of a semi-quantitative food frequency questionnaire (FFQ) (Appendix C) supplied by a 
registered dietician (J MacKeown, Dental Research Institute, MRC) collaborating with the 
study. This questionnaire was adapted from the original used at Rowett Research Institute, 
Aberdeen, Scotland, for South African populations (MacKeown 1999). It has been validated 
previously by Margetts et al. (1989). A quantitative FFQ has been proven as a reproducible, 
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relatively valid and culturally sensitive method for assessing the dietary intake of Black South 
African in the North-West province (MacIntyre1998, 2001a, 2001b). The repeatability and 
validity of the FFQ have not been re-evaluated in the current study. 
 
 
2. 4. 2. 1 Questionnaire procedure 
Participants were asked to indicate how frequently the listed food items were consumed per 
week, with an extension to a frequency per month for the rarely eaten foods (Appendix C). 
The questionnaire was separated into 8 major food groups, listing over 50 main food items. 
The participants also indicated how many main meals and how many snacks they ate per day. 
Data on portion sizes was collected. Examples of serving sizes were available for display to 
each person undergoing the interview. Where there was a difference in volume between the 
raw and the cooked food item (e.g. rice or pasta), the cooked nutrient was considered. No 
correction was made for seasonal food, like fruits and vegetables. At the end of the 
questionnaire, participants were asked about the number of portions of certain food groups 
they ate the day before the interview and if this was a typical intake or different from their 
normal daily intake. This 24-hour recall was not included in the coding for nutritional intake, 
but served as a cross-check of the information reported in the FFQ to minimise possible over 
or underestimation of food consumption. In the case of disagreement between the two 
methods, the respondent would have to repeat the procedure. 
The questionnaire was administered to each participating woman by one of the three 
trained interviewers (study coordinator, 2 nurses). Participants could choose to be interviewed 
also in their native languages Zulu (isiZulu), Xhosa (isiXhosa), Sotho (seSotho), or Tswana 
 110 
(seTswana; http://countrystudies.us/south-africa/45.htm), although the majority selected 
English. 
 
2. 4. 2. 2 Questionnaire coding and evaluation 
 The food information collected by the questionnaire was reviewed and coded onto 
computer coding sheets by the dietician, using the 1991 South African Medical Research 
Council (MRC) Food Composition Tables and codes (Langenhoven 1991a). Either the 
household measure recorded or standard portion sizes were used according to the National 
Research Programme for Nutrition Intervention (NRPNI) Food Quantities Manual 
(Langenhoven 1991b). A specific computer program written by the University of the 
Witwatersrand Computer and Networking Centre was used to determine the mean daily intake 
for each participant (MacKeown). Although only total energy and macronutrient intakes have 
been reported in this study, the micronutrient intakes were also recorded.  
 
The macro and micronutrients assessed using the FFQ were as follows:  
Macronutrients: protein (plant, animal, total), fat (saturated fatty acids - SAFA, 
monounsaturated fatty acids - MUFA, polyunsaturated fatty acids - PUFA, total) cholesterol, 
total available carbohydrate, dietary fibre, added sugar. 
Micronutrients: calcium, vitamin B12, iron, magnesium, phosphorus, potassium, sodium, zinc, 
copper, vitamin A (RE), thiamin (vit B1), riboflavin (vit B2), nicotinic acid, pyridoxin (vit 
B6), folic acid, ascorbic acid, panthotenic acid, biotin, vitamin D, vitamin E, manganese.  
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2. 5  ULTRASOUND SCAN  
 
2. 5. 1 Technical equipment 
The feasibility study was performed on a Toshiba ultrasound machine (Tecmed). The 
instrument employed in further scans was the SONOLINE Sienna Ultrasound Imaging System 
from Siemens Medical Systems, Inc., Ultrasound Group, USA. (Supplier: Authorized EC 
Representative Siemens Aktiengesellschaft Bereich Medizinische Technik in Erlagen, 
Germany).  
 
There were no significant differences found between the variances of fetal biometry 
measurements obtained from the Toshiba vs. the SONOLINE machine, therefore the 
Feasibility study results were merged with the Main study data. (Analysed by one-way 
ANOVA with the Levene’s test for homogeneity of variances. Petrie et al 2000c.) 
The gestational age (US MA) and the fetal weight estimates on both instruments were 
derived from different software pre-programmed formulas (Campbell and Shepard formulas 
respectively for Toshiba and the Hadlock formulas for SONOLINE). Therefore the estimates 
derived from the Toshiba instrument were recalculated using the Hadlock formulas only 
(Hadlock 1984; see Chapter 2.5.2.1) to enable comparisons between the data.  
 
Fetal biometry and amniotic fluid index were evaluated by the real time B-mode 
ultrasound. Fetal well being and utero-placental blood flow in the third trimester were assessed 
by the Doppler ultrasound techniques (http://www.ob-ultrasound). Only trans-abdominal scans 
using a 3.5 MHz curvilinear transducer probe were performed in this study.  
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2. 5. 2  Ultrasound examinations 
Ultrasound examination was carried out twice on all study participants. Routinely the 
scan followed directly after the OGTT procedure in the Day Ward or it was performed as close 
to this visit timing as possible. A requirement of the study was to carry out all scans on one 
ultrasound machine and by one operator.  
 
 
2. 5. 2. 1   Ultrasound examination at the first visit (V1; 20-24 gestational weeks) 
Fetal weight and pregnancy dating were assessed using following fetal biometry 
ultrasound measurements (see Figure 2.2):   
 
1. Biparietal diameter   (BPD) 
2. Head circumference  (HC) 
3. Abdominal circumference  (AC) 
4. Femur length (FL) 
 
These parameters are commonly measured at ultrasound examination during the second 
trimester (18 - 24th week of gestation) and further to estimate fetal growth and look for 
possible presence of fetal anomalies. At this time the fetal anatomy is well developed and 
structures of interest like face, spine, fingers are large enough to be visible for accurate 
evaluation (Reece 1993). 
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Figure 2.2 Ultrasound images of fetal biometry  
 
 
 
Gestational age estimate (Menstrual age by ultrasound; USMA) was derived from all 
four biometric measurements and the regression equation of Hadlock (1984): 
US MA [weeks] based on all four parameters (BPDcm, HCcm, ACcm, FLcm). 
US MA = 10.85 + 0.060 * HC * FL + 0.6700 * BPD + 0.1680 * AC 
 
Head circumference Abdominal circumference
Biparietal diameter Femur length
Fetal 
head 
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In some instances the HC measurement was not recorded. In these cases calculation of 
US MA was based on the regression equation by Hadlock using three measurements only 
(BPDcm, ACcm, FLcm; Sonoline Sienna User Reference 2000; Hadlock 1984).  
US MA [weeks] = 10.61 + 0.175 * BPD * FL + 0.2970 * AC + 0.7100 * FL 
 
Estimated date of delivery (EDD) (Sonoline Sienna User Reference 2000) 
US EDD = 280 days – US MA (in days) at “today’s” ultrasound scan, added to “today’s” date 
(where 280 days is an average length of human gestation). 
 
Estimated fetal weight (EFW) (Sonoline Sienna User Reference2000; Hadlock 1985) 
was calculated according to the regression equation by Hadlock employing all four 
parameters: (BPDcm, HCcm, ACcm, FLcm)  
EFW [g] = 
10^(1.3596 – 0.00386*AC*FL+0.0064*HC+0.00061*BPD*AC+0.0424*AC+0.174*FL) 
1SD = 7.4 %, 2 SD = 14.8 % 
(where 10^(x) means exponent for a base-10 ) 
 
For three measurements only: 
EFW [g] with exclusion of HC based on (BPDcm, ACcm, FLcm).  
EFW = 10^(1.335-0.0034*AC*FL+0.0316*BPD+0.0457*AC+0.1623*FL) 
2 SD = 15.0 % 
(where 10^(x) means exponent for a base-10 ) 
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2. 5. 2. 2  Ultrasound examination at the second visit (V2; 30-36 gest. weeks). 
The same fetal biometry measurements were carried out at ultrasound visit 2 in order 
to assess the fetal size and weight. As single parameters in later pregnancy, the fetal length and 
the abdominal circumference can give the best estimate of fetal age and fetal weight 
respectively (Reece 1993). 
 
The gestational age was calculated by the ultrasound software. However, the estimate 
from the first ultrasound scan was used for all pregnancy dating, as due to normal fetal 
biologic variations the third trimester ultrasound dating is not as reliable (Reece 1993).  
 
Amniotic fluid volume is an important indicator of fetal well-being. It is commonly 
estimated by the ultrasound technique and expressed as an amniotic fluid index (AFI; Phelan 
et al. 1987; Nwosu et al. 1993; Schrimmer et al. 2002). At term the index reaches level of 11-
16 cm (Durbin et al. 2005). Too high or too low AFI (Gramellini et al. 2004) is found with 
pathologic conditions of polyhydramnios and oligohydramnios respectively (Lewis et al. 
1990b). The former may be related to congenital malformations, or maternal diabetes, the later 
may be a consequence of placental insufficiency with decreased placental blood flow and 
growth restriction (Sadler 2000c, Lewis 1990b). 
  
Amniotic fluid index (AFI) was determined by the “four quadrant method” (Moore 
1990, Nwosu et al. 1993, Schrimmer et al. 2002). The AFI represents a sum of the largest 
vertical depth of fluid in each of four arbitrarily divided uterine quadrants (pockets; D1 – D4). 
See Figure 2.3. 
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Fig. 2.3  Four quadrant method for AFI estimation. 
 
 
Doppler measurements.   
To assess the uteroplacental blood flow, fetal well-being and predicting fetal distress, 
hypoxaemia or growth-retarded fetuses, the spectral Doppler ultrasound waveform analyses 
was carried out (see Chapter 1.4.2.4.2). The Doppler ultrasound is a non-invasive real time 
imagining technique commonly used in obstetrics to evaluate maternal and fetal 
haemodynamics, e.g. to study pattern of uteroplacental and umbilical blood flows (Maršál 
1989). The Doppler waveform analysis follows the maximum velocity of red blood cells from 
large arteries during the cardiac cycle (Maršál 1989; Maršál et al.1999). A forward flow is 
seen during the systole and the diastole in normal pregnancies. Low, absent or even reversed 
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diastolic flow indicates various degrees of increased down-stream resistance (Lewis 1990c). 
The velocity of blood flow can be calculated. 
The umbilical cord contains two arteries (carrying deoxygenated blood and waste 
products from fetus towards placenta) and one umbilical vein (carrying oxygenated blood and 
nutrients from placenta to fetus) branching into chorionic plate vessels. The cord on average is 
55 cm long and about 1-2 cm in diameter. The length may vary between 30 and 90 cm (Moore 
1993c). All Doppler scans were done on an umbilical artery.  
 
The spectral Doppler ultrasound waveform analysis uses three major indices to 
evaluate blood flow (Thompson et al. 1988; see Figure 2.4):  
 
1. The Resistance index (RI; also known as Pourcelot ratio) represents a measure of 
resistance to arterial flow (US-TIP):  
RI = (systole – diastole) / systole. With diastole missing (in severe cases of fetal distress) the 
ratio is equal to 1, which presents the index maximum.  
2. Pulsatility index (PI; also known as Gosling and King’s index; PI = (S – D) / A) can also 
reflect reverse flow (S states for a systole, D for a diastole and A is a mean height over one 
cardiac cycle). 
3. Systole to diastole (S/D) ratio introduced by Stuart et al in 1975 as simplified Pulsatility 
index (also known as A/B ratio) (Divon 2002).   
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Figure 2.4:  Spectral Doppler ultrasound  waveform analysis4 performed on the  
maximum velocity of red blood cells from umbilical artery. 
 
 
The fetal well-being was assessed from the global ultrasound outcome. 
 
 
 
 
 
                                                           
4
 All ultrasound images (Figures 2.2, 2.3, 2.4) were taken in the Antenatal Clinic by study sonographer Mrs. Z. 
Holland, for the purpose of this study. 
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Assessment of intrauterine growth retardation (IUGR).  
In addition to the RI, tabulated ratios of HC to AC (by Campbell et al.1977) and of FL 
to AC (by Hadlock et al. 1983) can be used in assessment of fetal growth retardation.  
 
The fetal liver is the most affected fetal organ in cases of abnormal fetal development 
like IUGR or macrosomia (see Chapter 1.1.3.2. Brain sparing effect). The AC measurement 
reflects the liver size and it is considered as the most sensitive single parameter for growth 
retardation detection with sensitivity of 83% and false positive rate of 10% (Reece 1993) Head 
measurements and femur length are usually unaffected (or head is larger) in asymmetrical 
IUGR, while AC is disproportionately reduced (Hadlock et al. 1983; Campbell 1989; see 
Chapter 1.4.1). Therefore, the HC/AC ratio in serial measurements is able to distinguish 
normal growth from symmetric and asymmetric IUGR. Until 36 gestational weeks the HC is 
larger than the AC giving a ratio >1 (Moore et al. 1993b).  
 
In the present study the ratio of Hadlock (FL/AC *100) was used. Between 21 to 42 
gestational weeks this ratio stays practically constant (22 ± 2) with upper limit (90th percentile) 
of 23.5. This limit corresponds to a sensitivity of 63.3% and specificity of 90% for detecting 
IUGR (Hadlock 1983). Values exceeding 23.5 after 21 are considered to be indicative of 
IUGR. 
 
Neonatal Ponderal index is also used as relatively reliable method for recognising 
asymmetric IUGR (Reece 1993.) 
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2.6 DELIVERY AND DELIVERY RECORDS.  
Nurses from the Labour Ward were asked to report to study investigators the 
admission or delivery of any woman volunteering in the study. Delivery information was 
available in the Labour Ward birth register. Detailed notes on labour proceedings and the well-
being of the mother and her infant were recorded in patient’s hospital file and kept in the 
Postnatal Ward where mother was admitted after delivery.  
 
The following information was captured from Delivery records:  
Date of delivery     Placental weight 
Time of delivery     Cord length 
Type of delivery:      Blood loss 
(Normal vaginal delivery;     
Caesarean section)   
Delivery complications 
 
Newborn’s details: 
Birth weight      Apgar score 
Birth length      Sex 
Head circumference     Assessment of age at delivery 
 
Apgar score (introduced by Dr. Virginia Apgar in 1952, Columbia University, USA; 
Casey et al 2001) is a quick and simple method to assess newborns health status. It is 
performed at 1, 5 and 10 minutes after birth. Baby is evaluated on five criteria: skin colour, 
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heart rate, reflex irritability, muscle tone and breathing on a scale of zero to two for each 
criterion. Total Apgar score is a sum of these scores. Scores over 7 are considered as generally 
normal (http://embryology.med.unsw.edu.au/Child/apgar.htm). 
The babies with an abnormal Apgar score (below 7 at 10 minutes) were not selected for 
further study. One neonate was excluded for this reason.  
 
 
 
2.7 BIOCHEMICAL ANALYSIS  
2.7.1 Specimen collection and storage. 
 
Pregnant women and mothers. 
 
Serum: blood was collected by venepuncture into plain blood collection tubes (Vacutainer 
blood collection tubes; BD Diagnostics; Becton Dickinson Vacutainer Systems; Franklin 
Lakes, New Jersey, USA), allowed to clot, and kept at 4°C until all the OGTT samples were 
collected. The chilled blood samples were processed further; serum was separated from cells 
by centrifugation (Beckman, TJ-6, table top horizontal rotor/swing-out head centrifuge) at 
speed of approximately 1300 - 1400 x g for 15 to 20 minutes at approximately 4°C. Samples 
were stored at -20°C until assayed.  For longer storage a set of samples was kept at -75°C, as 
well as samples for IGF-1 estimation.   
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Serum from fasting samples collected at each of the three maternal visits was used for 
measurement of insulin, proinsulin, leptin, IGF-1, IGF BP-1, IGF BP-3, thyroid hormones, 
HPL, C-Peptide and cortisol. In addition, the serum samples collected during postprandial 
time points (30’, 60’ and 120’) of the OGTT were used for insulin, proinsulin and C-peptide 
assays. The HPL was measured only during pregnancy (visits V1 and V2) and cortisol only at 
V2 and V3 from fasting blood samples collected between 8.00 and 8.30 a.m (see Chapter 
2.3.3.1). Haemoglobin concentration was obtained from the Antenatal Clinic records at the 
time of enrollment.  
 
Plasma: blood was collected into Vacutainer tubes containing potassium oxalate and sodium 
fluoride as an anticoagulant. Collected samples were thoroughly mixed with the anticoagulant. 
Tubes were kept at 4°C until all the OGTT samples were collected and the chilled samples 
were processed further. Plasma fraction was separated by centrifugation (Beckman, TJ-6, table 
top swing head centrifuge) at speed of approximately 1300 - 1400 x g for 15 to 20 minutes at 
4°C. Samples were stored at -20°C until assayed.  For longer storage a set of samples was kept 
at    -75°C. Plasma samples (F, 30’, 60’ and 120’ of the OGTT) were used for measurement of 
glucose levels. 
 
 
Baby samples.  
For babies, only blood for obtaining serum samples was collected to reduce volume of 
blood withdrawn. Therefore, the glucose measurement was performed on serum samples. The 
small-volume paediatric Microtainer tubes were used (BD Microtainer Brand Serum Separator 
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Tube (SST); Becton Dickinson Vacutainer Systems; Franklin Lakes, New Jersey, USA). 
Fasting blood samples were kept at 4°C until completion of baby’s visit (see the heel prick 
sampling procedure above). Afterwards, samples were spun down in centrifuge and stored at –
20°C. For longer storage one sample was kept at -75°C. Serum samples were used for the 
measurement of glucose, insulin, proinsulin, leptin and IGF BP-3.  
 
 
2.7.2 Determination of Glucose.  
Glucose in maternal plasma or babies’ serum samples was analysed using a Beckman 
Glucose Analyser 2 (Beckman Instruments, Fullerton, California, USA).  
 
Principle: The system employed an oxygen consumption rate method developed by 
Beckman Instruments and utilised specific Beckman reagents. The method is based on the 
enzymatic reaction of β-D-glucose from a standard or patient’s sample with dissolved oxygen 
present in the reagent solution as follows:.   
 
           glucose oxidase 
β-D-glucose  +  O2     →    Gluconic acid  +  H2 O2   
       H2O 
 
An electronic system equipped with a Beckman oxygen electrode detects a rate of 
oxygen consumption, which is directly proportional to the concentration of glucose in the 
sample. The technique was selected for its very low sample consumption of 10 microlitres.  
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Sensitivity:  Lowest detectable value 0.6 mmol/l (10 mg/dl; Beckman -User Manual)  
Cross reactivity: No interference found with pathologic levels of bilirubin, uric acid, 
creatinine, lipids or haemolysis up to 1 g of haemoglobin per 100 millilitres. No effect of 
drugs (DOPA, salicylates) or agents preventing glycolysis or coagulation.  
 
Precision. 
Intra assay variation – Standard deviation (SD) was less than 0.14 mmol/l for twenty replicates 
of the Beckman 8.3 mmol/l aqueous standard. 
Inter assay variation - was less than 0.17 mmol/l 
 
 
2.7.3  Immunoassays. 
The majority of analytical tests in this study utilised an enzyme immunoassay carried 
out on 96-well microplates to determine an antigen of interest from collected serum or plasma 
samples. Two basic approaches were used: Assays with competitive binding and assays with 
non-competitive binding.  
 
 
2.7. 3. 1 Instruments  
Instruments employed in present study were the following: 
Microplate shaker/incubator: Amesham UK, Model ZLE.164.  
Microplate washer: Labsystems Multiwash, Model 8070-06; Labsystems Ltd., Helsinki, 
Finland; manufactured in USA.  
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Microplate reader: Labsystem Multiscan Biochromatic, Type 348, Labsystems Ltd., Helsinki, 
Finland.  
 
 
2.7. 3. 2 Non-competitive immunoassay. 
Antigen present in the sample, standard or control is bound between two monoclonal 
antibodies with specific binding sites. The first antibody is attached to a solid phase (capture 
antibody) and the second antibody carries a label for detection: 
• wall – capture antibody – antigen – detection antibody - label  
The unbound fraction is separated from immobilised “sandwich” complex and the amount of 
labelled antibody is detected by a spectrophotometer. The amount of analyte is directly 
proportional to the concentration of the detection antibody, bound to the well of the 
microplate.  
 
 
2.7. 3. 3 Non-competitive assays used in the present study  
 
Insulin (INS) 
INS- EASIA (Enzyme Amplified Sensitivity Immunoassay) kit; BioSource Europe S.A., 
Nivelles, Belgium;  
Catalogue Number: KAP 1251 
Distributed by the Laboratory Specialities, cc, South Africa. 
 
 
 126 
Principle and procedure of the test: 
1) Standards, quality controls and samples were incubated with the capture monoclonal 
antibodies (Mab1) attached to the walls of a microtitre plate and with the detection 
antibody-horseradish peroxidase conjugate (Mab2-HRP).  A sandwich complex was 
achieved in one incubation step:  
• microtitre well wall – Mab 1 – human insulin – Mab 2-HRP.  
2) Unbound Mab2-HRP conjugate was washed off.   
3) Tetramethylbenzidine (TMB) – H2O2 was added as a substrate to produce a 
chromogenic reaction catalysed by the remaining bound Mab2-HRP conjugate.  
4) After a short incubation the reaction was stopped by an acid solution resulting in 
yellow reaction product.  
5) The absorbance values were measured on 96 well-plate reader with colorimetric 
detection at a wavelength of 450 nm.  
6) The concentration of unknown samples was obtained by interpolation from a standard 
curve plot of absorbance values against the known concentration values, of the 
standard samples.    
 
 
Analytical sensitivity. 
The assay detection limit (defined as Ablank + 2*SDblank above the mean of zero calibrator) was 
0.15 µIU/ml  (1.04 pmol/l) 
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Specificity. 
Cross-reactivity: was measured on the high value calibrator. Human proinsulin cross reactivity 
was negligible.  
 
Precision. 
Intra-assay and inter-assay coefficients of variation (CVs) were 5.3 % and 5.6 % for low, and 
3.0 % and 9.8 % respectively for low to medium concentrations of the analyte.  
Upper detection limit: 500 µIU/ml (3450 pmol/l)  
 
 
Proinsulin (PI) 
INTACT PROINSULIN ELISA kit; DakoCytomation Ltd, UK; 
Catalogue Number: K 6242 
Distributed by DakoCytomation, South Africa  
 
Principle of the test: 
The assay is based on the same principle as the insulin assay.  
 
Procedure:  
A sandwich complex was achieved in two incubation steps. Each step involved a washing 
procedure removing unbound antigen after the first incubation period and unbound Mab2-
enzyme following the second incubation period. Also the chromogenic reaction was achieved 
in two steps. After incubating the sandwich complex with an enzyme substrate, an amplifier 
was added into wells.  Nicotinamide adenine dinucleotide phosphate (reduced form; NADPH) 
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was the substrate for the chromogenic reaction. The enzyme amplification system served as a 
highly sensitive detector of alkaline phosphatase molecules, which was the enzymatic label 
used in this assay. The absorbance values were measured at the wavelength of 490 nm.  
 
Analytical sensitivity. 
The assay detection limit was below 0.5 pmol/l. 
 
Specificity. 
No cross-reactivity was detected with human insulin, C-peptide or 32-33 split proinsulin; 
100% cross-reactivity found for 64-65 split proinsulin. No interference from heterophilic (e.g. 
human anti-mouse) antibodies or rheumatoid factor was seen.  
 
Precision. 
Intra-assay and inter-assay CVs were 4.0 % and 5.5 % respectively for low and 
2.4 % and 3.3 % respectively for medium concentrations of the analyte.  
Upper detection limit: 100 pmol/l  
 
 
Leptin   
HUMAN LEPTIN ELISA, Clinical Range kit; Supplied directly from: BioVendor Laboratory 
Medicine, Inc., Czech Republic, EU. 
Cat. No: RD191001100 
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Principle of the test: 
The analysis is based on the same principle as in the insulin assay.  
Procedure:  
A sandwich complex was achieved in a two-step procedure as in the proinsulin assay. 
Horseradish peroxidase was used as an enzymatic label for Mab2. The chromogenic reaction 
was achieved in one step only using TMB as a substrate. The absorbance of the product was 
read at 450 nm.  
 
Analytical sensitivity. 
The assay detection limit (Ablank + 3*SDblank)) was 0.5 ng/ml. 
 
Specificity. 
No cross-reactivity was reported in the kit insert. 
 
Precision.  
Intra-assay and inter-assay CVs were 7.5 % and 9.2 % respectively for low and  
6.7 % and 3.2 % respectively for medium concentrations of the analyte.  
Upper detection limit: 50 ng/ml  
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Insulin-Like Growth Factor 1 (IGF-1) 
OCTEIA IGF-1 kit; IDS (Immunodiagnostic Systems Limited), UK.  
Catalogue Number: AC-27F1 
Distributed by the AEC-Amersham (PTY), LTD, South Africa 
 
Principle of the test: 
The assay is based on the same principle as the insulin assay.  
 
Procedure:  
Prior to the analysis, samples were pre-incubated with a proprietary reagent to dissociate IGF-
1 from binding proteins. The walls of microplate were pre-coated with purified sheep 
polyclonal anti-IGF-1 antibodies. Detection monoclonal antibodies were linked to HRP. A 
sandwich complex was achieved in a one-step procedure. The chromogenic reaction was 
accomplished in the same manner as in the insulin assay. The absorbance values were 
measured at a wavelength of 450 nm.  
 
Analytical sensitivity. 
The assay detection limit was 1.9µg/l. 
 
Specificity. 
Cross-reactivity: no interference was observed with IGF-2, insulin or proinsulin.  
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Precision.  
Intra-assay and inter-assay CVs were 3.5 % and 7.0 % respectively for low and 
2.3 % and 7.1 % respectively for low to middle concentrations of the analyte. 
Upper detection limit: 1070 µg/l (1 µg/l = 0.131 nmol/l) 
 
 
Insulin-Like Growth-Factor-Binding Protein 1 (IGF BP-1)  
IGFBP-1 IEMA (former PP12 IEMA) kit; Oy Medix Biochemica Ab, Finland. Catalogue 
Number: 108 51 ETMB 
Distributed by the AEC-Amersham (PTY), LTD, South Africa 
 
Principle of the test: 
The assay is based on the same principle as the insulin assay.  
 
Procedure:  
A sandwich complex was achieved in a two-step procedure. Further reaction steps and 
reagents used were as in the insulin assay. The absorbance values were measured at a 
wavelength of 414 nm.  
 
Analytical sensitivity. 
The assay detection limit was 0.4 µg/l. 
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Specificity. 
No cross-reactivity was observed with human IGFBP-2, IGFBP-4, IGFBP-5 or IGFBP-6 up to 
concentrations of 5000 µg/l or purified human IGF BP-3 up to hundred thousand micrograms 
per litre. 
 
Precision.  
Intra-assay and inter-assay CVs were 5.4 % and 5.8 % respectively for low and  
5.4 % and 5.9 % respectively for higher concentrations of the analyte.  
Upper detection limit: 180 µg/l  
 
 
Insulin-Like Growth-Factor-Binding Protein 3 (IGF BP-3)   
IGFBP-3 ELISA kit; BIOCODE S.A., Belgium.  
Catalogue Number: EL 2014 
Distributed by the AEC-Amesham (PTY) LTD, South Africa 
 
Principle of the test: 
The assay is based on the same principle as the insulin assay.  
 
Procedure:  
The assay procedure was as in the insulin assay. The enzyme label linked to Mab2 was 
alkaline phosphatase. Para-Nitro Phenyl Phosphate was used as a substrate for chromogenic 
reaction.  The absorbance values were measured at a wavelength of 405 nm.  
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Analytical sensitivity.  
The assay detection limit was 10.5 ng/ml. 
 
Specificity. 
No cross-reactivity was found with IGF-1, IGFBP-1 or IGFBP-2. 
 
Precision.  
Intra-assay and inter-assay CVs were 4.3 % and 13.7 % respectively for low and  
8.3 % and 8.3 % respectively for medium concentrations of the analyte.  
Upper detection limit: 6500 ng/ml  
 
 
Human Placental Lactogen (HPL) 
HPL ELISA kit; DRG Diagnostics, Germany.  
Catalogue Number: EIA-1283 
Distributed by AEC-Amersham (PTY) LTD, South Africa. 
 
Principle of the test: 
The assay is based on the same principle as the insulin assay.  
 
Procedure:  
The assay procedure, label, chromogenic reagent and wavelength at which absorbance 
readings were taken were as in the insulin assay.  
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Analytical sensitivity. 
The assay lower detection limit was 0.3mg/l.  
 
Specificity. 
No cross-reaction with human chorionic gonadotropin (HCG), alpha fetoprotein, human 
growth hormone or prolactin has been detected.  
 
Precision.  
Intra-assay and inter-assay CVs were 6.1 % and 8.8 % respectively for low and 6.7 % and 5.7 
% respectively for medium concentrations of the analyte. 
Upper detection limit: 20 mg/l 
 
 
2. 7. 3. 4  Competitive immunoassay with enzymatic label. 
A fixed quantity of labelled antigen and unknown amount of antigen present in the 
sample, standard or control (analyte) compete for a limited number of specific antibody 
binding sites. At equilibrium two types of immobilised complexes coexist:  
• wall – capture antibody – antigen – label   
• wall – capture antibody – analyte 
Unbound reagents are separated. Bound antigen-label complex is detected by a 
spectrophotometer. The amount of analyte is inversely proportional to the amount of labelled 
antigen.  
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2. 7. 3. 5 Competitive assays in the present study 
They were all solid phase immunoassays. 
 
Cortisol 
CORTISOL ELISA kit; DRG Diagnostics, Germany. 
Catalogue Number: EIA-1887 
Distributed by the AEC-Amersham (PTY) LTD, South Africa. 
Principle of the test and procedure:  
1. Cortisol-HRP conjugate and unknown amount of cortisol present in the sample, 
standard or control competed for a limited number of specific antibody binding sites 
coated on the wells of the microtitre plate. Two immobilized fractions were created:  
• wall – antibody – cortisol – HRP   
• wall –  antibody – cortisol from sample 
2. Washing step removed unbound reagents. 
3.  Tetramethylbenzidine (TMB – H2O2) was added as a substrate to produce a 
chromogenic reaction catalysed by the remaining bound cortisol-HRP conjugate.  
4. After a short incubation period the reaction was stopped by an acid solution resulting 
in a coloured reaction product. 
5. The absorbance values were measured on a 96 well-plate reader with colorimetric 
detection at a wavelength of 450 nm.  
6.  The concentration of unknown samples was obtained by interpolation from a standard 
curve plot of absorbance values against known standard sample concentration values. 
7. The unknown amount of cortisol in the sample was inversely proportional to the 
reaction product, and so to the amount of labelled cortisol. 
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Analytical sensitivity.  
The assay detection limit was 2.5 ng/ml (6.9 nmol/l). 
 
Specificity. 
Cross-reactivity was reported with cortisol (100%), corticosterone (31 %), progesterone, 
deoxycortisol  and dexamethazone <2%.  
 
Precision:  
Intra-assay and inter-assay CVs were 5.0 % and 4.4 % respectively for low and 
9.6 % and 4.0 % respectively for low to medium concentrations of the analyte.  
Upper detection limit: 800 ng/ml  
 
During the study, the manufacturer two times modified the test procedure. In the washing step 
(No 2) the volume of washing buffer was increased from 250 µl to 350 µl and eventually to 
400 µl. 
 
Cross-reactivity in the latest modified kit was reported higher for corticosterone (45 %) and 
for progesterone <9%. 
 
Precision of the latest modified kit:  
Intra-assay and Inter-assay CVs were 8.1 % and 6.6 % respective for low and 3.2 % and 7.7 % 
respective for low to medium concentration of the analyte. 
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A comparison was done between both assays and the results obtained from the new assay 
corresponded well (CV <10%) with the results obtained using the original assay.  
 
C-Peptide (C-PEP) 
C-PEP-EASIA kit; BioSource Europe S.A., Belgium. 
Catalogue Number: KAP 0401 
Distributed by the Laboratory Specialities cc, South Africa. 
 
Principle of the test and procedure:  
Principle and the procedure for the test were the same as for the cortisol assay, except that an 
extra incubation step was included to enhance the sensitivity of the assay. This was 
accomplished by carrying out the competitive incubation in two separate steps; first pre-
incubating samples in antibody-coated wells followed by later addition of the antigen-HRP 
conjugate. Afterwards the assay proceeded according to the routine as described for the 
cortisol assay.  
 
Analytical sensitivity. 
The assay lower detection limit was 0.01 nmol/l. 
 
Specificity. 
Cross-reactivity: 30% cross-reactivity found with monkey C-peptide, and low cross-reactivity 
with biosynthetic human proinsulin. No interference was detected with purified porcine 
proinsulin, C-peptide, insulin or glucagon or beef glucagon. 
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Precision.  
Intra-assay and inter-assay CVs were 6.2 % and 5.7 % respectively for low and 6.7 % and 3.7 
% respectively for low to medium concentrations of the analyte. 
Upper detection limit: 7.5 nmol/l 
(Conversion factor: 1 pmol = 3 ng)   
 
Second C-peptide EASIA kit. 
During the course of the study some changes were made to the original C-peptide kit by the 
manufacturer. The “increased sensitivity” option was removed, and the standard curve 
dilutions and conjugate preparation were changed. The volumes of calibrators, samples, 
standards, enzyme-labelled antigen and stop solution were also modified. The principle of the 
assay stayed identical.  
 
Analytical sensitivity:  
The assay lower detection limit was 0.01 pmol/ml (0.01 nmol/l) as in the previous assay.  
 
Precision:  
Intra-assay and inter-assay CVs were 5.8 % and 9.2 % respectively for low and  
8.4 % and 7.2 % respectively for low to medium concentrations of the analyte. 
Upper detection limit: 5.0 pmol/ml 
 
A comparison was done between both assays and the results obtained from the new assay 
corresponded well (CV <10%) with the results obtained using the original assay.  
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Free Thyroxine ( FT4) 
ACTIVE ®Free T4 EIA kit; DSL (Diagnostic System Laboratories, Inc.), USA. Catalogue 
Number: DSL-10-40100.  
Distributed by the Laboratory Specialities, cc, South Africa. 
 
Principle of the test and procedure:  
Principle and the procedure of the test were the same as in the cortisol assay.  
 
Analytical sensitivity. 
The assay lower detection limit was 0.05 ng/dl. 
 
Specificity. 
Cross-reactivity of the thyroxine antibody was with l-thyroxin 100%, d- thyroxine 98%, d-
triiodothyronine 1.5% and l-tri-iodothyronine 3.0%. No further cross-reactivity or interference 
was found. The enzyme-T4 conjugate did not show any measurable binding to serum proteins 
especially thyroid hormone binding globulin and albumin. 
 
Precision. 
Intra-assay and inter-assay CVs were 7.8 % and 10.8 % respectively for low and 6.5% and 7.9 
% respectively for low to medium concentrations of the analyte.  
Upper detection limit: 7.0 ng/dl 
Conversion factor: 1 ng/dl = 12.9 pmol/l 
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2.8 STATISTICAL ANALYSIS 
 
Statistical analysis was conducted using descriptive and analytical techniques.  
Software used: Statistica version 7, StatSoft, USA. 
 
2.8.1  Preparation of the database 
2.8.1.1 Dietary intake data. 
Dietary intakes of macronutrients were expressed as a percentage of the total energy 
intake. Total energy was reported in kilojoules (kJ; 1kJ=0.239kcal).  
 
Energy available to the body, metabolisable energy, was calculated using Atwater’s 
general factors: 16 kJ/g of carbohydrate, 17 kJ/g of protein and 37 kJ/g of fat based on the 
MRC Food Composition tables and codes (McKeown 1999; Langenhoven 1991a). The 
Atwater system enables one to estimate metabolisable energy of the food from the sum of its 
major components: carbohydrate, protein, fat and alcohol. The Atwater factors express the 
number of kilocalories (kJ) per gram of these nutrients (Mc Neill 2000). As there was no 
alcohol intake among the study participants recorded, this factor was excluded from the 
contribution towards the metabolisable energy. 
 
Thus the equation used was as flows: 
Tot Energy (kJ) = (17kJ/g x g tot protein) + (16 kJ/g x g tot carbohydrate) + (37 kJ/g x g tot 
fat) 
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Protein component. 
Total protein is made up of animal protein and plant protein. 
 
Fat component. 
The total fat includes mainly saturated fats (SAFA), monounsaturated fats (MUFA) and 
polyunsaturated fats (PUFA). The non-fatty acid components are phospholipids, sterols and 
glycerol from triacylglycerols. The composition tables adjust for the non-fatty acid 
components by means of conversion factors  (see Chapter 2.4.2.2; McKeown 1999; 
Langenhoven 1991a, 1991b). 
 
Carbohydrate. 
Total carbohydrate is a sum of the total available carbohydrate and dietary fibre. 
Total “available carbohydrate” is composed of free sugars, dextrins, starch and glycogen. 
It represents the part of carbohydrate that is digested and absorbed and produces a glycogenic 
effect. The dietary fibre is a sum of cellulose, soluble and insoluble polysaccharides (other 
than cellulose) and lignin. The fibre is not digestible, therefore it is not absorbed in the human 
small intestine (Englyst et al. 2000; Mc Neill 2000) 
 
For the analysis of the relationship between nutrient intakes and fetal, maternal and 
postnatal parameters the fat, protein and carbohydrate intakes were expressed as a percentage 
of the total energy intake [%E]. For macronutrient subtypes (animal protein, plant protein etc.) 
their percentage contribution to the total amount of the particular macronutrient was 
calculated. 
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2.8.1.2 Issue of the breast-feeding and formula feeding. 
 
 
At the baby’s first visit the majority of mothers were breast-feeding their babies and 
occasionally using infant formula. There were very few babies strictly breast-fed or babies fed 
with the infant formula only.  
At the infants’ second visit the majority of mothers used combination of infant formula 
and solids, sometimes babies were still breast-fed. Cases, where the baby was only breast-fed 
were very rare.  
Although some records were not available, it can be concluded, that the analysed 
population at both visits was quite homogenic and the categories of infants either breast-fed or 
fed with the infant formula only would have been too few for statistical analysis.  
 
 
 
2.8.1.3 Calculations and Indices 
The BMI for the mother and her infant and the PONDIX for the newborn were 
calculated from the weight and length measurements as stated in Chapter 2.3.1.1. 
 
 Area under curves (AUC) of glucose, insulin, proinsulin and C-peptide was 
calculated using trapezoidal integration (Le Floch et al. 1990). 
 
Insulin resistance as HOMA-IR index – see also Chapter 1.2.1.2.  
In the current study, the insulin resistance in mothers and infants was evaluated by means of 
the HOMA-IR; where:  
HOMA-IR = (Glucose F [mM] * Ins F [uIU/ml])/ 22.5     (Matthews et al. 1985) 
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For the analysis, the data was log-transformed (log HOMA-IR; see Appendix G).  
The HOMA- ß index was not used in the current analysis, although it may be considered in the 
future follow-up analysis, where it will be compared with some other indices.  
 
2.8.1.4 Variables in the database 
All variables were tested for normality using the Shapiro-Wilk’s test. Skewed variables were 
transformed (see Appendix G) before further analysis.  
 
2.8.1.5 Missing values 
The “missing data” in the database were due to the following reasons:  
- some variables were included into the study at later stages (see the Feasibility study). This 
applies to the C-peptide concentrations 30min-120min at V1, neonatal abdominal 
circumference, income index and the number of household occupants.  
Originally, the participant was asked about the family monthly income, however, in the 
majority of cases the mother did not know the father’s income. Therefore indicators such 
as the number of mother’s siblings, education and employment were used instead. Later in 
the study, the income index was introduced, splitting monthly income into divisions of R 
1000 difference. The women were asked how much money (as per income division) do 
they have each month to buy food and to run the household.  
 
- loss to follow-up between pregnancy period and delivery (see Chapter 3.2) 
- loss to follow-up between delivery and postnatal period (see Chapter 3.2) 
- missing records in the patient hospital file (birth records, haemoglobin data) 
- some measurements of the fetal head circumference were not available  
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- in the biochemical analysis a few results were excluded as the samples did not produce 
reproducible results (although re-tested in two separate assays from different triplicates) 
- other variables derived from variables with missing data  
 
 
2.8.2 Descriptive statistics. 
Data was expressed as the mean or median with standard deviation (SD) or 
interquartile range (25th and 75th centiles) in tables and with standard error of the mean (SEM) 
in graphs.  
Changes in mean values between visits were evaluated according to the number of 
visits being compared. For the data collected at two visits only, the variables were analysed by 
means of the Student’s paired t-test. Other variables such as the maternal anthropometry, 
maternal hormones and nutrient intakes collected at each of the three study visits were 
analysed by menas of a linear mixed model, accounting thus for multiple testing. Similarly, 
the OGTT results presented on glucose, insulin, proinsulin and C-peptide (in section 3.4.1) 
were analysed using the linear mixed model (xtreg in STATA statistical software) to evaluate 
the mean effect over time. The outcomes were adjusted (for 3 evaluations) at each visit using 
Bonferroni correction. In cases where the unadjusted p values were 0.000, the adjusted value 
was interpreted as p<0.01. (For details see Appendix I; Analysis framework see Figures 2.5 
and 2.6 – the fat arrows indicate comparison steps taken in the descriptive analysis).  
 
To evaluate the normality of the distribution, the Shapiro-Wilk’s W test was used. 
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Where necessary, the variables were transformed in order to normalise the distribution. Some 
Associations between some variables were evaluated by the Pearson correlation (Chapter 3.10; 
selection of variables). 
 
 
2.8.2.1 The z-scores for neonates and infants 
The birth and the postnatal infant anthropometry was also expressed as weight for length, 
weight for age, length for age, BMI for age and HC for age by means of the z-scores using the 
WHO child growth standards (WHO Anthro, version 3.1.0, June 2010).  
The z-score expresses how many standard deviations above or below the mean the certain 
value lies.  Using a defined international standard, the z-scores enable to compare the 
outcomes with other international studies. 
 
 
2.8.3 Analytical statistics 
 
The data analysis framework is presented in the Figures 2.5 and 2.6. 
The first Figure involves analysis of maternal nutrient intakes, whilst the seconf Figure 
involves analysis of maternal glucose and hormones. For further details see Chapters 3.9 and 
3.10. 
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2.8.3.1 Analysis of dietary intake. 
The major part of the analysis was carried out by multiple linear regression analysis. 
Each independent variable was assessed with particular dependent variable for a linear 
relationship and outliers using Residual Analysis (Predicted vs. residuals plot and Normal 
Probability plot; for transformations applied see Appendix G). Outliers reaching or exceeding 
3 standard residuals (SR) were excluded (see Appendix D,E,F and). 
The effect of maternal nutrient intake on fetal, birth, and postnatal parameters was assessed in 
regression models without and in the presence of confounders (See Appendix D,E,F). 
  
 The regression coefficients β (standardized) and B (non standardized) and p-value 
were recorded, as well as the squared multiple correlation coefficient (R2) and adjusted R2 to 
assess the predictability of the particular model. 
 
All outcomes from the multiple regression analysis involving nutrient intake and fetal, 
birth and postnatal parameters are entered in tables in Appendices D, E, F. The significant 
outcomes adjusted for confounders and outliers are summarised in the analytical section of the 
Results Chapter. 
  
 
 
2.8.3.2 Analysis of maternal pregnancy parameters vs fetal, birth and infant parameters. 
To evaluate possible effects of maternal anthropometry and metabolic profile on fetal 
growth, birth parameters and the postnatal factors indicating risk associated with future Type 2 
diabetes development, correlation analysis was performed. All maternal variables of the V1 
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were entered into parametrical analysis with fetal/birth and infant postnatal parameters. The 
same analysis was repeated for the maternal parameters of V2. All outcomes with p < 0.1 were 
selected for a subsequent analysis with a backward stepwise multiple linear regression to 
evaluate the strongest effects (see Appendix H and Chapter 3.10). 
 
 
 
2.8.3.3 Confounders.  
Selection of confounder for the current study. 
 
The choice of confounders used in the current study was based entirely on the 
literature.  
As birth weight represents a proxy outcome of fetal development, it was assumed, that 
the confounders for fetal development and birth did not differ.  However, their effects may 
differ according to the timing of the exposure. As there was not much information on 
confounders and the significance of different exposure times during fetal development, a set of 
four possible confounders with well-established effects on birth weight were selected (Kramer 
1987, Kramer 2003; See Chapter 1.4.2). Their number was limited with respect to the rule on 
the number of explanatory variables used in a regression analysis (Petrie et al 2000a). This set 
of confounders was applied in all the regression models for both pregnancy visits and for birth 
(See the diagram below).  
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“Exposure”     “Outcome” 
Maternal nutrition    Fetal growth, BW, postnat. development, 
Maternal glucose and hormones   markers of the infant β-cell function. 
       
 
 
   CONFOUNDERS 
Maternal V1 Weight/ Infant weight 
   Maternal height 
   Gestational age/ Birth age/ Infant age 
   Fetal gender 
 
Some of the tested confounders may have actually acted as modifiers (see Kramer 
1987), however, the effect of modification was not assessed in the current study. Effects of 
these confounders can be followed in Chapter 3.9 and 3.10 in Tables 3.10A-C and 3.12 A-C 
and in Appendix D,E,F Pg. 292. 
    
 
The effects of other potential confounders (such as ethnic origin, maternal age, 
maternal health during pregnancy, maternal habits, maternal and family health history; See 
Chapter 1.4.2) were not investigated in the current study, however they were dealt with in 
following ways: 
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In the study design:  
- Investigating only South African urban pregnant women of a Black ethnic origin, although 
ethnic language subgroups were not investigated. 
- By setting up study enrolment criteria (such as maternal age restriction by excluding 
teenage pregnancies and pregnancies of older mothers; non diabetic participants with no 
other chronic disease requiring treatment, normal blood pressure and a haemoglobin level 
above 10g/dl3; singleton pregnancy)  
In the analysis: 
- Confounders such as socio-economic status (education, employment, income, number of 
siblings, number of household occupants), mother’s physical activity or stress were 
investigated in separate statistical analyses. 
- Information was collected and filed for the further analysis (e.g. family health history; 
previous pregnancies, cultural-language groups; health problems during pregnancy; 
previous pregnancies…) 
Effect absent (smoking, drinking alcohol, malaria)  
 
 
2.8.3.4 Data analysis framework. 
 Figures 2.5 and 2.8 represent the study data analysis framework for maternal dietary 
intake and maternal hormones respectively. Broad arrows indicate comparisons in descriptive 
analysis. Changes between maternal paramenters comparing all visits were evaluated by the 
linear mixed model. Changes between the fetal or the infant postnatal parameters were 
analysed by the paired t-test. Thin arrows indicate regression analysis between maternal and 
fetal/birth/infant parameters, including the growth rates. 
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Figure 2.5. Data analysis framework: Effects of maternal nutrition on fetal, birth and postnatal parameters. Thin arrows indicate 
regression analysis between maternal and fetal/birth/infant parameters. Broad arrows indicate comparisons in descriptive analysis. 
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Figure 2.6. Data analysis framework: Effects of maternal glucose and hormones on fetal, birth and postnatal parameters. 
Thin arrows indicate regression analysis between maternal and fetal/birth/infant parameters. Broad arrows indicate comparisons in 
descriptive analysis. 
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CHAPTER 3          
 
RESULTS - DESCRIPTIVE DATA 
In this Chapter the results of the study are presented. The section of Descriptive data 
shows the characteristics of the study participants, the study follow-up and the descriptive data 
obtained from the mothers, fetuses, neonates and infants.  
 
 
3.1 CHARACTERISTICS OF STUDY PARTICIPANTS 
3.1.1  Ethnic groups 
The majority of the study participants were Zulu speakers (Figure 3.1), exceeding the 
other most frequent language groups, Xhosa and Sotho, by 3.4 and 4.8 fold respectively.  
 
3.1.2 Age distribution 
The age at enrolment was restricted by study selection criteria (Chapter 2.2.1) to 18-40 years.  
According to Figure 3.2 the majority of women enrolled into the present study were 25-30 
years of age. The remainder of women was predominantly in the older rather than the younger 
age groups.  
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Figure 3.1 Language-cultural background of women enrolled into the study.  
 
 
 
3.1.3 Socio-economic background 
 
3.1.3.1 Level of education (Figure 3.3) 
The majority of women participating in the study completed their education between 
14-18 years of age (standard 8 and matriculation category of the education level; see Chapter 
2.4.1). This category exceeded the other categories of education by at least 3.5 fold.  
* TSONGA/ SHANGAAN 
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Figure 3.2 Distribution of the mothers’ age at enrolment. 
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Figure 3.3 Education level of baby’s parents at the time of enrolment. (See Chapter 2.4.1) 
Levels of education correspond to the <12 years, 12-14 Years, 14-18 years and 
>18 years of age categories respectively. 
St = Standard 
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The education of the mothers was comparable with the education level of the infants’ 
fathers, although more men contributed to the lowest education category than women did. 
Educational status was known in 93.5% of the fathers. 
 
3.1.3.2 Employment status (Fig 3.4) 
Although similarly educated, women in their early pregnancy were twice as likely to 
be unemployed as were their partners. A small fraction of participating women and men were 
unemployed and studying, being supported by their parents or partner. Employment status of 
all fathers was known. 
 
3.1.3.3 Family income (Figure 3.5) 
Family monthly income in the majority of participants was in the lowest category 
(below R 1000).  
 
3.1.3.4 Number of household occupants (Figure 3.6). 
This figure demonstrates the crowding in the household. The most common number of 
household occupants was between 2-4 people, although larger “families” of more than 5 
individuals were not exceptional. (However, the exact information on the number of rooms in 
each household was not available. Two families sharing a household or one family sharing a 
single room with relatives or non-family members was not a rare situation). 
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Figure 3.4 Employment status of baby’s parents at the time of enrolment. Studying parent 
was economically supported by the partner or parents. 
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Figure 3.5 Family monthly income in categories (ranges) of Rands with minimum of  
R 400 and maximum of R 9 000. 
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3.1.3.5 Number of mothers’ siblings (Figure 3.7) 
The data in Figure 3.7 reflects the number of siblings of the mother. Between 1 to 6 
brothers or sisters was commonly reported, followed by a steep decline towards higher 
numbers. A single child in a family was rare.   
 
3.1.4 Family history of diabetes and hypertension (Figure 3.8) 
Although the study participants were pre-selected as non-hypertensive and non- 
diabetic, there was a small fraction of those who had a first-degree relative (mother, father, 
brother or sister) who had been treated for one or both of these conditions. Among these 
groups, the maternal family members showed a higher frequency of treated individuals for any 
of the above conditions. The family medical history of the infant’s father was not known by 
about 14% of the mothers. 
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Figure 3.6 Number of adults and children over 3 years of age sharing the household. 
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Figure 3.7 Number of mother’s siblings as an estimation of the size of the family the 
mother came from. 
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 Figure 3.8 Family history of diabetes and hypertension for mothers and fathers. 
 
For 14% of fathers the family health 
background was unknown 
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3.2 STUDY ATTENDANCE  
3.2.1 Follow-up profile  
Figure 3.9 demonstrates loss to follow-up in different stages of the study. From the 
original 126 enrolled mothers at the first visit, 108 (85.7%) completed both pregnancy visits 
and were included in the final pregnancy database. A small decline in these numbers occurred 
at the stage of delivery, when only 105 (83.3%) of the delivery records of enrolled participants 
became available. Considering all stages of the study, the major drop out in the participating 
volunteers was experienced during the postnatal period, as only 77 (61.1%) babies continued 
in the study with the first postnatal visit and 74 (58.7%) babies completed whole study by the 
second postnatal visit. Therefore 41.3 % of enrolled participants in total did not complete the 
study. Reasons are summarized in Table 3.1 (See also Discussion). 
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Figure 3.9 Frequency of the loss to follow-up at different stages of the study.  
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3.2.2 Reasons for the loss to follow-up (Table 3.1 A, B, C) 
The following tables summarise the reasons for exclusion of participants from a 
particular visit or from further follow-up. In a few cases, a participating woman was allowed 
to continue in the study if she missed one visit, as she could still significantly contribute to the 
study outcomes. The reasons for exclusion from the second follow-up (Table 3.1A) included a 
variety of causes, although premature delivery accounted for 7 of these. Two other reasons 
were miscarriage and a missed appointment. During the enrolment of the study a number of 
volunteering women were lost due to limited time given by the woman’s employer for these 
pregnancy visits. Cases like twin pregnancy, hypertension and pregnancy anomalies were 
excluded early in the study. In one case a women attending the antenatal clinic and enrolled 
into the study was found not to be pregnant and one woman with premature delivery still 
attended V2.  
 
In conclusion, from 126 women who were enrolled into the study 18 were excluded 
from the second pregnancy visit V2.  
 
Reasons for the loss to follow-up during delivery (Table 3.1 B) included deliveries in 
different hospitals. Some women who resided temporarily in Johannesburg for the period of 
gestation decided to deliver in their home area. Exceptions were two women who delivered 
out of the Johannesburg General Hospital (one in neighboring Botswana), obtained their birth 
records for the study purpose and returned with their infants for the study follow-up.  In one 
incident a women delivered her baby in her car on the way to Durban. For obvious reasons the 
complete birth records were not available, except the birth weight and the length taken by 
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paramedics. In total, 105 birth records were available, most of them complete with some 
exceptions when a particular measurement was not taken or was not recorded in the woman’s 
hospital file.  
 
 
Table 3.1 Reasons for excluding the woman/baby from a visit or from further  
follow-up (Tables A, B and C). 
 
A. Pregnancy period.  Number 
Twin pregnancy 1 
Pregnancy anomalies 1 
Hypertension 1 
Unwell during OGTT 1 
Not pregnant (negative hPL confirmed by ultrasound) 1 
Not able to attend visits/ refused to participate 3* 
Lost contact  1 
Miscarriage 3 
Premature birth 7 
* One woman missed the second visit, however she attended other visits and completed the study.  
 
B. Delivery. Number 
Stillbirth 1 
Delivered elsewhere and discontinued participation 4 
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After delivery many mothers discontinued their participation (Table 3.1 C) for various 
reasons (e.g. did not want to expose their neonate to heel pricks or baby’s father did not wish 
the mother to continue).  
 
From the total number of babies attending the study postnatally, some of the visits had 
to be cancelled. Two babies were suffering from recurrent episodes of upper respiratory tract 
infections during the winter season and were on antibiotic treatment. One baby was breast-fed 
before blood collection and therefore had to be excluded from the visit, and one mother 
became pregnant prior to the conclusion of the study.  
 
C. Postnatal period. Number 
Newborn with health problem   2 
Mother discontinued participation (unable to attend or refused to continue)  11 
Mother and baby left Johannesburg    3 
Subsequent pregnancy (before V2)   1 
Lost contact   9 
Mother and baby attended only one postnatal visit (stayed in follow-up)*  11 
* Includes also cases when baby was unwell or breast-fed before the blood collection. 
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3.3 ANTHROPOMETRY (Table 3.2) 
As expected, the mean maternal weight during pregnancy increased significantly (n=107; 
p<0.01). There were also significant differences between V1 and the postpartum visit V3 (n= 
73; p=0.018) and V2 and V3 (n=72; p<0.01). The differences in pattern and significance of 
outcomes for maternal BMI were as for the maternal weight. The linear mixed model and the 
subsequent Bonferroni correction for the p value were applied to evaluate differences between 
the repeated maternal visits (See Methods Chapter 2.8.2 and Appendix K). Maternal weight 
gain was calculated from the difference between two pregnancy visits, as no maternal weight 
was taken at delivery or before the V1.  
 
Mean systolic blood pressure at the first pregnancy visit (V1) was 108.1 mmHg 
(ranging from 80 – 130 mmHg) and a very similar value was recorded at the second pregnancy 
visit (V2; 109.2 mmHg ranging from 90-130 mmHg). Half a year postpartum (V3) a rise in the 
systolic blood pressure was noticed, reaching 115.9mmHg and ranging from 80 – 140 mmHg.  
This systolic BP was significantly different in comparison with the V1 (n=71; p=<0.01) or the 
V2 (n=70; p<0.01) level, using the linear mixed model analysis.  The very same pattern and 
significance of outcomes were obtained for the diastolic BP with means and ranges 68.2 
mmHg (50-90mmHg), 69.9 mmHg (50-90mmHg) and 77.4 mmHg (60-100 mmHg) for the 
V1, V2 and V3 respectively (See Appendix K, Table K1 for more details).  
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Table 3.2 Anthropometric measurements and BP of mothers at the antenatal (V1 and V2) and the postnatal visit (V3).  
 
 
 
V1 (n=108) V2 (n=107) V3 (n=73) 
Variable Mean SD Mean SD Mean SD 
Weight [kg] 74.1 13.3 78.6b 12.9 71.6e,g 15.5 
Height [m]                     1.59 0.06 - - - - 
BMI [kgm-2] 29.3 4.8 31.1b  4.6 28.5e,g 5.6 
MWG (V1-V2) [g/d]     - - 59.6#1 33.1 - - 
Systolic BP [mmHg] 108.1 10.1 109.2  10.7 115.9#2;e,h 13.2 
Diastolic BP [mmHg] 68.2 8.2 69.9 8.4 77.4#2;e,h 9.4 
MWG (maternal weight gain); #1(n=106), #2(n=71);  
 
 
b: p<0.010, V1-V2 
e: p<0.010, V2-V3 
g: p<0.050, h: p<0.010, V1-V3 
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3.4 MEASURED METABOLIC PROFILE   
The OGTT results presented on glucose, insulin, proinsulin and C-peptide below (in 
section 3.4.1) were analysed by a linear mixed model. The comparisons were adjusted (for 3 
evaluations) at each visit using Bonferroni correction. (See Chapter 2.8.2 and Appendix K).  
 
3.4.1. OGTT levels of glucose and hormones involved in glucose metabolism.  
3.4.1.1 Glucose levels during the two-hour OGTT (Fig 3.10). 
Maternal mean plasma glucose levels were higher at all time points during the two-
hour glucose tolerance test at V2 compared to V1. Except for the fasting levels (3.8 ± 0.05 
mmol/l at V1 and 3.9 ± 0.04 mmol/l at V2), significance was observed for differences at the 
time points of the glucose curve (5.7 ± 0.1 vs 6.2 ± 0.1 mmol/l at 30 min, 5.7 ± 0.1 vs 6.5 ± 
0.1 mmol/l at 60 min and 5.4 ± 0.1 vs 5.9 ± 0.1 mmol/l at 120 min with p<0.01 at all 
instances). Values are expressed as mean ± SEM. 
 
When V1 data was compared with V3, the V3 glucose levels were higher at all time 
points but only reached significance at fasting and 30 minutes (p<0.01 at both instances). The 
actual values were 3.8 ± 0.1 and 4.4 ± 0.1mmol/l for fasting glucose and 5.7 ± 0.1 and 6.3 ± 
0.2 mmol/l for 30-minute glucose levels at V1 and V3 respectively. When comparing V2 and 
V3 glucose concentrations, the fasting value was higher for V3 (3.9 ± 0.1 vs 4.4 ± 0.1 mmol/l 
at V3; p< 0.01), but at 30 min the levels were very similar (6.3 mmol/l for V3). Afterwards, at 
60 min and 120 min, the V3 levels fell below those for V2 reaching a significant difference 
(p<0.01) only at 1 hour (6.4 ± 1.4 and 6.0 ± 1.8 mmol/l for V2 and V3 respectively). 
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Figure 3.10 Glucose levels during the two-hour OGTT for mothers at all visits. 
Levels are presented as the mean value with a standard error of the  
mean (SEM).  
   
**p<0.01 V1 vs V2 
  ++p<0.01 V2 vs V3 
  ^^ p<0.01 V1 vs V3 
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3.4.1.2 Insulin levels during the two-hour OGTT (Figure 3.11). 
There was no significant difference between the mean serum insulin levels during the 
first pregnancy visit (V1) and levels at V3 at fasting (64.2 ± 2.5 vs 74.6 ± 4.7 pmol/l) or any 
further time point (504.1± 28.0 vs 502.9 ± 42.7 pmol/l respectively for 30 min, 399.5 ± 22.7 vs 
348.5 ± 24.7pmol/l respectively for 60 min and 335.7 ± 20 vs 318.5 ± 30.8 pmol/l respectively 
for 120 min). All insulin values for the third trimester pregnancy visit (V2; 645.1 ± 44.9 pM 
for 30 min, 653.2 ± 47.1 pM for 60 min and 461 ± 29.6 pM for 120 min) were significantly 
higher than the levels at V1 and V3 (p<0.01 at all instances), except for the fasting 
concentration (72.9 pM at V2). 
 
3.4.1.3 C-peptide levels during the 2-h OGTT (Figure 3.12). 
Mean serum C-peptide concentrations increased significantly from the first to the 
second pregnancy visit at the last two time points of the OGTT (from 2.9 ± 0.1 to 3,4 ± 0.1 
nmol/l at 60 min and from 2.8 ± 0.1 to 3.1 ± 0.1 nmol/l at 120 min with p<0.01 at both 
instances). Thus fasting levels (0.5 ± 0.02 vs. 0.6 ± 0.02 nmol/l) and 30 min levels (2.7 ± 0.1 
vs. 2.8 ± 0.1 nmol/l) did not significantly differ. C-peptide concentrations at the postpartum 
visit (V3) were significantly lower than the levels at the second pregnancy visit (2.5 ± 0.1, 2.5 
± 0.1 and 2.3 ± 0.1 nmol/l for 30, 60 and 120 min respectively, where p<0.05 at all instances), 
except for the fasting levels (0.5 ± 0.03 nmol/l). Mean C-peptide levels between the V1 and 
V3 differed significantly only at 1-h and 2-h concentrations (2.9 ± 0.1 vs 2.5 ± 0.1 at 60 min 
and 2.8 ± 0.1 vs 2.3 ± 0.1 nmol/l at 120min with p<0.01 at both instances).  
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Figure 3.11 Insulin levels during the OGTT for mothers at all visits. 
Levels are presented as the mean value with a SEM.  
 
**p<0.01 V1 vs V2 
  ++p<0.01 V2 vs V3 
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Figure 3.12 C-peptide levels during OGTT for mothers at all visits. 
Levels are presented as the mean value with SEM.  
 
**p<0.01 V1 vs V2 
  +p<0.05, ++p<0.01 V2 vs V3 
  ^^p<0.01 V1 vs V3 
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3.4.1.4 Proinsulin levels during the 2-h OGTT (Figure 3.13). 
The mean serum proinsulin pregnancy levels and levels half a year after delivery were 
different between all the three curves at each time point, except for all the visits’ fasting levels 
and the 30 min and 60 min concentrations during gestation. At all instances, concentrations 
rose from the fasting level until the two-hour collection time. The lowest proinsulin 
concentrations were found at the first pregnancy visit. The proinsulin levels continued to 
increase at the second pregnancy visit, and were the highest half a year after delivery. 
 
Measured proinsulin concentrations in the sequence of V1, V2 and V3 were as follows: 
4.3 ± 0.2, 4.9 ± 0.3 and 7.1 ± 0.5 pmol/l for 30 min, 5.9 ± 0.4, 7.0 ± 0.4 and 8.8 ± 0.6 pmol/l 
for 60 min and 8.5 ± 0.6, 9.9 ± 0.7 and 12.0 ± 0.8 pmol/l for 120 min with p<0.01 for all 
comparisons except for the non-significant outcomes for the pregnancy 30min and 60 min 
levels. Fasting proinsulin levels were 1.7 ± 0.1, 2.1 ± 0.1 and 2.6 ± 0.2 pmol/l, showing also 
no significant differences between these levels.  
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Figure 3.13 Proinsulin levels during OGTT for mothers at all visits. 
Levels are presented as the mean value with a SEM. ` 
 
**p<0.01 V1 vs V2 
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3.4.2  Area under the curve for glucose, insulin, proinsulin and C-peptide during the 2-h 
OGTT (Table 3.3 A) 
During pregnancy, the area under the curve for glucose, insulin, proinsulin and C-
peptide increased significantly (p <0.001 for all). The decline in the area under the glucose 
curve between V2 and V3 was not significant. However, in the case of the insulin curve, the 
area under the curve at V3 decreased significantly from V2 and it reached an even lower value 
than the one at the first pregnancy visit (p<0.001). The change between V1 and V3 was not 
significant. Similar changes in the area under the curve for C-peptide was discovered with a 
p<0.001 for V2 vs V3. 
 
The area under the proinsulin curve differed in its character between visits, as it was 
constantly increasing from V1 towards V3. All increases were significant (p<0.001 at all 
instances).  
 
 
Derived variables (Table 3.3 B).  
HOMA-IR index reflecting the mother’s insulin resistance increased significantly 
between both pregnancy visits (p<0.05) and also increased further after pregnancy (p < 0.05 
for V2 vs V3 and p<0.01 for the difference between V1 and V3).  
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Table 3.3 Areas under curves of glucose, insulin, proinsulin and C-peptide during the two-hour glucose tolerance test (Table A)  
and HOMA-IR index (Table B). 
 
V1 (n=108) V2 (n=107) V3 (n=73) 
Table A Mean/ Median SD/ IQR Mean/ Median SD/ IQR Mean/ Median SD/ IQR 
GLC AUC [mmol.l-1. min] 638 564-706 695c 633-785 693i 154 
INS AUC [pmol.l-1.min] 38994 27940-54136 50446c 35366-79302 34931f 24571-52847 
C-PEP AUC [pmol. ml-1. min]  306#2 104 322#3 c 239-424 264#1; f 96 
PI AUC [pmol.l-1.min]    588#3 401-783 665b 489-975 1007f,i 524 
#1(n=73), #2(n=79), #3(n=106); IQR [interquartile range]. For the comparison of AUC the paired t-test with Bonferroni correction were applied. 
 
Table B V1 (n=108) V2 (n=107) V3 (n=74) 
Variable Median IQR Median IQR Median IQR 
HOMA-IR [index]                                        1.42 1.07-1.83 1.73a 1.23-2.26 1.87d,h 1.22-2.77 
IQR (interquartile range; 25th and 75th centiles) 
 
 
a: p<0.050; b: p<0.010; c: p<0.001, V1-V2 
d: p<0.050; f: p<0.001, V2-V3 
h: p<0.010; i: p<0.001, V1-V3 
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3.4.3. Measurement of other metabolic products (Table 3.4 A) 
Mean haemoglobin level at the women’s registration at the antenatal clinic was 12.4 
g/dl. The HPL and IGF-1 concentrations increased from V1 to V2 (p<0.001 HPL and p<0.01 
for IGF-1), whilst the IGF-BP1 and FT4 concentrations decreased (p<0.05 for IGF-BP1 and 
p<0.01 for FT4).  
 
The IGF-1, IGF-BP1, FT4 and cortisol levels differed between the last pregnancy visit 
and the visit half a year following delivery (p<0.01 for each comparison). The mean IGF-1 
concentration peaked at V2, whilst the IGF-BP1 declined from V1 to V3.  The FT4 reached a 
nadir at V2. Cortisol declined between V2 and V3.  
  
The difference in IGF-1 and IGF-BP1 levels was found to be significant between the 
early pregnancy visit and half a year after delivery (p<0.01), while no significant difference 
between these two visits was observed for FT4 levels. Maternal serum leptin showed no 
significant differences for any pair visit comparison, just missing the 5% level significance for 
pregnancy fasting concentrations after the p value adjustment with Bonferroni correction. 
  
The linear mixed model analysis was applied for IGF-1, IGF-BP1, FT4 and LEPT 
between visits comparison, while the Student’s t-test was applied for the variables with the 
data measured at two occassions only. 
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Table 3.4 Levels of other metabolites measured at both pregnancy visits (V1, V2) and the visit (V3) of mothers.  
  
A. V1 (n=108) V2 (n=107) V3 (n=74) 
Variable Mean/ Median SD/ IQR Mean/ Median SD/ IQR Mean/ Median SD/ IQR 
HB [g dl-1]  12.4#1 1.1 - - - - 
HPL [mg l-1] 2.9 2.4-3.6 5.6c 4.5-7.1 - - 
IGF 1 [µg l-1] 182.3 148.5-235.1 324.1b 115.4 113.4e,h 31.2 
IGF BP1 [µg l-1] 68.0 47.1-88.8 61.4a 39.3-80.5 3.7e,h 2.3-7.5 
FT4 [pmol l-1] 12.5 11.2-14.1 11.5b 10.7-13.0 12.6e 1.6 
CORT [ng ml-1] - - 298.5 251.9-354.2 110.1f 44.6 
LEPT [ng ml-1] 24.4 15.3-40.1 28.2 14.3-42.4 24.3 12.5-40.5 
#1(n=105); HB (haemoglobin); IQR (interquartile range; 25th and 75th centiles) 
 
a: p<0.050; b: p<0.010; c: p<0.001, V1-V2 
e: p<0.010; f: p<0.001, V2-V3 
h: p<0.010, V1-V3 
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3.5 NUTRITIENT INTAKES 
The average daily nutrient intake for the study participants is summarised in Table 
3.5. No differences were found between the daily maternal energy or macronutrient intakes 
(in absolute or relative amounts) during pregnancy (i.e. between V1 and V2 visits). 
Between V2 and V3 maternal intake of total fat increased (p<0.05), as did monounsaturated 
(MUFA; p<0.05) and polyunsaturated fatty acid (PUFA; p<0.01) intakes. The total energy 
intake, plant protein, total carbohydrate, total available carbohydrate and added sugar levels 
produced non-significant outcomes only after the adjustment with the Bonferoni correction.  
 
The total energy intake differed between the first pregnancy visit and V3 (p<0.05). 
An increase was seen in plant protein intake, total fat intake, MUFA and PUFA intakes 
with p<0.01 at all instances. Total carbohydrate and total available carbohydrate intakes 
also showed increases at V3 (p<0.05 at both instances).  
 
Total protein expressed as a percentage of total energy intake significantly 
decreased after pregnancy (p<0.01 for both comparisons between V1 and V3 and V2 and 
V3). Increase in total fat expressed as a percentage of energy intake between V1 and V3 
was nearly significant (p=0.069), reaching significance for the comparison between V2. 
and V3 (p<0.05). … 
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Table 3. 5 Average daily nutrient intake per person during the antenatal (V1 and V2) and postnatal (V3) visits.  
 
V1 (n=107) V2 (n=107) V3 (n=74) 
Nutritional factor Median IQR Median IQR Median IQR 
ENERGY [kJ] 7002 5573-9346 7059 5619-9146 7890,g 6487-10274 
TOT PROT [g] 54.0 44.0-68.3 53.8 44.0-72.6 55.3 42.1-71.0 
PL PROT [g] 21.7 14.8-28.0 22.1 16.2-28.1 22.1h 18.5-32.4 
AN PROT [g] 31.8 23.6-42.0 31.4 23.5-45.3 30.6 19.9-38.8 
TOT FAT [g] 64.7 47.0-94.8 69.0 47.0-93.2 86.7d,h 64.7-104.7 
SAFA [g] 22.5 16.7-30.5 23.4 16.0-30.4 24.9 17.6-32.2 
MUFA [g] 20.6 13.8-28.2 21.1 14.6-29.0 28.2d,h 19.9-33.3 
PUFA [g] 16.7 11.0-30.1 15.7 11.6-27.6 25.5e,h 18.9-33.5 
Cholesterol [mg] 212.8 116.9-298.0 187.1 122.6-301.4 205.6 130.9-322.5 
Tot avail CHO [g] 215.4 167.0-280.9 218.7 167.5-273.4 235.1g 184.7-321.9 
TOT CHO [g] 234.5 183.5-300.7 234.8 179.1-288.4 249.9 g 201.1-338.8 
Added sugar [g] 51.9 28.8-74.8 50.1 33.4-74.6 59.8 40.2-77.4 
Dietary fibre [g] 14.6 10.5-20.3 15.4 11.7-21.3 15.0 11.5-21.3 
TOT PROT [% E]  12.9 11.0-15.4 13.0 11.2-14.8 11.7e,h 10.3-12.8 
TOT FAT [% E]  35.3 28.4-41.8 35.0 30.0-40.5 37.5d 31.4-44.6 
TOT CHO [% E] 51.9 45.9-59.4 53.3 46.5-59.7 51.2 45.3-58.0 
SAFA (saturated fatty acids), PUFA (polyunsaturated fatty acid); MUFA (monounsaturated fatty acid); TOT (total); AN (animal); PL (plant);  
PROT (protein); CHO (carbohydrate); SD (standard deviation), IQR (interquartile range; 25th and 75th centiles). 
d: p<0.050,  e: p<0.010, V2-V3; g: p<0.050,  h: p<0.010, V1-V3 
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3.6 ULTRASOUND EVALUATION (See Table 3.6) 
One hundred and seven ultrasound scans were performed at 22.7 ± 2.1 weeks (i.e. V1) 
and the mean estimate of fetal weight was 539.5 ± 192.4 g. The biparietal diameter (BPD) 
measurement was 5.6 ± 0.7 cm, the abdominal circumference (AC) of 17.7 ± 2.5 cm was still 
smaller than the fetal head circumference (HC), 20.3 ± 2.4 cm, and femur length (FL) was 3.9 
± 0.6 cm. As expected, the fetal weight and all the ultrasound biometric parameters increased 
significantly (p<0.001) between the two antenatal ultrasound evaluations. The second 
evaluation was carried out at 33.1± 2.1 weeks of gestation and included 105 mothers. The fetal 
weight estimate was 1968.3 ± 408.6 g, the BPD was 8.3 ± 0.4 cm, the size of the fetal 
abdomen was 28.1 ± 2.2 cm, slowly approaching the size of fetal head (HC of 29.8 ± 1.5 cm). 
The fetal femur was approximately 1.5 fold longer (6.2 ± 0.4cm) than that of the previous 
scan. Resistance index was measured at the second scan only and gave an average result of 0.7 
± 0.1. The mean amniotic fluid index at 33.1 weeks was 12.3 ± 4.4 cm. 
 
The fetal growth rate calculated from the difference in weights between ultrasound 1 
and 2 showed an increase of 20.0 ± 4.2 g per day on average. During the time period between 
ultrasound 2 and the birth, the mean fetal growth rate increased to 29.8 ± 13.3 g per day 
(p<0.001).  
 Hadlock’s ratio [FL/AC] for prediction of IUGR (Chapter 2.5.3.2) was evaluated from 
the second ultrasound scan and the proportion of IUGR cases was calculated. There were 8.6 
% of fetuses with the ratio exceeding the cut-off value of 23.5. Among them, 2.9% were 
borderline cases (with the ratio 23.6, the 90th percentile in the current study) and 1.9% of 
fetuses had both elevated FL/AC ratio and BW below or equal to 2500g.  
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Table 3.6 Ultrasound outcome: Fetal biometry, estimations of fetal weight, gestational age and growth rate, calculated indices 
and ratios.  
 
 
US 1 (n=107) US 2 (n=105) 
Variable Mean/ Median SD/ IQR Mean/ Median SD/ IQR 
Gestational age [weeks] 22.7 2.1 32.9c 31.7-34.4 
EFW [g] 511.0 388-660 1926c 1710-2155 
BPD [cm] 5.6 0.7 8.3c 0.4 
AC [cm] 17.7 2.5 27.9c 26.6-29.4 
HC [cm]                          20.3#4 2.4 29.8#2,c 1.5 
FL [cm] 3.9 0.6 6.2c 0.4 
RI [index] - - 0.7#1 0.1 
AFI [cm] - - 11.8#3 9.1-14.9 
GRRT  [g day-1]           19.7#6 17.4-22.2 27.4#5,c 23.4-33.2 
FL/AC ratio (n=85)§        22.1 1.4 22.0 1.2 
#1(n=94), #2(n=95), #3(n=96), #4(n=98), #5(n=102), #6(n=105);  
c: p<0.001 
 
GRRT-US1 is the growth rate between US1 and US2. GRRT-US2 is the growth rate between US2 and birth. 
§ In respect of the validity criteria for the use of the Hadlock ratio, only 85 values qualified for this analysis (See Chapter 2.5.2.2). 
 
EFW (estimated fetal weight), BPD (biparietal diameter), AC (abdominal circumference), HC (head circumference) 
FL(femur length), RI (resistance index), AFI (amniotic fluid index). 
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3.7 DELIVERY OUTCOMES 
 
Fifty female and fifty five male infants were born in the study for whom the birth 
records were available. The mean birth age was 39.5 ± 1.4 gestational weeks based on the fetal 
age estimate from the first ultrasound scan. The mean birth weight (BW) was recorded as 
3218.3 ± 440.1 g, birth length (BL) was 49.4 ± 2.4 cm, head circumference at birth (BHC) was 
34.6 ± 1.5 cm and placenta weighed 625.2 ± 121.1g (Table 3.7A). Ponderal index was 26.7 
kg/m3 in average and the BW/PLW ratio 5.31 ± 1.2. 
 
 
Table 3.7  Delivery outcomes for 50 female and 55 male newborns and Ponderal  
index (A). Birth weight by baby’s gender is shown in section B. 
 
A. Variable                             N Mean/Median SD/IQR 
Age at birth [weeks]          105 39.5 1.4 
Birth weight [g]                105 3170 2920 - 3400 
Birth length [cm]               101 49.4 2.4 
Head circumference [cm]  102 34.6 1.5 
Placental weight [g]               88 600.0 550.0 -700.0 
BW/PLW  88 5.1 4.5-6.1 
Ponderal Index  [kg.m-3]       101 26.2 24.8 - 28.3 
 
B. Variable                             N Median IQR 
Birth weight (girls) [g] 50 3105.0 2880-3386 
Birth weight (boys) [g] 55 3170.0 2996-3540 
p <0.05 girls vs boys  
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There was a significant difference in the birth weight between boys and girls (p=0.036; 
Table 3.7 B), which was lost if corrected for gestational age, maternal height or BMI. No 
further significant differences between genders were observed for the remaining birth 
parameters or the age at birth. The mean birth weight correlated significantly positively with 
all measured birth parameters. The birth length and the birth head circumference were the 
most strongly associated parameters (p<0.001; R=0.668 and R= 0.612 for BL and HC 
respectively). The ponderal index showed also relatively strong relationship (p=0.001; 
R=0.421), followed by the placental weight (p <0.05; R=0.238). Analyses were performed by 
the one way ANOVA and the parametrical correlation with Pearson p value.  
 
From 105 available birth weight records only 1.9 % (2 infants) of these full term babies 
had a birth weight below 2 500g, another 1.9% (2 infants) were of 2500g and 6.7% (7 babies) 
exceeded the weight of 4000g at birth. 
 
 
3.8 EVALUATION OF NEONATES AND INFANTS 
 
3.8.1 Infants’ age, weight and anthropometry (Table 3.8) 
At the first postnatal visit infants were 3.7 ± 1.3 weeks of age calculated from birth. As 
expected, the weight, length, BMI and abdominal circumference significantly increased 
between visits (n=74; p< 0.001 for all comparisons).  
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Table 3.8a Babies’ age, weight and anthropometry at both postnatal visits (Ba1, Ba2).  
 
Ba 1 (n=77) Ba 2 (n=74) 
Variable Mean/ Median SD/ IQR Mean/ Median SD/ IQR 
Age [weeks from deliv.] 3.7 1.3 22.7c 21.9-24.4 
Weight [g] 3925 595 7532#4,c 1003 
Length [cm] 52.2 2.9 64.8#4,c 3.0 
BMI [kgm-2] 14.6 13.3-15.4 17.5#3,c 16.5-18.9 
AC [cm]                             35.5#1 33.0-37.4 43.0#2,c 40.5-45.0 
#1(n=65), #2(n=71), #3(n=72), #4(n=73); 
c: p<0.001 
 
 
The birth and the postnatal anthropometrical parameters were expressed as z-scores 
(WHO Anthro 2010; see Chapter 2.8.2.1) in order to compare the size of babies with 
adjustment for age or length (Table 3.8b). From the table it is apparent that on average the 
babies in the current study are born slightly shorter and of a lower birth weight for either 
length or age (all the birth z-scores have a negative value), and with a relatively larger head 
circumference.  With increasing baby’s age, the weight z-scores become positive, whilst the 
baby’s length for age scores decreased. Both the weight for age and the length for age pass 
through a nadir at approximately 3-4 weeks of baby’s postnatal age, “catching-up” later 
around the second postnatal visit. However, the z scores for length remain behind the 
international standard at half a year after birth. The increases in BMI for age correspond to the 
increases observed in weight z-scores.  
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Table 3.8b.  Babies’ anthropometry at birth and at both postnatal visits expressed  
as z-scores. 
z-scores Birth (n=101) Ba 1 (n=77) Ba 2 (n=74) 
Variable Mean 95% CI Mean 95% CI Mean 95% CI 
Weight/Length -0.22 -0.47;  0.03 0.13 -0.25; 0.51 0.58 0.32; 0.84 
Weight/Age -0.20 -0.38; -0.02 -0.36 -0.55;-0.17 0.14 -0.10; 0.38 
Length/Age -0.05 -0.30;  0.20 -0.63 -0.94;-0.33 -0.34 -0.64;-0.04 
BMI/Age -0.26 -0.47; -0.05 -0.01 -0.29; 0.26 0.46 0.21; 0.71 
BHC/ Age 0.38 0.15;  0.62 - - - - 
No gender difference in z scores for birth parameters was found.  
 
 
3.8.2 Infants’ glucose and hormonal levels (Table 3.9) 
Average fasting glucose and leptin concentrations between the two postnatal visits 
increased from 4.0 ± 0.5 mmol/l to 4.3 ± 0.6 mmol/l (n=70, p < 0.001) for glucose and from 
3.9 ± 2.9 ng/ml to 4.1 ± 2.5 ng/ml (n=69, p< 0.001) for leptin. Insulin concentrations increased 
from 37.4 ± 17.0 pmol/l to 42.5 ± 15.9 pmol/l, however this change was insignificant (n=68, 
p=0.065). Mean fasting proinsulin (3.7 ± 1.5 pmol/l) concentration declined by the second 
postnatal visit to levels of 3.1 ± 1.3 pmol/l (n=70; p< 0.001). Insulin-like growth factor 
binding protein 3 (IFG BP3) increased between visits (from 1 535 ± 324 µg/l to 2 122 ± 536 
µg/l; n = 70; p< 0.001). Neonatal insulin resistance, measured by the homeostasis model 
analysis (HOMA-IR), increased significantly during the early postnatal life from 0.98 ± 0.41 
to 1.05 ± 0.47 (n=68, p< 0.001). There was no significant change in the postnatal growth rate. 
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Table 3.9 Babies’ glucose, hormones, insulin resistance assessment (HOMA-IR) and postnatal growth at both  
visits (Ba1, Ba2).  
 
Ba 1 (n=76) Ba 2 (n=74) 
Variable Mean/ Median SD/ IQR Mean/ Median SD/ IQR 
GLC F  [mmol.l-1]                                            4.0#7 0.5 4.3c 0.6 
INS F  [pmol.l-1]                34.2 28.0-41.1 38.0#4 32.1-50.0 
PI F [pmol.l-1]                              3.4#7 2.8-4.6 2.8c 2.2-3.5 
IGF BP3 [µg. l-1]                                        1535#7 324 2122c 536 
LEPT [ng ml-1]                                        3.0 1.9-5.2 3.3c 2.5-5.2 
HOMA-IR [mmol.mU.l-2]                                           0.88#6 0.69-1.11 1.05#4,c 0.91-1.37 
GR RT (Del – Ba1,Ba2) [g day-1]                                                                     29.1 10.7 26.9#4 24.0-30.1 
GR RT (Ba 1 – Ba 2) [g day-1]                                                                                                                - - 26.5#1 23.3-29.4 
#1(n=69), #2(n=70), #3(n=71), #4(n=72), #5(n=74), #6(n=75), #7(n=77) 
 
c:p<0.001 
 
 
Normally distributed variables and skewed variables transformed into the logarithmic scale were analysed by means of the Student’s paired t-test. 
For very skewed variables, or in instances where the paired distributions could not be transformed to normality in the same way, the non-
parametrical Wilcoxon matched pairs test was applied. 
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RESULTS - ANALYTICAL DATA 
 
The aim of the analytical part of the data analysis was to identify significant 
relationships between maternal dietary intakes, maternal glucose and hormonal levels and 
fetal, birth and infant parameters. The dietary intakes are relatively modifiable factors and 
they can influence maternal glucose and hormonal levels, and thus the maternal health 
during the childbearing age. Therefore great attention was given to this first-step analysis in 
order to identify macronutrients with possible impact on fetal/infant growth and the 
markers of infant pancreatic ß-cell function. The analysis of nutrient-hormone interactions 
and the building of a complex statistical model will be the next step in the data analysis of 
this study, however, it was not one of aims of the current report.  
 
 
 
3.9 SUMMARY TABLES ON MATERNAL DIETARY EFFECTS 
   
The maternal macronutrient intakes were analysed in an energy-adjusted form 
expressed as a percentage of energy intake.  As all the macronutrients contribute to the total 
energy intake, they are also highly intercorrelated. Thus, in a regression model, it is not 
possible to distinguish between their individual effects on the response variable (Willet et 
al.1986; Dallal 2007). For this reason, and to investigate the isolated effects of each 
macronutrient, the analysis was carried out in individual linear regression models. The 
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response variables were regressed on each of macronutrients with and without adjustment 
for the selected confounders (See Chapter 2.8.3.3) 
For the data analysis framework diagrams see Chapter 2.8.3.4, Figure 2.5. 
 
In this section of the Results Chapter the significant outcomes for energy and 
macronutrients presented in the Appendix D, E and F tables are summarised.  
 
Due to a large number of analyses and results it was not possible to display single 
models with all the covariates and also it was difficult to summarise such outcomes. 
Therefore, a graphical illustration was selected for this purpose, which also enables the 
effects of the selected confounders on the analysed variable to be followed (Tables 3.10 A-
C). All significant outcomes from the tables in Appendix D, E, F were entered in Tables 
3.10 A-C with significant p values indicated using astrices. The top (blue) astrices represent 
associations unadjusted for confounders, whilst the bottom (red) astrices represent the 
model adjusted for the confounders listed below the table.  
  
Again, due to a large number of analyses and data, only significant results of the 
regression models adjusted for confounders (see Appendix D, E, F) are presented in a 
summary form in the tables.  
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Variables of interest:  
 
- Fetal weight (FW), biparietal diameter (BPD), head circumference (HC), abdominal 
circumference (AC) and femur length (FL) from fetal biometry, 
- Birth weight (BW), birth length (BL), ponderal index (PONDIX) and birth weight to 
placental weight ratio (BW/PLAC W) from birth parameters,  
- Infant weight (WEIG), length (LENG) and body mass index (BMI) from the postnatal 
anthropometrical parameters  
- Fasting glucose (GLC F), insulin (INS F), proinsulin (PI F), leptin (LEPT F) and insulin-
like growth factor binding protein 3 (IGF BP3) as markers of infant β-cell function and 
obesity. 
 
As no significant relationships between maternal dietary intake and fetal growth rate 
were found, these results are not presented. 
 
Maternal intakes of macronutrients (except added sugar) were expressed as 
percentage of the total energy intake (%E). Unless stated otherwise, all further analyses 
used macronutrient intake expressed in this way.  
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3.9.1 Maternal dietary intake and associations with fetal weight and 
biometry (Table 3.10A). 
 
 
In all the significant associations between maternal dietary intake and the fetal 
biometry parameters, and where the regression model included adjustment for confounding 
variables, gestational age always dominated. This led to the loss of many significant 
correlations after the adjustment for age, and those that remained, were accompanied by a 
strong adjusted regression coefficient (AR2). In some instances maternal weight 
(associations involving BPD2, AC2 and HC2) and fetal sex (for AC1 associations) also 
showed significant relationships.  
 
Among unadjusted models, only the early pregnancy dietary intakes (V1) showed 
significant associations with concurrent (US1) and later (US2) fetal ultrasound parameters. 
These included maternal AN PROT1, PL PROT1 and SAFA1 intakes correlating with 
fetal weight and the biometrical parameters of the concurrent ultrasound visit. These 
associations were negative, except for the PL PROT1 intake. Similarly, the dietary intake 
of PUFA1 supported fetal growth at the later pregnancy visit and the intake of MUFA1 
was associated with the length of the fetal femur bone (FL2), also only at V2. These two 
positive relationships reflected in the TOT FAT1 intake, which also positively associated 
with FL2.   
  
In adjusted models, the early macronutrient intakes of the mother (V1) produced a 
lesser number of significant associations with the concurrent fetal ultrasound parameters 
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(US1). The strongest association observed was the positive correlation of the TOT 
ENERGY1 intake with the fetal AC1, possibly including a contribution from ADDED 
SUGAR1.  The TOT PROT1 intake was directly related to the fetal BPD1 measurement, 
whereas the TOT ENERGY1 intake correlated negatively with BPD1. However, this latter 
association was very weak and the significance of the outcome depended on exclusion of an 
outlier value.  The scatter plot confirmed a poor linear relationship between both variables 
(not presented), therefore this outcome may have been attributable to a Type I error. 
Similarly, this applied to the association between maternal TOT ENERGY2 intake and the 
concurrent size of fetal abdomen (AC2) and SAFA2 intake and HC2.  The fetal abdomen, 
in turn, was significantly and positively related to the intake of maternal protein (AN 
PROT2 and TOT PROT2). There were two significant positive associations for TOT 
ENERGY2 with the concurrent fetal weight (FW2) and length (FL2). The relationship 
between TOT CHO1 intake and the fetal head (BPD2) was very weak and may also 
indicate a chance outcome. 
  
The strongest relationship between the maternal dietary macronutrient intake and 
fetal biometry was found for the PROT1 intake and the fetal head size (HC2) at the later 
ultrasound scan, adjusted or unadjusted for confounders. The association was negative.  
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Table 3.10 A Associations between maternal dietary intakes and fetal  
weight and biometry. 
 
   US V1 parameters           US V2 parameters       
Fetal biometry 
FW
1 
BP
D
1 
A
C
1 
H
C
1 
FW
2 
BP
D
2 
A
C
2 
H
C
2 
FL
2 
 
TOT PROT1   
** 
  *- 
 
  ***- 
***- 
*- 
PL PROT1  
 
* 
 
** * 
 
     
AN PROT1 *-  **- *- 
 
*- 
 
    
TOT PROT2        
* 
  
AN PROT2  
 
   
   
** 
  
TOT FAT1       
     
                *** 
 
SAFA1 **- 
 
*- **- *-      
MUFA1  
 
       *** 
PUFA1  
 
   ***  *** * *** 
SAFA2 
    
  
 
 
 
*- 
 
TOT CHO1  
 *    
* 
 
  
ADDED SUGGAR1  
 
 
* 
    
  
TOT ENERGY1  
 
* 
 
*** 
    
  
TOT ENERGY2  
 
  
 
** 
  
* 
  
** 
 
+/- direction of the association (no mark indicates a positive association) 
 
Unadjusted  Adjusted for gestational age, MW1, M height, fetal sex 
***   *** p≤ 0.010 
**   ** p≤ 0.025 
*   * p< 0.050 
   
 
NOT APPLICABLE 
NOT APPLICABLE 
NOT APPLICABLE 
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3.9.2  Maternal dietary intake and association with the birth parameters.  
The total protein intake of the mother near her last pregnancy visit (TOT PROT2) 
correlated (p<0.05) with baby’s BW after adjustment for maternal height, weight, birth age 
and the baby’s gender. This was the only association found with any of the birth parameters 
(See Appendix H).  
 
 
 
 
3.9.3  Maternal dietary intake and the infants’ anthropometric 
parameters (Table 3.10 B).  
 
Neonatal visit Ba1: 
The babies’ neonatal length and BMI showed many strong correlations with all the 
maternal macronutrients intakes during the pregnancy period, except for the intake of 
carbohydrates and added sugar and the total energy.  There was a reciprocal relationship  
between  outcomes for the length and BMI variables. There was also a discrepancy between 
the direction (positive or negative) of the effects of the macronutrients taken during the 
second vs. the third pregnancy trimester. The PUFA1 and the TOT PROT2 (specifically 
PL PROT2) showed beneficial effects on the neonatal length (Length1), whilst the TOT 
PROT1 (namely AN PROT1) and the total fat (TOT FAT2 with a major contribution of 
the PUFA2) were found positively related to the neonatal BMI1. 
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Table 3.10 B  Association between maternal dietary intakes and the infants’ 
anthropometry  
 
      Postnatal Ba1     Postnatal Ba2 
TOT PROT1 **- *** 
*** 
 
* 
 *** 
*** 
AN PROT1 ***-  
*** 
   
* 
TOT PROT2 *** 
*** 
 
**- 
   
PL PROT2 *** 
* 
 
***- 
 
*- 
  
**- 
TOT FAT1  *- 
*- 
   
SAFA1     ** 
* 
MUFA1    *- 
**- 
 
PUFA1 **  
*** 
*- 
**- 
   
TOT FAT2 ***- 
***- 
** 
*** 
  **  
*** 
SAFA2     * 
** 
PUFA2 *- 
**- 
*** 
*** 
 
** 
 * 
*** 
ADDED SUGGAR1     *- 
*- 
TOT CHO2      
*- 
TOT ENERGY3    
* 
  
 
+/- direction of the association (no mark indicates a positive association) 
 
Unadjusted  Adjusted for babies’ age and sex 
***   *** p≤ 0.010 
**   ** p≤ 0.025 
*   * p< 0.050 
 
Postnatal  
Anthropom. 
Le
n
gt
h1
 
BM
I1
 
W
ei
gh
t2
 
Le
n
gt
h2
 
BM
I2
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Postnatal visit Ba2: 
There were no effects of maternal nutrient intake on the babies’ neonatal weight 
(Weight1) and only a few correlations with the babies’ postnatal weight at the second visit 
(Weight 2). These associations of the infant weight with TOTPROT1 (positive), PL 
PROT2 (negative), PUFA2 (positive) and with the concurrent mother’s intake of TOT 
ENERGY3 (positive) were all weak. Also, there was only one significant (negative) 
outcome seen for the babies’ postnatal length (Lenght2), and it was with the maternal 
intake of MUFA1.  
 
As with the first postnatal visit, there were also many correlations of macronutrients 
with the postnatal babies’ BMI2. These were for the protein intake TOT PROT 1, 
specifically AN PROT1 and the fat intake of SAFA1 and SAFA2, which all correlated 
positively. There were also negative, weak correlations of BMI2 with the maternal intakes 
of added sugar earlier in pregnancy and of the total carbohydrate (TOT CHO2) later in 
pregnancy. Further, there was a weak positive association between the concurrent maternal 
intake of total energy (TOT ENERGY3) and the babies’ postnatal weight (Weight2).  
 
In the majority of associations with the neonatal anthropometry, the adjustment for 
confounders strengthened the relationship between variables.  
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3.9.4  Maternal dietary intake and the infants’ metabolic parameters 
(Table 3.10 C).  
There were highly significant correlations found between maternal early pregnancy 
intakes of protein (TOT PROT1, AN PROT1) and fat (TOT FAT1, PUFA1) and the 
infant neonatal fasting insulin (INSF1) and the HOMA-IR1 levels. Both metabolic 
variables showed similar associations and directions with the maternal protein and fat 
intakes as those found for the postnatal infant BMI (i.e. positive for the protein and 
negative for the maternal fat intakes). However, the later pregnancy intakes of maternal PL 
PROT2 and fat (TOT FAT2, MUFA2 and PUFA2) were correlated negatively with INS 
F1 and HOMA-IR1 for the protein and positively for the fat intakes. The p values were 
strong and were unaltered by adjustment for the infant age, sex and weight. The maternal 
intake of carbohydrate during the last pregnancy trimester (TOT CHO2) correlated 
negatively with the neonatal INSF1 and the HOMA-IR1 levels. 
 
With a similar pattern, associations of maternal pregnancy macronutrient intakes with the 
babies’ later postnatal INSF2 and HOMA-IR2 levels were observed, although with a 
weaker significance compared to the neonatal levels. In addition, the AN PROT2 intakes 
correlated positively with the INSF2 concentrations, whilst the relationships of the INSF2 
and HOMA-IR2 with the TOT FAT1 and PUFA1 and 2 were non-significant or appeared 
very weak. 
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Table 3.10 C  Association between maternal dietary intakes and the infants’ metabolic 
parameters. 
   Ba1parameters   Ba2 parameters 
Postnatal 
Metabol. p. 
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TOT PROT1          *** 
*** 
*** 
*** 
*  *  ***   
PL PROT1       *- 
**- 
   
AN PROT1  *** 
*** 
*** 
*** 
* 
* 
 *  ***   
TOT PROT2      
 
     
* 
PL PROT2  ***- 
***- 
*- 
*- 
  ***- 
***- 
**- *- 
**- 
  
AN PROT2      * 
** 
   ** 
** 
TOT FAT1           *- 
*- 
**- 
*- 
      
 
 
PUFA1  **-  
**- 
***- 
***- 
   
*- 
   
 
TOT FAT2  *** 
*** 
**  
** 
  **     
MUFA2  *** 
*** 
 
* 
**  
** 
 *** 
** 
 ***   
PUFA2  *** 
*** 
*** 
*** 
     *** 
** 
 
TOT 
ENERGY2 
**- 
*- 
** 
** 
  *- 
*- 
    
 
TOT CHO2  ***- 
***- 
*- 
**- 
  ***- 
***- 
 **- 
***- 
 
 
ADDED 
SUGGAR2 
      * 
 
  
 
TOT 
ENERGY3 
     
 
***- 
  
*- 
*** 
* 
 
ADDED 
SUGGAR3 
   
 
  
   **  
   
+/- direction of the association   Unadjusted Adjusted for baby’s age, weight, sex                           
(no mark indicates a positive association) ***  *** p≤ 0.010 
**  ** p≤ 0.025 
*  * p< 0.050 
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The only associations with the infant fasting glucose levels (neonatal and later 
postnatal GLC F1 and 2) were observed with the TOT ENERGY2 maternal dietary 
intakes, in both instances negative and weak. A relatively stronger and positive association 
was observed for maternal TOT ENERGY2 intake and the neonatal INS F1 concentrations 
and for the maternal TOT ENERGY3 dietary intake and the concurrent INS F2 levels. The 
later relationship was negative. 
 
Whilst there was no association between any maternal dietary intake variables and 
the neonatal proinsulin levels, the later postnatal concentrations (PI F2) correlated 
significantly and negatively with the maternal intake of plant protein at both pregnancy 
visits (PL PROT 1 and 2). However, the later correlation with the PL PROT2 lost 
significance after correcting for baby’s age, sex and weight. A positive association of 
ADDED SUGAR2 with PIF2 was observed. 
 
The babies’ fasting IGF BP 1 (of visit 1 and 2) concentrations showed direct 
relationships with the mothers’ concurrent intakes of TOT PROT, specifically with the AN 
PROT. 
  
The positive associations found between the late pregnancy maternal intake of fat 
(PUFA2) and the concurrent intakes of ADDED SUGAR3 and TOT ENERGY3 with the 
babies’ postnatal leptin levels (LEPT2) decreasead in their significance after adjustment 
for the babies’ age, sex and weight.  
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The main focus of the nutritional analysis was to identify possible effects of 
maternal dietary intakes that could influence postnatal β-cell function of this infant. From 
Table 3.10C it is apparent, that the majority of associations include the neonatal INSF1 and 
HOMA-IR1 variables, and thus these variables may present the greatest opportunity for a 
possible nutritional intervention. As the neonatal INSF1 is the major component of the 
HOMA-IR1 index, and the GLCF1 was related only to the TOT ENERGY2 intake, a 
furthter detailed focus was placed on the associations of maternal dietary intake with 
INSF1.  
 
 
Table 3.11 includes associations of the INSF1 with macronutrient intakes adjusted 
and unadjusted for total energy intake.  The intakes of the crude TOT FAT1 and PUFA1 
earlier in pregnancy and of the PL PROT2 and TOT CHO2 during the second pregnancy 
visit did not produce any significant outcomes.   
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Table 3.11  Major outcomes for maternal dietary intakes and neonatal INSF1 levels 
 
NUTRIENT   Intake V1  (n=76)   Intake V2 (n=75)  
Variable [g] p β 95%CI(b) AR2 Variable [g] p β 95%CI(b) AR2 
TOT PROT1[%E] 0.002 0.231 -0.93; 3.10 0.108 PL PROT2[%E] 0.010 -0.298 0.00; 0.00 0.076 
Crude amount  0.045 0.231 -0.96; 3.02 0.041 Crude amount NSF    
AN PROT1[%E] 0.007 0.307 -0.01; 0.17 0.082 TOT FAT2[%E] 0.004 0.327 0.00; 0.00 0.095 
Crude amount  0.020 0.267 -0.96; 3.01 0.059 Crude amount 0.004 0.330 0.00; 0.01 0.096 
TOT FAT1[%E] 0.022 -0.263 0.00; 0.00 0.057 MUFA2[%E] 0.007 0.312 0.00; 0.00 0.085 
Crude amount  NSF    Crude amount 0.008 0.304 0.00; 0.00 0.080 
PUFA1[%E] 0.012 -0.287 0.00; -0.02 0.051 PUFA2[%E] 0.003 0.335 0.01; 0.03 0.100 
Crude amount  NSF    Crude amount 0.001 0.389 0.01; 0.02 0.140 
     TOT CHO2[%E] 0.005 -0.321 0.00; 0.00 0.091 
     Crude amount NSF    
     TOT ENERGY2 0.029 0.253 0.00; 0.03 0.051 
* The units for the confidence interval (CI) of the slope (b) are expressed in the units of transformation as stated in Appendix G. 
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Figure 3.14 Association between maternal protein and fat intakes and the neonatal fasting insulin and suggested mechanism. 
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3.10    MULTIPLE LINEAR REGRESSION INVOLVING MATERNAL     
AND FETAL - INFANT PARAMETERS  
 
Effects of maternal anthropometric and metabolic parameters on fetal growth rate, 
birth and infant postnatal parameters were investigated and results of this analysis are 
presented in this section (See Figure 2.6 for the analysis framework).  
 
A. Detailed parametrical correlation analysis was performed between maternal 
anthropometric and metabolic parameters and fetal, birth and infant variables of interest in 
order to select variables significantly associated for further analysis.  For this purpose a cut-
off level of p<0.1 was used. These pre-selected variables are listed in detail in Appendix I.  
 
B. The pre-selected variables were tested in the regression analysis as explannatory 
variables for their effects on the response variable using a “backwards selection” (Petrie et 
al. 2000b). Each regression analysis was performed with and without adjustment for 
confounders (see Chapter 2.8.3.3 and in Appendix D, E, F). In some instances both 
outcomes differed according to these approaches, therefore both final models were 
presented in the tables (Appendix J). Each of the presented models includes all final 
covariates significantly related to the fetal-infant parameter of interest. The summarised 
outcome can be followed below in Table 3.12 (A-C). 
 
Separate analyses were done for maternal parameters at visit 1 (V1) and visit 2 
(V2). Where necessary, the correction for an outlier was carried out. In such cases, when 
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differences in corrected/uncorrected B value-outcomes exceeded 10%, both outcomes were 
presented. Transformations and units of the variables are listed in Appendix G. 
 
 
3.10.1  Associations of the maternal anthropometry and her blood 
pressure with the fetal – birth – postnatal size and growth 
rate parameters (Table 3.12 A). 
 
 
As expected, the maternal pregnancy weight correlated strongly with the infants’ 
birth parameters and also with the neonatal Ba BMI1. Adjusting for the birth age, the 
associations with the BL and BHC lost signficance. The relationship of MW1 with the 
fetal growth rate between both pregnancy visits (GRRT1) was possibly mediated via fetal 
weight (Chapter 3.12; see confounders). The maternal height was positively associated with 
infant BW (Chapter 3.12; see confounders) and negatively with the late pregnancy growth 
rate.   
 
The table also displays correlations between the postnatal confounders (infant age 
and sex) and the infant anthropometry. Whilst the birth size and the neonatal BMI1were 
strongly influenced by the birth age, during the later stages (BaV2) the effect of the infant 
sex was more dominant (with girls having greater BMI2 than boys, and boys were growing 
faster than girls between both postnatal visits).  
A strong direct association between maternal SYS BP2 and the fetal GRRT1 
between both pregnancy visits was noted, adjusted or unadjusted for potential confounders.  
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Table 3.12 A  Associations of maternal anthropometry and her blood pressure with 
fetal – birth – postnatal size and growth rate parameters.   
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*** 
 
+/- direction of the association (+ is not entered in the table) 
 
Unadjusted  Adjusted for babies’age, weight, sex 
***   *** p≤ 0.010 
**   ** p≤ 0.025 
*   * p< 0.050 
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3.10.2 Associations of the maternal glucose and hormones with the  
infant birth – postnatal size and the growth rate parameters.   
  (Table 3.12B) 
 
The maternal concentrations of HPL at V1 and V2 and maternal LEPT2 were 
directly associated with the growth rate between these two visits (GRRT1).  
 
The binding proteins IGF BP1 and 2 were significantly associated with the size of 
newborn’s head (BHC), maternal proinsulins were associated with the neonatal BMIBa1 
and maternal fasting glucose (GLCF1) and IGF1 BP 2 concentration with the second-visit 
postnatal BMI Ba2. In all instances the relationships were negative.  
 
The infant BMIBa2 was also positively and strongly associated with the early 
pregnancy maternal levels of LEPT 1 and her insulin resistance at the end of pregnancy 
(INS RES2).  The INS RES2 was also positively related to the infant postnatal growth rate 
(GRRT D-Ba2). 
 
The maternal FT4 of the V1 showed a weak stimulatory effect on the late 
pregnancy (GRRT2) and the postnatal growth rates (GRRT D-Ba2). Some weak inverse 
associations were also seen for maternal PIF2 with GRRT2 and for IGF BP2 with the 
infant BL and the postnatal BMI Ba2. 
 
 
 
 
 204
TAB 3.12B  Associations between maternal glucose and hormones and  
Infants’ birth – postnatal size and the growth rates.  
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***   *** p≤ 0.010 
**   ** p≤ 0.025 
*   * p< 0.050 
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3.10.3 Associations of the maternal glucose and hormones with the 
infant postnatal glucose and metabolic parameters.   
  (Table 3.12C) 
 
 
The babies’ fasting glucose levels at both postnatal visits showed a number of 
associations with maternal hormones. The GLC F Ba1 was positively but weakly related to 
maternal GLCF1 and HPL2 if unadjusted for babies’ age, weight and gender. The neonatal 
GLC F Ba1 was also in a positvie and strong relationship with the maternal levels of 
CORT2 and babies’ concurent age, and inversely was associated with the maternal FT4 
V2  (see model in Appendix J, Table J 2.6). The concentrations of maternal HPL 1 and 2 
were also positively associated with the infant postnatal glucose GLC F Ba2.  
 
The early pregnancy maternal concentrations of FT4 (V1) were inversely related to 
fasting neonatal insulin INS F Ba1, HOMA-IR Ba1 and also to the later postnatal leptin 
LEPT F Ba2 levels. 
 
Both postnatal leptin concentrations were related to the infant sex, each time being 
higher for the female offspring. However, the male offspring was heavier than the female 
offspring of the same age (N=77, R=0.231, F=4.23, p= 0.041; means: 3783g vs. 4056g for 
female vs male Ba1; N=73, R=0.363, F=10.80, p=0.002; means: 7111 vs 7813g for female 
vs male Ba2; Analysed by ANOVA).  
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TAB 3.12C Associations between maternal glucose and hormones and  
   infants’ postnatal metabolic parameters 
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A similar but weaker relationship with the infant sex was also observed for INS F 
Ba2.  The infant weight showed a positive association with HOMA-IR Ba1.  
 
Some weak associations were also seen for maternal proinsulins of the later pregnancy visit 
(PIF2 and PIF-30’ V2) with HOMA-IR Ba1 and for maternal INS-30’ V2 and babies’ 
later postnatal LEPT Ba2. All associations were negative. 
 
 
The major outcomes obtained for maternal glucose and hormones and infants’ 
parameters and growth rates are summarized in Table 3.13 below. 
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Table 3.13 Summary of major outcomes for maternal glucose and hormones and infants’ parameters and growth rates 
 
ANTHROP.    (n=76) METABOL.   (n=76)  
Variable p β 95%CI(b)* AR2 Variable p β 95%CI(b)* AR2 
GRRT1     GLC F Ba1     
HPL1 <0.001 0.390  0.243 GLCF1 0.047 0.228 0.03; 1.69 0.039 
HPL2 0.028 0.217 -0.17; -2.60 0.038 FT4 (2) 0.003 -0.347 -4.46; -20.16 0.156 
LEPT2 <0.010 0.252 0.02; 0.12 0.055 HPL2 0.044 0.224 0.07; 3.15 0.156 
GRRT2     CORT2 0.012 0.293 0.30; 2.19 0.156 
FT4 (1) 0.046 0.197 0.02; 0.90 0.029 INS F Ba1     
PIF2     FT4 (1) 0.003 -0.343 -0.13; -0.58 0.106 
GRRT D-Ba2     HOMA Ba1     
INS RES2 0.006 0.325 0.05; 0.28 0.093 FT4 (1) <0.001 -0.417 -3.12; -9.10 0.227 
 
    GLC F Ba2     
     HPL1 <0.001 0.532 1.19; 2.92 0.270 
     HPL2 0.034 0.116 0.19; 3.99 0.049 
     LEPTF Ba2     
     FT4(1) 0.012 0.291 1.48;10.85 0.072 
* The units for the confidence interval (CI) of the slope (b) are expressed in the units of transformation as stated in Appendix G. 
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3.11  ASSOCIATIONS WITH THE SOCIO-ECONOMIC STATUS 
(SES) OF THE PARTICIPANTS. 
 
Both the mother’s and the father’s education showed significant relationships with 
the family income (p = 0.042 and p=0.017 respectively). Also, there was a strong direct 
relationship between mother’s and father’s educational status (P<0.001). Mothers who were 
employed were more physically active (p<0.001) and their education was inversely and 
strongly (p = 0.006) associated with the number of siblings, as mothers from larger families 
had fewer opportunities to study. Due to an occurrence of low frequencies in the 
contingency tables, the Fisher exact test was applied.  
 
Mothers who were employed were inclined to deliver taller babies (see Table 
3.14A). The employed status of the female also positively correlated with her pregnancy 
weight, BMI and leptin.  Furthermore, employed women showed elevated fasting insulin, 
and insulin resistance index at V1 and GLC F, area under GLC curve and PI levels at 
V2. The neonates of employed women had lower fasting glucose levels than neonates of 
unemployed women (Table 3.14A). Baby’s BL also positively correlated with father’s 
employment, whilst neonatal PONDIX was negatively associated with father’s 
employment status (Table 3.14B).  
 
(In all folowing tables, the 95% CI of the regression slope b is expressed in the 
transformation units of the particular variable. See Appendix G.) 
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Table 3.14 A Relationship between mother’s employment status and maternal, birth and 
infant postnatal parameters. 
Mo employment vs. 
Dependent variable: 
N p β 95% CI (b) AR2 
BL 99 0.034 0.212 1.96; 0.09 0.035 
MW1 106 0.002 0.294 0.07; 0.02 0.111 
MW2 105 0.004 0.280 0.06; 0.01 0.068 
BMI1 106 0.004 0.272 0.06; 0.01 0.093 
BMI2 105 0.010 0.252 0.05; 0.00 0.051 
GLC F2 107 0.038 0.201 0.00; 0.02 0.031 
Area GLC 2 107 0.009 0.252 0.06; 0.01 0.054 
INS F1 108 0.016 0.231 0.14; 0.02 0.044 
INS RES 1* 108 0.014 0.237 0.17; 0.02 0.049 
PI F2 105 0.010 0.247 0.15; 0.02 0.118 
LEPT F1;  106 0.007 0.180 0.18; 0.03 0.569 
LEPT F2 105 0.008 0.184 0.98; 0.16 0.538 
GLC F Ba1  75 0.032 -0.235 -0.02; -0.42 0.153 
Mo (mother); *Maternal insulin resistance was calculated as HOMA-IR; Analysed by the regression analysis. 
All the associations were significant either adjusted or unadjusted for the gestational/postnatal age (where 
appropriate). An exception was the birth length correlation, which, due to a strong relationship with the birth 
age lost the significance in adjustment. For all other variables, the table shows associations corrected for the 
age.  
 
 
Table 3.14 B Association of father’s employment status with birth and infant postnatal 
parameters. 
 
Father employment vs. 
Dependent variable: 
N p β 95% CI (b) AR2 
BL 100 0.001 0.306 0.74; 3.42 0.204 
PONDIX 101 0.006 -0.271 -0.01; 0.07 0.064 
Analysed by the regression analysis.  
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The associations including maternal weight, BMI, proinsulin, maternal leptin and 
infant glucose were adjusted for the gestational/baby’s age (as appropriate).  In addition, 
associations with maternal leptin were adjusted for maternal weight. All the other 
associations, where the age adjustment had no effect, are presented without adjustment. 
Maternal glucose, insulin and insulin resistance values lost their significance after adjusting 
for maternal BMI. An adjustment for the total energy intake did not change the above 
associations and was insignificant in the regression output. The strongest association 
observed was between the fathers’ employment status and the infant birth length (adjusted 
for the birth age).  
 
Interestingly, a correlation was found between parental education and maternal 
cortisol, where lower educational level of baby’s mother or father was associated with 
higher maternal cortisol levels at V2 (Table 3.15). 
 
 
 
 
Table 3.15  Association between parental education and maternal cortisol.  
 
Independent variable Dependent variable N p β 95% CI (b) AR2 
Mo education Mo CORT V2  106 <0.001 -0.329 -0.08; -0.03 0.213 
Fa education Mo CORT V2  99 <0.001 -0.360 -0.07; -0.02 0.233 
Analysed by the regression analysis. Adjusted for maternal BMI and gestational age. Mo (mother), Fa 
(father). 
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No correlation was observed between birth weight and any socio-economic 
indicators selected in this study.  
 
 
 
 
Association between SES and nutrient intake.  
 
Following variables were tested: 
Nutrient intakes at V1 and V2:  
Total Energy 
Total Protein 
Total Fat  
Total carbohydrate  
 
SES variables:  
Income index (4 categories) 
Household occupants (3 categories) 
Number of mother’s siblings (3 categories) 
Mother’s and father’s education (each 4 categories) 
Mother’s and father’s employment (2 categories; students were allocated to the non-
employed category, as their number was low) 
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The nutrient intakes were normalized and the associations between variables were 
tested by means of one-way ANOVA with “unequal HSD” post-hoc test (due to different 
numbers in each category). The Levene’s test was used to test for the variances in the 
groups. In the case of positive outcome of the Levene’s test, the Kruskal Wallis ANOVA 
was applied. (See Table 3.16). 
 
 
Table 3.16.  Relationship between maternal nutrient intakes and SES. 
Compared Variables N F p Post hoc p 
value 
Mother  education: 
TOT  ENERGY1 
TOT CHO1 
 
107 
 
 
4.1 
3.9 
 
0.009 
0.011 
 
0.028 
0.037 
Father education: 
TOT ENERGY1 
TOT PROT1 
TOT FAT1 
TOT CHO1 
 
101 
 
5.3 
3.6 
4.7 
4.2 
 
0.002 
0.017 
0.004 
0.008 
 
0.002 
0.019 
0.005 
0.006 
Mother employment: 
TOT ENERGY1 
TOT PROT1 
TOT FAT1 
TOT CHO1 
 
107 
 
9.4 
5.8 
5.9 
8.9 
 
0.003 
0.018 
0.017 
0.004 
 
0.006 
0.030 
0.029 
0.008 
Father employment: 
TOT ENERGY2 
TOT PROT2 
TOT FAT2 
TOT CHO2 
 
107 
 
14.2 
12.0 
10.9 
13.9 
 
<0.001 
0.001 
0.001 
<0.001 
 
0.006 
0.011 
0.015 
0.006 
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No significant association was found for the number of household occupants, the 
income index or the number of mother’s siblings. Although for the income index and the 
mother’s protein intake at V1 and also for mother’s number of siblings and her total energy 
intake at V1 the ANOVA p value was significant, after application of the post hoc test the 
significance was lost.  
 
Mother’s education, and even more strongly father’s education and mother’s 
employment were associated positively with the nutrient intake at the first pregnancy visit. 
The father’s employment status was associated positively with the mother’s nutrient intake 
at the second pregnancy visit.  
 
No significant association with maternal dietary intake was recorded for the family 
monthly income index.  
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3.12 FURTHER ASSOCIATIONS  
 
The following associations are discussed in Chapters 4.5.1 and 4.5.2. 
 
The strongest determinant of the fetal biometrical parameters was the gestational age at 
both pregnancy ultrasound visits (Table 3.17). 
 
Table 3.17  Gestational age association with fetal biometrical parameters 
 USMA1  (N=106) USMA2  (N=105) 
Parameter β 95%CI (b) AR2 β 95%CI (b) AR2 
FW 0.992 1.84;1.93 0.985 0.796 2.17;2.92 0.814 
BPD 0.973 0.29;0.32 0.973 0.680 8.99;13.72 0.700 
AC 0.952 0.01;0.01 0.947 0.677 0.31;0.47 0.718 
HC 0.983 1.05;1.14 0.961 0.690 30.36;46.81 0.690 
FL 0.971 0.25;0.27 0.966 0.784 9.61;13.08 0.817 
All p values are <0.001.  
95%CI of the slope – units are corresponding to the transformed form of the variable (see Appendix G2). 
 
 
In addition, a significant positive correlation was found for the birth weight and 
maternal height adjusted for the birth age (p=0.013, β=0.219 for height and p<0.001, 
β=0.423 for birth age, AR2= 0.220) and the maternal weight MW1 correlated with the FW1 
(N=107; R=0.207; p=0.033; see confounders). 
 
The male infants were growing faster than the female infants between birth and the 
last postnatal visit (p <0.001, AR2=0.210, F=20.1 by ANOVA). Also, a significant gender 
difference in the infant postnatal leptin concentrations (LEPT1 and 2) with higher levels in 
females (N=76; R=0.286, p=0.012; analysed by ANOVA) was found. The male offspring 
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was heavier than the female offspring of the same age (N=77, R=0.231, F=4.23, p= 0.041; 
means: 3783g vs. 4056g for female vs male Ba1; N=73, R=0.363, F=10.80, p=0.002; 
means: 7111 vs 7813g for female vs male Ba2; Analysed by ANOVA).  
 
A significant inverse relationship between both pregnancy visit maternal IGF BP1 
was found with the birthweight (p=0.002, Spear R=-0.306, N=105). 
 
These correlations are discussed in the Chapter 4.5.2.1. 
 
 
 
 
 
3.13 SAMPLE BIAS 
 
A possible sample bias due to attrition between the women who completed the 
study and the women who left the study after delivery was investigated. The data on the 
major variables (maternal age, nutrient intake, anthropometry and hormones) were 
compared for V1 and V2 with one-way ANOVA. No significant differences were found.  
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CHAPTER 4           
 
DISCUSSION - DESCRIPTIVE DATA 
This section of Chapter 4 includes discussion on the descriptive data. In the first 
part, the characteristics of the women enrolled into the study will be discussed. The next 
part will focus on the data obtained from anthropometric measurements and will compare 
the birth outcome with other studies. A discussion of the maternal dietary intakes and the 
selection of the food frequency questionnaire for this study will conclude this section.  
 
4.1 ENROLMENT AND CHARACTERISTICS OF STUDY 
PARTICIPANTS 
 
4.1.1 Ethnic composition of the study population 
The majority of the study participants were Zulu speaking. This reflects the 
ethnic/language composition of the Black population of Gauteng Province, which has the 
highest urban concentration of Zulu people, while Kwa-Zulu Natal is the most Zulu- 
populated rural area in South Africa (www.sahistory.org.za).  3 
                                                           
3
 The language groups among Black South Africans generally overlap with ethnic population groups. In South 
Africa there are four major ethnic divisions corresponding to four major subgroups of original Bantu 
languages: Nguni, Sotho, Tsonga-Shangaan and Venda (http://countrystudies.us/south-africa/45/htm). 
Nguni includes the Zulu, Xhosa, Swazi and Ndebele speaking groups, accounting for two thirds of the South 
African Black population (www.sahistory.org.za) 
Sotho includes the Northern Sotho (Pedi group), Southern Sotho and Tswana (Ba Tswana).   
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The women attending the 159ANC clinic came from all areas of Johannesburg and 
its townships, where they permanently resided or had moved to temporarily from other 
parts of the country for the duration of their pregnancy.  
 Only South African residents were included in the study. However, six women 
originating in Swaziland two women from Venda and one woman born in Zaire were also 
accepted. Swaziland and Lesotho are two small independent countries surrounded by South 
Africa. All these women were married to South Africans and resided in Gauteng for a 
minimum of 5 years. Thus, the study participants represented quite a variety of 
ethnic/language groups (Figure 3.1). However, due to small numbers in each of these 
groups, except the Zulu speakers, no further analysis in this respect has been carried out.  
The comparison of the Zulu vs. combined non-Zulu ethnic groups was not carried out, as 
the non-Zulu combined population would not represent a homogenic population.  The 
current study did not aim to investigate ethnic differences and such a study would require a 
different study design. 
 
 
4.1.2  Soci-economic background. 
The socio-economic background of participants was assessed from parental 
educational level, employment status, family monthly income, number of household 
occupants and number of mother’s siblings. The household crowding factor was used in the 
Helsinki study, which reported an association between less crowded homes and higher 
social class (Eriksson et al 1999).   
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The women came from different socio-economic strata ranging from middle class 
communities to those of a very poor socio-economic status. In this study there were no 
women from the higher socio-economic background as these women are not likely to seek 
medical attention within the public service and they invariably/preferably attend private 
clinics. Likewise, very few of the women in the study had a tertiary education.  
In South Africa, 80% of all pregnant women, of whom 85.2% are African, attend 
public sector antenatal clinics (SADHS, 1998).  
 
4.1.2.1 Employment status. 
Although similarly educated (Figure 3.3), women in their early pregnancy were 
twice as likely to be unemployed compared to their partners (Figure 3.4). This may be 
partially explained by the pregnancy, but more likely it reflects the pattern within the 
society. Richter et al (2006) followed immigrant groups from the Greater Johannesburg 
area and also found that unemployment of mothers was higher than that of fathers among 
migrants and original residents.  
 
4.1.2.2 Family income  
Family monthly income was difficult to evaluate.  Although an attempt was made to 
obtain direct values in Rands, many women were unsure about the exact amount or 
hesitated to reveal their true income. Therefore, it was more practical to assess the family 
monthly income using categories with the range of R 1000 (Figure 3.5). The majority of 
participants fell in the lowest category (below R 1000).  
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Comparing this classification with the national estimate of average monthly 
earnings for the year 2005 (see below) (Statistics South Africa 2006), it confirms that the 
vast majority of study participants was coming from a poor socio-economic background. 
Only one family had a monthly income that exceeded the national average. The monthly 
income estimates in the formal non-agricultural industry, including bonuses and overtime 
for 2005 were R 7006 with large variance between industries from R 4000 (construction) to 
over R 14 000 (electricity, gas and water supply) per month. 
 
 
4.1.3 Family history of diabetes and hypertension 
In the present study, 35.7% of mothers of the Xhosa speaking group reported a first-
degree relative having treatment for diabetes or hypertension or both, in comparison with 
the Zulu group, where 47.9% of the mothers’ close relatives had been treated for the above 
conditions (Figure 3.8).  However, these data may be biased, as mothers were not sure 
about their family members medical background, and it cannot be excluded, that in many 
cases the health status was unknown to members themselves. This situation was even more 
unclear in the case of the partner’s family members. Therefore 14% of the men had to be 
excluded from the data set. As the majority of mothers reported no family history of 
diabetes in the first-degree relatives, the data was not used in further analysis. 
 
 
In conclusion, the Black pregnant women enrolled into the study were women 
living, or temporarily residing, in the Gauteng area during their pregnancy. The majority 
were Zulu speakers, although a variety of ethnic/language groups was present and the 
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distribution of the major groups reflected the ethnic composition of the Gauteng Province 
(www.sahistory.org.za). A majority of women in the study had completed high school 
education, but few had any tertiary education. Despite similar education level with men, the 
unemployment rate among these women was almost twice as high.  
The study participants were from low and very poor socio-economic levels. This 
was confirmed by the family income figures, which showed that the majority of families 
had income below the national average.  
 
 
4.2 ANTHROPOMETRICAL DATA AND BIRTH OUTCOME 
Maternal anthropometry, birth data and maternal dietary intakes were compared 
with available data from similar studies carried out in developing and developed countries.  
 
4.2.1 Maternal anthropometry. 
Maternal anthropometry was compared with the data from mothers at 28 weeks of 
gestation from the Pune Maternal Nutrition Study (Table 4.1; Rao et al. 2001). This 
pregnancy timing fell between the PND study V1 (20-24 gest. weeks) and V2 (30-36 gest 
weeks).  At both visits, the PND study women were older, heavier with greater BMI and 
they were also taller. They had higher HC and ArC. However, the numbers of women in the 
PND study are much less than in the Pune study, which also is reflected in larger standard 
deviations. The measurements of the mother’s head and arm circumference were added 
only later during the feasibility study, therefore the numbers are low and the data were not 
considered in the analytical part of the study.   
 222
 
The records of mothers in the current study were also compared with the European 
mothers in the Helsinki study (Forsén et al. 1997). The records in the Helsinki study were 
taken at the onset of labour, whilst the records of the women in the current study were from 
30-36 weeks of gestation. However, despite similar heights, the weights and BMIs of the 
European mothers were much lower than those of the women in the current study. One also 
has to consider, that the European mothers were two years younger.    
 
 
 
TABLE 4.1: Comparison of maternal characteristics 
 PND V1 
(n=108) 
PND V2 
(n=107) 
PUNE 28 g.w. 
(n=633) 
HELSINKI* 
(n=3076) 
Variable Mean±SD Mean±SD Mean±SD Mean±SD 
Age [y] 29.0±4.6  21.4 27.4±5.7 
Weight [kg] 74.1±13.3 78.6±12.9 47.3±5.2 67.3±9.1 
Height [m]                      1.59±0.06 - 1.51.9±0.05 1.58±0.06 
BMI [kgm-2] 29.3±4.8 31.1±4.6 20.5±1.7 26.9±3.2 
MHC [cm] #1 - 57.0±2.3 52.3±1.5 - 
MArC [cm] #2 - 28.2±3.5 22.7±1.7 - 
#1(Mother’s head circumference; n=71); #2(Mother’s mid-upper arm circumference; n=68); 
* (Forsén et al. 1997; maternal weight taken on admission to labour) 
 
 
 
 
 
 223
4.2.2 Birth outcome.  
In comparison with the fullterm babies of the India study in Trivandrum - Kerala 
(Table 4.2; Jaya et al. 1995), the Johannesburg babies were heavier (female babies 3123.8g 
± 334.0 vs 2819.7 g ± 410.9 and male babies 3304.1g ± 506.1 vs 2905.2 g ± 431.4), longer 
(49.4 cm ± 2.4 vs 47.7 cm ± 2.2) and had bigger head circumference (34.6cm ± 1.5 vs 
32.4cm ± 1.7). The placental weight (625.5 g ± 121.1 vs 502.4 g ± 43.3) and ponderal index 
(26 kg.m-3 ± 3.0 vs 23 kg.m-3 ± 1.1) were higher. Despite an increasing average BW going 
from low to high socio-economic status in the Trivandrum-Kerala study (with a significant 
difference of 89.6g between the two extremes), the PND study babies’ BW was higher at 
all instances and did not differe with the socio-economic status. 
 
Table 4.2 shows the available data on birth outcomes of the Pune Maternal Nutrition 
Study (rural area; Rao et al. 2001), Southampton study (Godfrey et al. 1996) and of the 
Helsinki study (Forsén et al. 1997; see Chapter 1.1.2).  
  
The African babies had much higher BW than the Indian babies, but lower than the 
European babies, irrespective of gender. A similar relationship was also observed for 
babies’ BL and ponderal index. The HC of the PND study babies was very close to the 
Helsinki babies, with comparable SD, whilst the Indian babies were lower by more than 1 
cm when compared to the PND study. Also the placental weight in the current study was 
very close to the results of the Helsinki study and even larger than the Southampton study. 
However, the placental weight of the Pune mothers was 43% less than that of mothers 
participating in the PND study, despite very similar birth age. … 
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The larger size of the head of babies in the current study was confirmed by the z-
scores. Similarly, from comparison with the z-scores, it was obvious that these babies were 
born shorter and lighter. The fast improvement in the weight for length ratio, exceeding the 
mean value for the standard population (WHO), and the parallel delayed linear growth 
indicated fat accumulation in these relatively stunted infants.  This again was in agreement 
with the elevated BMI for age score (See Table 3.8b).  
 
In conclusion, the birth size of these African babies, although smaller in all 
parameters, is still closer to the size of the Caucasian babies than to the birth size of the 
babies from Trivandrum or Pune of India. These relatively smaller African babies have 
comparable (or even larger) maternal placental sizes in relation to the mothers of both 
European studies. However, in comparison with the small Indian babies, the major noted 
difference was a substantially lower placental size of the Pune mothers.  
………………………………………………………….
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TABLE 4.2: Comparison of the birth characteristics between different studies. 
N 105 3230 633 538 3302 
Variable PND Study Trivandrum, India Pune, India Southampton, UK Helsinki, Finland 
Birth weight ave [g] 3213.7 ± 439.7 2961 ± 348.8 2665 ± 358 3436±480 - 
Birth weight F [g] 3123.8 ± 334.0 2819.7 ± 410.9  3344±463 - 
Birth weight M [g] 3304.1 ± 506.1 2905.2 ± 431.4  3527±496 3440 ± 510 
Birth length [cm]               49.4 ± 2.4 47.7 ± 2.2 47.8 ± 2.0 - 50.2 ± 1.9 
Head circumference [cm]  34.6 ± 1.5 32.4 ± 1.7 33.1 ± 1.2 - 34.9 ± 1.4 
Placental weight                 625.2 ± 121.1 502.4 ± 43.3 360 ± 76.4 533.0±120 634 ± 127 
Ponderal Index  [kg.m-3]       26.6 ± 3.0 23 ± 11 25.0 ± 5.0 - 27.0 ± 2.5 
Age at birth [weeks] 39.5 ± 1.4 37-42 full term 39.4 ± 1.2 40.2±1.3 39.3 ± 2 
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4.3  MATERNAL DIETARY INTAKES IN COMPARISON 
WITH RDA AND OTHER STUDIES. 
 
The maternal dietary intakes were compared with the Pune Maternal Nutrition 
Study (intake at 28 gest. weeks) and the Southampton study (intake at 32.7 gest. weeks) due 
to their ethnic and socio-economic similarities or differences. In addition, the maternal 
dietary intake during pregnancy and at V3 was compared with the Dietary Reference 
Intakes (DRIs)4, with the overall dietary intakes of South African adult females (Steyn et al 
2006) and with an analysis of the American diet (Schaefer et al, 2000; Table 4.3A).  The 
American diet data was selected for comparison due to the known high caloric intake and 
prevalence of obesity among the American population (See Chapter 1.2.1.1). 
 
Under the category of the DRIs, the Recommended Dietary Allowences (RDAs) 
were used for comparison. The RDA values differ for pregnant and lactating and non-
pregnant women. The ranges of protein, fat and carbohydrate expressed as a percentage of 
total energy intakes are available only for the general adult population. Due to the half-year
                                                           
4
 DRIs (2005) include reference values for specific nutrients. They replaced previous Recommended Dietary 
Allowances (RDAs), published from 1941 to 1989 by the National Academy of Sciences in USA, and 
Recommended Nutrient Intakes, published by the Canadian government. DRIs were developed by the 
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes of the Food and Nutrition 
Board, Institute of Medicine, the National Academies, in collaboration with Health Canada. 
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Table 4.3 A:  Comparison of the maternal daily dietary intake of macronutrients with DRIs, overall intake in South African women, 
the Pune Maternal Nutrition Study, the Southampton study and the usual American diet. 
 
 PND PND RDA Pune St*1 South St*2 PND RDA SA women*3 American diet*4 
Nutritional factor V1 V2 Pregn. 28w 32.7w V3 Lactat. Non-pregn. Actual 
Energy [kJ] 7002 7059 - 7000 9682 7890 - 7239 9916 ± 1565 
TOT PROT [g] 54 53.8 71 43.5 85.7 55.3 71/46 61.6 88.9 ± 14.0 
TOT FAT [g] 64.7 69.0 - 32.4 93.2 86.7 - 46.6 92.2 ± 14.6 
TOT CHO [g] 234.5 234.8 175 - 301.9 249.9 210/130 244.5 290.3 ± 45.9 
Fiber [g] 14.6 15.4 - - - 15.0 - 18.7 28.4 ± 4.5 
Cholesterol [mg] 212.8 187.1 - - - 205.6 - 197.9 348.4 ± 55.0 
TOT PROT [%E]  12.9 13.0 10-35§ 10.4 14.7 11.7 10-35§ 14.1 15.0 ± 0 
TOT FAT [% E]  35.3 35.0 20-35§ 17.2 36.4 37.5 20-35§ 22.9 35.0 ± 0 
TOT CHO [% E] 51.9 53.3 45-65§ 72.3 49.0 51.2 45-65§ 62.1 49.0 ± 0 
PND (Pregnancy, Nutrition & Diabetes – current study); *1 (Rao et al 2001); *2(Southampton study; Godfreyet al. 1996);  
*
3
 (Steyn et al 2006); *4(Schaefer et al, 2000; N=1726, age=15-60y)  
DRI (Dietary Reference Intakes); RDA (Recommended Dietary Allowance); § Acceptable Macronutrient Distribution Ranges for general adult 
population (reprinted with permission of the National Academy of Sciences. See Appendix I) 
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time span between the delivery and the last maternal visit V3, there are two values entered 
in Table 4.3 for the postpartum period; the first one is the RDA for the lactation period and 
the second is for non-pregnant women.  
 
 
4.3.1  PND study and national South African data on women 15-64 years 
old (Table 4.3 A and B; Steyn et al 2006). 
   
The PND Study pregnancy total energy intakes were slightly lower than the national 
level for non-pregnant women (7002 and 7059 vs 7239 kJ), however the energy intake at 
V3 exceeded the national level.  The difference between the V2 and V3 intakes was 
838kJ/d. There are increased requirements for energy intake during pregnancy at 
approximately 800 – 1200 kJ/day extra and for the first six month of exclusive breast-
feeding of 2100kJ/d extra in well-nourished population (McNeill 2000). Considering these 
amounts, the total energy intake of the current study participants appears to be low. This 
was largely due to a low intake of protein (54 and 53.8 g/day vs 61.6g/day) and total 
carbohydrate. Comparing the quality of the crude protein with the intakes in similar age 
groups of South African non-pregnant women (Table 4.3B), the consumption of animal 
protein was similar, however, the intake of the plant protein was substantially lower. As the 
dietary intake of plant protein in this study was positively associated with linear growth 
(See Chapters 3.9 and 4.5.1.3), this could contribute to the relatively stunted growth of 
infants during the early postnatal period (see Chapter 4.2.2). In turn, there was a 
substantially higher intake of fat in the PND study (64.7 and 69.0 g/day vs 46.6 g/day). Fat 
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intake increased at V3 to almost double the level of the South African average. The crude 
amount of the dietary fat intake was compared with the similar age categories of South 
African non-pregnant women (Table 4.3.B). The PND study women ate between 1.5-1.9 
fold more of SAFA, 1.2–1.8 fold more of the MUFA and 1.2–2.5 fold more of PUFA. 
Thus, the most frequently consumed fat during the pregnancy period was SAFA, whilst the 
PUFA’s intake increased dramatically after delivery. Looking at the changes in fat 
consumption between visits, the MUFA and PUFA intakes increased significantly, whilst 
the intake of SAFA remained constant.  
The above findings may help explain the z-score data. The PUFA requirements 
during pregnancy are high (Al et al 1995 and 2000). The LC-PUFA is utilised by the fetus 
for brain and retina development, and for bone metabolism (see Chapter 4.5.1.1 and 
4.5.1.3) and during the first two trimesters it is also required by the mother to build her 
pregnancy fat reserves. The SAFA intake in the current study (and in the literature) was 
negatively associated with bone growth. This combined with the low levels of maternal PL 
PROT intake could eventually lead to a shorter, lighter baby with a relatively larger head 
(see Chapter 5 “Summary and Conclusions”). The decline in z-scores for weight/age and 
especially for length/age at the Ba1 visit could correspond to the switch from the maternal 
placental PUFA supply to the breast/formula feeding, which would not fully support 
growth of the baby. An improvement in these scores at the Ba 2 visit may then reflect a 
mobilisation of the infant fat reserves and its own production of PUFAs.  
 It would be expected that these effects were not isolated, but they were 
complemented by effects of other factors, such as vitamins, minerals and maternal 
hormones.  However, these were not components of the current study analysis.  
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Table 4.3 B:   Comparison of the protein and fat categories and the added sugar maternal 
daily dietary intake with the data on South African women 
 PND 
Study 
(N=107) 
PND 
Study 
(N=107) 
PND 
Study 
(N=74) 
SAurban 
women* 
(n=1196) 
SA women 
15-29 years* 
(n=1726) 
SA women 
30-44 years* 
(n=1726) 
Nutritional factor V1 V2 V3 Non-preg. Non-preg. Non-preg. 
PL PROT [g] 21.7 22.1 22.1 22.5 28.2 29.8 
AN PROT [g] 31.8 31.4 30.6 40.1 34.8 31.8 
SAFA [g] 22.5 23.4 24.9 17.6 15.1 13.1 
MUFA [g] 20.6 21.1 28.2 20.8 17.7 15.9 
PUFA [g] 16.7 15.7 25.5 13.1 13.7 10.2 
Added sugar [g] 51.9 50.1 59.8 53.8 48.2 39.0 
PL PROT [%E] 5.1 5.3 5.2 5.3 6.3 6.9 
AN PROT [%E] 8.0 8.0 6.5 9.2 7.2 7.2 
SAFA [%E] 11.8 11.7 11.1 8.6 6.7 6.3 
MUFA [%E] 10.7 10.9 12.1 10.1 7.9 7.6 
PUFA [%E] 10.4 10.2 12.4 6.5 6.5 5.1 
Added sugar [%E] 11.8 11.5 12.4 12.6 10.4 10.4 
*(Steyn et al 2006);  
 
However, there were differences between both investigated populations. The current 
study investigated only urban (and pregnant) women 18-40 years old, while the overall 
national data include rural populations of a wide age range. Also, there is a large samples 
size difference.  
 
MacIntyre (1998) reported differences in fat intake among 25-34.9 year old females 
in rural (50.6g/d), urban middle class (67.6 g/d) and urban upper class (73.0 g/d) 
 231
populations in the North West Province of South Africa. The pregnancy fat intake in the 
PND study was thus in accordance with these levels, considering that the women in the 
current study were of a low to middle class background.  
The large increase in fat intake after delivery may be related to the higher energy 
requirements for breast-feeding (breast milk has high content of fat; Gurr 2000).  
 
Bourne et al (2002) reviewed data from existing studies on the nutritional intake of 
the black population in South Africa and concluded, that within a 50-y period (1940-1990) 
there was a major shift occurring in the macronutrient intake in the urban Black South 
African population. Fat and animal protein intakes increased, while carbohydrate 
consumption and plant protein substantially decreased. Fat consumption increased from 
16.4% to 26.2%, and carbohydrate intake decreased from 69.3% to 61.7% expressed as % 
of total energy (%E), producing a relative increase of 59.7% for fat and relative decrease of 
10.9% for carbohydrate over the 50-y period.  Women in the PND study seem to follow this 
same trend when considering the maternal V1 intake, fat intake (35.3 %E) would represent 
a relative increase of 34.7% between years 1990-2005 whilst the carbohydrate intake of 
51.9%E would correspond to the relative decrease of 15.9% over the 15-y period.   
 
4.3.2 Comparison with the RDA.  
During the pregnancy period, women in the current study had lesser crude protein 
and higher carbohydrate intake than was the RDA.  Expressing the macronutrients as a %E, 
the protein intake was on the low side of the recommended range, whilst total CHO was 
higher and the fat intake was equal or exceeded this range. Intake of crude protein after 
 232
delivery was low for the lactating women, but sufficiently high for the non-pregnant 
women. Total carbohydrate intake exceeded both ranges. The relationship between the 
intake of macronutrients expressed as a %E and RDA was similar as during the gestational 
period.  
In conclusion, based on the comparison with the RDA, it was the protein intake 
adjusted or unadjusted for energy, which appeared to be low and possibly insufficient for 
the requirements of pregnancy and lactation in the current study group.  Although the fat 
intake appeared to be sufficient, this was largely due to the high consumption of SAFA. 
This reflects an unbalanced diet composition, amplified by the low energy intakes, and 
supports the above theory for the possible mechanism explaining the lower weight and 
length z-scores. 
 
4.3.3 Comparison with other studies.  
The energy intake in South African women was much lower than in the 
Southampton study or in comparison with the American diet. Also, total fat intake during 
pregnancy was lower than in the Southampton or American populations and corresponded 
with the value found in the MacIntyre study for middle class women in urban areas of 
South Africa (see above). Total carbohydrate during all visits was below the levels of the 
Southampton and American data. The American population consumed more fibre than did 
the pregnant women in the current study. However, they also consumed more cholesterol.  
When comparing protein, fat and carbohydrate adjusted for energy intake, the Southampton 
study and American data were similar, whilst the protein intake of South African women 
was lower. The energy-adjusted protein consumption in women in the PND study sits at the 
lower limit of the acceptable range of DRIs, below the levels found in the Southampton and 
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American diets. Energy-adjusted amounts of fat and carbohydrate are comparable or 
slightly higher than in the American population.   
 
In comparison with the Pune Maternal Nutrition Study, the pregnancy intake of 
energy was very similar, although the protein intake (crude or energy adjusted) was higher 
and the fat intake (crude or energy adjusted) was twice as high in African women in the 
current study. However, in the Indian women the intake of carbohydrate was the major 
source of the total energy intake, and was found the highest among all the compared 
studies.  
The Pune women were shorter and lighter than the women in the current study, even 
though the energy intakes of both study groups (PND and Pune) were similar. Indian rural 
women are involved in hard physical labour, associated with high energy expenditures 
(NNMB 1991; http://www.unsystem.org/scn/archives/india/ch07.htm). In the PND Study 
the energy expenditure has not been evaluated. However, low levels of physical activity in 
South African urban women have been reported by other authors (Kruger et al 2003) and it 
is possible that this may explain differences in anthropometry between the Pune and the 
PND women. Also low energy reporting by study participants cannot be excluded, although 
the 24-hour recall was used as a crosscheck in the study. 
 
In conclusion, the study participants had a lower intake of energy, especially during 
the pregnancy period, when compared to populations in the developed world. This could 
have been due to a generally lower physical activity in the urban South African women 
and/or due to the low to middle social class of the current study participants. The energy 
intake was also positively influenced by the parental level of education and by their 
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employment status (see Chapter 3.11).  Low energy reporting by study participants also 
cannot be excluded, although the 24-hour recall was used as a crosscheck in the study to 
minimize under- or over-reporting. 
 
The total protein intake was low at all visits in comparison with the national average 
for non-pregnant women or with the Southampton study or for the usual American diet. 
The energy-adjusted intake of fat and carbohydrate were comparable with the Southampton 
and American data. This study population was therefore more comparable to that of Pune 
than to American or Southampton populations. However, despite similar total energy 
intakes compared to the Pune Study, the total protein and fat intakes were higher in the 
African mothers, which may explain their relatively higher weights and larger birthweights 
of their babies. 
 
 
 
4.3.4 LOW ENERGY REPORTING 
The actual level of the energy expenditure and the basal metabolic rate were not 
measured in the current study. Although the age- and sex- specific tables for energy 
expenditure are available (Black 2000), they are not optimal for an assessment of pregnant 
women, as they do not account for the energy supplied for the growth of the fetus, placenta, 
uterus, adipose tissue and breasts (Kramer 1987, McNeill 2000).  
However, underreporting of calorie intake in the South African Black and Indian 
women was evaluated by Waisberg (2009a,b). The assessment was based on the calculation 
of the ratio for the reported energy intake vs. the basic metabolic rate (assessed by means of 
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the electrical impedance measurement) with the cut-off level of ≤ 1.14 for the low energy 
reporters. The study also utilized the same food frequency questionnaire as the current 
study. According to this evaluation, there were 10% among lean, 0% among overweight 
and 45% among obese African women who underreported energy intakes.  
 
 
 
4.4. SELECTION OF THE METHOD FOR DIETARY 
INTAKE ASSESSMENT IN THE CURRENT STUDY 
 
At present there is no dietary assessment method that could accurately measure the 
individual’s true nutrient intake. Any method evaluating a dietary intake has its benefits and 
limitations (Schaefer et al. 2000) and has to be considered as an estimate (MacIntyre 1998; 
MacKeown 1999; Sempos et al. 1999).  
 
A FFQ administered interview was selected for the present study as the most 
suitable way for the dietary intake assessment of the study volunteers. Selection of the 
method depends on the study design, the target population and aims of the study. For 
example, the diet records should not be used in populations where literacy levels are low, 
unless a trained observer is present. Although this method allows quite accurate dietary 
intake, it is labour-intensive and many subjects misreport, especially over longer periods of 
recording, resign or refuse to participate (MacKeown 1999, Nelson 2000, Schaefer et al. 
2000, Erkkola et al. 2001).  
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Food frequency questionnaires are not designed to collect detailed data. The intakes 
of certain food categories or nutrients may be underestimated or overestimated and they 
depend on the respondent’s memory  (Sempos et al. 1999; Schaefer et al. 2000; MacIntyre 
2001a,b; Molag et al. 2007). Therefore they are considered as a less accurate measure of 
the absolute levels of nutrient intakes than recalls or diet records (MacKeown 1999; 
Schaefer et al. 2000). However, the dietary recalls and diet records, if applied over a short 
period of time, do not accurately represent the habitual dietary intake as they may miss 
variations in the intake of less commonly eaten foods (Willet et al.1986; Basch et al 1994; 
Nelson 2000). Therefore 3-7 day long weighed-food record or collection of several dietary 
recalls is recommended (Sempos et al. 1999; Schaefer et al. 2000; Bloemberg et al. 1989). 
Average daily intake is then based on a combination of these records (Bloemberg et al. 
1989). This would increase the precision of estimate, but also the costs and inconvenience 
of repeated interviews  (Nelson 2000, MacIntyre2001a,b).  
 
Epidemiological studies often use FFQs for an assessment of an individual’s 
nutrient intake (MacKeown 1999, Sempos et al. 1999), because the FFQs are generally 
easier to administer, quicker to complete, cheaper than diet records or 24h dietary recall, 
and require minimal coding (Margetts et al. 1989, Sempos et al. 1999). This allows their 
application to a larger number of subjects, which in turn increases statistical power of the 
study. Due to the longer time period they cover, for the assessment of usual dietary intake 
they are considered to be better by some authors than the 24-h dietary recalls (Margetts et 
al. 1989). The semi-quantitative questionnaires are also a useful tool for ranking individual 
intakes. 
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The FFQ employed in this study was easy to complete and its length of 
administration complied with the available time during the study visit. The food list 
composition was based on many years of experience in dietary assessment (MacKeown 
2007) and included food items commonly consumed among the African population group.  
As a part of this questionnaire, a 24-h dietary recall section was inserted as a cross-check 
(see Chapter 2.4.2.1). 
 
 
For a comparison, the dietary intake assessment methods used in the studies of 
Pune, Southampton and South Africa are summarised below. 
 
The assessment of dietary intakes of energy and macronutrients in the Pune 
Maternal Nutrition Study was carried out twice during the pregnancy period (weeks 18 and 
28) and it was based on a modified 24-h dietary recall. The authors also assessed the dietary 
intakes in the form of food groups and this evaluation was performed by means of a FFQ 
(Rao et al 2001). 
 
In the Southampton study, a FFQ was administered to mothers twice during 
gestation (weeks 15.3 and 32.7) for an assessment of the average daily nutrient intake. The 
study used a dietary history crosscheck in the form of a 4-day record during early 
pregnancy (Godfrey et al 1996). 
 
The data on South African women (Steyn et al. 2006) were part of a study 
comparing nutrient intake between South Africa and Kenya and they are based on a 
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secondary analysis of previous dietary studies and of the National Food Consumption 
Survey and the South African Demographic and Health Study. Dietary intake was assessed 
by means of a 24-h dietary recall questionnaire. 
 
All these studies employed trained field workers (nurses) who visited participating 
mothers at home to take anthropometrical measurements, to evaluate the socio-economic 
status and complete the dietary intake assessment.  
 
American data are based on triplicate samples of a 3-day menu cycle, which was 
evaluated by a chemical analysis. 
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4.5  DISCUSSION OF THE ANALYTICAL PART OF THE 
DATA ANALYSIS. 
 
4.5.1 Discussion of the maternal nutrient intake effects. 
Tables 3.10 A-C and Appendices D,E,F and H show the associations between 
maternal dietary intake and the fetal – birth – infant postnatal parameters. Table 3.17 
includes the relationship between fetal weight and biometry and the gestational age. 
 
 
4.5.1.1 Maternal nutrients and fetal biometry at US1 and US2. 
The gestational age adjusted models “explained” over 90% of variation in the 
response variable and the effect of maternal dietary intake in these models has only a weak 
contribution. This shows that the effect of maternal nutrient intake on fetal biometry is not 
so apparent as it becomes in the postnatal period. However, there were some significant 
relationships and these will be discussed below. 
 
Amino acids are the essential building material for fetal growth. The timing of the 
first pregnancy visit fell into the period of major brain development, which requires protein 
and polyunsaturated fatty acids (Westermarck 2000). This may explain the positive 
correlation observed between the fetal biparietal diameter of the first visit (BPD1) and 
maternal total protein intake analysed for the same visit (TOT PROT1; see Table 3.10 A).  
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The maternal plant protein intake near the early pregnancy visit showed a 
supportive effect on the concurrent size of fetal head and abdomen, whilst the intake of 
animal protein showed a negative relatioship. Similarly, the early intake of SAFA revealed 
a negative association with these fetal biometrical parameters. On the other hand, the early 
dietary consumption of PUFA showed supportive effects on fetal growth later in gestation. 
The association with fetal head and length may involve other factors such as effects of 
micronutrients (e.g. calcium; rapid bone mineralisation occurs during the third trimester; 
Lucas 1991), or growth factors and other hormones, which stimulate the bone growth or 
mediate the transfer and availability of nutrients (Chapter 4.5.1.3). However, the strong 
positive relationships of PUFA1 maternal intake with FW2, AC2, HC2 and FL2 
measurements seemed to be in agreement with the timing of the early pregnancy maternal 
adaptations. The PUFA1, next to its utilisations in fetus for the brain, retina and bone 
development, is contributing towards the building of maternal pregnancy fat stores, which 
in turn serve as the major energy source for the fetus especially during the last pregnancy 
trimester (see discussion Chapter 4.5.1.3). All these parameters were taken during the same 
ultrasound scan, therefore adjustment for the gestational age may bias these associations by 
“overcorrecting” in the regression model, resulting in loss of significance.  
 
The strong association of the HC2 with maternal TOT PROT intake at V1 was 
negative. However, the results do not indicate, which source of protein contributed towards 
this association the most. From the descriptive part of the study it is known that maternal 
intake of animal protein was the primary source of protein during pregnancy (Chapter 
4.3.1). Therefore, as both proteins are expressed as % energy, it may be possible, that the 
negative direction reflects decreasing supplies of maternal PL PROT as fetal growth 
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accelerates in late pregnancy. However, it also may be possible that these negative effects 
of maternal dietary intake on skull growth represent some kind of a negative feedback 
system that will ensure that excessive skull growth does not occur at high levels of energy 
intake. However, we cannot currently prove this hypothesis. A rather complex relationship 
between maternal protein intake and the size of a baby was addressed by other authors 
before (Duggleby et al 2002), involving protein conservation and metabolic adaptation of 
the mother. Also the partitioning of nutrients between the mother, placenta and fetus needs 
to be considered. 
 
The maternal total energy intake at V2 (TOT ENERGY2) positively correlated 
with the fetal abdominal circumference of the same visit (AC2; Table 3.12 A), and this may 
be related to TOT PROT2 (possibly derived from AN PROT1) as this variable also 
correlated with AC2 (Table 3.10 A). The fetal abdomen reflects the size of fetal liver 
(Godfrey et al 1996; see Chapter 2.5.3.2), especially during the third trimester, when the 
liver undergoes rapid growth (Reece et al. 1993).  
Protein is important in liver development; the content of the liver protein reflects the 
quantity of dietary protein (Kosterlitz 1947). Maternal protein restriction during gestation 
led to significant growth retardation of neonatal rats (Desai et al 1996), involving decreased 
body weight and weight of liver and brain and changes in liver and serum IGF-I levels.  
Therefore a positive association between the TOT PROT2 intake and fetal AC at V2 may 
be expected (Table 3.10 A). Similarly it would explain the correlation between the TOT 
ENERGY1 and AC1 during the second trimester (Table 3.12 C), however, the positive 
association of AC1 with maternal protein intake just “missed” significance (at p=0.050; see 
Appendix D) at this visit. High maternal protein density intakes in some studies, however, 
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were reported to restrict fetal growth and resulted in low BW (Sloan 2001; Andreasyan et 
al. 2007; see Chapter 1.4.2.3.3). On the other hand, animals fed a low protein diet during 
pregnancy are known to have growth-retarded offspring with a reduced β-cell mass. Earlier 
in pregnancy another energy source related to AC may be derived from carbohydrate (data 
of the current study shows an association with added sugar). Parretti et al (2001) showed a 
significant positive correlation between maternal 60-minute glucose levels of the OGTT (at 
28 gestational weeks) with fetal abdominal circumference. Similar correlations were 
reported also for 32 and 36 gestational weeks for maternal glucose levels at different times 
of the OGTT, whilst a negative association was found for the HC/AC ratio with the 
maternal glucose levels. During the third trimester maternal PUFA1 may be the further 
contributor, as the accelerated fat accumulation by fetus during the third trimester would 
reflect in the AC measurement. 
 
The maternal energy intake during the third trimester (TOT ENERGY2) correlated 
positively with the concurrent fetal weight (EFW2) and femur length (FL2). The positive 
correlations between fetal size and weight during the V2 and maternal intake of total energy 
was expected, as during the third trimester the fetus increases its size quite rapidly and 
requires therefore increased energy supplies (at least 800 extra kJ/d for mother; McNeill 
2000).  The contribution of PUFA (also MUFA) towards the TOT ENERGY2 to support 
the bone growth of femur would also be expected (see Chapter 4.5.1.3). 
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4.5.1.2 Maternal nutrients and birth weight. 
 
While many studies have reported no association between BW and maternal 
macronutrient intake, in the current study maternal protein intake (TOT PROT2) at the end 
of pregnancy showed a positive correlation with baby’s BW.  
 
A prospective study in Adelaide in Australia (Moore et al 2004) including over 500 
Caucasian women 18-41 y old, found also a significant positive correlation between the 
16w-gestation maternal protein intake and the baby’s BW and placental weight. The protein 
intake in the Adelaide women was much higher than in the African women of the current 
study (89g/d = 16.6%E at 16 and 86g/d=16.2%E at 30-34 weeks of gestation).  
 
The Aberdeen study in Scotland (Campbell et al 1996), which carried out a 
retrospective analysis of dietary and birth records of 253 mothers from 1948-1954, found, 
in turn, an inverse association between the maternal protein intake (as %E) at 30 weeks of 
gestation and the birthweight. Although the protein contribution to the total energy intake in 
the African population was slightly higher in comparison with the protein intake of mothers 
in Aberdeen (13% vs 12.2% in Aberdeen), the amount of crude protein intake in 
Johannesburg mothers was much lower (53.8 g vs. 73 g).  
 
High protein supplementary intakes (≥85g/d) lead to a decreased birth weight by 
71g in the New-York trial (Sloan et al 2001, See Chapter 1.4.2). This was in comparison 
with a mean intake of protein 50-84.9g/d.   
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The study from the rural area of Haryana in India (Rao et al. 2007) detected an 
association between a very low maternal daily caloric intake (below 6276 kJ) and low 
protein intake (below 40g) during the third trimester with the baby’s low birth weight.  
The Pune study in India (see Chapter 1.1.2) did not find any association between 
protein intake or energy intake and BW, however the authors found a strong association for 
micronutrients derived from green leafy vegetables and fruits and the fat derived from milk 
(Rao et al 2001). The amount of protein present in consumed milk was associated with 
increased birth size and placental weight in the study from Denmark (Olsen et al 2007; see 
Chapter 1.4.2.3.3). 
 
Therefore, the association between maternal protein intake and baby’s BW may be 
an inverted U-shape, where not only low but also high protein intakes may impact 
negatively on baby’s birth weight.  However, since the nutrient intakes with respect to the 
total energy intake are intrrelated, it is likely that the low/high protein intake effect will be 
related to the ratio of other nutrient intakes, the total energy intake or to the quality of the 
protein itself.  Unfortunately, the current study results did not show any further significant 
associations with BW and the effect of dietary intake with different ratios of macronutrinets 
was not evaluated. 
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4.5.1.3 Maternal nutrient intake and postnatal anthropometry. 
 
The maternal total energy intake during pregnancy in the current study did not show 
any associations with the postnatal infant anthropometry, however the concurrent energy 
intake (TOT ENERGY3) was positively related to infant’s weight (WEIG2) at the last 
postnatal visit. The majority of mothers breastfed their infants for a few months after 
delivery and many of them were continuing with breastfeeding in addition to using infant 
feeds near V3. Many studies analysed the relationship of postnatal nutrition to infant size 
(Lucas 1991), and found similar associations.  
As stated already in the Results Chapter (3.10), in comparison with the fetal 
biometrical parameters, there were numerous associations between maternal macronutrient 
intakes and the infant neonatal length and both postnatal BMI measurements. As length is 
inversely related to BMI, these associations with BMI were in the reverse direction for 
length. 
 
The total protein dietary intake at V1 (TOT PROT1) showed an association with 
baby’s postnatal weight (WEIG2) and BMI 1 and 2 (adjusted or unadjusted for 
confounders), which is most probably related to the animal protein intake (AN PROT1) 
also at V1. This would emphasise the importance of maternal protein intake in early 
gestation influencing the infant’s BMI at 6 months after birth. Similarly, there was an effect 
of maternal protein intake later in pregnancy on baby’s neonatal and later postnatal 
anthropometry. Also, this supported the association seen already between the fetal AC2 and 
TOT PROT2 intake (Chapter 4.5.1.1). 
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It was noted that the intakes of animal and plant proteins produced different effects 
on infant anthropometry. Whilst the animal protein contributed towards the infant’s BMI 
(and the fetal AC2 adjusted for age druing V2), the plant protein (or minerals associated 
with its intake) seemed to be supportive of linear growth.  Therefore the association of 
plant protein with linear growth was studied using the available literature.  
 
Duggleby et al (2002) studied protein metabolism in pregnant women and found a 
strong association between maternal protein synthesis and fetal growth during the second 
trimester. Thus, the mothers who had larger protein turnover also had babies who were 
longer at birth. However, this relationship appeared to be independent of the mother’s 
height and protein dietary intake.  
 
Muaku et al (1996) showed in pregnant, dietary-protein restricted Wistar rats that 
reduction in serum IGF-I may contribute to the reduced somatic and organ growth 
associated with low protein diet. Also, feeding a high protein diet to malnourished children 
due to diarrheal disease in Bangladesh (Kabir et al. 1998) led to an increase in their linear 
growth during the 6-month follow-up period, suggesting a key role for protein in the 
children’s growth. An increased dietary protein intake in adolescents was associated with 
bone growth independently of calcium intake and mediated by IGF-1 (Bonjour et al 2001).  
 
Inadequate protein intake seems to be associated with delayed skeletal growth and 
reduced bone mass, whilst sufficient intake of protein has to be accompanied with a 
sufficient intake of calcium (Vatanparast et al. 2007) to produce a beneficial effect on bone 
growth.  
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Different types of protein show different effects. The animal protein is high in 
sulphur-containing amino-acids, generating an acidic cellular environment. The plant 
protein (fruits and vegetables) is less acidic, or more basic. If the renal buffering capacity is 
overwhelmed, the bone reacts by releasing the carbonate, citrate and sodium and calcium to 
neutralize this acid (Barzel et al. 1998). However, the plant proteins found in soy, corn, 
wheat and rice (purified plant proteins) have similar sulphur content as some animal 
proteins in eggs, milk and muscle from meat, poultry and fish and increase urinary calcium 
(Massey 2003). On the other hand, the calcium in milk, potassium and magnesium in fruits 
and vegetables (e.g. legumes, grains) can decrease the urinary calcium losses (Massey 
2003; Vatanparast et al. 2007).  (In addition, there are also effects of other nutrients, such 
as vitamin D or caffeine on the bone health.) 
 
Therefore, it may be possible that the plant protein intake recorded for the 
participants in the current study could contribute to the linear growth of the offspring 
measured during the neonatal period. The negative association of the animal protein intake 
with neonatal length could indicate either the increased intake of this protein or insufficient 
intake of the plant protein to stimulate the linear growth. The ratio between these two 
protein intakes may then be important. 
 
Thus, during the early antenatal period, maternal protein intake (possibly the animal 
protein) may support general growth, i.e. increasing fetal size (as a “fuel to the growth 
process”; Lucas 1991) stimulating various growth factors. The plant protein, in turn, might 
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stimulate the growth in length, which association was then apparent in the postnatal infant 
parameters.  
 
The maternal dietary intake of saturated fat during both pregnancy visits (SAFA1 
and SAFA2) was positively associated with the later postnatal infant BMI. According to 
Mensink et al (2003), dietary fats produce different effects on the blood lipid levels. The 
SAFA acts in the opposite direction to the PUFA and MUFA, which both lower the blood 
levels of triglycerides and LDL cholesterol. The SAFA-mediated increase in levels of 
maternal lipids during pregnancy may thus contribute to the programming of increased 
BMI of the child.  
 
The demand for the long chain PUFA (LC-PUFA) by the fetus is well documented, 
as it is required for brain and retina development and for their future function (Burdge et 
al.2006). As maternal intakes of PUFA and MUFA showed associations with the postnatal 
anthropometry, the mechanism of their involvement in the bone growth was further 
investigated.  
 
There is limited data on the effects of PUFA on human and especially infant skeletal 
metabolism, however, the involvement of fatty acids in bone modeling and remodeling was 
demonstrated in a number of animal studies. Some of these studies are discussed below. 
 
The effect of PUFA on bone metabolism is produced via changes in prostaglanding 
synthesis (Watkins et al. 2000a, 2001). Arachidonic acid (AA, 20:4 n-6 – a long chain 
PUFA) is a precursor of prostaglandin (2-eicosanoids). Prostaglandin E2 (PGE2) produced 
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in bone tissue (Sardesai 1992) can stimulate bone formation as well as bone resorption. 
This action depends on its concentrations. Whilst a low concentration of PGE2 stimulates 
bone formation, a high concentration decreases this effect, and can further lead to bone 
resorption (Watkins 2001, Mollard et al 2005).  
 
The stimulatory effect of PGE2 is mediated via increased osteoblastic production of 
the insulin-like growth factors and their binding proteins (McCarthy et al 1991; Baylink et 
al 1993). 
 
Studies with chickens and rats showed that increasing n-3 PUFA by dietary intake 
decreased the n-6 to n-3 ratio and reduced PGE2 and increased the serum levels of alkaline 
phosphatase (Li et al 2003; Watkins et al 2003 and 2006), leading to a preservation of 
femur bone.  
 
In addition, studies on rats and men (Kruger et al 2005; Watkins et al 2006; 
Högström et al 2007; Li et al 2010) confirmed the beneficial effect of the docosahexaenoic 
acid (DHA; 22:6n-3 PUFA) and also of the conjugated linoleic acid (CLA; butter and milk 
fat; Li et al 1999; Watkins et al 2000b) on bone metabolism. Downregulation of PGE2 
stimulated IGF/IGF-BP mediated bone formation.  
 
 
Another mechanism by which n-3 PUFAs regulate birth weight involves their effect 
on gestational length. Increased intakes of n-3 PUFA decrease the production of uterine 
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prostaglandins, which initiate uterine contractions at the beginning of labour (Olsen et al 
1986).  
 
There is not much information on the effects of dietary MUFA on bone metabolism. 
Authors of a study on healthy men and women in Athens, Greece, reported a direct 
relationship between dietary intake of MUFA (from olive oil) and bone mineral density 
(Trichopoulou et al.1997). However, the association with the infant postnatal length in the 
current study was negative. 
 
Dietary intake of SAFA was found to be inversely associated with bone density in 
animals and men (Wohl et al 1998; Corwin et al 2005).  
 
Therefore, the effect of PUFA1 on neonatal length most likely represents a real 
association. Unfortunately, the ratio between n-3 and n-6 PUFA was not investigated in this 
study. The positive relationship of PUFA1 with neonatal length may indicate sufficient 
supply of n-3 PUFA during early pregnancy stages for the establishment of fetal long bones 
(gest. month 3-5; See Chapter 1.3.2.1).  
 
The weaker negative association of PUFA2 with neonatal length is more difficult to 
explain, as it is not supported by data in the literature. The assocition is weak and it is 
possible that the result occurred by chance.   
 
As the effects of nutrients are not isolated, it is possible that, while the maternal fat 
intake (together with maternal fat stores) supports the accumulation of the fetal fat deposits, 
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the PL PROT2 intake may support bone metabolism. However, further research is required 
to confirm this.  
In combination this data shows differential effects of macronutrients on postnatal 
growth that may act during different stages of pregnancy.  
 
 
4.5.1.4 Maternal nutrients and postnatal metabolic parameters 
 In this section the postnatal metabolic parameters associated with glucose 
metabolism (glucose and markers of the infant β-cell function INS, PI, HOMA-IR), 
obesity (LEPT) or nutrient status (IGF-BP3) were evaluated.  
 
As described in Chapter 3.9, there were many associations between maternal dietary 
intake and markers of infant postnatal β-cell function. These mainly involved the neonatal 
INS and HOMA-IR levels.  There were similar associations for the neonatal and later 
postnatal INS and HOMA-IR concentrations, therefore a similar mechanism is expected 
for these relationships. Also, both sets of metabolic variables showed similar associations 
with the maternal protein and fat intakes as were found for the postnatal infant BMI (i.e. 
positive for the protein and negative for the maternal fat intakes). No effects for SAFA 
consumption during any pregnancy visit were found.  
 
Maternal total energy intake in the second trimester (TOT ENERGY1) did not 
show any significant correlations with postnatal glucose, or other examined variables. For 
the third trimester TOT ENERGY2 intake, there were significant relationships found with 
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neonatal glucose (GLC F1; inverse correlation) and fasting insulin (INS F1; direct 
correlation) and with the 6-months postnatal fasting glucose (GLC F2; also inverse 
correlation). These outcomes are the result of the combined effects of protein, fat and 
carbohydrate energy sources.  
 
 
An interesting observation was the concurrent negative association between 
maternal total energy intake at V3 (TOT ENERGY3) and infant insulin (INS F2) and 
HOMA-IR2 and a positive correlation with infant leptin (LEPT2). Leptin involvement 
could be related to infant weight, as serum/plasma leptin is known to correlate with body 
mass (Helland et al 1998) and also the TOT ENERGY3 showed a significant positive 
relationship with the concurrent infant weight.  
Similarly this applied to the correlation between LEPT2 and PUFA2. The study of 
Ogueh et al (1999) found that human fetal blood levels of leptin increased with gestational 
age in agreeement with fetal adipose tissue development and accretion of fat. The authors 
also suggested that leptin had a role in fetal bone development, as it was assocaited with 
decreses in bone resorption, with a resulting increase in bone mass.  
 
For the relatively increased insulin secretion (INS F 1 and 2) and elevated HOMA-
IR1 index it seems that the animal protein intake is responsible, while the plant protein 
intake (PL PROT2) has rather a protective role showing negative relationships with INS 
F1 and 2 and HOMA IR 1 and 2. The PL PROT1 intake also showed a negative 
relationship with infant proinsulin (PI F2) levels.  
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The effect of the plant protein may be mediated via its effect on the growth in length 
and decreased BMI. In addition, there may be a further protective effect on infant β-cell 
function (see negative correlations with INS F1 and 2 and HOMA-IR1) of maternal 
PUFA1 intake, which also shows a stimulatory effect on infant length. The animal protein 
intake is reflected in the total protein intake (TOT PROT1) where both have positive 
effects on INS F1 and HOMA-IR1. Protective effect of PUFA was shown in the study of 
Salmerón et al (2001) in decreasing the risk of Type 2 diabetes in women. 
A study in India found that a partial substitution of dietary linoleic acid (18:2 n-6 
PUFA) with alpha- linolenic acid (18:3 n-3 PUFA) was associated with decreased blood 
lipid levels and improved peripheral insulin sensitivity in sucrose fed rats (Ghafoorunissa 
et al. 2005). An epidemiologic study of over 3000 people in Japan 35 –66 years old, 
assessed nutrient intake based on a diet history questionnaire and observed that increased 
intakes of alpha-linolenic acid lowered the prevalence of insulin resistance among normal 
weight individuals (Muramatsu et al. 2010).  
 
Low carbohydrate intake (TOT CHO2) was related to elevated levels of infant INS 
F1 and 2 and HOMA-IR1 and 2 possibly due to their relationship with the infant BMI2.  
 
The reasons for the positive correlations of maternal dietary intake of MUFA2 and 
PUFA2 (third trimester) and negative correlations of the total carbohydrate intake (TOT 
CHO2) with infant INS F1 and 2 and HOMA-IR1 and 2 are unclear. As explained in 
Chapter 4.5.1.3, the maternal intake of PUFA2 may have improved fetal weight/fat mass 
during the accelerated growth phase of the third pregnancy trimester, which may have 
effects on infant insulin levels.  
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To further evaluate the association of the maternal dietary intake with neonatal INS 
F1, an analysis employing crude intakes of macronutrients was carried out. 
All these associations also revealed significant outcomes, except for the TOT FAT1 and 
PUFA1 intakes for early pregnancy and the PL PROT2 and TOT CHO2 for late 
pregnancy.   
 
The levels of the baby’s IGF-BP3 correlated with maternal AN PROT and 
MUFA2 intakes, always showing a positive relationship. Therefore, maternal protein, 
specifically animal protein (AN PROT 1 and 2) seemed to be involved in the regulation of 
the infant postnatal concentrations of IGF-BP3. IGF BP3 concentrations are known to 
decrease, whilst IGF BP1 concentrations increase with maternal food restriction (Gluckman 
1995). This was seen in studies with experimental animals, where reduced levels of IGF-
BP3 in fetal sheep correlated with maternal preconceptional malnutrition (Gallaher et al. 
1998).  Qiu et al (2004) investigated early nutrition intervention in IUGR neonatal rat pups 
and discovered that pups on a high protein diet presented with the fastest catch-up growth. 
They had highest IGF-1 and IGF BP3 serum levels, while the low protein diet intervention 
group pups were small and IGF-1 and IGF-BP3 were significantly lower. IGF-BP3, due to 
its binding with IGFs, serves as a pool for the growth factors in the circulation (Murphy 
2006). Therefore significantly increased levels of IGF BP3 between the neonatal and the 
second postnatal visit in the current study may reflect a good nutritional status of the child. 
 
The nutrient intake associations with infant postnatal metabolic parameters were 
adjusted for infant BMI, to exclude possible interference of BMI in their relationship. In 
the case of the protein results, the correction for BMI in the majority of outcomes 
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weakened the effect of protein. However, these associations still remained significant or 
near significance. Therefore, there is some small involvement of infant BMI in the 
outcomes. However, the direct influence of protein still remains (Appendix H).  
After adjusting for fat intake and infant BMI, a number of significant outcomes 
between the maternal fat intake and the fetal metabolic parameters, weakened. The 
correlation between PUFA2 and LEPT2 however lost significance completely, therefore 
this association is driven mainly by infant BMI and the contribution of PUFA2 is minimal 
(Table H2). 
 
A few weakened correlations were seen after adjustment for BMI for TOT CHO, 
added sugar and TOT ENERGY intakes (Table H3), however most of the relationships 
maintained significance indicating that maternal total carbohydrate and total energy intakes 
do have direct effects on neonatal and infant metabolic parameters.  
 
 
4.5.2 Discussion on maternal vs. fetal - infant metabolic   
parameters.  
Maternal hormones in fetal growth, birth parameters and infant growth with respect 
to the risk assessment for the development of future Type 2 diabetes. 
 
See Chapter 3.10 and Tables 3.12 A-C. The separate regression models are presented in 
Appendix J. Each of these models includes only the covariates that were significantly 
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related to the fetal-infant parameter of interest. All other covariates, which were included in 
these regression models, are presented in Appendix I. 
 
 
 
4.5.2.1. Fetal and postnatal growth rates 
 
 
GRRT1: Fetal growth rate between the two pregnancy visits (V1 and V2) was 
positively related to the maternal weight (MW1) and the placental lactogen (HPL1 and 2) 
at these visits (see Chapter 3.10). The concentration of maternal HPL, secreted by the 
placenta, reflects the placental function (Gluckman 1995; Picciano 2003). A well 
functioning placenta will stimulate fetal growth, as HPL directly stimulates insulin and 
IGF-1 secretion and possibly regulates the supply of glucose and amino acids to the fetus 
(Brelje et al. 1993; Handwerger et al. 2000; Picciano 2003). The above finding supports 
the role of HPL in fetal growth. A similar outcome was reported by Sørensen et al (2000), 
who found a significant positive correlation between the HPL slope and the fetal growth 
rate.  
The maternal size influences the neonatal size, partially due to the genetic 
component and partially because the maternal size reflects her own nutrient status (see 
Chapter 1.4). Thus, mothers of a larger weight (BMI) will tend to have babies of a large 
BW (univariate correlation in this study: p=0.002, R=0.306, N=104) and the BW is an 
outcome of the fetal growth (Forsén et al. 1997; Romundstad et al. 2007). Low pregnancy 
weight gain was associated with underweight mothers, leading to growth retarded fetus 
(Strauss et al. 1999; Schieve et al. 2000). There was a direct correlation between maternal 
weight and the placental volume and then between the placental volume and the fetal 
growth rate shown in the study of Thame et al. (2004). Obese mothers, however, also tend 
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to have smaller babies, therefore the relationship between maternal weight and birth weight 
is an inverted U-shape with a consequence of impaired glucose tolerance in the offspring of 
the thin and obese mothers (McMillen et al. 2005) 
 
The regression analysis of the V2 parameters showed also a significant positive 
contribution of the maternal systolic blood pressure of V2 (BP SYS2) to the fetal GRRT1. 
It should be reminded, that hypertensive patients were not enrolled into the study. Results 
of various studies showed, that there was an increased incidence of preterm birth, low birth 
weight and also fetal death with low systolic and diastolic blood pressures (Zhang et 
al.2001b). This was possibly due to a low placental blood flow (Jones et al. 1983), 
resulting in a low nutrient supply to the fetus and in low oxygenation. However, high blood 
pressure present in mother before pregnancy was also linked to the small size of the 
newborn (Romundstad et al. 2007). Therefore the relation between the maternal blood 
pressure and fetal GRRT may also be an inverted U-shape.  
 
 
Finally, the regression model adjusted for confounders (gest. age, fetal sex, maternal 
height and maternal weight), showed a significant influence of maternal leptin (LEPT2; 
removing significance of maternal weight). The major reason for this is likely to be the 
known positive effect of leptin on fetal growth (Harigaya et al.1997; Helland et al. 1998).  
 
GRRT2: The fetal growth rate between V2 and delivery was significantly 
positively related to maternal height and maternal FT4 at V1 or maternal fasting PI at 
V2. Maternal height adjusted for the birth age, was significantly associated with baby’s 
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BW (p=0.013, β=0.219 for height and p<0.001, β=0.423 for birth age, AR2= 0.220; see 
Appendix H.1.2). As with the maternal weight, there is an effect of maternal height on 
baby’s size (Kramer 2003). Thus, taller mothers will have bigger babies than shorter 
mothers delivered at the same gestational age, which reflects the larger placental size of 
taller mothers (see maternal constraint, Chapter 1.4.2.2.1).  
 
T4 is an anabolic hormone and its active form is free thyroxine (FT4). FT4 
concentration peaks during the first trimester and from the second trimester declines slowly 
until delivery. Maternal FT4 in early pregnancy crosses the placental membrane and from 
about week 20 the fetal thyroid gland is able to produce its own T4, however for the 
production of its own thyroid hormones, the fetus stays dependent on the maternal iodine 
supply until delivery. FT4 regulates the metabolic rate of the mother, and therefore it is 
involved in the efficiency of placental transport and substrate availability to the fetus. 
Downregulated maternal thyroid hormones in early pregnancy would delay nutrient 
transport and may also contribute to an inadequate development of the fetal thyroid gland. 
Fetal thyroxine regulates uptake of oxygen by fetal tissues. Hypothyroidic sheep fetuses 
have decreased oxygen uptake, which slows down the fetal oxidative metabolic rates, 
involving glucose cellular uptake and the fetal levels of glucose and insulin. This situation 
is reversed by an external thyroxine supply. Hypothyroidic fetuses are growth retarded 
(Fowden et al. 1995). Thus, maternal thyroid hormones earlier in pregnancy may positively 
affect the fetal growth rate during the third trimester. Further, FT3, generated from FT4, is 
known to stimulate bone formation (activates GH and IGF-1 signalling; O’Shea et al. 
2005).  
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Proinsulin (PI2) as a precursor of insulin, an anabolic hormone, should stimulate the 
fetal growth rate. PI (or INS) of V2 will be more effective, as their levels increase during 
the course of pregnancy. Insulin increases the fetal umbilical glucose uptake, glucose 
utilisation and oxidation (Fowden et al. 1988). Increased fetal insulin levels lead to fetal 
macrosomia (such as in maternal diabetes – fetal insulin levels rise due to high maternal  
glucose levels), while lack of insulin impairs fetal growth (body weight and length of limbs 
seen in neonatal sheep after fetal pancreatectomy; Fowden 1992). SGA neonates had low 
levels of venous cord blood insulin levels (Murphy 2006). However, neither maternal 
insulin levels nor glucose levels correlated with fetal growth rate before delivery and 
therefore it is also possible that PI may have some direct effects on placental glucose 
transport or some other placental function. A biological role for PI has been demonstrated 
by Kamoda et al (2006), who investigated serum levels of PI in obese children. The authors 
discovered that PI, as well as INS, can participate in the suppression of hepatic IGF BP-1 
production. Although there was no correlation between maternal FT4 at V1 and PI at V2, 
an effect of thyroid hormones on β-cell function was shown in the study of Wu et al (1998). 
In this study, thyroxine therapy of hypothyroid patients elevated their previously 
suppressed levels of proinsulin and, in hyperthyroid patients, antithyroid drugs decreased 
the proinsulin levels.  
 
GRRT D-Ba2: The postnatal infant growth rate assessed between delivery and the last 
postnatal visit Ba2 showed independent positive contributions of fetal gender and INS 
RES2. The boys in the current study showed higher postnatal growth rate; p <0.001, 
AR2=0.210, F=20.1 by ANOVA (see Chapter 3.12; Gilbert et al. 2007). A gender 
difference in the fetal growth rate was not found in the current study. However, growth 
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charts constructed by various large studies for monitoring fetal growth, demonstrated sex 
differences in the second half of pregnancy with higher growth rate for male fetuses 
(Maršál et al. 1996; See Chapter 1.4.1). 
The increase in the insulin resistance (INS RES2) allows for enhanced placental 
glucose transport and supply to the fetus, stimulating thus the fetal growth (Dunne 1999; 
Jansson et al. 2001). Elevated insulin levels stimulate the glucose entry into fetal tissues 
and the subsequent glucose utilization and oxidation (Hay et al. 1986). This would explain 
the positive association between maternal insulin resistance at V2 and baby’s growth rate 
after birth, which is the continuation of the fetal growth before delivery. 
 
 
4.5.2.2 Birth size 
BW:  In regression model, correcting for confounders, the strongest effect on BW 
was produced purely by these confounders. BW was associted with maternal weight (MW 
1 and 2), maternal height and the birth age and the BW was significantly higher in boys. 
As the pre-selected variables that correlated with the BW (see Appendix I) included INSF2 
and LEPT2, the model had to be adjusted for maternal weight/ BMI. After adjustment, no 
influence of maternal pregnancy hormones was found.  
 
BHC and BL: The associations obtained for BL and BHC were similar for both 
variables and included MW, gestational age, maternal leptin at V1 (LEPT1), which 
correlated positively and the IGF BP1 at V1/V2, which correlated negatively. 
Transplancental transfer of maternal leptin to the fetus increases during late pregnancy as 
reported by McMillen et al (2006) and cord leptin levels were found to be correlated with 
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birth weight, ponderal index, birth length and head circumference in the study of Ong et al. 
(1999; ALSPAC cohort of the Avon Longitudinal Study of Pregnancy and Childhood). 
Also, as reported earlier (Chapter 4.5.1.4), according to the study of Ogueh et al (1999) 
leptin had a positive role in fetal bone development, as it was associated with decreases in 
bone resorption, with a resulting increase in bone mass.  
 
During pregnancy, the IGF BP1 is secreted by the liver and maternal decidua and it 
is the main controlling factor for IGF-1 action (Murphy 2006). A negative correlation 
between the IGF BP1 with BW was reported by other studies (Murphy 2006), whilst the 
IGF-1 and IGF BP3 were correlated positively. Therefore, the indirect association of IGF-
BP1 with the neonatal size found in the current study would be expected, especially as the 
fetal parameters involve bone growth.  Thus, elevated concentrations of maternal IGF-BP1 
have been associated with IUGR fetuses in connection with delayed bone ossification 
(Verhaeghe et al. 1993; Lagha et al. 2006). 
 
 
 
4.5.2.3 Postnatal infant anthropometry 
 
BMI Ba1: The infant neonatal BMI Ba1 was, as for birth weight, determined by the 
baby’s age (Age Ba1) and maternal pregnancy weight (MW1 and 2) and further negatively 
associated with the maternal proinsulin levels (PIF1 and PI 30min at V1 and PI F2 and 
PI  60min at V2). Higher baby’s BMI will reflect the mother’s BMI, maternal nutrition 
and also may be connected to the increasing maternal pregnancy insulin levels. The 
negative correlation with proinsulin levels is not completely clear. Low proinsulin may 
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reflect increased conversion of PI to INS in the environment of high glucose levels. 
Glucose crosses to the fetus and drives fetal insulin secretion. However, no significant 
relationship was found for maternal insulin or glucose concentration of V1 with neonatal 
BMI Ba1. 
 
BMI Ba2: The infant BMI Ba2 at six months after delivery reflected more the fetal 
gender, with boys having greater BMI values. Although the maternal pregnancy weight did 
not show a significant association with BMI Ba2, maternal leptin at the earlier pregnancy 
visit (LEPT1), which correlated with maternal weight (see above), had a strong positive 
relationship. BA BMI2 was also positively related to maternal INS RES2 levels. A similar 
mechanism as for the GRRT D-Ba2 is expected, with insulin stimulating fetal growth. 
Both infant variables (BaBMI2 and GRRT D-Ba2) are strongly correlated (R = 0.680, 
p<0.001), which is mediated via infant weight.  A weak negative association of BMI Ba2 
was observed with maternal levels of IGF BP1 (V2).  A negative association would be 
expected, as circulating levels of IGF BP1 have been shown to be inversely correlated with 
leptin in non-obese adults (Söderberg et al 2001) and also inversely correlated with insulin 
(Hwang et al 2003) and insulin resistance. Also, the study of Kamoda et al (2006) found 
that the best predictive parameters for IGF-BP1 in obese non-diabetic children were BMI 
and proinsulin and that proinsulin was involved in the suppression of hepatic IGF-BP1 
production.  
Further, a negative association of the baby’s BMI with maternal glucose of V1 
(GLC F1) was observed. The reason for this inverse correlation is unclear, as the fetal 
glucose reflects maternal glucose levels and stimulates fetal growth (see above). Therefore, 
similarly as with the proinsulin correlation, some other factors may be involved in this 
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relationship. High glucose concentrations in culture media with amino acids (in vitro 
experiments with isolated fetal rat islets of Langerhanse) in the study of Hogg et al. (1993) 
stimulated IGF-BPs release in a dose-dependant manner, while increased concentration of 
amino acids in the media stimulated release of growth factors, especially IGF-2. With 
increasing concentrations of both the amino acids and glucose, insulin secretion rose. The 
negative relationship of maternal glucose with baby’s BMI may thus reflect the balance 
between the concentrations of the growth factors and their binding proteins, which will 
depend on the ratio of protein and maternal glucose concentrations.   
 
 
4.5.2.4 Postnatal infant metabolic variables 
GLC F1: Baby’s neonatal fasting glucose (GLC F Ba1) was proportionally related 
to baby’s age (Age Ba1) and weight (W Ba1) and mother’s fasting glucose at V1 (GLC 
F1). In addition, maternal HPL2 and CORT2 showed a direct relationship, whilst the 
maternal FT4 (V2) concentrations were related negatively.  All three hormones were 
associated independently, as they were all part of one regression model. The HPL2 was 
significant only in the analysis unadjusted for confounders.  
 
Maternal cortisol was measured only at the second pregnancy visit (V2) and the 
last postpartum study visit (V3) and its levels at V2 were more than double the levels after 
delivery (Table 3.4).  
In animal studies, external glucocorticoids administered in late pregnancy are 
known to reduce BW, resulting in hypertension and elevated glucose levels in adulthood 
(Nyirenda et al. 1998; Ozanne2001). Glucocorticoids can cross the placenta and their 
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excessive amount may override the control mechanism of the placental 11ß-hydroxysteroid 
dehydrogenase2 (HSD2), the activity of which is also downregulated by maternal low 
protein intake (see Chapter 1.4.2.4.4; Langley-Evans et al. 1996).  Glucocorticoids can 
inhibit insulin release and β-cell replication (see Chapter 1.2.5.6), therefore exposure of the 
fetus to higher levels of maternal glucocorticoids may lead to elevated glucose levels 
during the early postnatal life. The protein intake of the study participants was found low 
(see Dietary intakes), which would also support this explanation. 
An association of the neonatal fasting glucose (GLC F1) with maternal placental 
lactogen (HPL 2) may result from the stimulatory effects of maternal HPL on glucose 
delivery to fetus (Fowden 2004). This would support fetal growth and relatively larger 
neonates would present with relatively higher levels of glucose, although within a normal 
range. 
 
GLC F Ba2: An association of the infant 6-month postnatal fasting glucose (GLC 
F2) with maternal placental lactogen from both pregnancy visits (HPL1 and 2) supports 
the previous association with GLC F Ba1.  
The inverse relationship with maternal proinsulin levels was also part of the 
regression outcome for Glc F Ba2 and HOMA-IR Ba1. Again, low PI may reflect higher 
PI conversion to insulin in the mother due to high maternal glucose levels.  
 
Metabolic parameters: Fasting baby’s neonatal insulin (INS F Ba1) and also the 
homeostatic index (HOMA-IR Ba1) were inversely related to maternal thyroid hormones 
of the first pregnancy visit (FT4 V1).  The recombinant human IGF-1 administered to rats 
diminished FT4 concentrations in these rats (Pellizas et al. 1998), possibly due to decreased 
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number of TH receptor expression which lead to downregulated metabolic action of FT4 in 
the liver. Therefore, elevated blood levels IGF1 concentrations (still in normal range range) 
may cause a decline in the maternal serum FT4 concentration still supporting the fetal 
growth, with lower levels of FT4 indicating higher levels of the growth factor. 
 
There was a significant gender difference in the infant postnatal leptin 
concentrations (LEPT1 and 2) with higher levels in females (see Chapter 3.12). With 
increasing age, as the infant is gaining weight (W Ba 1 and 2), leptin levels also increase 
(Harigaya et al. 1997). The correlation between BMI and leptin is well known (McMillen 
et al. 2006), as is its gender difference (Helland et al. 1998). Maternal leptin blood levels 
before birth were associated with fetal leptin blood levels from the umbilical vessels in a 
study in Brazil (Castro et al. 2006). A high carbohydrate diet given to pregnant sows 
increased the neonatal leptin levels (Litten et al. 2004), therefore an elevated maternal 
glucose level (Glc 60’ V1) may contribute to the elevated neonatal leptin concentrations as 
observed in the current study.  
 
Some of the effects of maternal hormones on infant markers of β-cell function may 
be mediated by maternal adiponectin, which is known to modulate glucose tolerance and 
insulin sensitivity.  It is also present in the breast milk, where it is believed it may have a 
preventive role against obesity, if found in lower amounts (Savino et al. 2008).  
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Summary:  
The regression analysis has shown that maternal anthropometry and maternal 
hormones during the second and also the third trimester do influence the rate of fetal or 
infant growth and early metabolic health. These relationships are probably very complex, as 
there will also be influences of variables, which were not measured in the current study. 
Many hormones mediate the effects of maternal nutrient intake, their processing and 
partitioning between mother, placenta and fetus, therefore these interactions may also 
reflect in the analysis outcomes. Certain associations, especially with birth weight may be 
an inverted U-shape, or some studies report also J shaped curves, however, proving such a 
relationship requires larger subject numbers.   
 
4.5.3 Discussion on the correlations with Socio-Economic Status (SES)  
Mother’s and father’s education showed significant relationships with family 
income. There was a very strong relationship between mother’s and father’s educational 
status (Chapter 3.11), women were more likely to be unemployed as were their partners 
(see Chapter 3.1.3.2). Maternal employment positively correlated with her physical activity. 
The mothers who grew up with many siblings in the family (and thus had fewer 
opportunities to study), were also the women with lower education, lower family income, 
less physically active during their gestation and more stressed. On the other hand, the 
higher education of mothers and also fathers was associated with lower maternal cortisol 
levels measured at V2. However, this relationship was not associated with family income, 
as the income did not show any correlation with maternal cortisol.  
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Employed mothers showed higher weight, BMI and leptin levels during pregnancy, 
elevated serum insulin concentration and insulin resistance index at V1 and plasma glucose, 
area under the glucose curve and proinsulin levels at V2 (see Table 3.14A). However, all 
these associations were attributable to the correlations with maternal weight and BMI, 
except for the PI F of V2 (evaluated by the regression analysis).  
 
The neonates of employed women had lower fasting glucose levels (Table 3.14A). 
The published expected glucose range for infants over 7 days of age are between 3.00 
mmol/l and 6.49mmol/l (Soldin et al. 2007). The fasting glucose range in the current study 
was 2.8mmol/l to 5.3 mmol/l. Based on the regression equation, the employed mother had a 
baby with 3.86 mmol/l fasting glucose concentration in average, whilst an unemployed 
mother’s baby had fasting glucose levels of 4.08 mmol/l.  
Both mother’s and father’s employment were also directly related to the neonatal 
length and also employed fathers had offspring of a lower ponderal index (PONDIX), 
however there was no significant correlation between the PONDIX and income. 
 
Although the family income did not directly correlate with maternal weight, it 
seems to be an explanation, together with the inverse significant correlation between 
maternal weight and cortisol, which was also associated negatively with maternal and 
paternal education. More educated parents may provide better for the family (better job and 
better income), resulting in less stress (Table 3.15) and better nutrition. As there were no 
diabetics included into the study, the “high” maternal glucose and hormonal levels of 
proinsulin, insulin and insulin resistance index reflect “healthy” adaptation to the 
pregnancy.  Similarly, the inverse associations of infant fasting glucose and PONDIX with 
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the employment of parents rather represents a baby with parameters on the “healthier” side 
of the study population range. On the other hand, stressed mothers may experience 
inadequate elevation of insulin, poor delivery of glucose to the fetus, resulting in low 
adipose tissue mass and possibly shorter birth length. High cortisol levels in mothers were 
shown to downregulate the fetal growth (Benediktsson et al. 1993). 
 
No correlation was observed between birth weight and any socio-economic 
indicators selected in this study. This may be due to a narrow range of the socio-economic 
differences in this studied population. However, in the Helsinki cohort, the links between 
the poor material wealth and future disease were found only in those born thin (Barker 
2004). 
 
 
 
CHAPTER 5          
 
SUMMARY AND CONCLUSIONS 
To the authors’ knowledge, this study is the first in Africa that followed a group of 
pregnant (urban) Black African women in order to identify factors during pregnancy, which 
may predispose their offspring to future Type 2 diabetes. 
The study has evaluated the effects of the maternal dietary intake of energy and 
macronutrients and hormonal levels during pregnancy on fetal growth, birth weight and 
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size and infant postnatal glucose tolerance and β-cell function, which are among the known 
risk factors predisposing subjects to Type 2 diabetes later in life.   
 
1. The first aim of the study was to assess if the maternal pregnancy dietary 
intake of macronutrients affect fetal, birth or postnatal size or growth.  
 
The timing of the first pregnancy visit fell into the period of major brain 
development and of the linear growth which both require protein and polyunsaturated fatty 
acids. The third pregnancy trimester is characterized by accelerated fetal growth and fetal 
fat accretion.  
 
The nutritional intake of mothers during pregnancy in this study was characterized 
by rather low energy intake, mainly due to a low consumption of dietary protein, especially 
of plant protein. The total crude amount of fat intake was higher than was the intake 
observed in South African non-pregnant women of child-bearing age, with the main 
contribution from saturated fat and lowest contribution from polyunsaturated fat. The intake 
of total carbohydrate adjusted for the energy intake was well in range of the RDA.  
 
The effects of the above maternal dietary intake on fetal biometry were analysed. 
The gestational age adjusted models “explained” over 90% of variation in the fetal 
biometry variables with the effect of maternal dietary intake in these models being very 
weak. However, there were some significant relationships and these will be discussed 
below. 
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Adjusting for gestational age (and other confounders), associations between total 
maternal energy intake and fetal parameters were found, with maternal protein and 
carbohydrate acting as the major energy sources for fetal growth. Although correlations 
between maternal TOT ENERGY2 intake and fetal weight and length at V2 were also 
significant, from the adjusted results it was not obvious what nutrient contributed  the most. 
Among unadjusted parameters this effect would be attributable to the PUFA1 intake.  
 
The strongest association observed was of HC2 with maternal TOT PROT intake 
at V1 and it was negative. However, the results do no indicate, which source of protein 
contributed the most towards this association. A suggestion was made, that the negative 
relationship may be due to a decreasing supply of PL PROT or possibly this may represent 
a negative feedback system that ensures that excessive skull growth does not occur at high 
levels of energy intake. However, we cannot currently prove this hypothesis. 
No significant correlation between maternal intake of energy or macronutrients was 
found for fetal growth rate.  
 
In conclusion, maternal total energy intake was associated with fetal weight, length 
and size of abdomen, whilst maternal protein intake was related to fetal head development 
and animal protein intake was reflected in the concurrent size of the fetal abdomen at the 
end of pregnancy.  Polyunsaturated fat intake may be related to fetal fat accumulation 
(FW2, AC2) and linear growth (FL2). However, not many significant correlations of 
maternal dietary intake with fetal biometry were observed. This confirms that the effects of 
maternal nutrition during pregnancy were not as very obvious during fetal life as during 
early postnatal life.  
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The current study has found a positive relationship between the maternal total 
dietary protein intake (expressed as a percentage of the total energy intake) during the third 
trimester and the infant birth weight. A similar finding was reported in the study 
conducted in Haryana, India (Rao et al. 2007).  
 
Comparing maternal nutrient intakes during pregnancy with the V3, the postpartum 
maternal dietary intakes of some nutrients significantly changed. The TOT ENERGY 
intake significantly increased reflecting elevations in PL PROT. Increased intakes were 
seen for MUFA and PUFA (and so TOT FAT) and for the total carbohydrate.  The TOT 
PROT contribution toward energy intake, however, decreased. These nutrient changes may 
reflect the maternal adaptation to the increased requirements for breast-feeding.   
 
Whilst the plant protein intake at V2 did not produce any significant association 
with fetal biometry or neonatal size, it showed many correlations with the postnatal infant 
BMI and the metabolic variables and possibly stimulated growth in length. Maternal fat 
intake during the second trimester also did not produce many significant correlations with 
the ultrasound data, however, postnatally, from maternal pregnancy intakes the most 
effective was PUFA intake, which on one side may have contributed to the growth in 
length, whilst together with SAFA it was also related to increase in the postnatal BMI. 
Although there were no significant differences in the maternal macronutrient intake 
during pregnancy, the effects of the dietary intake of V1 and V2 differed, which indicates 
the importance of timing for the effect of a particular nutrient. It was interesting that from 
the maternal dietary intakes at V3, only TOT ENERGY3 showed a relationship with 
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concurrent infant anthropometrical variables, which was a weak association with infant 
weight.  
 
From the mothers’ dietary intakes and their effects on fetal biometry, BW, infant 
postnatal anthropometry and infant birth and postnatal z-scores, the following conclusion 
can be drawn: 
In early pregnancy, the maternal dietary supplies of total energy, protein and fat 
were probably sufficient for normal fetal growth and development. Maternal PL PROT1 
and the PUFA1 intakes were associated directly or indirectly (e.g. via calcium and other 
minerals intake) with growth of the fetal skull. Maternal PL PROT1 intake also positively 
affected the fetal liver development (based on the correlation with fetal AC). The AN 
PROT intake during early pregnancy was associated with neonatal BMI, and thus possibly 
contributing to fetal fat accretion during later prenatal development.  
The PUFA1 intake, may have contributed to the building of maternal adipose stores 
(not measured in the current study), utilized by fetus in the later stages of pregnancy. This 
may have included abdominal organ growth and fetal fat accretion, being reflected in the 
increased AC2 and FW2. Also PUFA1 was still involved in linear growth, showing strong 
associations with FL2 and neonatal length.    
Maternal SAFA intake was positively linked to neonatal BMI, possibly via the 
route of fat accumulation. Also, as the intake of SAFA was relatively high during 
pregnancy, the negative associations with early fetal biometry may point towards its 
inhibitory role in linear growth.  Taking into account low levels of maternal PL PROT 
intake, the likely outcomes could be lighter and shorter offspring with a relatively larger 
BMI.   
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Protein intake during the last pregnancy trimester, when there are increased 
requirements for energy, seem inadequate. The nutrient reserves may therefore be directed 
to the development of the fetal brain (brain sparing effect) in the current study (and in the 
literature), which was negatively associated with the fetal bone growth. This could 
eventually lead to a shorter, lighter baby with a relatively larger head. The decline in z-
scores for weight/age and especially for length/age at Ba1 visit could correspond to the 
switch from the maternal placental PUFA supply to the breast/formula feeding, when the 
baby could not fully support its growth. An improvement in these scores at Ba 2 visit may 
then reflect a mobilisation of the infant fat reserves and its own production of PUFAs.  
 
2. The second aim of the study was to assess if the maternal pregnancy dietary 
intake of macronutrients affect infant glucose and markers of infant β-cell 
function i.e. INS, PI, HOMA-IR. 
 
The data analysis showed significant correlations between maternal nutrient intake 
and postnatal glucose and markers of infant β-cell function.  
 
The third trimester TOT ENERGY intake was inversely related to the neonatal and 
the 6-month postnatal infant fasting GLC and positively to neonatal fasting INS. These 
outcomes are the result of the combined effects of protein, fat and carbohydrate energy 
sources.   
Maternal intake of TOT CHO (including added sugar) at the first pregnancy visit 
(V1) was related to the size of fetus/infant, whilst carbohydrate at the second pregnancy 
visit (V2) was related to infant markers of β-cell function.  
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Maternal protein, specifically animal protein at both pregnancy visits seems to be 
involved in the regulation of the infant postnatal concentrations of IGF-BP3. Maternal 
protein intake (animal protein intake) at the first visit was positively related to the infant 
neonatal insulin and HOMA-IR index, whilst the plant protein intake at V2 was correlated 
negatively with the neonatal and postnatal infant β-cell function. This indicates a protective 
role for the plant protein.  
 
There is some involvement of infant BMI in the protein and carbohydrate results, 
although, the direct influence of protein and carbohydrate still remained after adjusting for 
BMI in the regression analysis. Infant BMI correlated with fat intake and also showed 
significant correlation with the infant β-cell function, which reflected possible protective 
effect of PUFA.   
 
A concurrent inverse association between maternal total energy intake at V3 and 
levels of infant INS and HOMA-IR2 and a positive correlation with infant leptin (LEPT2) 
were found, indicating a direct effect of maternal energy intake on infant β-cell function 
and adipose tissue. 
 
 
3. The third aim of the study was to assess if the maternal pregnancy hormonal 
levels affect fetal, birth or postnatal size or growth.  
 
Fetal growth rate. Contrary to the lack of effect of maternal dietary intakes on the 
fetal growth rate, positive correlations with maternal anthropometry and her hormonal 
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levels of placental lactogen, leptin, free thyroxine and proinsulin were found. Postnatal 
growth rate was associated with fetal gender and mother’s level of insulin resistance at V2. 
 
Birth parameters. In addition to maternal protein intake, the significant association 
with the baby’s birth weight was also found with maternal weight, fetal gender and the 
gestational length. Similar correlations also applied to the birth length, with the exception 
of baby’s gender and a positive effect of maternal leptin and negative effect of the IGF 
BP1 on BL.  The correlations with baby’s birth head circumference were as for the birth 
length. The association of BL and BHC with the IGF-BP1 may reflect a delayed bone 
ossification. 
 
Postnatal infant anthropometry. 
The major factors positively influencing neonatal BMI were maternal weight and 
baby’s age, and negatively, maternal proinsulin levels, whilst in older babies there was a 
major influence of the gender and maternal leptin concentrations.   
 
 
4. The fourth aim of the study was to assess if the maternal pregnancy hormonal 
levels affect infant glucose and markers of infant β-cell function i.e. INS, PI, 
HOMA-IR. 
 
The outcomes of the current study show that maternal hormones can affect the 
neonatal and early postnatal infant glucose levels, β-cell function and are also linked to the 
programming of early obesity.  This involves maternal free thyroxin levels, glucose at the 
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first pregnancy visit, HPL at the both pregnancy visits and maternal cortisol, proinsulin and 
insulin of the third-trimester visit. The maternal thyroid hormones seem to play an 
important role in fetal and postnatal growth and insulin metabolism.  
 
The regression analysis has shown that maternal anthropometry and maternal 
hormones during the second, and also third trimester of pregnancy do influence the rate of 
fetal or infant growth and early metabolic health. These relationships are probably very 
complex, as there may also be variables that will have additional effects but which were not 
measured in the current study.  
 
It is also possible that some associations between particular variables were not 
identified, due to insufficient power. The sample size assessment was based on the general 
rule for the relationship between the sample size and the number of explanatory variables 
entering the multiple regression models (Petrie et al 2000a; Chapter 2.2.1). However, the 
loss to follow-up was underestimated. The retrospective evaluation of the study power with 
regard to some key infant variables indicated a wide power range between 70-95%. (The 
power calculator used was: 
 http://hedwig.mgh.harvard.edu/sample_size/js/js_associative_quant.html).  
One of the strongest outcomes included the relationship between maternal FT4 (1) and 
neonatal INS F1. 
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LIMITATIONS OF THE CURRENT STUDY    
 
1. The sample size of pregnant women and infants included in this study is 
comparatively small. It is therefore possible that some associations were missed due 
to a lack of power. However, the study was of sufficient power to uncover a number 
of important associations, which will be the focus of future investigations.  
2. Food frequency questionnaires are considered to be a less accurate measure of the 
absolute intakes of nutrients compared to dietary recalls or diet records, as the FFQs 
may be biased by the respondent’s memory.  However, they are better in assessing 
habitual dietary intakes, they are less expensive and require a shorter period of time 
for their administration. The FFQ in the current study was supplemented with a 24-h 
dietary history crosscheck. It may, however, have been better to support it with a 
full 24-h dietary recall questionnaire.  
3. The correlation and regression analysis used in this study identified significant 
associations between variables of interest. However, it could not explain the full 
mechanisms behind these associations.  
4. As the current study aimed to investigate crude associations and how they are 
mediated, it did not adjust for multiple testing in the analytical part of the analysis.  
5. The statistical analyses in the current study were exploratory. Although certain steps 
to correct for the Type I statistical error were performed (the Bonferroni correction 
in the linear mixed models of the Descriptive part of the analysis and grading 
outcomes according to the p levels in the analytical part of analysis; comparison of 
results with existing literature), the study had many variables and full adjustment for 
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multiple testing was not done, and we therefore cannot exclude the fact that some 
results may have gained their significance by pure chance. 
6. There were too many variables to be tested separately for confounding, therefore the 
study used a literature based set of well-established confounders for birth weight. It 
was assumed, that these confounders are common for all the other tested variables. 
However, in some instances these confounders were not significant and for some 
variables they may have acted as modifiers.    
 
 
IMPLICATIONS OF THE STUDY  
The study revealed low maternal intakes of total energy largely as a result of low 
intakes of protein. The offspring of this study cohort were born lighter and shorter, but with 
a larger head circumference in comparison with the standard population z-scores (WHO 
2010). Clearly there is a potential area for future interventions.  
 
This study also shows that infant neonatal insulin sensitivity could be improved by 
an increase in neonatal length and in the lean body mass. This could be achieved in a 
number of ways.  
 
1. Changing the composition of the maternal diet. The process of urbanisation is 
generally associated with dietary changes, leading to diet rich in animal protein and 
saturated fat, includes elevated ratio of n-6 PUFA to n-3 PUFA and increased levels of 
carbohydrate.  
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Although the levels of essential amino acids found in animal protein are more   
suitable for human requirements than that of plant protein (O’Brien et al. 1987), it is not 
supportive of linear growth. Linear growth in the present study benefited from plant rather 
than animal protein consumption. Therefore, increasing consumption of the plant protein in 
early pregnancy would be suggested. However, some natural sources of plant protein found 
in corn, wheat and rice, which are among the frequently consumed food categories, have 
similar sulphur content to animal proteins, and therefore would not stimulate linear growth. 
However, the calcium in milk, the plant protein in fruits and vegetables (e.g. legumes, 
grains) can stimulate linear growth due to their mineral content and stimulatory effect on 
IGF-I concentrations (Chapter 4.5.1.3).  
 A further potential area for intervention is to decrease the dietary n-6 PUFA to n-3 
PUFA ratio in order to decrease production of PGE2 and thus stimulate bone cell-derived 
growth factors. Intervention early in pregnancy is required, as the PUFA contributes to 
maternal adipose tissue generation, which serves as the main energy source during later 
pregnancy for accelerated infant growth. The richest natural sources of n-3 fatty acids are 
oily fish, or the precursor of n-3 PUFA, alpha linolenic acid, is found in plants such as 
green leafy vegetables or rape-seed oil (Williams et al 2006). 
 
2. Increasing the total energy intake. Even with improved protein consumption, if total 
dietary energy intake is low, protein malnutrition cannot be improved (O’Brien et al 1987). 
Therefore increasing the energy intake is important. The intake of energy is known to be 
positively associated with the physical activity, which among the South African urban 
women is low (Chapter 4.3.3). In the current study the dietary intake of energy was also 
linked to the parental education and employment. This intervention is difficult, as it is not 
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achievable without improvement of the educational level and employment status of the 
parents.  
 
3. Regulating maternal hormonal levels. The combined effect of maternal nutrition and 
hormones will be investigated in future research. However, improvements in the 
composition of the maternal diet and increasing the physical activity of urban women will 
lead to changes in their anthropometry and thus to beneficial changes in hormonal levels.  
 
 
FOLLOW-ON RESEARCH FROM THIS PROJECT 
• Investigation of the effects of the n-6 and n-3 PUFA ratio on fetal and neonatal 
growth.  
• As the effects of the macronutrients on the fetal development are not isolated, the 
interaction of macronutrients and hormones will be carried out in the regression analysis 
(interactions terms). 
•  The effects of maternal intake of micronutrients as assessed by the food frequency 
questionnaire, will be explored.  
• Influence of other determinants of fetal development/ birth weight will be 
investigated, such as the number of previous pregnancies, maternal birth size, mother’s 
health history using appropriate statistical tools for low numbers and unequal balance  
•  The information collected by means of the food frequency questionnaire will be 
coded and analysed according to food groups (such as milk and dairy consumption, fish, 
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fruits and vegetables..) to support the findings related to the individual nutrients (e.g. 
PUFA). 
•  Complex model development employing statistical modelling tools  
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APPENDIX A:
                                                 
Enrolment diagram
159 ANC: FILE INFORMATION
Applicant suitable – Blood test
results known, Pre-selected
Unsuitable applicant (mother’s
age, gestational age, ethnic
origin, health, parity, no
consent for blood tests given,
participating in another study…)
⇒  NOT SELECTED
Applicant suitable – Pre-selected
Blood test results still unknown ⇒
WAITING
Wrong information,
over 24 weeks of gest.
age, not accessible,
no time,
too far to travel,
employer or husband
would not agree, does
not agree to
participate
⇒ NOT SELECTED
Needs time
to decide ⇒
WAITING
Positive blood tests
results/ on treatment
Negative blood test
results/ no treatment
SELECTED VOLUNTEER
Gestation below 20 weeks
⇒ FOLLOWED IN THE
CLINIC, WAITING until 20
 
weeks of gestation
Lost contact, ill
health, does not
wish to volunteer
any more…
⇒ EXCLUDED
Within the interval of 20-24 weeks of gestational age
⇒ Applicant ENROLLED
First visit for an OGTT to the DAY WARD arranged
⇒ INTERVIEW
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APPENDIX B. Inclusion Criteria Questionnaire.
 QUESTIONNAIRE (inclusion criteria) PND Study Pg1
Study No      Hosp. No First Names Surename                                         Age Ethnic 
group           
.                
.          .                             
Occupation
Home Address                Tel No - home Cell phone No Neighbour- tel. Note:
                                                                                                                     
                                                                                                                    
Employer - address Tel No - homework Husband / close relative (w/home) Tel. No
                                                                                                             
                                                                                                      
FAMILY:
Soc.-econom. Status: No of people in a household/flat
Average income/ month
How many brothers and sisters do you have?
Genetic Status: Any diseases which commonly occur in your family?
Any Down Syndrom or neural tube defect? Other?
Is/was your mother short? Thin?
If you know: Were you born premature?
If you know: Were you a small/thin baby?
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Mothers background Pg 2 Resrv. for changes
Education:
Previous pregnancies:
Spont. Abortions? Stillbirth? Other?
Other children: How many?
How old are they?
Medical history: Do you suffer from any chronic disease?
Have you ever been diagnosed with following:
{tuberculosis, HIV, syphilis - other STD?
chronic respiratory disease (asthma), chronic renal disease
congenital heart disease, high blood pressure
cystic fibrosis, anaemia, thyroid disease, toxoplasmosis}
If yes, state which one and when:
Have you been irradiated during pregnancy or shortly before? (X-ray, …)
Mothers present state
General health: Are you taking any MUTI?
Any present treatment?
What medicaments? Any allergy?
Stress? Do you have any stress?
Do you have any occupational hazards?
Are you working standing?
Are you a smoker? How many cigarettes do you smoke/day?
Do you drink alcohol? How often, how much?
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Baby's father Pg 3 Resrv. for changes
Ethnic origin:
Age:
Education:
Occupation:
General health
Height & Weight:
Genetic status: Is there any genetic disease in baby's father family?
If yes, which one?
Further information
Do you plan to attend all visits in the 159 ANC? Y N
Do you plan to stay at the present address? Y N
Do you plan to move out of Johannesburg? When? Y N
For how long?
Do you plan to deliver your baby in this hospital? Y N
Do you plan to stay with your newborn baby in Johannesburg? Y N
Will you look after your baby yourself? (Somebody else?) Y N
Do you plan to come with your baby for both visits:          after 2-3 weeks Y N
after 5 months Y N
What is the best way to contact you? Tel:
Any comments?
Please note: If you need any help, do not hessitate to ask the interviewer.
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APPENDIX C.   FOOD FREQUENCY QUESTIONNAIRE  1 
 
NAME__________________________________ 
DATE OF BIRTH_________________________ AGE (YEAR AND MONTHS)__________________ 
SEX _______________________________ 
ETHNIC GROUP_____________________ 
DAY OF INTERVIEW_____________________ 
DATE OF INTERVIEW____________________ 
 
INSTRUCTIONS 
 
The following questions are about the foods you USUALLY eat during an average week. 
Please indicate the number of days per week that you eat item on average. Ring the answer as in the example: 
If you eat the food every day, ring 7    7  6  5  4  3  2  1  M  R 
If you eat the food 3 days / week, ring 3    7  6  5  4  3  2  1  M  R 
If you eat the food only monthly, ring M    7  6  5  4  3  2  1  M  R 
If you never or rarely eat the food, ring R    7  6  5  4  3  2  1  M  R 
_______________________________________________________________________________________ 
GRAIN AND CEREAL GROUP 
        No. days / week 
Bread        7  6  5  4  3  2  1  M  R 
Provitas/ cream crackers etc.     7  6  5  4  3  2  1  M  R 
Do you mainly eat white, brown or wholewheat bread? _______________________ 
How many slices of bread do you have per day? _____________________________ 
 
BREAKFAST CEREALS AND PORRIDGES 
 
No. days / week 
Cereals (Rice Krispies, Cornflakes)     7  6  5  4  3  2  1  M  R 
Sugar coated cereals (Coco pops, Frosties)    7  6  5  4  3  2  1  M  R 
Whole wheat cereals (All Bran, Weetbix)    7  6  5  4  3  2  1  M  R 
Porridge (Oats, Maltabella, Maize meal)    7  6  5  4  3  2  1  M  R 
Muesli        7  6  5  4  3  2  1  M  R 
Pronutro        7  6  5  4  3  2  1  M  R 
 
OTHER STARCHES 
 
No. days / week 
Rice, pasta       7  6  5  4  3  2  1  M  R 
Stiff maize meal  - with amasi (sour milk)    7  6  5  4  3  2  1  M  R 
  - without amasi     7  6  5  4  3  2  1  M  R 
Samp/mielie rice  - with beans     7  6  5  4  3  2  1  M  R 
  - without beans     7  6  5  4  3  2  1  M  R 
 
MEATS AND MEAT SUBSTITUTES 
No. days / week 
Read meat (beef, lamb, pork or mince)    7  6  5  4  3  2  1  M  R 
Processed meat (bacon, sausages, polony)     7  6  5  4  3  2  1  M  R 
Chicken        7  6  5  4  3  2  1  M  R 
Fish        7  6  5  4  3  2  1  M  R 
Eggs and egg dishes      7  6  5  4  3  2  1  M  R 
Cheese, cheese spread and cheese dishes    7  6  5  4  3  2  1  M  R 
Nuts, including peanut butter     7  6  5  4  3  2  1  M  R 
Dried peas, beans, baked beans or legumes    7  6  5  4  3  2  1  M  R 
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VEGETABLES AND FRUIT         2 
No. days / week 
Green and/ or yellow vegetables     7  6  5  4  3  2  1  M  R 
Potatoes        7  6  5  4  3  2  1  M  R 
Fresh fruit       7  6  5  4  3  2  1  M  R 
Canned fruit       7  6  5  4  3  2  1  M  R 
Dried fruit (raisins, prunes, dates)     7  6  5  4  3  2  1  M  R 
Fresh fruit juice (Ceres, Liquifruit)     7  6  5  4  3  2  1  M  R 
 
Name some of the vegetables you have eaten this past week 
 
______________________________________________________________________________________ 
 
 
Do you eat your vegetables most frequently cooked or raw?  
_____________________________________________ 
 
 
Do you mainly eat your potatoes as boiled, baked in jacket, mashed, roasted or as chips? _______________ 
 
What types of fresh fruit have you eaten this past week? 
 
______________________________________________________________________________________ 
 
 
FATS AND OILS 
No. days / week 
 
Oil/butter/margarine      7  6  5  4  3  2  1  M  R 
Salad dressing/mayonnaise     7  6  5  4  3  2  1  M  R 
Cream        7  6  5  4  3  2  1  M  R 
Non dairy creamers (Cremora)     7  6  5  4  3  2  1  M  R 
Ice-cream       7  6  5  4  3  2  1  M  R 
 
Please estimate, on average, the total amount of fat (oil/butter/margarine/dressing/cream/ non-dairy creamers) 
you use per day in teaspoons. ________________ tsp.  
(includes the fat on bread, in cooking and frying and on vegetables/salads) 
 
No. days / week 
How often do you fry your food?     7  6  5  4  3  2  1  M  R 
 
 
MILK AND MILK PRODUCTS 
No. days / week 
Milk        7  6  5  4  3  2  1  M  R 
Yoghurt - plain       7  6  5  4  3  2  1  M  R 
  - flavoured       7  6  5  4  3  2  1  M  R 
Milo/ Nesquick/cocoa/ Horlicks     7  6  5  4  3  2  1  M  R 
Custard        7  6  5  4  3  2  1  M  R 
 
Please estimate, on average, how much milk you have per day, including that on cereal, in tea or coffee and 
milk drinks 
_______________________________ ml    or   ___________________________   cups 
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What type of milk do you use:         3 
Full cream  __________________________ 
Low-fat (2 % fat)  __________________________ 
Skimmed  __________________________ 
Condensed  __________________________ 
 
 
MISCILLANEOUS 
 
Please estimate how many teaspoons of sugar you have, in total, per day? ________________ tsp. 
(in tea/coffee/milk drinks, on cereal/ porridge, added to vegetables) 
 
 
No. days / week 
Sweets (sucking/ jelly type/ fudge/ toffee)    7  6  5  4  3  2  1  M  R 
Chocolates/ chocolate bars      7  6  5  4  3  2  1  M  R 
Jam, syrup, honey      7  6  5  4  3  2  1  M  R 
Jelly        7  6  5  4  3  2  1  M  R 
Sweet biscuits/ cakes/ pastries/ doughnuts    7  6  5  4  3  2  1  M  R 
tarts/ scones/ pancakes 
Crisps        7  6  5  4  3  2  1  M  R 
Popcorn (plain or candied)      7  6  5  4  3  2  1  M  R 
Puddings (trifle, baked puddings etc.)    7  6  5  4  3  2  1  M  R 
Coldrinks (Coke, Fanta etc. ) or cordials     
- sweetened    7  6  5  4  3  2  1  M  R 
- diet     7  6  5  4  3  2  1  M  R 
 
Tea        7  6  5  4  3  2  1  M  R 
Coffee        7  6  5  4  3  2  1  M  R 
Spreads (bovril, marmite, fish paste, sandwich)   7  6  5  4  3  2  1  M  R 
 
 
How many meals do you have per day ie. Breakfast, lunch and/or dinner? ________________ 
 
How many inbetween snacks do you have per day  
ie. mid-morning, mid-afternoon and or late evening? ________________________________ 
 
Please indicate how many portions of the following food groups you ate yesterday by circling the 
appropriate number. 
 
Eg. If you had 1 egg for breakfast, cheese for lunch, and chicken for dinner, ring 3 for number 2. 
If you had cereal and 1 slice of toast for breakfast, a sandwich for lunch (2 slices of bread) and rice for 
dinner, ring 5 for number 4. 
 
No. Portions yesterday 
1. milk, yoghurt (1 portion = 1 cup/ 200 ml)    1  2  3  4  5  6  7  8  9  10 
2. meat/ fish/ chicken/ cheese/ eggs/ nuts/ legumes   1  2  3  4  5  6  7  8  9  10 
3. fruit/ fruit juice      1  2  3  4  5  6  7  8  9  10 
4. vegetables (green and yellow)     1  2  3  4  5  6  7  8  9  10 
5. potatoes       1  2  3  4  5  6  7  8  9  10 
6. bread/ cereal/ porridge/ rice/ pasta/ maize meal/ samp/ mielie rice 1  2  3  4  5  6  7  8  9  10 
7. oil/ butter/ margarine/ cream/ non dairy creamers/ salad dressings 1  2  3  4  5  6  7  8  9  10 
    (1 portion = 1 tspn) 
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            4 
 
Were these number of portions typical of what you would normally consume on an average day ? 
 
Yes ___________________________  No ________________________ 
 
If you answered No, was the difference due to: 
 
Illness _______________________ 
 
A party  _______________________ 
 
Eating out _____________________ 
 
Other reasons ___________________________________________________________________ 
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Appendix D, E, F.  
Maternal energy and macronutrients dietary inatake regression analyses.  
 
The Appendices D, E, F include tables of maternal energy and macronutrient dietary 
intakes and their effects on selected fetal, birth and infant parameters.  
The variables were analysed in the multilinear regression models with and without 
adjustment for possible confounders (see also Chapter 2.8.3.3).  
 
The following confounders were used in adjustment:  
Due to restricted space in the result tables, a short abbreviation was used for the variables 
as described below.  For analyses related to the gestation period, gestational age and 
maternal weight were included as confounders and for the postnatal period, the analyses 
were corrected for the infant age and weight. The analysis of birth parameters took into 
account maternal height, maternal weight and birth age. All analyses were corrected for 
infant gender. Abbreviations: 
A (gestational/ birth/ infant age)    w (maternal/infant weight)1  
s (sex)        h (maternal height) 
 
Significant results (p<0.05) are in red type, whilst the results near significance  
(p≥5 and p<0.10) are in black, bold type.  
 
 
                                                           
1
 Please note: Baby’s BMI cannot be corrected for the baby’s weight, as it is the part of the formula. The 
similar applies for the growth rate. 
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Outliers on or above three standard residuals (SR) were excluded. If exclusion of 
the outlier produced a change in the non-standardised B-coefficient greater than 10%, both 
outcomes are presented. The same applies for the instances where outlier exclusion led to a 
change in the outcome (significant/non significant). The result including the outlier is 
presented below the main table.  
For the units of the B-coefficients see Appendix G. 
 
 
Significance of confounders in individual regression models. 
 
Due to restricted space in the regression outcome tables, the significance of confounders 
used in adjustment of the individual regression models is listed below: 
 
Significant confounders associated with the following variables: 
Maternal dietary intakes and fetal biometry: 
FW1  Gestational age /(maternal weight*) 
BPD1  Gestational age 
AC1  Gestational age, sex /(maternal weight*) 
HC1  Gestational age,  
FL1  Gestational age, sex /(maternal weight*) 
FW2  Gestational age, maternal weight 
BPD2  Gestational age, maternal weight 
AC2  Gestational age, maternal weight 
HC2  Gestational age 
FL2   Gestational age 
 
(* significant association with the fetal biometry variable if gestational age removed) 
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Birth weight: Birth age, maternal weight, sex 
 
 
Postnatal anthropometry: 
Weight1 infant age, sex 
Length1 infant age 
BMI1  infant age 
Weight2 sex 
Length2 infant age 
BMI2  sex 
 
 
Infant metabolic parameters: 
GLCF1 infant weight 
INSF1  - 
PIF1  - 
HOMA1 infant weight 
LEPT  infant weight, age, sex 
IGF-BP3 (1) infant weight 
GLCF2 - 
INSF2  infant weight, sex 
PIF2  infant weight 
HOMA2 infant weight, sex 
LEPT2 infant weight, sex 
IGF-BP3 (2)  infant weight 
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APPENDIX D. Maternal protein intake analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF RESULTS: D1 Maternal protein intake at V1 vs fetal weight and size at US1. 
Protein intake V1 FW1 BPD1 AC1 HC1 FL1
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 106 104 106 103 106 102 97 95 104 103
TOT Prot (%E)
B coef -5.823 -0.936 -0.075 0.372 0.022 0.007 -2.620 -0.315 -0.522 0.225
Beta coef -0.138 -0.023 -0.075 0.054 0.127 0.047 -0.111 -0.013 -0.087 0.038
p value 0.159 0.079 0.446 0.024#1 0.194 0.134 0.284 0.513 0.374 0.141
PL Prot (%E)
B coef 5.300 -0.458 0.967 0.074 -0.026 -0.003 3.70 0.245 0.744 -0.060
Beta coef 0.187 -0.016 0.207 0.016 -0.229 -0.032 0.222 0.015 0.186 -0.015
p value 0.055 0.208 0.033 0.512 0.018 0.298 0.029 0.456 0.057 0.539
AN Prot (%E)
B coef -1.480 -0.080 -0.193 0.046 0.007 0.002 -0.904 -0.080 -0.160 0.043
Beta coef -0.204 -0.011 -0.162 0.039 0.225 0.062 -0.214 -0.020 -0.156 0.042
p value 0.036 0.394 0.098 0.109 0.021 0.050#2 0.035 0.331 0.111 0.085#3
Analysis including outliers: #1 #2 #3
N number 104 104 104
B coef 0.305 0.001 0.042
Beta coef 0.044 0.044 0.041
p value 0.077 0.175 0.119
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TABLE OF RESULTS: D2 Maternal protein intake at V1 vs fetal weight and size at US2. 
Protein intake V1 FW2 BPD2 AC2 HC2 FL2
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 104 102,101* 104 102 103 102 95 92,93* 104 102
TOT Prot (%E)
B coef -0.188 -0.032 -0.784 -0.213 0.028 0.009 -4.322 -2.882 -0.785 -0.043
Beta coef -0.205 -0.036 -0.169 -0.046 0.181 0.057 -0.276 -0.187 -0.194 -0.011
p value 0.037 0.572 0.087 0.538 0.067 0.450 0.007 0.014#2 0.049 0.871
PL Prot (%E)
B coef 0.049 0.023 0.150 0.164 -0.007 -0.008 -0.419 -0.396 0.010 0.069
Beta coef 0.080 0.038 0.048 0.052 -0.071 -0.072 -0.041 -0.039 0.004 0.025
p value 0.417 0.531 0.626 0.471 0.479 0.321 0.694 0.615* 0.968 0.687
AN Prot (%E)
B coef -0.032 -0.006 -0.137 -0.055 0.005 0.002 -0.511 -0.372 -0.100 -0.003
Beta coef -0.202 -0.040 -0.172 -0.069 0.181 0.076 -0.195 -0.142 -0.144 -0.004
p value 0.040 0.525* 0.081 0.354 0.068#1 0.310 0.058 0.063 0.145 0.946
Analysis including outliers: #1 #2
N number 104 93
B coef 0.006 -2.084
Beta coef 0.205 -0.136
p value 0.037 0.085
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TABLE OF RESULTS: D3 Maternal protein intake at V2 vs fetal weight and size at US2. 
Protein intake V2 FW2 BPD2 AC2 HC2 FL2
Adjusted for conf. None A,h,w,s None A,h,w,s None Age A,h,w,s None A,h,w,s None A,h,w,s
N number 105 102 105 103 104 102 104 95 93 105 103
TOT Prot (%E)
B coef -0.346 -0.133 0.316 1.412 0.156 0.134 0.092 8.711 1.137 0.762 0.690
Beta coef -0.060 -0.025 0.011 0.050 0.169 0.145 0.094 0.096 0.049 0.032 0.028
p value 0.523 0.683 0.909 0.485 0.087 0.048#1 0.192 0.357 0.619 0.750 0.649
PL Prot (%E)
B coef 0.004 -0.002 0.032 0.010 0.000 0.001 0.001 0.054 0.012 0.016 -0.005
Beta coef 0.057 -0.024 0.103 0.031 0.001 0.050 0.049 0.054 0.049 0.059 -0.019
p value 0.567 0.739 0.295 0.669 0.990 0.496 0.513 0.607 0.624 0551 0.773
AN Prot (%E)
B coef 0.006 0.015 -0.210 -0.176 -0.014 -0.016 -0.013 -1.185 -0.184 -0.163 -0.054
Beta coef 0.011 0.028 -0.076 -0.064 -0.149 -0.169 -0.140 -0.133 -0.081 -0.068 -0.023
p value 0.916 0.649 0.441 0.373 0.133 0.021#2 0.054 0.200 0.414 0.489 0.715
Analysis including outliers: #1 #2
N number 105 105
B coef 0.120 -0.012
Beta coef 0.124 -0.125
p value 0.085 0.085
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TABLE OF RESULTS: D4 Maternal protein intake at V1 vs birth parameters. 
Protein intake V1 BW BL   PONDIX   BW/PLW
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 103 103 100 100 100 100 86, 88* 86
TOT Prot (%E)
B coef 0.101 -0.003 2.728 0.270 0.007 0.002 -0.014 -0.008
Beta coef 0.179 -0.005 0.110 0.011 0.014 0.003 -0.037 -0.031
p value 0.071 0.953 0.278 0.909 0.889 0.978 0.738 0.781
PL Prot (%E)
B coef 0.043 0.055 2.857 2.542 -0.005 -0.001 -0.012 -0.006
Beta coef 0.111 0.137 0.164 0.146 -0.010 -0.004 -0.044 -0.023
p value 0.264 0.096 0.102 0.116 0.900 0.970 0.690 0.839
AN Prot (%E)
B coef 0.010 -0.009 0.084 -0.293 1.419 0.000 0.001 0.000
Beta coef 0.100 -0.093 0.020 -0.068 0.020 0.005 0.017 -0.002
p value 0.316 0.272 0.847 0.470 0.844 0.963 0.874*  0.984
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TABLE OF RESULTS: D5 Maternal protein intake at V2 vs birth parameters. 
Protein intake V2 BW BL   PONDIX   BW/PLW
Adjusted for conf. None A A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 103 103 103 100 100 100 100 87 85,87*
TOT Prot (%E)
B coef -0.647 -0.716 -0.608 -13.142 -16.338 -0.116 -0.140 0.386 0.412
Beta coef -0.187 -0.207 -0.171 -0.090 -0.111 -0.040 -0.045 0.134 0.181
p value 0.059 0.021#1 0.038#2 0.379 0.234 0.711 0.665 0.220 0.105
PL Prot (%E)
B coef -0.003 -0.003 0.001 -0.077 -0.049 -0.001 0.000 0.000 0.000
Beta coef -0.066 -0.067 0.017 -0.050 -0.031 -0.010 -0.006 -0.008 -0.014
p value 0.504 0.456 0.841 0.637 0.748 0.894 0.956 0.940 0.903*
AN Prot (%E)
B coef 0.049 0.052 0.037 0.835 1.153 1.414 0.011 -0.036 -0.037
Beta coef 0.144 0.147 0.106 0.058 0.080 0.033 0.036 0.134 -0.156
p value 0.147 0.101 0.205 0.566 0.393 0.741 0.730 0.220 0.164
Analysis including outliers: #1 #2
N number 104 104
B coef -0.624 -0.575
Beta coef -0.172 -0.159
p value 0.054 0.062
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TABLE OF RESULTS: D6 Maternal protein intake at V1 vs infant anthropometry (Ba1 and Ba2). 
Protein intake V1
  Weight 1   Length 1 BMI 1   Weight 2   Length 2 BMI 2
Adjusted for conf. None A, s None A, s None A, s None A, s None A, s None A, s
N number 77 76 77 77 76 77 73 73 72 73 72 72
TOT Prot (%E)
B coef 351.1 621.4 -7.770 -0.072 0.071 0.093 0.120 0.129 0.844 1.057 -0.016 -0.016
Beta coef 0.059 0.104 -0.263 -0.050 0.291 0.353 0.210 0.227 0.030 0.035 -0.288 -0.287
p value 0.613 0.238 0.021 0.635 0.011#1 0.001 0.074 0.038 0.801 0.754 0.014 0.012
PL Prot (%E)
B coef 838.0 517.5 1.529 -0.362 0.036 0.027 0.013 0.020 0.402 2.027 0.000 0.001
Beta coef 0.199 0.123 0.072 -0.017 0.206 0.143 0.031 0.047 0.020 0.092 0.009 0.019
p value 0.084 0.159 0.535 0.870 0.074#2 0.203 0.798 0.675 0.871 0.416 0.941 0.871
AN Prot (%E)
B coef -44.68 79.86 -1.430 -0.998 0.007 0.013 0.015 0.016 0.078 -0.023 -0.002 -0.002
Beta coef -0.042 0.075 -0.273 -0.191 0.158 0.275 0.154 0.170 0.016 -0.005 -0.231 -0.238
p value 0.716 0.400 0.016 0.062 0.172#3 0.012 0.193 0.122 0.891 0.968 0.051 0.039
Analysis including outliers: #1 #2 #3
N number 77 77 77
B coef 0.086 0.036 0.010
Beta coef 0.328 0.188 0.209
p value 0.004 0.101 0.068
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TABLE OF RESULTS: D7 Maternal protein intake at V2 vs infant anthropometry (Ba1 and Ba2). 
Protein intake V2   Weight 1   Length 1 BMI 1   Weight 2   Length 2 BMI 2
Adjusted for conf. None A, s None A, s None A, s None A, s None A, s None A, s
N number 76 76 76 76 75 76 72 72 71 72 71 71
TOT Prot (%E)
B coef -2177.3 517.1 -51.194 -44.737 0.327 0.398 0.139 0.452 -17.444 2.351 -0.025 -0.042
Beta coef -0.059 0.014 -0.289 -0.252 0.221 0.247 0.039 0.128 -0.104 0.013 -0.073 -0.124
p value 0.610 0.876 0.012 0.014 0.057#1 0.026 0.743 0.262 0.389 0.911 0.548 0.301
PL Prot (%E)
B coef 14.887 -22.845 0.513 0.408 -0.002 -0.005 -0.006 -0.009 0.046 -0.090 0.001 0.001
Beta coef 0.039 -0.060 0.277 0.220 -0.142 -0.283 -0.166 -0.238 0.026 -0.047 0.218 0.269
p value 0.739 0.510 0.016 0.032 0.225#2 0.010 0.164 0.033 0.833 0.683 0.069 0.021
AN Prot (%E)
B coef -38.900 54.484 0.905 1.309 -0.017 -0.008 0.012 0.006 0.548 -0.177 -0.002 -0.002
Beta coef -0.011 0.016 0.053 0.077 -0.119 -0.050 0.036 0.018 0.033 -0.010 -0.064 -0.059
p value 0.924 0.862 0.649 0.453 0.309 0.656 0.763 0.873 0.782 0.929 0.595 0.615
Analysis including outliers: #1 #2
N number 76 76
B coef 0.309 -0.004
Beta coef 0.191 -0.216
p value 0.098 0.061
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TABLE OF RESULTS: D8 Maternal protein intake at V1 vs infant glucose, HOMA index and metabolics (Ba1). 
Protein intake V1   Glc F 1   Ins F 1 PI F 1   HOMA-IR 1     Leptin 1    IGF BP3 (1)
Adjusted for conf. None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w
N number 77 75 76 76 76 76 75,74* 75,74* 76 76 76,77* 76,77*
TOT Prot (%E)
B coef -0.186 -0.036 -0.037 -0.037 -0.184 -0.246 0.610 0.612 0.164 -0.054 707.9 558.6
Beta coef -0.039 -0.008 -0.346 -0.348 -0.112 -0.140 0.379 0.381 0.021 -0.007 0.231 0.182
p value 0.738 0.945 0.002 0.003 0.337 0.237 0.001 0.001 0.859 0.933 0.045#1 0.095#2
PL Prot (%E)
B coef 0.367 0.182 -0.006 -0.005 0.072 0.059 0.204 0.169 0.782 -0.125 -69.10 -226.6
Beta coef 0.106 0.055 -0.081 -0.063 0.061 0.047 0.181 0.149 0.138 -0.022 -0.029 -0.096
p value 0.359 0.627 0.489 0.599 0.603 0.700 0.124* 0.204* 0.234 0.788 0.800* 0.391*
AN Prot (%E)
B coef -0.107 -0.059 -0.006 -0.006 -0.048 -0.059 0.092 0.100 -0.067 0.003 136.2 133.6
Beta coef -0.125 -0.073 -0.307 -0.323 -0.165 -0.188 0.318 0.345 -0.048 0.002 0.236 0.231
p value 0.277 0.516 0.007 0.006 0.154 0.115 0.005 0.003 0.680 0.981 0.039* 0.036*
Analysis including outliers: #1 #2
N number 77 77
B coef 673.7 552.3
Beta coef 0.207 0.169
p value 0.071 0.123
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TABLE OF RESULTS: D9 Maternal protein intake at V2 vs infant glucose, HOMA index and metabolics (Ba1). 
Protein intake V2   Glc F 1   Ins F 1 PI F 1   HOMA-IR 1     Leptin 1    IGF BP3 (1)
Adjusted for conf. None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w
N number 76 75 75 75 76 76 74,73* 73 75 74 75,76* 76
TOT Prot (%E)
B coef 2.319 3.436 -0.075 -0.095 -1.036 -0.989 1.166 1.137 6.370 4.712 -1290.0 -918.9
Beta coef 0.079 0.117 -0.114 -0.145 -0.103 -0.098 0.118 0.122 0.132 0.097 -0.064 -0.049
p value 0.500 0.309 0.330 0.228 0.376 0.416 0.317 0.300 0.260 0.232 0.581* 0.662
PL Prot (%E)
B coef 0.048 0.039 0.002 0.002 0.002 0.001 -0.024 -0.023 -0.028 -0.008 -41.48 -39.31
Beta coef 0.155 0.126 0.298 0.329 0.021 0.011 -0.233 -0.237 -0.056 -0.017 -0.211 -0.188
p value 0.180 0.272 0.010 0.005 0.854 0.928 0.046 0.042#1 0.632 0.840 0.070#2 0.093
AN Prot (%E)
B coef -0.537 -0.516 -0.006 -0.006 0.031 0.031 0.045 0.039 -0.385 -0.249 365.7 361.9
Beta coef -0.190 -0.183 -0.101 -0.098 0.032 0.032 0.051 0.041 -0.083 -0.054 0.190 0.188
p value 0.100 0.103 0.389 0.407 0.785 0.790 0.671* 0.727 0.480 0.505 0.100* 0.085
Analysis including outliers: #1 #2
N number 74 76
B coef -0.028 -39.16
Beta coef -0.269 -0.189
p value 0.022 0.103
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TABLE OF RESULTS: D10 Maternal protein intake at V1 vs infant glucose, HOMA index and metabolics (Ba2). 
Protein intake V1 Glc F 2 Ins F 2 PI F 2   HOMA-IR  2    Leptin 2    IGF BP3 (2)
Adjusted for conf. None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w
N number 74 73 72 71 74 72 75 71 74 73 73,74* 73
TOT Prot (%E)
B coef -0.460 -0.529 0.193 0.159 0.139 -0.010 0.610 0.257 0.139 -0.153 618.3 170.5
Beta coef -0.081 -0.093 0.259 0.211 0.076 -0.006 0.379 0.158 0.058 -0.065 0.115 0.031
p value 0.495 0.457 0.028 0.078 0.519 0.963 0.001 0.190 0.621 0.524 0.330* 0.786
PL Prot (%E)
B coef 0.279 0.269 -0.019 -0.026 -0.321 -0.355 0.204 -0.016 -0.006 -0.040 -481.8 -713.2
Beta coef 0.066 0.064 -0.034 -0.046 -0.237 -0.262 0.181 -0.013 -0.004 -0.023 -0.129 -0.178
p value 0.578 0.601 0.777 0.696 0.042 0.021 0.124 0.911 0.976 0.817 0.277 0.112
AN Prot (%E)
B coef -0.073 -0.077 0.032 0.027 0.045 0.028 0.092 0.044 0.020 -0.019 130.7 98.40
Beta coef -0.075 -0.080 0.254 0.211 0.145 0.089 0.318 0.160 0.048 -0.048 0.153 0.107
p value 0.528 0.516 0.031 0.075 0.217 0.443 0.005 0.178 0.684 0.633 0.197 0.347
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TABLE OF RESULTS: D11 Maternal protein intake at V2 vs infant glucose, HOMA index and metabolics (Ba2). 
Protein intake V2 Glc F 2 Ins F 2 PI F 2   HOMA-IR  2    Leptin 2    IGF BP3 (2)
Adjusted for conf. None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w
N number 73 72 71 70 72,73* 71 74,73* 70 73 72 73,72* 72
TOT Prot (%E)
B coef 0.138 0.630 -0.201 -0.562 1.246 1.087 1.166 -1.048 2.256 1.508 -5201.1 -7972.4
Beta coef 0.004 0.018 -0.045 -0.120 0.115 0.097 0.118 -0.103 0.158 0.103 -0.172 -0.236
p value 0.973 0.887 0.712 0.328 0.332* 0.417 0.317 0.398 0.183 0.315 0.149* 0.040
PL Prot (%E)
B coef 0.019 0.025 -0.019 -0.016 -0.032 -0.007 -0.024 -0.029 -0.024 0.001 -62.58 -47.20
Beta coef 0.050 0.069 -0.379 -0.318 -0.273 -0.060 -0.233 -0.268 -0.152 0.007 -0.178 -0.134
p value 0.675 0.591 0.001 0.008 0.020#1 0.620 0.046 0.027 0.199 0.948 0.131 0.254
AN Prot (%E)
B coef -0.239 -0.294 0.113 0.118 -0.038 -0.057 0.045 0.202 -0.123 -0.165 839.3 860.8
Beta coef -0.071 -0.088 0.256 0.264 -0.036 -0.053 0.051 0.210 -0.088 -0.118 0.263 0.267
p value 0.551 0.473 0.031 0.024 0.763* 0.646 0.671* 0.073 0.460 0.233 0.024 0.016
Analysis including outliers: #1
N number 73
B coef -0.016
Beta coef -0.138
p value 0.246
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APPENDIX E. Maternal fat intake analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF RESULTS: E1 Maternal dietary fat intake at V1 vs fetal weight and size at US1. 
FAT Intake V1 FW1 BPD1 AC1 HC1 FL1
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 105,106* 104 106 104 105 102 97 93 106 103
Total Fat (%E)
B coef -0.042 0.010 -0.011 -0.002 0.000 0.000 -0.034 0.000 -0.006 0.000
Beta coef -0.094 0.023 -0.144 -0.032 0.136 0.008 -0.134 0.000 -0.100 -0.001
p value 0.340* 0.074 0.140 0.178 0.166 0.807 0.193 0.990 0.309 0.983
SAFA (% E)
B coef -7.389 0.721 -1.158 -0.131 0.029 0.002 -4.372 -0.541 -0.853 0.086
Beta coef -0.232 0.022 -0.214 -0.024 0.227 0.014 -0.225 -0.029 -0.184 0.019
p value 0.018#1 0.106 0.028 0.369 0.020#2 0.675 0.026 0.174 0.060 0.475
MUFA (% E)
B coef -2.401 0.765 -0.596 -0.164 0.014 -0.002 -2.082 -0.289 -0.317 0.119
Beta coef -0.079 0.025 -0.119 -0.032 0.118 -0.012 -0.113 -0.016 -0.074 0.027
p value 0.420* 0.052 0.225 0.181 0.232 0.686 0.269 0.426 0.453 0.262
PUFA (% E)
B coef 0.635 0.207 -0.030 -0.074 -0.002 -0.001 0.381 0.227 0.069 -0.009
Beta coef 0.036 0.015 -0.010 -0.026 -0.023 -0.007 0.037 0.022 0.027 -0.004
p value 0.717* 0.229 0.917 0.288 0.815 0.826 0.718 0.273 0.780 0.884
Analysis including outliers: #1 #2
N number 106 106
B coef -5.866 0.026
Beta coef -0.179 0.196
p value 0.066 0.044
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TABLE OF RESULTS: E2 Maternal dietary fat intake at V1 vs fetal weight and size at US2. 
FAT Intake V1 FW2 BPD2 AC2 HC2 FL2
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 103,104* 101,102* 104 102 103,104* 102 95 93 103,104* 102
Total Fat (%E)
B coef 0.001 0.000 0.003 -0.007 0.000 0.000 0.025 -0.005 0.013 0.001
Beta coef 0.137 -0.061 0.057 -0.134 0.137 0.029 0.154 -0.028 0.308 0.023
p value 0.165* 0.408* 0.563 0.073 0.167* 0.702 0.134 0.722 0.002#5 0.725
SAFA (% E)
B coef -0.035 -0.060 -0.033 -0.396 0.008 0.017 0.019 -0.502 0.019 -0.088
Beta coef -0.050 -0.086 -0.009 -0.108 0.064 0.135 0.002 -0.042 0.006 -0.028
p value 0.614* 0.182#2 0.926 0.154 0.519 0.077 0.988 0.600 0.950* 0.677
MUFA (% E)
B coef 0.110 0.023 0.292 -0.294 -0.014 -0.002 1.694 0.006 0.741 0.216
Beta coef 0.168 0.035 0.088 -0.085 -0.127 -0.013 0.152 0.001 0.255 0.071
p value 0.089* 0.538 0.377 0.256 0.200 0.866 0.141 0.995 0.010* 0.268
PUFA (% E)
B coef 0.102 0.034 0.201 -0.095 -0.017 -0.008 1.302 0.173 0.455 0.088
Beta coef 0.272 0.091 0.103 -0.049 -0.254 -0.121 0.202 0.027 0.267 0.052
p value 0.006#1 0.150#3 0.299 0.522 0.010#4 0.109 0.049 0.734 0.006* 0.430
Analysis including outliers: #1 #2 #3 #4 #5
N number 104 102 102 104 104
B coef 0.088 -0.098 0.025 -0.018 0.011
Beta coef 0.229 -0.136 0.064 -0.267 0.253
p value 0.020 0.066 0.388 0.006 0.010
 307
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF RESULTS: E3 Maternal dietary fat intake at V1 vs fetal weight and size at US2. 
FAT Intake V2 FW2 BPD2 AC2 HC2 FL2
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 105 103,102* 105 103 105,104* 103 95 92,93* 105 103
Total Fat (%E)
B coef -0.001 0.000 -0.007 -0.001 0.000 0.000 -0.016 0.001 -0.002 0.002
Beta coef -0.093 0.019 -0.123 -0.019 0.120 0.002 -0.094 0.007 -0.051 0.051
p value 0.343 0.795 0.212 0.794 0.224 0.981 0.367 0.933* 0.604 0.435
SAFA (% E)
B coef -0.013 -0.008 -0.089 -0.091 0.000 0.001 -0.494 -0.498 -0.009 -0.034
Beta coef -0.068 -0.042 -0.093 -0.095 0.003 0.032 -0.162 -0.167 -0.012 -0.042
p value 0.488 0.493* 0.344 0.189 0.976* 0.661 0.118 0.029#1 0.907 0.512
MUFA (% E)
B coef -0.001 0.001 -0.004 0.007 0.000 0.000 -0.016 0.006 0.002 0.012
Beta coef -0.027 0.046 -0.026 0.042 0.058 -0.020 -0.032 0.013 0.013 0.794
p value 0.786 0.515 0.790 0.564 0.556 0.781 0.760 0.873* 0.894 0.168
PUFA (% E)
B coef -0.019 0.027 -0.182 0.102 0.006 -0.005 0.033 0.751 -0.097 0.165
Beta coef -0.041 0.065 -0.077 0.043 0.067 -0.060 0.004 0.099 -0.050 0.081
p value 0.675 0.294 0.434 0.553 0.500 0.413 0.967 0.201* 0.615 0.199
Analysis including outliers: #1
N number 93
B coef -0.382
Beta coef -0.127
p value 0.105
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TABLE OF RESULTS: E4 Maternal dietary fat intake at V1 vs birth parameters. 
FAT Intake V1 BW BL   PONDIX   BW/PLW
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 103,104* 103,104* 100 100 100 100 86,88* 86,88*
Total Fat (%E)
B coef -0.001 -0.001 -0.021 -0.004 -0.001 -0.001 0.000 0.000
Beta coef -0.152 -0.100 -0.079 -0.016 -0.086 -0.094 -0.007 -0.036
p value 0.123* 0.268* 0.438 0.864 0.396 0.370 0.947* 0.747*
SAFA (% E)
B coef -0.007 -0.069 -1.699 -3.251 0.013 0.000 -0.017 0.020
Beta coef -0.007 -0.150 0.084 -0.160 0.030 0.000 -0.054 -0.063
p value 0.944 0.084#1 0.408 0.099 0.768 0.999 0.624 0.592
MUFA (% E)
B coef -0.140 -0.059 -1.483 -0.750 -0.017 -0.020 0.004 -0.008
Beta coef -0.140 -0.132 -0.081 -0.041 -0.043 -0.051 0.015 -0.027
p value 0.158 0.113 0.422 0.663 0.670 0.628 0.892 0.813
PUFA (% E)
B coef -0.112 -0.001 0.459 1.096 -0.022 -0.022 -0.018 -0.023
Beta coef -0.112 -0.004 0.045 0.104 -0.101 -0.099 -0.108 -0.136
p value 0.261 0.968 0.657 0.267 0.318 0.345 0.324 0.230
Analysis including outliers: #1
N number 104
B coef -0.066
Beta coef -0.139
p value 0.122
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TABLE OF RESULTS: E5 Maternal dietary fat intake at V2 vs birth parameters. 
FAT Intake V2 BW BL   PONDIX   BW/PLW
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 104,103* 103,104* 100 100 100 100 85,87* 85,87*
Total Fat (%E)
B coef 0.000 0.000 0.012 0.008 0.000 0.000 -0.001 -0.001
Beta coef 0.031 0.006 0.041 0.027 -0.007 -0.022 -0.118 -0.103
p value 0.755 0.946* 0.688 0.779 0.944 0.841 0.283 0.359
SAFA (% E)
B coef -0.001 -0.012 -0.170 -0.201 -0.001 -0.002 -0.014 -0.014
Beta coef -0.012 -0.102 -0.034 -0.040 -0.009 -0.020 -0.151 -0.154
p value 0.903* 0.226 0.737 0.670 0.933 0.849 0.164* 0.174*
MUFA (% E)
B coef 0.001 0.000 -0.011 0.000 0.002 0.001 -0.002 0.002
Beta coef 0.047 0.005 -0.014 -0.001 0.096 0.061 -0.100 -0.113
p value 0.636 0.956 0.888 0.997 0.343 0.567 0.357* 0.318*
PUFA (% E)
B coef 0.020 0.010 1.183 0.888 1.421 -0.001 0.008 0.001
Beta coef 0.070 0.032 0.094 0.070 0.007 -0.003 0.039 0.053
p value 0.483* 0.697 0.354 0.449 0.945 0.979 0.725 0.636
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TABLE OF RESULTS: E6 Maternal dietary fat intake at V1 vs infant anthropometry (Ba1 and Ba2). 
FAT Intake V1   Weight 1   Length 1 BMI 1   Weight 2   Length 2 BMI 2
Adjusted for conf. None A,s None A,s None A,s None A,s None A,s None A,s
N number 76,77* 77 77 77 76,77* 77 73 73 73 73 72 72
Total Fat (%E)
B coef -11.19 -5.476 0.022 0.034 -0.001 -0.001 0.000 0.000 -0.029 -0.039 0.000 0.000
Beta coef -0.181 -0.084 0.069 0.107 -0.241 -0.217 -0.029 -0.033 -0.085 -0.115 -0.040 -0.058
p value 0.118 0.340 0.550 0.293 0.035* 0.047 0.810 0.766 0.477 0.307 0.740 0.622
SAFA (% E)
B coef -852.9 -203.7 -4.452 -1.915 -0.018 0.002 0.080 0.063 -0.722 -1.954 -0.012 -0.011
Beta coef -0.174 -0.042 -0.185 -0.079 -0.091 0.011 0.176 0.138 -0.033 -0.082 -0.269 -0.254
p value 0.130* 0.650 0.108 0.451 0.436 0.922 0.135 0.211 0.786 0.465 0.022 0.027
MUFA (% E)
B coef -648.7 -317.6 -0.190 -0.119 -0.018 -0.020 -0.030 -0.044 -5.776 -6.373 -0.005 -0.004
Beta coef -0.147 -0.070 -0.008 -0.005 -0.090 -0.099 -0.066 -0.099 -0.246 -0.271 -0.113 -0.095
p value 0.205 0.433 0.942 0.959 0.435* 0.372 0.578 0.371 0.036 0.014 0.344 416.0
PUFA (% E)
B coef -15.46 4.374 3.474 3.535 -0.025 -0.029 -0.016 -0.007 1.014 0.858 0.003 0.002
Beta coef -0.006 0.002 0.270 0.275 -0.233 -0.252 -0.063 -0.029 0.083 0.066 0.140 0.102
p value 0.959* 0.985 0.018 0.006 0.043#1 0.022 0.598 0.794 0.487 0.562 0.241 0.385
Analysis including outliers: #1
N number 77
B coef -0.029
Beta coef -0.256
p value 0.025
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TABLE OF RESULTS: E7 Maternal dietary fat intake at V2 vs infant anthropometry (Ba1 and Ba2). 
FAT Intake V2   Weight 1   Length 1 BMI 1   Weight 2   Length 2 BMI 2
Adjusted for conf. None A,s None A,s None A,s None A,s None A,s None A,s
N number 76,75* 76 76 76 75,76* 76 72 72 72,71* 72 71 71
Total Fat (%E)
B coef -1.763 1.373 -0.104 -0.101 0.001 0.001 0.001 0.001 -0.064 -0.028 0.000 0.000
Beta coef -0.026 0.021 -0.319 -0.310 0.262 0.309 0.106 0.204 -0.207 -0.084 -0.279 -0.339
p value 0.822 0.822 0.005 0.002 0.023* 0.005 0.374 0.072 0.083#2 0.471 0.018 0.004
SAFA (% E)
B coef -125.2 -42.60 -1.244 -0.976 0.001 0.005 0.002 0.009 -1.203 -0.822 -0.003 -0.003
Beta coef -0.105 -0.036 -0.215 -0.168 0.022 0.093 0.018 0.080 -0.202 -0.138 -0.246 -0.277
p value 0.369 0.691 0.063 0.099 0.855 0.402 0.883 0.482 0.089 0.229 0.038 0.018
MUFA (% E)
B coef -6.282 0.938 -0.175 -0.162 0.001 0.001 0.001 0.003 -0.084 -0.053 0.000 0.000
Beta coef -0.033 0.005 -0.188 -0.174 0.143 0.176 0.067 0.138 -0.096 -0.056 -0.177 -0.226
p value 0.779 0.957 0.103 0.090 0.217* 0.115 0.575 0.220 0.426* 0.624 0.140 0.055
PUFA (% E)
B coef 418.4 317.5 -3.582 -3.804 0.038 0.051 0.059 0.084 -1.843 0.435 -0.008 -0.009
Beta coef 0.143 0.104 -0.241 -0.256 0.297 0.377 0.193 0.275 -0.127 0.028 -0.262 -0.305
p value 0.220* 0.251 0.036 0.012 0.010#1 0.001 0.105 0.014 0.291* 0.807 0.027 0.009
Analysis including outliers: #1 #2
N number 76 71
B coef 0.047 -0.057
Beta coef 0.349 -0.173
p value 0.002 0.148
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TABLE OF RESULTS: E8 Maternal dietary fat intake at V1 vs infant glucose, HOMA index and metabolics (Ba1). 
FAT Intake V1   Glc F 1   Ins F 1 PI F 1   HOMA-IR 1     Leptin 1    IGF BP3 (1)
Adjusted for conf. None A, s,w None A, s,w None A, s,w None A, s,w None A, s,w None A, s,w
N number 75 32 25 25 43
Total Fat (%E)
B coef -0.002 -0.004 0.000 0.000 0.000 0.000 -0.005 -0.004 0.005 0.010 -2.472 -0.620
Beta coef -0.036 -0.071 0.263 0.249 0.004 0.004 -0.271 -0.245 0.060 0.116 -0.070 -0.019
p value 0.758 0.524 0.022 0.033 0.974 0.976 0.019 0.034 0.608 0.147 0.547 0.866
SAFA (% E)
B coef -0.627 -0.485 0.003 0.002 -0.136 -0.187 -0.140 -0.099 -0.604 0.600 236.7 377.8
Beta coef -0.161 -0.130 0.037 0.022 -0.101 -0.130 -0.113 -0.080 -0.095 0.093 0.089 0.142
p value 0.161 0.258 0.753 0.857 0.385 0.287 0.337 0.505 0.414 0.258 0.443 0.211
MUFA (% E)
B coef -0.149 -0.375 0.006 0.006 -0.168 -0.188 -0.112 -0.087 0.396 0.875 3.117 59.00
Beta coef -0.041 -0.104 0.068 0.070 -0.125 -0.141 -0.090 -0.074 0.066 0.142 0.001 0.025
p value 0.725 0.350 0.560 0.554 0.278 0.237 0.443#1 0.522 0.573 0.073 0.991 0.819
PUFA (% E)
B coef -0.056 -0.169 0.013 0.013 0.024 0.059 -0.225 -0.224 0.460 0.169 -207.8 -210.5
Beta coef -0.027 -0.084 0.287 0.282 0.033 0.077 -0.319 -0.319 0.135 0.049 -0.146 -0.148
p value 0.818 0.456 0.012 0.015 0.777 0.517 0.005 0.006#2 0.244 0.544 0.205 0.179
Analysis including outliers: #1 #2
N number
B coef -0.092 -0.194
Beta coef -0.079 -0.293
p value 0.502 0.010
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TABLE OF RESULTS: E9 Maternal dietary fat intake at V2 vs infant glucose, HOMA index and metabolics (Ba1). 
FAT Intake V2   Glc F 1   Ins F 1 PI F 1   HOMA-IR 1     Leptin 1    IGF BP3 (1)
Adjusted for conf. None A, s,w None A, s,w None A, s,w None A, s,w None A, s,w None A, s,w
N number 43 43
Total Fat (%E)
B coef -0.010 -0.004 0.000 0.000 -0.004 -0.004 0.005 0.005 0.013 0.005 6.351 6.656
Beta coef -0.179 -0.223 -0.327 -0.364 -0.223 -0.223 0.253 0.287 0.142 0.057 0.173 0.181
p value 0.121 0.063 0.004 0.002 0.053 0.063 0.029 0.014 0.226 0.486 0.135#2 0.105#3
SAFA (% E)
B coef -0.169 -0.031 -0.003 -0.003 -0.030 -0.031 0.019 0.030 0.021 0.050 94.52 101.7
Beta coef -0.176 -0.093 -0.128 -0.155 -0.092 -0.093 0.057 0.093 0.014 0.032 0.144 0.165
p value 0.129 0.437 0.275 0.193 0.427 0.438 0.627 0.430 0.908 0.697 0.214 0.133
MUFA (% E)
B coef -0.031 -0.004 -0.001 -0.001 -0.004 -0.004 0.011 0.013 0.023 0.007 26.87 28.22
Beta coef -0.020 -0.071 -0.312 -0.340 -0.076 -0.071 0.221 0.249 0.093 0.028 0.256 0.269
p value 0.082 0.556 0.007 0.004 0.516 0.556 0.058 0.034 0.426 0.736 0.026 0.014
PUFA (% E)
B coef -0.210 -0.186 -0.018 -0.019 -0.188 -0.186 0.261 0.267 0.716 0.187 -0.343 -79.98
Beta coef -0.085 -0.220 -0.335 -0.355 -0.223 -0.220 0.314 0.322 0.178 0.046 0.000 -0.048
p value 0.464 0.068 0.003 0.003 0.053 0.068 0.006 0.006 0.127 0.575 0.999 0.674
Analysis including outliers: #1 #2 #3
N number
B coef 713.1 7.048 7.070
Beta coef 0.254 0.204 0.205
p value 0.052 0.080 0.065
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TABLE OF RESULTS: E10 Maternal dietary fat intake at V1 vs infant glucose, HOMA index and metabolics (Ba2). 
FAT Intake V1 Glc F 2 Ins F 2 PI F 2   HOMA-IR  2    Leptin 2    IGF BP3 (2)
Adjusted for conf. None A,s,w None A,s,w None A,s,w None A,s,w None A,s,w None A,s,w
N number
Total Fat (%E)
B coef -0.002 -0.001 -0.002 -0.002 -0.001 0.000 -0.004 -0.004 0.002 0.003 -2.967 -1.700
Beta coef -0.032 -0.011 -0.214 -0.224 -0.026 -0.014 -0.212 -0.214 0.090 0.116 -0.049 -0.028
p value 0.790 0.928 0.071 0.056 0.830 0.905 0.074 0.068 0.447 0.239 0.682 0.803
SAFA (% E)
B coef -0.689 -0.657 0.002 -0.015 0.157 0.081 -0.076 -0.105 -0.019 -0.108 412.1 123.7
Beta coef -0.150 -0.144 0.003 -0.025 0.108 0.055 -0.058 -0.080 -0.010 -0.057 0.095 0.029
p value 0.201 0.239 0.983 0.832 0.362 0.639 0.628 0.502 0.932 0.565 0.419 0.802
MUFA (% E)
B coef -0.077 0.022 -0.091 -0.072 -0.213 -0.185 -0.197 -0.150 -0.046 0.124 -182.62 -113.40
Beta coef -0.017 0.005 -0.150 -0.118 -0.149 -0.128 -0.151 -0.115 -0.024 0.067 -0.043 -0.027
p value 0.886 0.968 0.208 0.314 0.204 0.266 0.206 0.328 0.837 0.500 0.717 0.814
PUFA (% E)
B coef 0.135 0.162 -0.072 -0.082 -0.071 -0.063 -0.130 -0.147 0.105 0.097 -296.8 -296.8
Beta coef 0.054 0.065 -0.217 -0.247 -0.089 -0.078 -0.182 -0.206 0.101 0.094 -0.125 -0.125
p value 0.648 0.596 0.068 0.036 0.450 0.503 0.126 0.082 0.394 0.342 0.287 0.287
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TABLE OF RESULTS: E11 Maternal dietary fat intake at V2 vs infant glucose, HOMA index and metabolics (Ba2). 
FAT Intake V2 Glc F 2 Ins F 2 PI F 2   HOMA-IR  2    Leptin 2    IGF BP3 (2)
Adjusted for conf. None A,s,w None A,s,w None A,s,w None A,s,w None A,s,w None A,s,w
N number 48 56
Total Fat (%E)
B coef -0.008 -0.010 0.002 0.002 0.001 -0.001 0.004 0.003 0.005 0.002 1.694 -1.500
Beta coef -0.127 -0.151 0.276 0.225 0.034 -0.037 0.205 0.152 0.184 0.077 0.028 -0.025
p value 0.283 0.238 0.020 0.067 0.777 0.764 0.086 0.220 0.119 0.459 0.814 0.834
SAFA (% E)
B coef -0.208 -0.266 0.025 0.020 0.004 -0.015 0.029 0.013 -0.014 -0.059 10.63 2.700
Beta coef -0.182 -0.233 0.169 0.134 0.011 -0.041 0.088 0.038 -0.029 -0.125 0.010 0.003
p value 0.124 0.057 0.160 0.265 0.927 0.731 0.466 0.751 0.808 0.214 0.935 0.983
MUFA (% E)
B coef -0.009 -0.014 0.008 0.007 0.003 0.000 0.014 0.012 0.009 0.000 9.473 6.100
Beta coef -0.052 -0.075 0.321 0.272 0.058 0.000 0.276 0.224 0.112 -0.001 0.055 0.036
p value 0.663 0.545 0.006 0.022 0.625#1 0.998 0.020#2 0.060 0.346 0.995 0.641 0.756
PUFA (% E)
B coef 0.060 0.102 0.051 0.021 0.061 -0.011 0.107 0.052 0.392 0.291 23.53 -268.4
Beta coef 0.020 0.033 0.133 0.052 0.066 -0.011 0.128 0.059 0.319 0.229 0.008 -0.092
p value 0.865 0.798 0.269 0.678 0.578 0.927 0.290 0.638 0.006 0.028 0.944 0.446
Analysis including outliers: #1 #2
N number
B coef 0.013 0.015
Beta coef 0.217 0.332
p value 0.068 0.005
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TABLE OF RESULTS: E12 Maternal dietary fat intake at V3 vs infant glucose, HOMA index and metabolics (Ba2). 
FAT Intake V3 Glc F 2 Ins F 2 PI F 2   HOMA-IR  2    Leptin 2    IGF BP3 (2)
Adjusted for conf. None A, s,w None A, s,w None A, s,w None A, s,w None A, s,w None A, s,w
N number 76
Total Fat (%E)
B coef 0.009 0.008 -0.001 -0.001 0.001 0.001 0.000 0.000 0.001 0.000 -8.790 -7.100
Beta coef 0.135 0.117 -0.063 -0.056 0.042 0.042 -0.010 -0.011 0.023 14.00 -0.153 -0.114
p value 0.251 0.335 0.602 0.633 0.725 0.715 0.937 0.924 0.848 0.891 0.196 0.308
SAFA (% E)
B coef 0.009 0.003 0.002 0.002 0.119 0.002 0.006 0.005 0.015 0.013 -24.15 -14.00
Beta coef 0.045 0.013 0.088 0.090 0.030 0.024 0.098 0.087 0.171 0.149 -0.134 -0.071
p value 0.702 0.916 0.460 0.444 0.801 0.833 0.412 0.458 0.146 0.125 0.258 0.524
MUFA (% E)
B coef 0.012 0.009 0.000 0.001 0.003 0.002 0.002 0.002 -0.005 -0.006 -5.029 -5.500
Beta coef 0.063 0.049 0.013 0.024 0.045 0.033 0.031 0.036 -0.068 -0.073 -0.032 -0.032
p value 0.592 0.688 0.917 0.841 0.703 0.773 0.799 0.764 0.567 0.456 0.791 0.773
PUFA (% E)
B coef 0.014 0.014 -0.002 -0.002 0.001 0.001 -0.003 -0.003 -0.001 -0.001 -13.46 -12.10
Beta coef 0.138 0.133 -0.163 -0.159 0.020 0.029 -0.100 -0.099 -0.025 -0.024 -0.136 -0.122
p value 0.241 0.272 0.171 0.173 0.869 0.802 0.403 0.399 0.834 0.810 0.247 0.275
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APPENDIX F. Maternal intake of total energy, total CHO and added sugar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF RESULTS: F1 Maternal energy and carbohydrate intakes at V1 vs fetal weight and size at US1. 
E & CHO Intake V1 FW1 BPD1 AC1 HC1 FL1
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 106 104 106 103,104* 106,105* 104,101* 96 93,95* 106 103,104*
Total Energy
B coef -1.890 0.465 -0.547 -0.196 0.003 -0.007 -0.922 -0.049 -0.336 -0.004
Beta coef -0.081 0.020 -0.141 -0.052 0.031 -0.087 -0.070 -0.004 -0.101 -0.001
p value 0.411 0.124 0.148 0.036#1 0.758* 0.004#3 0.502 0.857* 0.305 0.960
Total CHO (%E)
B coef 0.081 -0.009 0.013 0.002 0.000 0.000 0.047 0.001 0.008 -0.002
Beta coef 0.183 -0.019 0.175 0.023 -0.200 -0.029 0.183 0.007 0.127 -0.024
p value 0.061 0.143 0.073 0.361* 0.041#2 0.372 0.075#5 0.722 0.194 0.328
Added Sugar 
B coef -0.098 0.008 -0.022 -0.009 0.000 0.000 -0.039 0.007 -0.019 -0.005
Beta coef -0.061 0.005 -0.082 -0.034 0.022 -0.065 -0.032 0.008 -0.083 -0.022
p value 0.535 0.689 0.404 0.163 0.823 0.027#4 * 0.674 0.697 0.399 0.385*
Analysis including outliers: #1 #2 #3 #4 #5
N number 104 105 104 104 96
B coef -0.173 0.000 -0.008 0.000 0.045
Beta coef -0.045 -0.185 -0.085 -0.050 0.166
p value 0.078 0.058#2 0.009 0.117 0.104#5
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TABLE OF RESULTS: F2 Maternal energy and carbohydrate intakes at V1 vs fetal weight and size at US2. 
E & CHO Intake V1 FW2 BPD2 AC2 HC2 FL2
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 104 101,102* 104 102 104,103* 102,101* 95,93* 92,93* 103 102
Total Energy
B coef 0.063 0.039 0.107 -0.004 -0.008 0.000 0.970 1.183 0.350 0.158
Beta coef 0.124 0.080 0.042 -0.004 -0.095 -0.101 0.112 0.139 0.162 0.070
p value 0.209 0.204 0.675 0.984 0.339* 0.175 0.281 0.065#1 0.102 0.274
Total CHO (%E)
B coef 0.000 0.000 0.000 0.008 -0.014 0.013 -0.012 0.010 -0.007 -0.001
Beta coef -0.056 0.086 0.009 0.150 -0.056 0.057 -0.072 0.060 -0.157 -0.022
p value 0.570 0.230* 0.928 0.041 0.576 0.450* 0.491* 0.438* 0.114#2 0.740
Added Sugar 
B coef 0.001 0.001 0.003 0.013 0.000 0.000 0.038 0.066 0.004 0.002
Beta coef 0.023 0.033 0.014 0.072 0.011 -0.059 0.065 0.114 0.029 0.012
p value 0.814 0.596 0.888 0.320 0.909 0.415 0.532 0.134* 0.773 0.852
Analysis including outliers: #1 #2
N number 93 103
B coef 0.929 -0.008
Beta coef 0.109 -0.189
p value 0.163 0.055
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TABLE OF RESULTS: F3 Maternal energy and carbohydrate intakes at V2 vs fetal weight and size at US2. 
E & CHO Intake V2 FW2 BPD2 AC2 HC2 FL2
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 103 102,103* 103 103 104,105* 103,102* 95 93 105,104* 103
Total Energy
B coef -0.016 0.081 -0.199 0.267 0.001 -0.015 -0.778 0.697 0.099 0.352
Beta coef -0.031 0.162 -0.076 0.101 0.009 -0.165 -0.093 0.085 0.013 0.155
p value 0.752 0.011#1 0.443 0.183 0.932 0.031 0.369 0.305 0.898* 0.018
Total CHO (%E)
B coef 0.000 0.000 0.006 0.001 0.006 -0.017 0.018 -0.001 0.002 -0.002
Beta coef 0.066 -0.051 0.121 0.015 0.026 -0.078 0.116 -0.005 0.058 -0.058
p value 0.501 0.484* 0.220 0.836 0.793 0.303* 0.263 0.953 0.556 0.370
Added Sugar 
B coef 0.000 0.000 0.002 0.001 0.000 0.000 0.001 0.002 0.000 0.001
Beta coef -0.023 0.007 0.048 0.075 0.039 -0.002 0.020 0.036 0.015 0.035
p value 0.820 0.924* 0.627 0.306 0.697* 0.974 0.845 0.644 0.883 0.585
Analysis including outliers: #1
N number 103
B coef 0.082
Beta coef 0.158
p value 0.032
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TABLE OF RESULTS: F4 Maternal energy and carbohydrate intakes at V1 vs birth parameters. 
E & CHO Intake V1 BW BL   PONDIX   BW/PLW
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 103,104* 103 100 100 100 100 86,88* 86,88*
Total Energy
B coef -0.001 -0.002 1.426 1.323 -0.022 -0.032 0.004 0.006
Beta coef -0.043 -0.005 0.105 0.097 -0.078 -0.111 0.020 0.027
p value 0.965 0.950 0.299 0.312 0.438 0.301 0.855 0.821
Total CHO (%E)
B coef 0.001 0.001 0.014 0.008 0.001 0.001 0.000 0.000
Beta coef 0.107 0.146 0.052 0.029 0.080 0.092 0.004 0.022
p value 0.280* 0.077#1 0.605 0.758 0.430 0.376 0.971* 0.842*
Added Sugar 
B coef -0.002 0.000 -0.028 -0.012 0.001 0.001 0.001 0.001
Beta coef -0.070 0.017 -0.030 -0.012 0.030 0.025 0.065 0.084
p value 0.484 0.835 0.768 0.895 0.766 0.812 0.550 0.458
Analysis including outliers: #1
N number 104
B coef 0.001
Beta coef 0.102
p value 0.235
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TABLE OF RESULTS: F5 Maternal energy and carbohydrate intakes at V2 vs birth parameters. 
E & CHO Intake V2 BW BL   PONDIX   BW/PLW
Adjusted for conf. None A,h,w,s None A,h,w,s None A,h,w,s None A,h,w,s
N number 104,103* 104,103* 100 100 100 100 85,87* 85,87*
Total Energy
B coef -0.004 0.008 2.117 2.513 -0.026 -0.033 -0.020 -0.016
Beta coef -0.012 0.023 0.152 0.181 -0.090 -0.114 -0.088 -0.073
p value 0.901* 0.789* 0.130 0.061 0.371 0.295 0.424 0.541
Total CHO (%E)
B coef -0.001 -0.001 0.101 -0.020 0.000 0.000 0.001 0.001
Beta coef -0.092 -0.088 -0.073 -0.079 -0.017 -0.011 0.167 0.157
p value 0.352 0.320 0.469 0.410 0.864 0.917 0.128#1 0.174#2
Added Sugar 
B coef 0.000 0.000 0.003 0.002 0.000 0.000 0.000 0.000
Beta coef -0.010 -0.045 0.037 0.023 -0.039 -0.057 -0.070 -0.060
p value 0.922 0.611 0.718 0.809 0.746 0.590 0.522* 0.597*
Analysis including outliers: #1 #2
N number 87 87
B coef 0.000 0.000
Beta coef 0.082 0.089
p value 0.449 0.443
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TABLE OF RESULTS: F6 Maternal energy and carbohydrate intakes at V1 vs infant anthropometry (Ba1 and Ba2). 
E & CHO Intake V1   Weight 1   Length 1 BMI 1   Weight 2   Length 2 BMI 2
Adjusted for conf. None A,s None A,s None A,s None A,s None A,s None A,s
N number 77,76* 77 77 77 76,77* 77 73 73 73,72* 73 72 72
Total Energy
B coef -352.2 -203.6 -0.670 -0.157 -0.008 -0.009 -0.018 -0.012 -1.949 -2.067 -0.001 -0.002
Beta coef -0.109 -0.063 -0.042 0.010 -0.063 -0.064 -0.059 -0.039 -0.128 -0.127 -0.028 -0.052
p value 0.346 0.476 0.717 0.923 0.589 0.561 0.619 0.724 0.282* 0.257 0.813 0.655
Total CHO (%E)
B coef 9.957 3.196 0.008 -0.012 0.001 0.000 0.000 0.000 0.028 0.035 0.002 0.000
Beta coef 0.159 0.048 0.025 -0.037 0.174 0.107 -0.039 -0.043 0.081 0.104 0.000 0.150
p value 0.172* 0.588 0.828 0.715 0.132 0.333 0.744 0.699 0.497 0.359 0.126 0.200
Added Sugar 
B coef -36.12 -18.65 0.036 0.103 -0.002 -0.002 -0.003 -0.003 0.001 0.055 0.001 0.046
Beta coef -0.153 -0.079 0.031 0.089 -0.208 -0.172 -0.143 -0.117 0.001 0.047 0.246 0.229
p value 0.184 0.372 0.791 0.385 0.069* 0.119 0.228 0.292 0.994 0.673 0.037 0.046
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TABLE OF RESULTS: F7 Maternal energy and carbohydrate intakes at V2 vs infant anthropometry (Ba1 and Ba2). 
E & CHO Intake V2   Weight 1   Length 1 BMI 1   Weight 2   Length 2 BMI 2
Adjusted for conf. None A,s None A,s None A,s None A,s None A,s None A,s
N number 76 76 76 76 76 76 72 72 72 72 71 71
Total Energy
B coef -260.1 50.40 -0.042 0.264 -0.009 0.000 -0.012 0.016 -0.605 -0.019 0.001 -0.001
Beta coef -0.080 0.016 0.716 0.017 -0.062 0.001 -0.038 0.049 -0.036 -0.001 0.039 -0.042
p value 0.491 0.866 0.665 0.874 0.600 0.995 0.755 0.672 0.764 0.992 0.749 0.733
Total CHO (%E)
B coef 2.231 -0.658 0.061 0.056 0.000 -0.001 0.000 0.000 0.040 0.024 0.000 0.000
Beta coef 0.038 -0.011 0.217 0.198 -0.154 -0.197 -0.074 -0.144 0.138 0.083 0.210 0.258
p value 0.742 0.901 0.060 0.054 0.185 0.079 0.536 0.202 0.247 0.469 0.080 0.027
Added Sugar 
B coef -3.537 0.413 -0.016 -0.002 0.000 0.000 0.000 0.000 0.017 0.018 0.000 0.000
Beta coef -0.162 0.019 -0.149 -0.016 -0.061 0.037 0.047 0.093 0.153 0.168 0.081 0.037
p value 0.161 0.838 0.198 0.880 0.603 0.747 0.693 0.407 0.198 0.140 0.501 0.758
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TABLE OF RESULTS: F8
Maternal energy and carbohydrate intakes at V3 vs infant anthropometry (Ba2). 
E & CHO Intake V3   Weight 2   Length 2 BMI 2
Adjusted for conf. None A,s None A,s None A,s
N number 73 73 72 73 72 72
Total Energy
B coef 0.054 0.084 0.756 1.710 -0.006 -0.008
Beta coef 0.146 0.228 0.042 0.088 -0.160 -0.215
p value 0.219 0.040 0.728 0.440 0.179 0.066
Total CHO (%E)
B coef 0.000 0.000 0.011 0.019 0.000 0.000
Beta coef 0.053 0.045 0.030 0.052 -0.008 -0.014
p value 0.657 0.683 0.804 0.646 0.946 0.908
Added Sugar 
B coef 0.002 0.004 0.107 0.177 0.000 0.000
Beta coef 0.082 0.147 0.080 0.123 -0.002 -0.059
p value 0.488 0.186 0.507 0.278 0.986 0.622
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TABLE OF RESULTS: F9 Maternal energy and carbohydrate intakes at V1 vs infant glucose, HOMA index and metabolics (Ba1). 
E & CHO Intake V1   Glc F 1   Ins F 1 PI F 1   HOMA-IR 1     Leptin 1    IGF BP3 (1)
Adjusted for conf. Out A, s, w Out A, s, w Out A, s, w Out A, s, w Out A, s, w Out A, s, w
N number 75 32 32 25 43
Total Energy
B coef -0.293 -0.330 -0.002 -0.003 0.049 0.042 -0.182 0.071 0.199 0.251 21.57 115.1
Beta coef -0.113 -0.133 -0.036 -0.055 0.678 0.047 -0.204 0.087 0.046 0.058 0.012 0.069
p value 0.328 0.231 0.761 0.640 0.043#1 0.691 0.086 0.453 0.691 0.468 0.916 0.526
Total CHO (%E)
B coef 0.003 0.004 0.000 -0.001 0.002 0.002 0.002 0.002 -0.004 -0.010 -0.276 -1.659
Beta coef 0.051 0.068 -0.147 -0.131 0.087 0.091 0.117 0.116 -0.050 -0.110 -0.008 -0.046
p value 0.659 0.545 0.207 0.268 0.453 0.446 0.330 0.340 0.669 0.168 0.948 0.678
Added Sugar 
B coef -0.028 -0.019 0.000 0.000 0.009 0.009 -0.006 0.002 -0.038 -0.009 2.856 4.660
Beta coef -0.147 -0.099 0.009 -0.014 0.128 0.133 -0.104 0.027 -0.122 -0.030 0.022 0.038
p value 0.201 0.380 0.941 0.908 0.268 0.265 0.384 0.819 0.296 0.707 0.848 0.728
Analysis including outliers: #1
N number 104
B coef 0.007
Beta coef 0.007
p value 0.951
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TABLE OF RESULTS: F10 Maternal energy and carbohydrate intakes at V2 vs infant glucose, HOMA index and metabolics (Ba1). 
E & CHO Intake V2   Glc F 1   Ins F 1 PI F 1   HOMA-IR 1     Leptin 1    IGF BP3 (1)
Adjusted for conf. Out A, s, w Out A, s, w Out A, s, w Out A, s, w Out A, s, w Out A, s, w
N number 25/56 43
Total Energy
B coef -0.685 -0.617 -0.015 -0.018 -0.070 -0.064 0.047 0.172 0.426 0.079 99.60 129.1
Beta coef -0.259 -0.234 -0.253 -0.306 -0.078 -0.072 0.051 0.208 0.098 0.018 0.056 0.073
p value 0.024 0.044 0.029 0.011 0.501 0.556 0.672 0.081#1 0.403 0.828 0.630 0.523
Total CHO (%E)
B coef 0.009 0.009 0.000 0.000 0.003 0.003 -0.004 -0.005 -0.007 -0.001 -6.170 -6.577
Beta coef 0.195 0.181 0.321 0.354 0.194 0.192 -0.273 -0.328 -0.087 -0.014 -0.194 -0.207
p value 0.091 0.113 0.005 0.002 0.094 0.109 0.021 0.006#2 0.457 0.869 0.093 0.062#3
Added Sugar 
B coef -0.003 -0.001 0.000 0.000 0.001 0.001 0.000 0.000 0.001 0.004 -0.631 -0.366
Beta coef -0.138 -0.060 -0.107 -0.154 0.116 0.132 0.013 0.096 0.028 0.124 -0.053 -0.031
p value 0.234 0.612 0.362 0.211 0.318 0.283 0.914 0.428 0.813 0.134 0.650 0.789
Analysis including outliers: #1 #2 #3
N number 104 104 104
B coef 0.195 -0.002 -6.830
Beta coef 0.221 -0.256 -0.228
p value 0.068 0.036 0.038
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TABLE OF RESULTS: F11 Maternal energy and carbohydrate intakes at V1 vs infant glucose, HOMA index and metabolics (Ba2). 
E & CHO Intake V1 Glc F 2 Ins F 2 PI F 2   HOMA-IR  2    Leptin 2    IGF BP3 (2)
Adjusted for conf. None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w
N number 76
Total Energy
B coef 37.41 -0.065 -0.089 -0.093 -0.063 -0.044 -0.182 -0.187 -0.073 -0.058 -0.673 81.30
Beta coef 0.014 -0.021 -0.217 -0.226 -0.063 -0.044 -0.204 -0.211 -0.056 -0.045 0.000 0.028
p value 0.909 0.864 0.067 0.052 0.595 0.701 0.086 0.071 0.636 0.647 0.998 0.806
Total CHO (%E)
B coef 0.003 0.001 0.001 0.001 -0.001 0.000 0.002 0.003 -0.003 -0.003 -0.366 -0.100
Beta coef 0.040 0.022 0.104 0.136 -0.025 -0.013 0.117 0.139 -0.117 -0.100 -0.006 -0.002
p value 0.736 0.859 0.384 0.250 0.830 0.912 0.330 0.239 0.320 0.311 0.960 0.990
Added Sugar 
B coef 28.10 -0.002 -0.004 -0.003 0.008 0.011 -0.006 -0.006 -0.005 -0.001 27.35 40.00
Beta coef 0.146 -0.007 -0.123 -0.105 0.110 0.154 -0.104 -0.096 -0.051 -0.016 0.133 0.193
p value 0.216 0.955 0.304 0.376 0.352 0.181 0.384 0.418 0.668 0.870 0.260 0.085
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TABLE OF RESULTS: F12 Maternal energy and carbohydrate intakes at V2 vs infant glucose, HOMA index and metabolics (Ba2). 
E & CHO Intake V2 Glc F 2 Ins F 2 PI F 2   HOMA-IR  2    Leptin 2    IGF BP3 (2)
Adjusted for conf. Out A, s, w Out A, s, w Out A, s, w Out A, s, w Out A, s, w Out A, s, w
N number 48 56 76
Total Energy
B coef -0.763 -0.810 0.063 0.043 -0.099 -0.115 0.047 0.002 -0.085 -0.193 -93.44 -84.70
Beta coef -0.236 -0.253 0.149 0.101 -0.097 -0.114 0.051 0.002 -0.063 -0.145 -0.033 -0.028
p value 0.044 0.041 0.215 0.408 0.414 0.338 0.672 0.985 0.597 0.155 0.785 0.813
Total CHO (%E)
B coef 0.008 0.008 -0.003 -0.002 0.001 0.002 -0.004 -0.004 -0.003 -0.001 -3.745 -4.000
Beta coef 0.143 0.152 -0.355 -0.312 0.059 0.112 -0.273 -0.232 -0.122 -0.031 -0.077 -0.076
p value 0.227 0.220 0.002 0.008 0.622 0.343 0.021#2 0.051 0.303 0.756 0.522 0.508
Added Sugar 
B coef -0.002 -0.002 0.000 0.000 0.001 0.001 0.000 0.000 0.001 0.000 -1.176 -1.600
Beta coef -0.101 -0.116 0.058 0.006 0.207 0.182 0.013 -0.040 0.061 -0.026 -0.064 -0.080
p value 0.395 0.346 0.630 0.960 0.078#1 0.116 0.914 0.741 0.607 0.793 0.595 0.484
Analysis including outliers: #1 #2
N number 104 104
B coef 0.002 -0.005
Beta coef 0.260 -0.328
p value 0.027 0.006
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TABLE OF RESULTS: F13 Maternal energy and carbohydrate intakes at V3 vs infant glucose, HOMA index and metabolics (Ba2). 
E & CHO Intake V3 Glc F 2 Ins F 2 PI F 2   HOMA-IR  2    Leptin 2    IGF BP3 (2)
Adjusted for conf. None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w None A, s, w
N number 76
Total Energy
B coef 0.713 0.649 -0.100 -0.163 0.062 -0.049 -0.124 -0.254 0.566 0.321 -379.8 -603.4
Beta coef 0.191 0.175 -0.205 -0.334 0.052 -0.041 -0.117 -0.241 0.364 0.209 -0.108 -0.171
p value 0.104 0.164 0.084 0.005 0.665 0.735 0.326 0.048 0.001 0.039 0.361 0.142
Total CHO (%E)
B coef -0.012 -0.010 0.000 0.000 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 9.078 5.700
Beta coef -0.159 -0.140 0.031 0.015 -0.044 -0.051 -0.028 -0.035 -0.016 -0.024 0.143 0.084
p value 0.176 0.248 0.795 0.900 0.714 0.658 0.816 0.768 0.892 0.807 0.227 0.454
Added Sugar 
B coef 0.046 0.042 -0.003 -0.006 0.018 0.013 -0.001 -0.007 0.032 0.018 -9.936 4.100
Beta coef 0.168 0.154 -0.088 -0.169 0.201 0.149 -0.016 -0.096 0.283 0.161 -0.041 0.016
p value 0.152 0.212 0.463 0.158 0.089 0.200 0.895 0.427 0.015 0.106 0.732 0.890
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Appendix: G1 List of variables and their transformations for data on mothers
DATA ON MOTHERS V1 V2 V3 DATA ON MOTHERS V1 V2 V3
Variable Transformation Variable Transformation
Age, anthropom., BP Nutritional intake
AGE ENERGY log log log
HEIGHT TOTAL PROTEIN log rec
WEIGHT log log PLANT PROTEIN log
BMI log log ANIMAL PROTEIN sqrt log
BP SYS TOTAL FAT
BP DIA SAFA log sqrt log
MUFA log
Metabolics PUFA log log sqrt
GLC F sqrt rec CHOLESTEROL
GLC AUC log log TOTAL AVAIL. CHO
INS F log log ADDED SUGAR sqrt sqrt
INS AUC log ln PROTEIN (% EN.) log
PI F log log FAT (% ENERGY)
PI AUC log log TOTAL CHO (% EN.)
CPEP F log
CPEP AUC sqrt
HGB BMI - body mass index IGF-1 - insulin like growth factor 1
HPL log rec, sqrt BP - blood pressure IGF-BP1 - IGF-binding protein 1
IGF1 log, sqrt GLC - glucose FT4 - free thyroxine
IGFBP1 log log AUC - area under the curve SAFA - saturated fatty acids
FT4 rec rec INS - insulin MUFA - monounsaturated fatty acids
CORTISOL log PI - proinsulin PUFA - polyunsaturated fatty acids
LEPTIN log sqrt CPEP - C-peptide CHO - carbohydrate
HOMA-IR log log HGB - haemoglobin
HPL - human placental lactogen
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Appendix: G2 List of variables and their transformations for data from ultrasound, delivery and on infants
ULTRASOUND DATA US1 US2 DELIVERY DATA INFANT DATA Ba1 Ba2
Variable      Transformation Variable      Transf. Variable      Transformation
GEST AGE log BIRTH AGE Age, anthropom. GRRT
EFW sqrt log B WEIGHT log AGE (FROM DEL.) log rec, ^2
BPD B LENGTH WEIGHT log
AC rec, sqrt rec, log HEAD_CIR LENGTH
HC SEX BMI log, sqrt rec
FL PLAC_W rec, sqrt
RI sqrt PONDIX log D-Ba1/2 GRRT log
AFI BW/PLAC W rec, sqrt Ba1 - Ba2 GRRT log
GRRT sqrt rec, sqrt
FL/AC MATER  W  GAIN Metabolic data (fasting)
GLC 
INS rec sqrt
EFW - estimated fetal weight BMI - body mass index PI log log
BPD - biparietal diameter D-Ba 1 GRRT - delivery to Ba1 growth rate HOMA-IR log log
AC - abdomnal circumference Ba1-Ba2 GRRT - Ba1 to Ba2 growth rate LEPTIN log log
HC - head circumference IGF BP3
FL - femur length US - ultrasound
RI - resistance index Ba1, Ba2 - babies' visits
AFI - amniotic fluid index
GRRT - growth rate GLC - glucose
PONDIX - ponderal index INS - insulin
PI - proinsulin
HOMA-IR - homeostasis index
IGF-BP3 - insulin-like growth factor binding protein 3
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APPENDIX H.   Maternal dietary intakes summary tables 
 
Table H 1 contains results corrected for infant BMI, replacing the infant weight as a 
confounder (see the data in grey font). Correcting for BMI in many instances produced a 
weaker effect (lower p value and β-coefficient and increased AR2) for maternal dietary 
protein intake on the particular infant metabolic parameter. This means, that the model with 
BMI explains more variation than the model with infant weight. However, in most cases 
BMI did not completely negate the relationship between the maternal dietary intake and the 
metabolic variable, with the p-value remaining < 0.05. The only cases when p value was 
greater than 0.05 was for IGF BP3 (Ba1 and Ba2) and HOMA-IR1.   
  
Table H1 Maternal protein dietary intake summary tables vs fetal biometric and 
postnatal anthropometric and metabolic parameters and birth weight. (Table 
1 for total protein intake, Table 2 for plant protein intake and Table 3 for 
animal protein intake).  
 
 
 
Table H1.1 
TOT PROT 
[%E] 
 
Intake 
V1 
   
Intake 
V2 
 
Variable p β AR2 Variable p β AR2   
BPD 1 0.024 0.054 0.946 AC 2 0.048 0.145 0.459 
HC 2 0.014 -0.187 0.537 BW 0.038 0.171 0.347 
BMI 1 0.001 0.353 0.208 LENG 1 0.014 0.252 0.284 
INS F 1 0.003 0.348 0.098 BMI 1 0.026 -0.247 0.146 
 0.014 0.296 0.117     
HOMA 1 0.001 0.381 0.155 IGFBP3 (2) 0.040 0.236 0.161 
 0.005 0.330 0.173  0.068 0.224 0.041 
WEIG 2 0.038 0.227 0.180     
BMI 2 0.012 0.287 0.128     
Orange font indicates fetal biometric measurements and the blue font indicates infant postnatal parameters of 
visit 1 or visit2 (antenatal or postnatal).  Grey font indicates outcomes of models corrected for infant BMI 
instead of the weight. 
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Table H 1.2 
PLPROT 
[%E] 
 
Intake 
V1 
   
Intake 
V2 
 
Variable p β AR2 Variable p β AR2 
PI F 2 0.021 -0.262 0.152 LENG 1 0.032 0.220 0.269 
 0.045 -0.244 0.032 BMI 1 0.010 -0.283 0.165 
    INS F 1 0.005 -0.329 0.084 
     0.019 -0.280 0.110 
    HOMA 1 0.042 -0.237 0.099 
     0.081 -0.209 0.114 
    WEIG 2 0.033 -0.238 0.180 
    BMI 2 0.021 -0.269 0.118 
    INS F 2 0.008 -0.318 0.141 
     0.006 -0.336 0.125 
    HOMA 2 0.027 -0.268 0.133 
     0.024 -0.264 0.116 
Blue font indicates the infant postnatal parameters of visit 1 or visit 2. Grey font indicates outcomes of models 
corrected for infant BMI instead of the weight. 
 
 
 
 
Table H 1.3 
ANPROT 
[%E] 
 
Intake 
V1 
   
Intake 
V2 
 
Variable p β AR2 Variable p β AR2 
BMI 1 0.012 0.275 0.156 INS F 2 0.024 0.264 0.116 
     0.017 0.283 0.101 
INS F 1 0.006 0.323 0.079 IGF BP3 (2) 0.016 0.267 0.181 
 0.021 0.273 0.108  0.015 0.288 0.078 
HOMA 1 0.003 0.345 0.127     
 0.012 0.294 0.156     
IGFBP3 (1) 0.036 0.231 0.150     
 0.099 0.194 0.088     
BMI 2 0.039 0.238 0.102     
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TABLE H 2 Fat dietary intake summary tables vs. fetal biometric and postnatal 
anthropometric and metabolic parameters. (Table 1 includes total fat intake, 
Table 2 saturated fat, Table 3 monounsaturated and Table D polyunsaturated 
fat intakes.) 
Table H 2.1 
TOT FAT 
[%E] 
 
Intake 
V1 
   
Intake
V2 
 
Variable p β AR2 Variable p β AR2   
BMI 1 0.047 -0.217 0.128 LENG 1 0.002 -0.310 0.316 
INS F1 0.033 -0.249 0.037 BMI 1 0.005 0.309 0.180 
 0.075 -0.206 0.081     
HOMA 1 0.034 -0.245 0.068 INS F1 0.002 0.364 0.107 
 0.076 -0.203 0.116  0.010 0.311 0.125 
    HOMA 1 0.014 0.287 0.030 
     0.071 0.218 0.117 
    BMI 2 0.004 0.339 0.157 
Blue font indicates the infant postnatal parameters of visit 1 or visit 2. Grey font indicates outcomes of models 
corrected for infant BMI instead of the weight. 
 
 
Table H 2.2 
SAFA  
[%E] 
 
Intake 
V1 
   
Intake
V2 
 
Variable p β AR2 Variable p β AR2   
BMI 2 0.027 0.254 0.110 HC 2 0.029 -0.167 0.530 
    BMI 2 0.018 0.277 0.121 
Orange font indicates fetal biometric measurements.  
 
 
 
Table H 2.3 
MUFA 
[%E] 
 
Intake 
V1 
   
Intake
V2 
 
Variable p β AR2 Variable p β AR2   
LENG 2 0.014 -0.271 0.177 INS F 1 0.004 0.340 0.093 
     0.009 0.302 0.127 
    HOMA 1 0.034 0.249 0.070 
     0.039 0.238 0.146 
    IGFBP3 (1) 0.014 0.269 0.170 
     0.052 0.223 0.102 
    INS F2 0.022 0.272 0.118 
     0.032 0.264 0.085 
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Table H 2.4 
PUFA 
[%E] 
 
Intake 
V1 
   
Intake
V2 
 
Variable p β AR2 Variable p β AR2   
LENG 1 0.006 0.275 0.298 LENG 1 0.012 -0.256 0.286 
BMI 1 0.022 -0.252 0.144 BMI 1 0.001 0.377 0.227 
INS F1 0.015 -0.282 0.055 INS F1 0.003 0.355 0.100 
 0.054 -0.227 0.085  0.015 0.303 0.116 
HOMA 1 0.006 -0.319 0.110 HOMA 1 0.006 0.322 0.111 
 0.025 -0.260 0.139  0.035 0.260 0.132 
INS F 2 0.036 -0.247 0.105 BMI 2 0.009 0.305 0.137 
 0.053 -0.234 0.071     
    LEPT 2 0.028 0.229 0.361 
     0.851 0.021 0.193 
Blue font indicates the infant postnatal parameters of visit 1 or visit 2. Grey font indicates outcomes of models 
corrected for infant BMI instead of the weight. 
 
 
Table H 3 Total energy, total CHO and added sugar dietary intake summary tables vs 
fetal biometric and postnatal anthropometric and metabolic parameters. 
(Table 1 includes total energy intake, table 2 total carbohydrate intake and 
Table 3 an intake of added sugar.) 
 
Table H 3.1 
TOT CHO 
[%E] 
 
Intake 
V1 
   
Intake 
V2 
 
Variable p β AR2 Variable p β AR2   
BPD 2 0.041 0.150 0.504 INS F1 0.002 -0.354 0.101 
     0.007 -0.313 0.133 
    HOMA 1 0.006 -0.328 0.094 
     0.057 -0.221 0.122 
    BMI 2 0.027 -0.258 0.111 
    INS F2 0.008 -0.312 0.141 
     0.010 -0.316 0.113 
Orange font indicates fetal biometric measurements and the blue font indicates infant postnatal parameters of 
visit 1 or visit2 (antenatal or postnatal).  Grey font indicates outcomes of models corrected for infant BMI 
instead of the weight. 
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Table H 3.2 
ADDED 
SUGAR[g] 
 
Intake 
V1 
   
Intake 
V2 
 
Variable p β AR2 Variable p β AR2   
AC 1 0.027 0.065 0.919 No     
BMI 2 0.046 -0.229 0.098 associations    
 
 
 
Table H 3.3 
TOTAL 
ENERGY 
 
Intake 
V1 
   
Intake 
V2 
 
Variable p β AR2 Variable p β AR2   
BPD 1 0.036 -0.052 0.945 EFW 2 0.011 0.162 0.659 
AC 1 0.009 0.087 0.929 AC 2 0.031 0.165 0.503 
    FL2 0.018 0.155 0.635 
    GLC F1 0.044 -0.234 0.119 
     0.048 -0.231 0.103 
    INS F1 0.011 0.306 0.065 
     0.008 0.308 0.131 
    GLC F2 0.041 -0.253 0.020 
     0.036 -0.263 0.185 
Orange font indicates fetal biometric measurements and the blue font indicates infant postnatal parameters of 
visit 1 or visit2 (antenatal or postnatal). Grey font indicates outcomes of models corrected for infant BMI 
instead of the weight. 
 
 
 
Table H 3.4 
TOTAL 
ENERGY 
 
Intake 
V3 
 
Variable p β AR2   
WEIG 2 0.040 0.228 0.179 
INS F2 0.005 -0.334 0.149 
 0.008 -0.327 0.119 
HOMA 2 0.048 -0.241 0.098 
 0.058 -0.235 0.067 
LEPT 2 0.039 0.209 0.355 
 0.023 0.248 0.255 
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APPENDIX I.  
Correlations used in the regression models listed in APPENDIX J. 
 
I.1.1  Associations with fetal growth rates: 
 
Maternal visit 1 (V1) and GRR1 (between V1 and V2): 
 
GRRT1 Valid N Pearson R p-level 
WEIGHT1  105 0.213 0.029 
BMI1      105 0.216 0.027 
GLC1_30 105 0.202 0.039 
GLC1_60  105 0.212 0.030 
GLC1_120  105 0.201 0.039 
AREA_GLC1 105 0.235 0.016 
INS1_60  105 0.184 0.061 
CPEPF1 79 0.168 0.086 
CPEP1_60  79 0.187 0.099 
CPEP1_120 79 0.225 0.047 
HPL1      105 0.322 0.001 
LEPT1  105 0.178 0.070 
 
 
Maternal visit 1 (V1) and GRR2 (between V2 and delivery): 
GRRT2 Valid N Pearson R p-level 
HEIGHT    101 0.185 0.065 
FT4V1     101 0.188 0.060 
 
 
 
 
I.1.2. Associations with the birth parameters: 
 
Maternal V1 and BW: 
 
BW Valid N Pearson R p-level 
WEIGHT1  105 0.348 <0.001 
HEIGHT    105 0.237 0.015 
BMI1      105 0.279 0.004 
INS1_0 105 0.186 0.057 
INS1_60  105 0.187 0.099 
AREA_INS1  105 0.189 0.053 
IGFBP1_V1  105 -0.256 0.008 
LEPT1  105 0.295 0.002 
INS_RES1  105 0.191 0.051 
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Maternal V1 and BL: 
 
BL Valid N Pearson R p-level 
WEIGHT1  101 0.287 0.004 
BMI1      101 0.255 0.010 
INS1_0  101 0.196 0.050 
IGFBP1_V1  101 -0.257 0.010 
LEPT1  101 0.262 0.008 
INS_RES1  101 0.208 0.037 
 
 
Maternal V1 and BHC: 
 
BHC Valid N Pearson R p-level 
WEIGHT1 102 0.275 0.005 
BMI1      102 0.334 0.003 
GLC1_120  102 0.209 0.035 
INS1_0  102 0.213 0.032 
INS1_60  102 0.236 0.017 
INS1_120 102 0.213 0.032 
AREA_INS1  102 0.216 0.029 
IGFBP1_V1  102 -0.359 <0.001 
LEPT1 102 0.343 <0.001 
INS_RES1 102 0.216 0.029 
 
 
 
I.1.3 Associations with the postnatal parameters: 
 
Maternal V1 and the postnatal growth rate between delivery and Ba2 (GRRT Del-Ba2): 
No correlations found 
 
 
 
Maternal V1 and baby’s BMI at the first visit (Ba1): 
 
BMI_Ba1    Valid N Pearson R p-level 
WEIGHT1  77 0.309 0.006 
BMI1    77 0.284 0.012 
PI1_0  77 -0.261 0.022 
PI1_30  76 -0.261 0.042 
LEPT1  77 0.222 0.053 
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Maternal V1 and baby’s BMI at the second visit (Ba2): 
 
BMI_Ba2 Valid N Pearson R p-level 
GLC1_O  72 -0.267 0.024 
FT4_V1     72 0.205 0.083 
IGFBP1_V1  72 -0.236 0.046 
LEPT1 72 0.242 0.040 
 
 
Maternal V1 and baby’s fasting glucose levels at the first visit (Ba1): 
 
GLC F Ba1 Valid N Pearson R p-level 
GLC1_O  77 0.228 0.047 
HAEMOGLOBIN 77 -0.194 0.092 
 
 
 
Maternal V1 and baby’s fasting glucose levels at the second visit (Ba2): 
 
GLC F Ba2 Valid N Pearson R p-level 
C-PEP1_30 74 -0.258 0.051 
HPL1  74 0.279 0.016 
 
 
Maternal V1 and baby’s fasting insulin levels at the first visit (Ba1): 
 
INS F Ba1 Valid N Pearson R p-level 
BMI1      76 0.202 0.081 
FT4_V1 76 -0.371 0.004 
 
 
 
Maternal V1 and baby’s fasting insulin levels at the first visit (Ba2): 
 
No correlations found 
 
 
 
Maternal V1 and baby’s HOMA-IR index at the first visit (Ba1): 
 
HOMA Ba1 Valid N Pearson R p-level 
BMI_1      75 0.236 0.072 
FT4_V1    75 -0.423 0.001 
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Maternal V1 and baby’s HOMA-IR index at the second visit (Ba2): 
 
No correlations found 
 
 
 
 
Maternal V1 and baby’s fasting leptin levels at the first visit (Ba1): 
 
No correlations found 
 
 
 
Maternal V1 and baby’s fasting leptin levels at the second visit (Ba2): 
 
LEPT F Ba2 Valid N Pearson R p-level 
FT4_V1    74 0.291 0.012 
 
 
 
 
 
I.2.1 Associations with fetal growth rates: 
Maternal visit 2 (V2) and GRR1 (between V1 and V2): 
 
GRRT 1 Valid N Pearson R p-level 
WEIGHT2  105 0.193 0.049 
BMI2 105 0.192 0.049 
BP_SYS2 105 0.271 0.005 
BP_DIA2 105 0.247 0.011 
INS2_60 105 -0.163 0.096 
PI2_60 105 -0.082 0.067 
HPL2 103 0.217 0.028 
LEPT 103 0.253 0.010 
 
 
 
Maternal visit 2 (V2) and GRR2 (between V2 and delivery): 
GRRT2 Valid N Pearson R p-level 
BP_DIA2 101 -0.178 0.075 
INS2_120 101 0.173 0.083 
PI2_0  101 0.187 0.064 
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I.2.2 Associations with the birth parameters: 
Maternal V2 and BW: 
 
BW Valid N Pearson R p-level 
WEIGHT2   104 0.345 <0.001 
BMI2 104 0.266 0.006 
INS2_0  104 0.170 0.085 
IGFBP1_V2  104 -0.205 0.038 
LEPT2 104 0.212 0.031 
INS_RES2  104 0.193 0.050 
 
 
Maternal V2 and BL: 
 
BL Valid N Pearson R p-level 
WEIGHT2   100 0.298 0.003 
BMI2 100 0.259 0.009 
GLC2_O  100 0.217 0.030 
IGFBP1_V2  100 -0.278 0.005 
LEPT2  100 0.241 0.016 
INS_RES2  100 0.212 0.035 
 
 
Maternal V2 and BHC: 
 
BHC Valid N Pearson R p-level 
WEIGHT2   101 0.255 0.010 
BMI2 101 0.308 0.002 
INS2_0  101 0.197 0.049 
IGFBP1_V2  101 -0.315 0.002 
LEPT2  101 0.240 0.017 
INS_RES2  101 0.211 0.037 
 
 
 
 
I.2.3 Associations with the postnatal parameters: 
 
Maternal V2 and the postnatal growth rate between delivery and Ba2 (GRRT Del-Ba2): 
GRRT D-Ba2 Valid N Pearson R p-level 
INS_RES2  72 0.222 0.063 
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Maternal V2 and baby’s BMI at the first visit (Ba1): 
 
BMI Ba1 Valid N Pearson R p-level 
WEIGHT2   76 0.278 0.015 
BMI2 76 0.251 0.029 
PI2_0  76 -0.323 0.005 
PI2_30 76 -0.224 0.052 
PI2_60 76 -0.336 0.003 
PI2_120  76 -0.238 0.040 
AREA_PI2  76 -0.274 0.017 
 
 
 
Maternal V2 and baby’s BMI at the second visit (Ba2): 
 
BMI Ba2 Valid N Pearson R p-level 
IGF1_BP1_V2  71 0.252 0.034 
LEPT_2  71 0.210 0.080 
 
 
 
Maternal V2 and baby’s fasting glucose levels at the first visit (Ba1): 
 
GLC F Ba1 Valid N Pearson R p-level 
GLC2_O   76 0.195 0.092 
HPL2 76 0.223 0.053 
FT4_V2 76 -0.212 0.067 
CORT2 76 0.225 0.052 
 
 
 
Maternal V2 and baby’s fasting glucose levels at the second visit (Ba2): 
 
GLC F Ba2 Valid N Pearson R p-level 
INS2_60  73 -0.243 0.039 
AREAINS_2  73 -0.216 0.067 
PI2_30  73 -0.206 0.082 
PI2_60  73 -0.228 0.054 
AREA_PI2  73 -0.201 0.090 
HPL_2    73 0.273 0.020 
CORT_2 73 0.249 0.035 
IGFBP1_V2  73 0.201 0.089 
 
 
 
Maternal V2 and baby’s fasting insulin levels at the first visit (Ba1): 
 
INS F Ba1 Valid N Pearson R p-level 
PI2_0  75 -0.216 0.062 
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Maternal V2 and baby’s fasting insulin levels at the first visit (Ba1): 
INS Ba1 Valid N Pearson R p-level 
PI2_0  71 0.221 0.064 
 
 
Maternal V2 and baby’s fasting insulin levels at the second visit (Ba2): 
No correlations found 
 
 
 
Maternal V2 and baby’s HOMA-IR index at the first visit (Ba1): 
 
HOMA Ba1 Valid N Pearson R p-level 
BMI_2 74 0.212 0.070 
PI2_0  74 -0.246 0.036 
 
 
 
Maternal V2 and baby’s HOMA-IR index at the second visit (Ba2): 
No correlations found 
 
 
 
Maternal V2 and baby’s fasting leptin levels at the first visit (Ba1): 
 
LEPT F Ba1 Valid N Pearson R p-level 
BP_SYS2 75 0.209 0.071 
 
 
 
Maternal V2 and baby’s fasting leptin levels at the second visit (Ba2): 
 
LEPT F Ba2 Valid N Pearson R p-level 
INS2_30 73 -0.214 0.069 
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APPENDIX J 
 
Table J1.1: Fetal growth rate    Maternal parameters at visit 1 
 
Table J1.2: Birth weight and postnatal growth rate 
 
Table J1.3: Birth parameters 
BW GRRT D-Ba2
Adjusted B BETA p Adjusted B BETA p
N=104; AR2=0.248 N=101; AR2=0.054
Intercept 2.478 Intercept 1.031
BIRTH AGE 0.016 0.379 <0.001 SEX 0.076 0.434 <0.001
MW1 0.210 0.281 0.002
Not Adjusted B BETA p Adjusted B BETA p
N=104; AR2=0.115
Intercept 3.014
MW1 0.263 0.351 <0.001 no correlations
BL BHC
Adjusted B BETA p Adjusted B BETA p
N=101; AR2=0.168 N=102; AR2=0.228
Intercept 23.049 Intercept 22.805
BIRTH AGE 0.609 0.346 <0.001 BIRTH AGE 0.316 0.292 0.002
LEPT 1 1.695 0.199 0.035 LEPT1 1.037 0.199 0.045
IGF BP1 V1 -1.143 -0.202 0.044
Not Adjusted B BETA p Not Adjusted B BETA p
N=101; AR2=0.073 N=102; AR2=0.154
Intercept 33.045 Intercept 35.679
MW1 8.782 0.287 0.004 LEPT1 1.192 0.229 0.027
IGF BP1 V1 -1.458 -0.258 0.013
GRR1 GRR2
Adjusted B BETA p Adjusted B BETA p
N=75; AR2 =0.243 N=101; AR2=0.054
Intercept -0.848 Intercept 0.320
MW1 2.266 0.396 <0.001 HEIGHT 0.104 0.194 0.049
HPL1 1.334 0.390 <0.001 FT4 (V1) 0.456 0.197 0.046
Not Adjusted B BETA p Not Adjusted B BETA p
N=76;  AR2=0.243
Intercept -0.392 same outcome 
MW1 2.282 0.398 <0.001
HPL1 1.328 0.388 <0.001
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Table J1.4: Postnatal anthropometric parameters 
 
Table J1.5: Postnatal glucose  
 
Table J1.6: Neonatal insulin and HOMA-IR index 
 
 
BMI Ba1 BMI Ba2
Adjusted B BETA p Adjusted B BETA p
N=76; AR2 =0.274 N=72; AR2=0.263
Intercept 0.352 Intercept 0.037
PI F1 -0.010 -0.314 0.002 SEX 0.004 0.339 0.002
AGE Ba1 0.125 0.354 0.001 LEPT1 0.007 0.358 0.001
MW1 0.113 0.354 0.001 GLC F1 -0.018 -0.410 <0.001
Not Adjusted B BETA p Not Adjusted B BETA p
N=76; AR2=0.163 N=72; AR2=0.157
Intercept 0.385 Intercept 0.035
MW1 0.114 0.357 0.001 LEPT1 0.007 0.346 0.003
PI 30' V1 -0.033 -0.302 0.006 GLC F1 -0.016 -0.365 0.002
GLC Ba1 GLC Ba2
Adjusted B BETA p Adjusted B BETA p
N=76; AR2=0.082 N=72; AR2=0.146
Intercept 3.029 Intercept 3.586
WEIG Ba1 0.0002 0.228 0.047 HPL1 1.668 0.398 0.001
Not Adjusted B BETA p Not Adjusted B BETA p
N=77; AR2=0.039 N=73; AR2=0.132
Intercept 2.309 Intercept 3.602
GLC F1 0.086 0.228 0.047 HPL1 1.605 0.379 0.001
INS Ba1 HOMA-Ba1
Adjusted B BETA p Adjusted B BETA p
N=76; AR2=0.106  =74; AR2 =0.227
Intercept 0.059 Intercept -0.888
FT4 V1 -0.355 -0.343 0.002 WEIG Ba1 <0.001 0.344 0.002
FT4 V1 -6.109 0.417 <0.001
Not Adjusted B BETA p Not Adjusted B BETA p
N=76 ; AR2=0.106 N=101; AR2=0.054
Intercept 0.059 Intercept -0.508
FT4 V1 -0.355 -0.343 0.002 FT4 (V1) -5.686 0.364 0.001
same outcome
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Table J1.7: Postnatal leptin 
 
Table J2.1: Fetal growth rate    Maternal parameters at visit 1 
     
Table J2.2: Birth weight  
 
 
LEPT Ba1 LEPT Ba2
Adjusted B BETA p Adjusted B BETA p
N=75; AR2=0.539 N=73; AR2=0.302
Intercept -0.970 Intercept -8.111
SEX -0.729 -0.465 <0.001 SEX -0.201 -0.430 <0.001
WEIG Ba1 0.001 0.473 <0.001 WEIG Ba2 2.315 0.557 <0.001
AGE Ba1 2.743 0.264 0.012
Not Adjusted B BETA p Not Adjusted B BETA p
N=74; AR2=0.072
Outcome not significant Intercept 1.041
FT4 V1 -6.163 -0.291 0.012
BW BW
Adjusted B BETA p Adjusted B BETA p
N=104; AR2=0.252 N=103; AR2=0.336 (one outlier excluded)
Intercept 2.416 Intercept 2.289
BIRTH AGE 0.017 0.390 <0.001 BIRTH AGE 0.018 0.417 <0.001
MW2 0.229 0.277 0.002 MW2 0.259 0.315 <0.001
SEX 0.020 0.164 0.046
Not Adjusted B BETA p Not Adjusted B BETA p
N=104; AR2=0.110
Intercept 2.967
MW2 0.284 0.345 <0.001 no outliers present
GRR1 GRR2
Adjusted B BETA p Adjusted B BETA p
N=101; AR2=0.223 (2 outliers excluded) N=100; AR2=0.066
Intercept 3.732 Intercept 0.390
BP SYS2 0.011 0.278 0.002 HEIGHT 0.119 0.231 0.021
LEPT2 0.090 0.334 0.001 PI F V2 0.035 0.221 0.027
HPL2 2.174 0.341 <0.001
Not Adjusted B BETA p Not Adjusted B BETA p
N=103; AR2=0.223 (2 outliers excluded)
Intercept Outcome not significant
BP SYS2
LEPT2 same outcome
HPL2
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Table J2.3: Birth parameters  
 
Table J2.4: Postnatal growth rate 
 
Table J2.5: Postnatal anthropometric parameters 
 
BL BHC
Adjusted B BETA p Adjusted B BETA p
N=100; AR2=0.193 N=101; AR2=0.195
Intercept 27.513 Intercept 22.422
BIRTH AGE 0.642 0.366 <0.001 BIRTH AGE 0.371 0.341 <0.001
IGF BP1 V2 -1.967 -0.231 0.013 IGF BP1 V2 -1.390 -0.266 0.004
Not Adjusted B BETA p Not Adjusted B BETA p
N=99 ; AR2=0.073 N=77; AR2=0.257
Intercept 31.547 Intercept 37.500
MW2 9.487 0.287 0.004 IGF BP1 V2 -1.626 -0.311 0.002
GRRT D-Ba2
Adjusted B BETA p
N=71; AR2=0.026
Intercept 1.282
SEX 0.074 0.422 <0.001
INS RES2 0.142 0.275 0.010
Not Adjusted B BETA p
N=71; AR2=0.093
Intercept 1.389
INS RES2 0.168 0.325 0.006
BMI Ba1 BMI Ba2
Adjusted B BETA p Adjusted B BETA p
N=76; AR2=0.254 N=71; AR2=0.071
Intercept 0.395 Intercept 0.062
AGE Ba1 0.124 0.354 0.001 SEX -0.003 -0.291 0.014
PI F V2 -0.046 -0.327 0.002
MW2 0.086 0.247 0.017
Not Adjusted B BETA p Not Adjusted B BETA p
N=76; AR2=0.195 N=71; AR2=0.030
Intercept 0.390 Intercept 0.060
MW2 0.116 0.333 0.002 LEPT2 -0.001 -0.210 0.000
PI 60' V2 -0.040 -0.376 0.001
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Table J2.6: Postnatal glucose 
 
Table J2.7: Neonatal insulin and HOMA-IR index 
 
Table J2.8: Postnatal leptin 
 
GLC Ba1 GLC Ba2
Adjusted B BETA p Adjusted B BETA p
N=75; AR2=0.217 N=72; AR2=0.049
Intercept -1.516 Intercept 5.197
AGE Ba1 2.069 0.324 0.003 HPL2 2.090 0.250 0.034
CORT2 1.562 0.367 0.001
FT4 V2 -12.223 -0.332 0.003
Not Adjusted B BETA p Not Adjusted B BETA p
N=76; AR2=0.156 N=73; AR2=0.096
Intercept -1.491 Intercept 5.638
HPL2 1.611 0.224 0.044 HPL2 2.275 0.271 0.018
CORT2 1.247 0.293 0.012 PI 30' V2 -0.577 -0.228 0.046
FT4 V2 -12.310 -0.347 0.003
INS Ba2 HOMA Ba1
Adjusted B BETA p Adjusted B BETA p
N=74; AR2=0.063 N=74; AR2=0.053
Intercept -0.475 Intercept 0.006
WEIG Ba2 0.260 0.346 0.041 PI F V2 -0.224 -0.258 0.027
SEX -0.041 -0.271 0.034
Not Adjusted B BETA p Not Adjusted B BETA p
Intercept Intercept
No significant outcome PI F V2 same outcome
LEPT Ba1 LEPT Ba2
Adjusted B BETA p Adjusted B BETA p
N=74; AR2=0.539 N=7; AR2=0.353
Intercept -0.986 Intercept -7.946
SEX -0.726 -0.460 <0.001 SEX -0.207 -0.438 <0.001
WEIG Ba1 0.001 0.473 <0.001 WEIG Ba2 2.416 0.580 <0.001
AGE Ba1 2.736 0.263 0.013 INS 30' V2 -0.203 -0.237 0.017
Not Adjusted B BETA p Not Adjusted B BETA p
Intercept Intercept
No significant outcome No significant outcome
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APPENDIX K 
 
Tables of outcomes from the linear mixed model analyses.  
(Where applicable, the varialbes were used in their transformed form as described in the 
Appendix G. Results are expressed in units of particular transformation.) 
 
 
 
 
 
Table K1. Maternal anthropometry and blood pressure. 
 
      
Variable Coef. SE z P value Adj. P* 95% CI 
Weight [kg]       
V1 vs V2 
-4.38 0.40 -11.00 0.000 <0.01 -5.16; -3.60 
V1 vs V3 1.28 0.46 0.76 0.006 0.018 0.37; 2.19 
V2 vs V3 5.66 0.47 12.2 0.000 <0.01 1.75; 6.57 
BMI [kgm-2]       
V1 vs V2 
-1.75 0.16 -11.0 0.000 <0.01 -2.06; -1.44 
V1 vs V3 0.51 0.18 2.72 0.006 0.018 0.14; 0.86 
V2 vs V3 2.25 0.19 12.2 0.000 <0.01 1.89; 2.61 
SYSTOLIC BP 
[mmHg] 
      
V1 vs V2 
-1.16 1.27 -0.92 0.359 1.000 -3.63; 1.32 
V1 vs V3 
-8.29 1.44 -5.74 0.000 <0.01 -11.12; -5.46 
V2 vs V3 
-7.13 1.45 -4.92 0.000 <0.01 -9.97; -4.29 
DIASTOLIC 
BP [mmHg] 
      
V1 vs V2 
-1.66 1.01 -1.64 0.100 0.300 -3.65; 0.32 
V1 vs V3 
-9.35 1.16 -8.08 0.000 <0.01 -11.62; -7.08 
V2 vs V3 
-7.68 1.16 -6.63 0.000 <0.01 -9.95; -5.41 
*Adjustment with the Bonferroni correction.  
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Table K2. Maternal glucose in the OGTT. 
 
GLUCOSE       
Time points Coef. SE z P value Adj. P* 95% CI 
0 min       
V1 vs V2 
-0.14 0.12 -1.21 0.228 0.684 -0.38; 0.09 
V1 vs V3 
-0.66 0.13 -4.95 0.000 <0.01 -0.92;-0.40 
V2 vs V3 
-0.52 0.13 -3.86 0.000 <0.01 -0.78; -0.25 
30 min       
V1 vs V2 
-0.51 0.12 -4.26 0.000 <0.01 -0.74; -0.27 
V1 vs V3 
-0.66 0.13 -4.99 0.000 <0.01 -0.92; -0.40 
V2 vs V3 
-0.16 0.13 -1.17 0.242 0.726 -0.42; 0.11 
60 min       
V1 vs V2 
-0.74 0.12 -6.23 0.000 <0.01 -0.98; -0.51 
V1 vs V3 
-0.25 0.13 -1.89 0.058 0.174 -0.51; 0.01 
V2 vs V3 0.49 0.13 3.68 0.000 <0.01 -0.23; 0.75 
120 min       
V1 vs V2 
-0.45 0.12 -3.78 0.000 <0.01 -0.68; -0.22 
V1 vs V3 
-0.27 0.13 -2.02 0.044 0.132 -0.53; -0.01 
V2 vs V3 0.18 0.13 1.36 0.172 0.516 -0.08; 0.44 
*Adjustment with the Bonferroni correction.  
 
 
 
 
Table K3. Maternal insulin in the OGTT. 
 
INSULIN 
 
      
Time points Coef. SE z P value Adj. P* 95% CI 
0 min       
V1 vs V2 
-8.31 32.40 -0.256 0.798 1.000 -71.81; 55.20 
V1 vs V3 
-19.77 36.17 -0.547 0.585 1.000 -90.67; 51.13 
V2 vs V3 
-11.46 36.26 -0.316 0.752 1.000 -82.53; 59.60 
30 min       
V1 vs V2 
-140.66 32.40 -4.34 0.000 <0.01 -204.16; -77.15 
V1 vs V3 
-7.50 36.33 -0.206 0.836 1.000 -78.71; 63.71 
V2 vs V3 133.16 36.41 3.66 0.000 <0.01 61.79; 204.53 
60 min       
V1 vs V2 
-253.39 32.40 -7.82 0.000 <0.01 -316.89; -189.88 
V1 vs V3 42.26 36.33 1.16 0.245 0.735 -28.95; 113.47 
V2 vs V3 295.64 36.41 8.12 0.000 <0.01 224.27; 367.01 
120 min       
V1 vs V2 
-125.25 32.40 -3.87 0.000 <0.01 -188.75; -61.74 
V1 vs V3 8.62 36.33 0.237 0.813 1.000 -62.59; 79.83 
V2 vs V3 133.87 36.41 3.68 0.000 <0.01 62.49; 205.24 
*Adjustment with the Bonferroni correction.  
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Table K4. Maternal C-peptide in the OGTT. 
 
C-PEPTIDE       
Time points Coef. SE z P value Adj. P* 95% CI 
0 min       
V1 vs V2 
-0.01 0.11 -0.081 0.936 1.000 -0.22; 0.20 
V1 vs V3 0.03 0.12 0.252 0.801 1.000 -0.20; 0.26 
V2 vs V3 0.04 0.12 0.323 0.747 1.000 -0.20; 0.27 
30 min       
V1 vs V2 
-0.17 0.12 -1.46 0.144 0.432 -0.40; 0.06 
V1 vs V3 0.12 0.13 0.948 0.343 1.000 -0.13; 0.37 
V2 vs V3 0.29 0.12 2.41 0.016 0.048 0.05; 0.52 
60 min       
V1 vs V2 
-0.44 0.12 -3.81 0.000 <0.01 -0.67; -0.21 
V1 vs V3 0.39 0.13 3.08 0.002 0.006 0.14; 0.64 
V2 vs V3 0.84 0.12 6.98 0.000 <0.01 0.60; 1.07 
120 min       
V1 vs V2 
-0.37 0.12 -3.15 0.002 0.006 -0.59; -0.14 
V1 vs V3 0.41 0.13 3.2 0.001 0.003 0.16; 0.66 
V2 vs V3 0.77 0.12 6.45 0.000 <0.01 0.54; 1.01 
*Adjustment with the Bonferroni correction.  
 
 
 
 
Table K5. Maternal proinsulin in the OGTT. 
 
PROINSULIN 
 
      
Time points Coef. SE z P value Adj. P* 95% CI 
0 min       
V1 vs V2 
-0.32 0.46 -0.695 0.487 1.000 -1.22; 0.58 
V1 vs V3 
-0.77 0.52 -1.49 0135 0.405 -1.78; 0.24 
V2 vs V3 
-0.45 0.52 -0.871 0.384 1.000 -1.47; 0.56 
30 min       
V1 vs V2 
-0.52 0.46 -1.12 0.264 0.792 -1.42; 0.39 
V1 vs V3 
-2.76 0.52 -5.32 0.000 <0.01 -3.77; -1.74 
V2 vs V3 
-2.24 0.52 -4.33 0.000 <0.01 -3.26; -1.23 
60 min       
V1 vs V2 
-1.08 0.46 -2.32 0.020 0.060 -1.99; -0.17 
V1 vs V3 
-2.83 0.52 -5.45 0.000 <0.01 -3.85; -1.81 
V2 vs V3 
-1.75 0.52 -3.38 0.001 0.003 -2.77; -0.74 
120 min       
V1 vs V2 
-1.43 0.46 -3.09 0.002 0.006 -2.33; -0.52 
V1 vs V3 
-3.51 0.52 -6.78 0.000 <0.01 -4.53; -2.50 
V2 vs V3 
-2.08 0.52 -4.02 0.000 <0.01 -3.10; -1.07 
*Adjustment with the Bonferroni correction.  
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Table K6. Maternal hormones and the HOMA-IR index. 
 
 
 
      
Variable Coef. SE z P value Adj. P* 95% CI 
IGF 1        
V1 vs V2 
-125.35 8.10 -15.50 0.000 <0.01 -141.22; -109.48 
V1 vs V3 81.03 9.24 8.77 0.000 <0.01 62.93; 99.13 
V2 vs V3 206.38 9.26 22.30 0.000 <0.01 188.23; 224.54 
IGF BP1        
V1 vs V2 8.72 3.12 2.79 0.005 0.015 2.60; 14.84 
V1 vs V3 70.70 3.57 19.8 0.000 <0.01 63.70; 77.71 
V2 vs V3 61.99 61.99 17.3 0.000 <0.01 54.96; 69.02 
FT4        
V1 vs V2 1.08 0.17 6.50 0.000 <0.01 0.76; 1.41 
V1 vs V3 0.10 0.19 0.54 0.593 1.000 -0.27; 0.48 
V2 vs V3 
-0.98 0.19 -5.13 0.000 <0.01 -1.36; -0.61 
LEPT        
V1 vs V2 
-2.63 1.13 -2.33 0.020 0.060 -4.85; -0.41 
V1 vs V3 0.211 1.30 0.16 0.871 1.000 -2.34; 2.76 
V2 vs V3 2.85 1.31 2.18 0.029 0.087 0.29; 5.40 
HOMA-IR        
V1 vs V2 
-0.26 0.10 -2.72 0.007 0.021 -0.45; -0.07 
V1 vs V3 
-0.57 0.11 -5.14 0.000 <0.01 -0.78; -0.35 
V2 vs V3 
-0.30 0.11 -2.74 0.006 0.018 -0.52; -0.09 
*Adjustment with the Bonferroni correction.;  
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Table K7a. Maternal dietary intakes (a) 
 
      
Variable Coef. SE z P value Adj. P* 95% CI 
ENERGY        
V1 vs V2 
-0.02 0.04 -0.43 0.667 1.000 -0.10; 0.06 
V1 vs V3 
-0.12 0.05 -2.67 0.008 0.024 -0.21; -0.03 
V2 vs V3 
-0.11 0.05 -2.28 0.023 0.069 -0.20; -0.02 
TOT PROT        
V1 vs V2 
-0.03 0.05 -0.60 0.549 1.000 -0.12; 0.06 
V1 vs V3 
-0.01 0.05 -0.26 0.792 1.000 -0.11; 0.09 
V2 vs V3 0.01 0.05 0.27 0.790 1.000 -0.09; 0.11 
PL PROT        
V1 vs V2 
-0.06 0.05 -1.23 0.220 0.660 -0.15; 0.03 
V1 vs V3 
-0.16 0.05 -3.14 0.002 0.006 -0.27; -0.06 
V2 vs V3 
-0.11 0.05 -2.05 0.040 0.120 -0.21; -0.01 
AN PROT        
V1 vs V2 
-0.02 0.06 -0.29 0.78 1.000 -0.13; 0.09 
V1 vs V3 0.06 0.06 1.00 0.32 0.960 -0.06; 0.19 
V2 vs V3 0.08 0.06 1.25 0.21 0.630 -0.05; 0.21 
TOT FAT        
V1 vs V2 
-0.02 0.06 -0.33 0.742 1.000 -0.14; 0.10 
V1 vs V3 
-0.20 0.07 -3.01 0.003 0.009 -0.34; -0.07 
V2 vs V3 
-0.19 0.07 -2.72 0.007 0.021 -0.32; -0.05 
SAFA        
V1 vs V2 
-0.01 0.06 -0.11 0.91 1.000 -0.12; 0.11 
V1 vs V3 
-0.07 0.07 -1.02 0.31 0.930 -0.20; 0.06 
V2 vs V3 
-0.06 0.07 -0.92 0.36 1.000 -0.19; 0.07 
MUFA        
V1 vs V2 
-0.04 0.06 -0.68 0.496 1.000 -0.16; 0.08 
V1 vs V3 
-0.24 0.07 -3.50 0.000 <0.01 -0.38; -0.11 
V2 vs V3 
-0.20 0.07 -2.89 0.004 0.012 -0.34; -0.07 
PUFA        
V1 vs V2 
-0.03 0.08 -0.42 0.678 1.000 -0.19; 0.13 
V1 vs V3 
-0.34 0.09 -3.71 0.000 <0.01 -0.51; -0.16 
V2 vs V3 
-0.30 0.09 -3.34 0.001 0.003 -0.48; -0.13 
TOT CHO        
V1 vs V2 
-0.02 0.04 -0.39 0.700 1.000 -0.09; 0.06 
V1 vs V3 
-0.10 0.04 -2.42 0.015 0.045 -0.19; -0.02 
V2 vs V3 
-0.09 0.04 -2.08 0.037 0.111 -0.17; -0.01 
TOT AV CHO        
V1 vs V2 
-0.01 0.04 -0.32 0.752 1.000 -0.09; 0.06 
V1 vs V3 
-0.11 0.04 -2.47 0.014 0.042 -0.19; -0.02 
V2 vs V3 
-0.09 0.04 -2.19 0.029 0.087 -0.18; -0.01 
*Adjustment with the Bonferroni correction.  
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Table K7b. Maternal dietary intakes (b). 
 
 
      
Variable Coef. SE z P value Adj. P* 95% CI 
CHOLEST. [mg]       
V1 vs V2 0.03 0.07 0.43 0.667 1.000 -0.11; 0.17 
V1 vs V3 
-0.07 0.08 -0.89 0.372 1.000 -0.23; 0.08 
V2 vs V3 
-0.10 0.08 -1.27 0.205 0.615 -0.26; 0.06 
DIET. FIBRE [g]       
V1 vs V2 
-0.06 0.05 -1.27 0.202 0.606 -0.16; 0.03 
V1 vs V3 
-0.06 0.06 -1.03 0.303 0.909 -0.16; 0.05 
V2 vs V3 0.01 0.06 0.10 0.922 1.000 -0.10; 0.11 
ADDED SUGAR [g]       
V1 vs V2 0.06 0.25 0.25 0.806 1.000 -0.44; 0.56 
V1 vs V3 
-0.61 0.29 -2.12 0.034 0.102 -1.17; -0.05 
V2 vs V3 
-0.67 0.29 -2.33 0.020 0.060 -1.23; -0.11 
TOT PROT [%E]       
V1 vs V2 
-0.16 0.38 -0.41 0.680 1.000 -0.91; 0.59 
V1 vs V3 1.49 0.43 3.49 0.000 <0.01 0.66; 2.33 
V2 vs V3 1.65 0.43 3.86 0.000 <0.01 0.81; 2.49 
TOT FAT [%E]       
V1 vs V2 0.16 1.12 0.14 0.887 1.000 -2.03; 2.35 
V1 vs V3 
-2.83 1.24 -2.28 0.023 0.069 -5.27; -0.40 
V2 vs V3 
-2.99 1.24 -2.40 0.016 0.048 -5.43; -0.55 
TOT CHO [%E]       
V1 vs V2 
-0.15 1.09 -0.14 0.892 1.000 -2.29; 1.99 
V1 vs V3 1.32 1.22 1.08 0.279 0.937 -1.07; 3.72 
V2 vs V3 1.47 1.22 1.20 0.229 0.687 -0.93; 3.87 
*Adjustment with the Bonferroni correction. 
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